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Abstract 
 
Progressive supranuclear palsy (PSP) belongs to a group of neurodegenerative 
disorders that are characterised by hallmark pathology consisting of intra-neuronal 
aggregates of the microtubule-associated protein, tau. In PSP, these aggregates are 
almost exclusively composed of one of the two major tau protein isoform groups 
normally expressed at similar levels in the healthy brain, indicating a role for 
altered isoform regulation in PSP aetiology. 
 
Although no causal mutations have been identified, common variation within the 
gene encoding tau, MAPT, has been highly associated with PSP risk. The A-allele 
of the rs242557 single nucleotide polymorphism has been repeatedly shown to 
significantly increase the risk of developing PSP. Its location within a distal 
region of the MAPT promoter region is significant, with independent studies – 
including this one – demonstrating that the rs242557-A allele alters the function 
of a transcription regulatory domain. As transcription and alternative splicing 
processes have been shown to be co-regulated in some genes, it was hypothesised 
that the rs242557-A allele could directly affect MAPT alternative splicing through 
its differential effect on transcription. 
 
This project describes an investigation into the molecular mechanism linking the 
MAPT association with the tau isoform dysregulation characteristic of PSP. The 
design, construction and in vitro investigation of minigenes representing common 
MAPT variants will be presented in detail and will demonstrate that promoter 
identity plays an important role in regulating the alternative splicing of MAPT 
transcripts. The specific role of the rs242557 polymorphism in MAPT 
transcription and splicing are investigated and the two alleles of the 
polymorphism are shown to differentially influence these two molecular 
processes, providing a plausible mechanism linking the two phenomena known to 
be associated with PSP – a common genetic variant within the MAPT promoter 
region and detrimental changes to tau isoform production. 
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1 Introduction 
 
1.1 Overview 
It is becoming increasingly apparent that the molecular processes responsible for 
normal gene expression do not occur independently of each other and are, in fact, 
co-regulated. A growing number of studies have described mechanistic links 
between transcription and splicing and have shown that an alteration in the 
regulation of transcription can simultaneously affect the alternative splicing of its 
mRNA [1-9]. It therefore follows that genetic variation that modifies the 
transcription rate of a gene can simultaneously affect the inclusion rate of its 
alternatively spliced downstream exons [10], leading to alterations in protein 
isoform production that are the hallmarks of a wide variety of diseases.  
 
The tauopathies are a heterogeneous group of neurodegenerative disorders that are 
characterised by intra-neuronal aggregates of the microtubule-associated protein, 
tau. Pathological examination of the aggregates has shown that the tightly 
controlled balance of the two major tau isoform groups (3R- and 4R-tau) is altered 
in the tauopathy brain. This provided the first indication that disturbances in 3R- 
and 4R-tau homeostasis could be associated with disease pathogenesis. Genetic 
studies have further confirmed the link between tau dysfunction and the 
tauopathies, in the first instance by identifying a number of highly penetrant 
dominant mutations in the gene encoding tau (MAPT) that cause familial 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTLD-17). 
It is the discovery, however, that common variation in MAPT – in the absence of 
pathogenic mutations – can influence an individual’s risk of developing a 
tauopathy that has opened up new avenues in the search for a molecular link 
between the genetic and pathological findings. 
 
The strongest association of common MAPT variation is with the 4R tauopathy, 
progressive supranuclear palsy (PSP). The key polymorphism – denoted rs242557 
– that drives the association of MAPT with PSP lies within a highly conserved 
region located approximately 47kb downstream to the MAPT core promoter (exon 
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0), yet upstream to the first coding exon. Studies have shown that this region has 
the potential to exert influence on MAPT transcription and that the two alleles of 
this highly associated polymorphism differentially alter the extent of this 
influence [11, 12]. When added to the neuropathological changes in tau isoform 
expression observed in the tauopathy brain, these findings indicate that MAPT is a 
likely candidate for the exhibition of co-regulation of transcription and alternative 
splicing.  
 
This project describes an investigation into the molecular mechanism linking the 
MAPT association with the tau isoform dysregulation characteristic of PSP. The 
design, construction and in vitro investigation of minigenes representing common 
MAPT variants will be presented in detail and will demonstrate that promoter 
identity plays an important role in the regulation of the alternative splicing of 
MAPT exons, exerting influence over the delicate balance of 3R- and 4R-tau 
expression. The specific role of the rs242557 polymorphism in MAPT 
transcription and splicing will also be investigated and the two alleles of the 
polymorphism shown to differentially influence these two molecular processes, 
providing a plausible mechanism linking the two phenomena known to be 
associated with PSP – a common genetic variant in the MAPT promoter and 
detrimental changes to tau isoform production. 
 
Many of the findings described here are currently being written up for publication. 
 
1.2 The regulation of mammalian gene expression 
 
1.2.1 Genetic elements in the regulation of expression 
Mammalian gene expression is a multi-layered process involving a series of 
highly regulated and inter-related steps. The correct functioning of these processes 
is dependent upon precise signals situated at specific locations throughout the 
gene. Most mammalian protein-coding genes can be split into three major 
sections: the 5’ intronic region lying upstream to the first coding exon, the coding 
region and the 3’ intronic region lying downstream to the final STOP codon. Each 
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section contains signalling motifs relating to different, though inter-related stages 
of gene expression.  
 
The 5’ intronic region contains the core promoter, often around exon 0, which 
forms the principal site at which transcription is initiated. Numerous cis-acting 
regulatory domains located within this region regulate transcription rate by 
enhancing or repressing core promoter activity. 
 
The protein-coding exons are relatively short (on average around 150 nucleotides) 
and are separated by long stretches of non-coding sequence – called introns – that 
are removed from mRNA transcripts in a process called splicing. Splicing brings 
the exons into alignment for translation into protein and regulates the differential 
inclusion of certain exons in a developmental and/or tissue-specific manner. Thus, 
a single pre-mRNA transcript can be spliced in numerous different ways to 
produce a heterogeneous population of mature mRNAs. Current estimates suggest 
that over 90% of mammalian genes are alternatively spliced [13]. 
 
The 3’ intronic region (3’UTR) has important roles in the further processing, 
transport and stability of the mRNA transcript, containing signal sequences for 
polyadenylation, cellular localisation and degradation [14]. Well-characterised 
localisation signals are particularly important in neuronal cells due to their unique 
morphology, with axons extending out over particularly long distances from the 
cell body and nucleus. The correct sub-cellular localisation of mRNA transcripts 
is vital for maintaining the polarity of neurons, which in turn is vital for neuronal 
function. 
 
1.2.2 The machineries involved in gene expression 
 
1.2.2.1 Overview 
Gene expression begins in the nucleus with transcription, where an RNA 
intermediate is synthesised from the genomic DNA template. During 
transcription, the nascent transcript undergoes a series of processing steps that 
result in the addition of a 5’ cap, the removal of introns and the cleavage and 
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polyadenylation of the 3’ end. The mature mRNA transcript is then released from 
the transcription machinery and transported into the cytoplasm where it is 
translated into protein. This whole process is precisely regulated and undergoes 
surveillance, with incorrectly processed or mutant transcripts identified and 
subject to degradation or nonsense-mediated decay (NMD). Although each 
reaction is catalysed by 
different machineries, there 
are physical and functional 
interactions between them 
(figure 1.1). 
 
 
Figure 1.1 The complex and 
inter-related steps involved in 
mammalian gene expression.  
Taken unchanged from 
Maniatis and Read (2002) [2]. 
 
 
1.2.2.2  Transcription 
Messenger RNA (mRNA) is a vital component of the gene expression process, 
forming an intermediate between the DNA template and its expressed protein 
product. Precursor mRNA (pre-mRNA) is synthesised from the DNA template by 
transcription, one of the most highly regulated cellular processes. Transcription is 
catalysed by a DNA-dependent RNA polymerase, of which there are three distinct 
types in eukaryotic cells, each with a specific function [15]:  
 RNA polymerase I (Pol I) transcribes ribosomal RNA precursors that 
eventually form the primary site of protein synthesis in the cell  
 RNA polymerase II (Pol II) is the major RNA polymerase that transcribes 
mRNA from protein-coding genes 
 RNA polymerase III (Pol III) primarily transcribes transfer RNA, a 
necessary component of the machinery that translates the mature mRNA 
into protein  
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Of particular importance in the expression of protein-coding genes is the carboxy-
terminal domain (CTD) of Pol II. The CTD is not only vital for transcription, but 
supports the recruitment and regulation of the independent machineries 
responsible for the capping, splicing and polyadenylation of pre-mRNA 
transcripts [16, 17]. The mammalian CTD consists of 52 tandem repeats of a 
heptapeptide motif: YSPTSPS. Dynamic phosphorylation and dephosphorylation 
of specific residues within the motif is vital to CTD function, providing signals to 
the processing machineries regarding the progress of the transcription complex 
and regulating the recruitment of specific processing factors to the nascent 
transcript [18, 19]. Thus, the exact pattern of CTD post-translational modification 
is referred to as ‘the CTD code’ and changes as Pol II moves through the different 
stages of transcription (figure 1.2) [20-22].    
 
Figure 1.2 The ‘CTD code of phosphorylation.  
The five stages of transcription (A-E) are initiated by the ‘CTD code’ of 
phosphorylation and each stage is associated with different processing factors. A 
detailed description is given below. Taken unchanged from Montes et al (2012) [4]. 
 
Transcription can be split into five separate stages (A-E), each involving specific 
modifications to the CTD of Pol II which leads to its interaction with the various 
processing machineries [4]. A summary of the different phosphorylation states of 
Pol II throughout transcription is given in figure 1.2, which is described below: 
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A. Hypophosphorylated Pol II (IIa) associates with transcription factors 
(denoted TFIID, B, E, F and H) to from the pre-initiation complex (PIC) at 
the gene promoter [23, 24]. 
  
B. Transcription is initiated following the phosphorylation of the serine 
residues at positions 5 (represented in red; figure 1.2) and 7 (green) of the 
CTD heptapeptide motif. This is catalysed by the kinase CDK7, which 
forms part of the transcription factor TFIIH. When the nascent transcript is 
approximately 20-40 nucleotides in length, the TFII initiation factors 
dissociate from the CTD, disbanding the PIC [19]. Serine-5 
phosphorylation also signals the recruitment of the 5’ capping machinery 
(pink oval) [22, 25, 26], with the addition of the cap preventing immediate 
degradation of the nascent transcript. A net reduction in serine-5 
phosphorylation releases the capping machinery. This is followed by the 
CDK9- and CDK12/13-catalysed phosphorylation of serine-2 (blue), 
which converts Pol II into its hyperphosphorylated form (IIo) and signals 
the switch into the elongation phase of transcription [19, 22].  
 
C. During elongation, hyperphosphorylated Pol II associates with specific 
elongation factors such as P-TEFb and TAT-SF1 [2, 27]. These factors 
recruit the splicing machinery (orange oval) and initiate intron removal, a 
more detailed description of which is given in sections 1.2.2.2 and 1.2.2.3.  
 
D. As the transcription machinery moves towards the 3’ end of the gene, the 
serine-5 residues are dephosphorylated by Ser5 phosphatase and this 
initiates the recruitment of polyadenylation factors (blue square). One such 
factor, CstF, plays an important role in the final stages of transcription, 
facilitating 3’ cleavage and polyadenylation, transcription termination and 
transcript release. Throughout elongation, the activity of CstF is inhibited 
by its association with elongation factor PC4. As the transcription 
machinery nears the 3’ end of the gene, PC4 releases CstF, allowing it to 
become functional [2, 28]. 
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E. Final dephosphorylation of serine-2 residues by Ser2 phosphatase results 
in dissociation of the transcription machinery for re-initiation or recycling. 
Mutant pre-mRNAs, such as those incorrectly spliced, fail to release 
normally from the transcription machinery and instead accumulate at the 
site of transcription where they are targeted for degradation [29]. 
 
1.2.2.3 Splicing 
Splicing, the process by which introns are removed from the pre-mRNA 
transcript, requires the formation of a spliceosome – a large complex comprising 
five core small ribonucleoprotein particles (snRNPs) denoted U1, U2, U4, U5 and 
U6 along with up to 200 other proteins [30]. The spliceosome components are 
recruited in a highly regulated, unidirectional order [31, 32] to specific 
recognition sequences at the 5’ and 3’ ends of the intron (the 5’ and 3’ splice sites 
or SS). The 5’ SS defines the boundary between the upstream exon and the start of 
the intron and is usually signalled by a ‘GU’ dinucleotide motif. The 3’ SS defines 
the boundary between the intron and the downstream exon and most commonly 
comprises an ‘AG’ dinucleotide motif. Two additional 3’ intronic motifs are 
required for intron excision: the branch point sequence (BPS) consisting of a 
single ‘A’ nucleotide, and a polypyrimidine (Py) tract [4, 33, 34]. 
 
Spliceosome assembly requires the formation of a series of intermediate 
complexes in a four-step assembly process that results in the excision of the intron 
and the alignment of the upstream and downstream exons (figure 1.3A) [4]. The 
first complex is denoted complex ‘E’ (the commitment complex) and is formed by 
the binding of the U1 snRNP to the 5’ GU dinucleotide signal and the co-
operative binding of the SF1 and U2AF splicing factors to the BPS, the Py tract 
and the 3’ AG motif [33, 34]. In the presence of ATP, the U2 snRNP binds to the 
BPS, forming the pre-spliceosomal complex ‘A’ [35]. A tri-snRNP comprising 
U5-U6-U4 binds to both the U1 and U2 proteins bound at the 5’SS and 3’SS 
respectively, forming a loop that brings the two exons into close proximity within 
complex ‘B’. Subsequent RNA-RNA and RNA-protein rearrangements results in 
the release of U4 and U1 and the formation of complex ‘C’ (the catalytic 
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complex). Two trans-esterification reactions result in the excision of the intron 
and the ligation of the upstream and downstream exons [31].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 The assembly of the mammalian spliceosome on pre-mRNA.  
A: Spliceosome assembly requires the formation of four complexes denoted E, A, B 
and C. Each complex comprises interactions between specific splicing factors 
including the major snRNPs; B: Intronic and exonic splicing enhancers (ISE/ESE) 
and silencers (ISS/ESS) regulate splice site competition in alternative splicing. Taken 
unchanged from Montes et al (2012) [4]. 
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1.2.2.4 Alternative splicing 
In an added layer of complexity, most mRNAs can potentially be spliced in a 
number of ways to produce different mature RNA messages coding for different 
isoforms of the same protein. This occurs via a process called alternative splicing, 
where specific exons are differentially removed from a subset of pre-mRNA 
transcripts. This is possible due to variation in the strength of splicing signals at 
intron-exon boundaries producing competition for spliceosome assembly. The 5’ 
GU motif, the 3’ AG motif, the BPS and the Py tract are all poorly conserved [36, 
37] and the 5’ and 3’ splicing signals are open to modulation by numerous cis-
acting silencer and enhancer sequences (figure 1.3B). These regulatory sequences 
can be either intronically or exonically located and are bound by specific RNA-
binding proteins that interact with the spliceosome to facilitate or inhibit exon 
recognition, thus increasing or decreasing the splicing signal respectively [38]. A 
strong splice site will out-compete a weaker splice site for spliceosome assembly, 
leading to the weaker site being skipped and the intervening exon excised along 
with the introns. The pattern of exon inclusion/exclusion is defined by the 
‘splicing code’, which is still not completely characterised and can vary among 
different tissues and at different stages of development [39-41]. 
 
1.2.3 Co-regulation of transcription and alternative splicing 
 
1.2.3.1 Overview 
It is now widely understood that transcription and splicing are not independent 
processes and are, in fact, physically and functionally coupled. In 1988 two 
groups used electron microscopy to show that intron removal occurred in nascent 
transcripts that were still tethered to their DNA templates [42, 43], a finding 
supported by further experiments comparing the splicing patterns of chromatin-
tethered nascent RNA with that of RNA released into the nucleoplasm post-
transcription [1]. Furthermore, fluorescent in-situ hybridisation of RNA molecules 
(RNA-FISH) using probes to distinguish between processed and unprocessed 
species demonstrated that intron removal occurs at or very close to the 
transcriptionally active template [44, 45]. 
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Co-transcriptional coupling plays a vital role in the regulation of splicing and 
alternative splicing patterns, either by recruiting regulatory splicing factors to the 
nascent pre-mRNA (‘physical’ coupling) or by modulating splice site competition 
through the alteration of transcription rate (‘kinetic’ coupling). These two models 
are distinct, but not mutually exclusive. 
 
1.2.3.2  Physical coupling 
Physical coupling describes a mechanism by which the transcription and splicing 
machineries physically interact with each other and with components of the 
chromatin template. RNA polymerase II (Pol II) plays a major role in this 
coupling. As described earlier, the CTD of Pol II is vital in overseeing the 
production of mature mRNA transcripts, driving each stage of maturation from 
transcription and processing to transcript release and transport (section 1.2.2.2). 
The ‘CTD code’ of dynamic post-translational modifications sends important 
signals to the spliceosome regarding the progress of the transcription complex, 
allowing for the tight regulation of splicing factor recruitment and release 
throughout transcription [20-22].  
 
A number of studies have confirmed that the CTD is required for pre-mRNA 
splicing, most notably by demonstrating that truncation of the CTD causes a 
significant reduction in splicing efficiency in vivo [17, 46, 47]. It has also been 
shown that Pol II-dependent initiation of transcription directly leads to the 
recruitment of splicing factors to the transcription site, but only when CTD 
integrity is maintained [48-50]. Further in vitro evidence has revealed that purified 
hypophosphorylated Pol II inhibits splicing during the initiation stage of 
transcription, whereas hyperphosphorylated Pol II activates splicing during the 
elongation phase [51].  
 
The CTD alone is not sufficient to fully regulate splicing and its role is believed to 
be dependent on a number of adaptor or ‘coupling’ factors that are thought to 
interact with transcription and splicing components to regulate the physical 
coupling of the two machineries [32, 52, 53]. This, however, does appear to be 
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achieved through interaction of the coupling factors with the hyperphosphorylated 
CTD [7]. One class of coupling factors are the family of serine/arginine-rich 
proteins (SR proteins), of which splicing regulation is one of their primary 
functions. SR proteins have been shown to physically interact with the CTD of 
Pol II [54, 55] and in vitro studies have revealed that these proteins can partially 
enhance the co-transcriptional splicing of pre-mRNA transcripts, a role thought to 
involve the recruitment of the early spliceosome to the nascent transcripts [52, 
56]. In addition, cell depletion of the essential splicing factor SC35 inhibited the 
recruitment of transcription elongation factor P-TEFb (section 1.2.2.2 C) to Pol II, 
reducing the level of CTD phosphorylation and impairing transcription elongation 
[57]. 
 
1.2.3.3 Kinetic coupling 
Following the initiation of transcription, Pol II pauses at a site approximately 30-
50 nucleotides downstream to the transcription start site. It is believed that this 
promoter-proximal pause – initially identified in the transcription of heatshock 
genes in Drosophila [58] – acts as a checkpoint to ensure only Pol II transcription 
complexes that have assembled correctly are allowed to enter the elongation phase 
of transcription [58-61]. This modulation of elongation rate has important 
implications for splicing events that are co-transcriptionally regulated. Following 
synthesis of a splice site, there is a certain period of time in which the spliceosome 
can functionally assemble on the site before it is subject to competition from a 
downstream splice site. Thus, a fast rate of elongation shortens the so-called 
‘window of opportunity’ for spliceosome assembly and increases the likelihood of 
two splice sites being presented to the splicing machinery at the same time. In this 
scenario a weak site loses out to a stronger splice site, thus linking elongation rate 
to alternative splicing (figure 1.4) [3, 7, 62]. 
 
The first evidence of kinetic coupling was reported in 1988, with the discovery 
that the rate of transcription could influence alternative splicing by altering the 
secondary structure of the mRNA transcript [63]. It had previously been shown 
that exons lying within stem loop structures were more likely to be skipped [63-
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66], due to the inability of the splicing machinery to access the splice sites. There 
is, however, a short period of time between transcription and RNA folding in 
which spliceosome assembly can take place. Thus, the slower the transcription 
rate (and the larger the stem loop), the more time the spliceosome has to assemble 
before sequestration of the 5’ splice site into the loop [63].  
Figure 1.4 The effect of transcription elongation rate on splice site recognition. 
Alternative exons are often preceded by a weak 3’ splice signal (SS) which is subject 
to competition from a strong downstream 3’SS when elongation rate is high. 
Constitutive exons are preceded by a strong 3’SS and therefore out-compete their 
downstream counterparts regardless of elongation rate. Taken unchanged from 
Kornblihtt et al (2004) [7]. 
 
The artificial introduction of pause sites downstream to weak alternative splice 
sites has been shown to significantly increase exon recognition and inclusion [67]. 
The best evidence supporting the kinetic model, however, was gained from the 
study of the fibronectin extra domain I (EDI). The 3’ splice site proximal to the 5’ 
end of the EDI exon is degenerate [7] and therefore requires a low rate of Pol II 
elongation for preferential recognition and inclusion in the mature RNA 
transcript. When mutant Pol II enzymes were used to drive cell transcription in 
vitro, mutants conferring low rates of transcription elicited greater inclusion of the 
EDI exon than those demonstrating higher processivity [68]. Furthermore, the C4 
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Pol II mutant [69] was later shown to be associated with changes in alternative 
splicing of the ultrabithorax gene in Drosophila, highlighting a potential 
physiological and developmental function for kinetic coupling [68]. 
 
More recent evidence has shown that both the 5’ and 3’ ends of genes contain 
transcriptional pause sites, with Pol II pausing correlated with the recruitment of 
processing factors [70]. Pol II has also been shown to accumulate within the body 
of genes and this is greatest within the terminal exon, approximately 250 
nucleotides upstream to the poly(A) site [71].  
 
There is also a role for coupling factors within the kinetic model, acting as 
checkpoint regulators and influencing the length of Pol II pausing [72]. Indeed, 
putative coupling factor TCERG1 is thought to promote exon skipping in the Bcl-
x gene by relieving Pol II pausing [5]. This may have important repercussions for 
disease, as insufficient time spent at pause sites increases the likelihood of the 
production of transcripts containing errors and/or being incorrectly processed.  
 
1.2.3.4 Local regulation of co-transcriptional splicing by chromatin 
The above sections have described global mechanisms for the co-regulation of 
transcription and alternative splicing. There are, however, tissue-, cell- and time-
specific differences in the regulation of co-transcriptional splicing and these are 
believed to be influenced by local chromatin modifications. The major component 
of chromatin is the nucleosome, which describes a short stretch of DNA 
(approximately 147bp) wrapped around an octamer core of four histones (H3, H4, 
H2A and H2B) [73]. The precise positioning of the nucleosomes along the gene 
and reversible modifications to the core histones – including methylation, 
acetylation and phosphorylation [74] – have been shown to modulate transcription 
rate [75]. Compacted chromatin is a repressor of transcription, limiting access of 
the transcription machinery to the DNA template. Acetylation of the N-terminal 
tails of certain histones causes the chromatin to ‘open’ and is therefore regarded as 
a positive marker of transcription. This is because histone acetylation neutralises 
the charge of the basic histone proteins, leading to relaxation of DNA-protein 
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interactions and allowing access to the transcription machinery. Acetylated 
histone tails additionally promote transcription by acting as binding platforms for 
transcription factors [76]. 
 
A more intriguing finding, however, concerns the role of chromatin in co-
transcriptional exon recognition and splicing. The average length of a mammalian 
exon is approximately 150 base pairs – strikingly similar to the length of DNA 
wrapped around each histone octamer [77]. Indeed, it has been shown that 
nucleosome positioning and histone modifications are closely correlated with the 
intron-exon structure of genes, with nucleosomes particularly concentrated around 
alternatively spliced exons (figure 1.5) [77, 78]. It is thought that nucleosomes act 
as ‘speed bumps’ and therefore an increase in accumulation causes a reduction in 
elongation rate; presumably followed by an increase in alternative exon 
recognition. Supporting evidence includes the finding that inhibition of the 
chromatin remodelling enzyme topoisomerase I by camptothecin results in Pol II 
pausing and increased splicing factor recruitment [79], and additional remodelling 
factors, SW1/SNF, have been shown to promote cluster exon inclusion in the 
CD44 gene [80].  
Figure 1.5 Nucleosome positioning and intron-exon structure. 
A: Transcription elongation is affected by changes in chromatin organisation 
brought about by chromatin remodelling factors (blue ovals), histone tail 
modifications (green star) and/or nucleosome position. A low elongation rate favours 
exon inclusion (yellow) whereas a high rate favours exclusion (red). B: Alternative 
splicing can also be influenced independently of transcription rate by the promotion 
of splicing factor recruitment through interactions between histone modifications 
(red star) and chromatin adaptors (orange/green shapes). Taken unchanged from 
Montes et al (2012) [4].   
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Histone modifying enzymes have also been shown to interact with components of 
the splicing machinery. The gene encoding the histone acetyltransferase (HAT) 
subunit of Gcn5 – a component of the transcription co-activating complex 
STAGA, which loosens chromatin and facilitates pre-initiation complex (PIC) 
formation – was found to share genetic interactions with the genes of two U2 
snRNP-associated proteins Msl1 and Lea1. In fact it was shown that Gcn5 HAT 
activity was required for the co-transcriptional recruitment of U2 snRNP and its 
downstream interactors to the splicing branch point [76]. 
 
The ‘histone code’ refers to the specific pattern of post-translational histone 
modifications and provides important information required for the regulation of 
gene expression [81-83]. Such modifications play an active role in the coupling of 
transcription and alternative splicing and there is a growing body of evidence in 
support of this hypothesis. As described above, histone acetylation is required for 
the assembly of the spliceosome and recent studies have shown that deacetylase 
inhibitors, which prevent the reversal of histone acetylation, significantly alter the 
alternative splicing pattern of both reporter and endogenous genes [84, 85]. 
Acetylation, however, is not the only method of histone modification that 
influences splicing. Phosphorylation of histone H3 triggers the release of the SR 
protein coupling factor from chromatin during the cell cycle [86], whereas histone 
H3 tri-methylation has been shown to enhance the recruitment of splicing 
components [87]. In fact, enrichment of certain histone modifications at the 
intron-exon boundaries is thought to play an active role in exon recognition, with 
accumulation of histone 4 and histone 2B lysine methylation marking the 5’ end 
and histone 3 tri-methylation marking the 3’ end of exons [88, 89].  
 
Thus, the histone code has an important role to play in the regulation of 
alternative splicing, with changes to histone methylation shown to influence the 
rate of alternative exon inclusion. In 2000, Carstens and colleagues studied 
histone modifications of the FGFR2 gene and found that differences in the 
methylation pattern of histone 3 determined the differential inclusion of exons IIIb 
and IIIc. Tri-methylation of lysine residue 36 and mono-methylation of lysine 4 
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were enriched when exon IIIc was included, however, lysine 27 methylation and 
lysine 4 tri-methylation was correlated with the preferential inclusion of exon IIIb 
[90, 91].  
 
Histone modifications, however, are unlikely to act alone and may function in 
conjunction with other factors to regulate splicing. Genome-wide association 
studies have shown that the transcriptional repressor and chromatin insulator 
CTCF binds downstream to alternative exons, in direct correlation with Pol II 
accumulation [92]. This suggests that insulation of chromatin – which prevents its 
conversion into an open structure – affects alternative splicing by modulating 
transcription elongation rate. An example of this is given by the CD45 gene, 
where the specific histone methylation pattern that inhibits exon 5 inclusion is in 
complete opposition to the CTCF methylation pattern that promotes exon 5 
inclusion [4]. As histone methylation patterns have been shown to fluctuate during 
development, this may provide a mechanism for the tissue-specific regulation of 
alternative splicing events through the differential recruitment of the CTCF 
chromatin modifier. 
 
Thus, histone modifications have a role to play in both the physical and kinetic 
models of transcriptional coupling, with careful regulation of the conversion 
between closed and open chromatin conformations conferred by the histone 
modification code [93, 94] shown to affect both splicing factor recruitment and 
Pol II elongation rate.  
 
1.2.3.5 The role of the promoter in alternative splicing regulation 
The above sections describe the strong evidence supporting the coupling of the 
transcription machinery with the independent processing machineries, providing 
plausible cellular mechanisms for the co-transcriptional regulation of alternative 
splicing. There is another aspect to this regulation, however, which acts at the 
DNA level and is of particular relevance to the role of MAPT in PSP. 
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In 1997, Cramer and colleagues used the fibronectin gene to demonstrate that 
differences in promoter structure can influence alternative splicing patterns [10]. 
They created a number of constructs in which expression of the fibronectin gene 
(FN) was driven by different promoter elements in vitro. The FN gene contains 
the alternative exon EDI, the splicing of which changes during development and 
varies between cell types. The EDI exon contains a splicing enhancer, which 
increases the recognition of its sub-optimal upstream 3’ splice site. When 
expression was driven by the α-1 globin promoter, the ratio of EDI+/EDI- was 
low, with exclusion favoured. When this promoter was replaced by the CMV 
promoter, EDI inclusion significantly increased (figure 1.6, left-hand lane). To 
ensure that differences in transcription start site did not influence alternative 
splicing, expression was driven by two 
variants of the FN proximal promoter, 
with one mutated to increase 
transcriptional activity. Both FN variants 
demonstrated significantly increased EDI 
inclusion compared to the α-1 globin 
promoter, however, the mutant promoter 
exhibited a 2.7-fold increase in EDI+/EDI- 
ratio compared to its wildtype counterpart 
(figure 1.6, right-hand lane) [10].  
 
Figure 1.6 Fibronectin (FN) EDI exon inclusion with different promoters.  
EDI+/EDI- ratio determined by reverse-transcription PCR (RT-PCR), Southern 
blot and Northern blot. α-1gb = α-1 globin promoter; CMV = cytomegalovirus 
promoter; wt = wildtype fibronectin promoter; mut = mutated fibronectin 
promoter. Taken unchanged from Cramer et al (1997) [10]. 
 
This, for the first time, highlighted the importance of promoter structure in the 
regulation of alternative splicing. In fact, only five single nucleotide mutations in 
a 220bp promoter element were sufficient to significantly alter the EDI splicing 
pattern. Perhaps a more intriguing finding of this study was that up-regulation of 
transcription from each promoter type, leading to an increase in the overall 
abundance of mRNA transcripts, did not affect EDI splicing ratio. This suggests 
that the strength of the promoter is not relevant to the regulation of alternative 
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splicing in this gene; instead it is the nature of the promoter and thus the physical 
interactions with the processing machineries that regulates expression. 
 
Further evidence supporting the role of promoter specificity in mRNA processing 
was gained following the creation of chimaeric constructs in which genes 
normally transcribed by Pol II were put under the control of promoters usually 
expressed by Pol III. In vitro analysis in mouse and kidney cells revealed that Pol 
III-synthesised mRNA was not subject to splicing, with transcripts still containing 
their introns despite the presence of consensus 5’ and 3’ splicing signals. Neither 
were transcripts polyadenylated, even though native 3’ cleavage and poly(A) 
motifs were present [95]. 
 
Together, the evidence presented here for a co-transcriptional mechanism of 
mRNA splicing add layers of complexity to the study of gene expression in 
disease, as genetic variants found to differentially affect one process are likely to 
indirectly – or directly – affect numerous other processing pathways. This project 
aims to link together the transcription and splicing processes in the regulation of 
MAPT expression in an attempt to find a plausible mechanism that could form the 
pathway between a common MAPT variant and altered tau isoform expression in 
PSP.  
 
1.3 The tauopathies 
  
1.3.1 Overview 
The tauopathies are a group of neurodegenerative diseases that are characterised 
neuropathologically by brain lesions comprising insoluble aggregates of tau 
protein. Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), 
corticobasal degeneration (CBD) and Pick’s disease (PiD) are just a few examples 
of tauopathies, although significant clinical and pathological differences exist 
between them. The hallmark pathological feature linking these diseases is the 
abnormal intracellular accumulation of hyperphosphorylated tau and subsequent 
neuronal loss [96-98]. The specific factors that trigger tau aggregation remain 
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largely unknown. There is, however, now overwhelming evidence that common 
variation in the gene encoding tau (MAPT) can significantly influence disease 
risk, with a particularly strong effect observed for PSP [99-104].  
 
1.3.2 Progressive supranuclear palsy (PSP) 
PSP is a progressive neurodegenerative movement disorder, mainly sporadic, 
which commonly presents as atypical parkinsonism followed by dementia [105]. 
Diagnosed clinically as Richardson’s syndrome (PSP-RS), classical symptoms 
include parkinsonism, supranuclear gaze palsy, postural instability with 
unexplained falls early in the disease course, and cognitive impairment [106, 107]. 
PSP is, however, a heterogeneous disorder and clinical variants of the PSP 
phenotype include PSP-parkinsonism (PSP-P), in which bradykinesia and 
dystonia are characteristic, PSP-pure akinesia with gait freezing (PSP-PAGF), and 
PSP-corticobasal syndrome (PSP-CBS) and PSP-non-fluent aphasia (PSP-NFA), 
where cortical degeneration is more pronounced [106-108]. Although rare (with a 
prevalence of 3.1-6.5 per 100,000 people [109]), PSP is the second most common 
cause of parkinsonism after Parkinson’s disease [11, 110]. The average age at 
onset is 63 years with a disease duration of around six to seven years before 
eventual death [111]. At present disease-modifying options are limited and 
treatment instead focuses on the management of individual symptoms [107, 112].  
 
PSP is classed as a primary tauopathy as tau is the only abnormal protein observed 
in the brain post mortem. This separates PSP from secondary tauopathies, such as 
Alzheimer’s disease (AD) where tau pathology is accompanied by amyloid 
plaques [106]. Characteristic neuropathological features of PSP include 
neurofibrillary tangle (NFT) formation and neuronal loss in the basal ganglia, 
diencephalon and brainstem, with the substantia nigra, the globus pallidus and 
subthalamic nucleus most affected [105]. The NFTs in PSP are composed of 
straight filaments of hyperphosphorylated tau and are distinct from the paired 
helical filaments forming the NFTs of AD. Tau-positive inclusions in 
oligodendrocytes and tufted astrocytes are also typical of PSP [105].  
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PSP is sporadic in most cases, although approximately seven percent of patients 
have a positive family history of parkinsonism or dementia, consistent with an 
autosomal dominant pattern of inheritance [106]. The G303V mutation, located 
within exon 10 of the tau gene, has been associated with PSP in one large family 
and demonstrates autosomal dominant inheritance among the affected members. 
Several features atypical of PSP, however, including a much lower age of onset 
(average 40.3 years), has raised questions over the reliability of the PSP diagnosis 
in this study [106]. One member of a PSP family with autosomal dominant PSP 
was found to have a novel L284R mutation [113], and a recent study of MAPT in 
Asian PSP families identified four mutations in six individuals associated with 
sporadic early onset PSP, including one de novo mutation. The latter study 
reported that the MAPT mutations were only found in patients exhibiting 
abnormal eye movements – additional to supranuclear gaze palsy and not 
characteristic of sporadic PSP – and may suggest co-morbidity with an 
underlying, secondary disorder [114]. The above mutations occur extremely rarely 
in PSP and most sporadic cases do not have an identifiable genetic cause. There 
are, however, common genetic factors that can increase an individual’s risk of 
developing PSP. 
 
It is thought that a combination of environmental and hereditary factors modulate 
an individual’s risk of developing PSP [108]. Repetitive brain trauma has been 
shown to cause the progressive tauopathy, dementia pugilistica [115], and a recent 
genome-wide association study (GWAS) has identified a number of genetic risk 
factors for PSP (see section 1.6.2.3) [104]. Demographic factors including gender, 
ethnicity, geographical location and occupation do not appear to influence PSP 
risk [104], though an association with low education levels has been reported 
[116]. The biggest risk factor for PSP, however, is located within the gene 
encoding the cellular protein, tau. 
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1.4 Microtubule-associated protein, tau 
 
1.4.1 Function 
Tau belongs to the family of microtubule-associated proteins (MAPs) that bind to 
tubulin and regulate its assembly into microtubules – the dynamic cytoskeletal 
tracks that are vital for cell transport, shape and polarity [117-119]. MAP 
expression is specific to cell type and individual MAPs can function either to 
stabilise or destabilise microtubules [120]. Activity is regulated by 
phosphorylation, with the addition of phosphate groups to specific protein 
residues resulting in its detachment from tubulin and subsequent microtubule de-
stabilisation. 
 
Tau is a developmentally regulated protein of around 50-65kD in size [68, 121]. It 
is most abundant in the neurons of the central nervous system (CNS) where it is 
enriched in axons [121-123]. It is also expressed to a much lesser extent in glia, 
astrocyctes and oligodendrocytes and in certain tissues outside the CNS [120, 
124]. Its primary role is to promote and stabilise the polymerisation of tubulin into 
microtubules [125, 126], which is of particular importance in the long axonal 
extensions that are a unique feature of neurons.  
 
The tau protein has been shown to function synergistically with the other major 
MAP family member, MAP1B. Double knock-out mice (MAPT-/-, MAP1B-/-) 
demonstrate severe defects in microtubule extension and neuronal migration, a 
phenotype that is much less severe in single knockout mice (MAPT+/+, MAP1B-
/-) [127]. Indeed, tau knockout mice (MAPT-/-) do not exhibit major brain defects, 
suggesting the presence of a compensatory mechanism in which MAPT function is 
fulfilled by other MAPs [128]. 
 
1.4.2 Tau isoform expression 
In the adult brain, the tau protein has six major isoforms, each characterised by the 
presence or absence of two N-terminal inserts and one of the four C-terminal 
microtubule binding repeat domains. The inclusion of the extra C-terminal 
1 Introduction 
36 
 
binding repeat domain produces 4R-tau isoforms, with 3R-tau the result of its 
specific exclusion. It has been shown that 4R-tau has a three-fold stronger binding 
affinity for microtubules than 3R-tau [124] and is also more fibrillogenic [129, 
130], though all six tau isoforms are capable of forming pathological aggregates 
[131].  
 
Tau isoform expression changes throughout development, with the foetal brain 
containing only the shortest 3R isoform as a result of the constitutive exclusion of 
the two N-terminal inserts and the C-terminal binding domain. In the healthy adult 
brain, all six tau isoforms are expressed, albeit in slightly different abundances. In 
2003, Takuma and colleagues compared the tau 
isoform pattern in brain tissue from a 20-week 
human embryo and a 70-year old adult (figure 1.7) 
[132]. Using the pool-2 antibody against all six 
isoforms (figure 1.7A), foetal tau was shown to 
comprise only the shortest 0N3R isoform, as 
expected. The elderly brain, also as expected, 
contained all six isoforms, with the 1N3R and 
1N4R isoforms most abundant (3
rd
 and 4
th
 bands 
from the top, right hand lane). The 2N isoforms 
(2N3R and 2N4R) were the least abundant and 
were barely visible on the Western blot (top two 
bands, right hand lane). The absence of 1N, 2N 
and 4R isoforms in foetal tau was confirmed using 
antibodies specific for these inserts (figure 1.7, 
panels B and C).  
Figure 1.7 Tau isoform expression in the human brain 
Western blots of tau protein extracted from human brain tissue of a 20-week 
embryo (E20w) and a 70-year old adult (70yr). A: Reactivity of global tau antibody, 
pool-2; B: Reactivity of three antibodies specifically targeting 0N (top), 1N (middle) 
and 2N (bottom) isoforms; C: Reactivity of an antibody specifically targeting 4R 
isoforms. Adapted from Takuma et al (2003) [132]. 
 
This suggests that the tau isoforms have differing functions, with alterations in 
isoform production made to meet the changing tau-microtubule interactions 
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required throughout development [124].  A recent study of isoform expression in 
the adult brain has confirmed that ~50% of total tau comprises 1N isoforms, with 
~40% representing 0N isoforms and just 10% containing both exons 2 and 3 (2N).  
This isoform pattern was consistent in most of the brain regions (figure 1.8; top 
panel), with the only significant change comprising a reduction in 0N3R in the 
cerebellum. The ratio of 4R- and 3R-tau expression was approximately equal in 
all brain regions, as expected [133]. This research, however, has been followed by 
a similar study, which reported a significant increase in 4R-tau expression in the 
occipital lobe and globus pallidus compared to four other regions (figure 1.8; 
bottom panel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Expression of the tau isoforms in different adult brain regions.  
Top: Expression of all six isoform (C-H) measured in cerebellum (CRBL); frontal 
cortex (FCTX); occipital cortex (OCTX); putamen (PUTM) and white matter 
(WHMT). Taken from Trabzuni et al (2012 [133]. 
Bottom: The ratio of 4R-tau/total tau isoforms by H1 (blue) and H2 (green) 
haplotypes measured in frontal cortex (FC), temporal cortex (TC), Pons, cerebellum 
(CB), occipital lobe (OL) and globus pallidus (GP). Taken from Majounie et al 
(2012)[134]. 
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1.4.3 Tau phosphorylation 
The biological activity of tau is regulated by its phosphorylation state [135]. The 
addition of phosphate groups to specific residues generally reduces the binding 
affinity of tau for tubulin and thus microtubules formed in the presence of 
phosphorylated tau (p-tau) are usually less stable than those formed with the 
unphosphorylated species [117, 129]. As with isoform production, the 
phosphorylation of tau is dynamic and developmentally regulated. Foetal tau is 
highly phosphorylated, significantly more so than the tau of the adult brain [136]. 
In the healthy adult brain, the level of tau phosphorylation is thought to decrease 
with age, though some evidence suggests this finding may be the result of de-
phosphorylation post mortem [137]. In the tauopathy brain, however, the tau 
species forming the neurofibrillary tangles (NFTs) is hyperphosphorylated and 
resembles the phosphorylation pattern found in the foetal brain. [138].  
 
The longest isoform of tau has 79 potential phosphorylation sites at serine and 
threonine residues, with phosphorylation confirmed to occur at over 50 of them 
[139-142]. Five tyrosine residues have also been shown to be phosphorylated 
[142]. These residues are phosphorylated by a number of different kinases, many 
of which have been implicated in neurodegenerative disease. These include the 
major serine-theronine kinases: glycogen synthase kinase 3β (GSK-3β), cyclin-
dependent kinase 5 (cdk5), cyclic AMP-dependent protein kinase A (PKA), 
protein kinase N (PKN), microtubule affinity regulating kinase (MARK) and the 
mitogen-activated protein kinase (MAPK) and casein kinase 1 (CK1) families 
[129, 140, 142, 143]. Several tyrosine kinases have also been associated with tau 
pathology including Fyn, c-Abl and Syk [144-146]. The dual serine/threonine and 
tyrosine kinase, tau-tubulin kinase 1 (TTK1), has been implicated in Alzheimer’s 
disease [140].  
 
There is a large body of research concerned with the characterisation of tau 
phosphorylation and its role in neurodegeneration but as this is not directly 
relevant to this project it will not be discussed further here.   
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1.4.4 Tau aggregation 
Tau aggregation is thought to occur following a change in the conformation of tau 
monomers that leads to hydrophobic sections of the protein becoming exposed. 
This allows contact between monomers at these hydrophobic sites, resulting in 
their association into oligomers, and eventually filaments [131]. These filaments 
(NFTs) are a feature of normal ageing, but occur with much greater frequency in 
the tauopathy brain [124]. The heat-shock protein 70 (Hsp70) family are a group 
of molecular chaperones that work to prevent abnormal tau aggregation. They 
bind to the exposed hydrophobic regions of tau and assist in its refolding. Voss 
and colleagues have demonstrated that Hsp70 directly inhibits the aggregation of 
all six tau isoforms, without affecting normal microtubule formation. They also 
showed that Hsp70 was more effective at inhibiting 3R-tau than 4R-tau isoforms 
and that the 2N3R isoform was inhibited at a lower Hsp70 concentration than the 
other 3R isoforms, 0N3R and 1N3R. All three 4R isoforms displayed inhibition at 
similar Hsp70 concentrations. Heat shock proteins are up-regulated in response to 
cellular and environmental stresses and Hsp70 expression has been shown to be 
increased in AD [147, 148]. 
 
1.5 The MAPT gene 
 
1.5.1 Structure 
Tau is encoded by the MAPT gene which is 134kb in size and located on 
chromosome 17q21.1 [122]. It consists of 16 exons, with exons 4A, 6 and 8 
absent from most brain transcripts and exons -1 and 14 untranslated [149]. The 
alternative splicing of exons 2, 3 and 10 produces the six major isoforms of tau 
expressed in the adult brain (figure 1.9).  
 
Exon 4A is the largest of the tau exons and, along with exon 6, is included in the 
tau isoform preferentially expressed in the retina, spinal cord and peripheral 
nervous system where it is referred to as high molecular weight tau (or ‘big tau’) 
due to its large size (approximately 110 kDa). Big tau is observed in the brain, 
albeit at much lower levels and in a different regional pattern to that of the major 
alternatively spliced exons 2, 3 and 10 [150]. Exon 6 contains three potential 
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splice sites and brain-specific changes in exon 6 splicing have been implicated in 
myotonic dystrophy type 1 (DM1), along with more minor changes in exon 2 and 
exon 10 splicing [150-152]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 The structure of the MAPT gene and the six major tau isoforms.  
Exons 4A, 6 and 8 are transcribed in very low abundance in the brain. Exon -1 
constitutes the MAPT promoter region and is non-coding. Exon 14 constitutes the 
3’UTR. Exons 9-12 each encode one of four microtubule binding domains. Exons 2, 
3 and 10 are alternatively spliced giving rise to six isoforms which can be split into 
two groups based on the presence or absence of the binding domain encoded by exon 
10. 
 
1.5.2 Exons 2 and 3 
Exons 2 and 3 each encode 29 amino acid N-terminal inserts that form part of the 
protein’s acidic projection domain [153]. This domain is believed to interact with 
the plasma membrane and is also thought to regulate the spacing between 
microtubules, potentially acting as a polymer brush or spring to keep the 
microtubules apart. It has been suggested that failure of the polymer brush could 
lead to tau aggregation [154].  
 
The alternative splicing of exons 2 and 3 produce three N-terminal isoforms 
denoted 0N (2-/3-), 1N (2+/3-) and 2N (2+/3+). These exons demonstrate so-
called ‘incremental combinatorial’ splicing, which describes a situation where the 
downstream exon of an alternatively spliced pair is never present alone. This is a 
very rare occurrence and other reported instances include exons 7 and 8 of the 
amyloid precursor protein (APP) – the major pathological protein in AD – and the 
neuronal-specific N1 and N2 exons of the gene encoding the tyrosine-kinase Src. 
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This suggests that such splicing pairs have an important function in neuronal cells 
and that a shift in the balance of the expression of these exons may contribute to 
neurodegeneration.  
 
In 1995, Andreadis and colleagues created splicing constructs that placed MAPT 
exons 2 and 3 between insulin exons 2 and/or 3. In vitro expression was driven by 
the simian virus (SV) promoter. They demonstrated that exon 2 behaves as a 
constitutive exon as it was always present in expressed mRNA regardless of 
whether the surrounding exons were from the tau or insulin genes or whether the 
in vitro cell line was neuronal or non-neuronal. Exon 3 was inefficiently 
incorporated into the mRNA transcripts unless either the insulin splicing signals 
were modified or exon 2 was pre-spliced downstream to exon 3. Exon 3 inclusion 
was detected, however, when exon 2 was physically absent from the construct, 
though inclusion significantly increased when exon 2 was present. In this instance 
the in vivo expression pattern was recapitulated and ex2-/ex3+ was not detected 
[155]. 
 
Although most studies have focussed on the splicing of exon 10, the 
inclusion/exclusion rates of the N-terminal exons has been shown to be altered in 
the brains of individuals with certain variants of the MAPT gene and this will be 
discussed in more detail in section 1.7.3.  
 
1.5.3 Exon 10 
Exon 10 encodes one of four microtubule-binding domains located in the C-
terminal half of tau. Each domain is 31-32 amino acids in length and is encoded 
by one of four imperfect repeats constituting exons 9-12 [11]. Thus, inclusion of 
exon 10 produces tau protein isoforms with four microtubule-binding domains 
(4R-tau) and its exclusion produces isoforms with three (3R-tau). The two isoform 
groups appear to form distinct structures with complex intramolecular folding 
interactions, suggesting that they may have different functions [135]. This is 
consistent with the changes in tau isoform expression that occur during 
development (figure 1.6), with the exclusive expression of 0N3R in the foetal 
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brain suggesting that 3R-tau is important in neuronal plasticity [118].  
 
Another piece of the MAPT puzzle was presented by Chen and colleagues, who 
investigated the effect of exon 10 inclusion on the expression level of other genes.  
Whole genome expression profiling of SH-SY5Y neuroblastoma cells over-
expressing either 4R- or 3R-tau detected a decrease of transcripts involved in 
embryonic development when exon 10 was present, accompanied by a 
corresponding up-regulation of transcripts related to neurite outgrowth. The Wnt 
signalling pathway – which has been implicated in AD – was also shown to be 
differentially altered by the presence/absence of exon 10 [156]. 
 
Changes in exon 10 inclusion have been massively implicated in tauopathy 
pathogenesis and most of the MAPT mutations leading to FTDP-17 (section 1.6.1) 
are located in or around exon 10. The pathological consequences of changes to the 
rate of exon 10 inclusion are discussed below. 
 
1.5.4 Tau pathology 
The healthy adult brain has approximately equal amounts of 3R- and 4R-tau 
[153]; however in some tauopathy brains this ratio is disrupted with a 
predominance of one isoform group over the other. The different tauopathies are 
therefore classed according to the direction of the isoform ratio change, with PSP 
and CBD classed as 4R tauopathies due to their observed shift towards 4R-tau 
production. Conversely, Pick’s disease is a 3R tauopathy. Over-expression of 4R-
tau in transfected cell lines results in the displacement of 3R-tau from 
microtubules, indicating that a change in isoform regulation that favours 4R 
production is likely to impair both the properties of the microtubules and 
microtubule-dependent functions [122]. 
 
The splicing factor polypyrimidine tract-binding protein 2 (PTBP2) plays an 
important role in 3R-/4R-tau production, with knockdown in Neuro2a cells 
causing a significant reduction in 4R-tau levels and 4R:3R ratio. PTBP2 
expression is decreased following binding of the microRNA miR-132 to its 
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3’UTR. Interestingly, miR-132 expression was found to be reduced in the brains 
of PSP patients compared to controls [157]. 
 
Alzheimer’s disease (AD) – a secondary tauopathy – does not exhibit an overall 
shift in 3R/4R ratio. Recent evidence, however, suggests that tau isoform profiles 
in the hippocampal pyramidal neurons of AD brains are not homogeneous across 
the neuronal population and actually vary from one neuron to another. Double 
immunofluorolabelling of the 3R- and 4R-tau species has shown that each of the 
three tau isoform profiles (3R+/4R+, 3R+/4R- and 3R-/4R+) are present in the 
neuronal population and correlate with distinct neuronal morphologies. In line 
with previous observations [158-162], neurons exclusively expressing 4R-tau 
(3R-/4R+) resembled the so-called ‘pre-tangle’ stage, staining positively for 
diffuse cytoplasmic tau but without the neurofibrillary structures. Neurons 
exclusively expressing 3R-tau (3R+/4R-) had loosened, widely-spaced parallel 
fibres commonly termed ‘ghost tangles’. Neurons expressing both 3R- and 4R-tau 
(3R+/4R+) exhibited the tight fibrillary structures of typical NFTs [163].  
 
In PSP brains, cortical neurons displayed the 3R-/4R+ pre-tangle morphology, as 
expected. In the substantia nigra and midbrain, however, 3R-tau was detected in 
low abundance [164, 165], though double immunofluorolabelling showed it was 
only present alongside 4R-tau in NFTs (3R+/4R+) [163]. In CBD brains, 3R-tau 
reactivity was more widespread, including in a small number of structures in the 
cortex, but was still at much lower abundance than – and co-expressed with – 4R-
tau [165].  
 
These results together show that tau expression profiles differ not only between 
different regions of the brain and neuronal populations, but also between different 
tauopathies. It has been suggested that the 4R-selective cortical neurons in PSP 
and CBD may represent early tau deposition, with the superimposition of 3R-tau 
onto 4R-tau in nigral neurons indicating more advanced tau deposition. It would 
therefore follow that the presence of 3R-selective neurons in AD indicates further 
advancement of tau deposition and the absence of such neurons in PSP and CBD 
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may account for the lack of ghost tangles in these patients [163]. It is still unclear 
as to the exact contribution of each isoform to tau aggregation, though recent 
biochemical studies with synthetic tau have suggested that isoform recruitment to 
tau aggregates via a seeding model is dependent upon the initial composition of 
the seed. Pre-formed seeds of 3R-tau recruit both 3R and 4R isoforms to form 
larger aggregates; whereas aggregates seeded by 4R-tau exclusively recruit 4R 
isoforms [163]. 
 
These data provide an insight into the pathological consequences resulting from 
alterations to the inclusion rate of exon 10 in the tau protein. This project, 
however, focuses on elucidating the molecular mechanism behind these protein 
changes and to achieve this an understanding of the genetic complexities in and 
around the MAPT gene is required.   
 
1.6 The genetics of MAPT  
 
1.6.1  Genomic architecture 
The tau gene, MAPT, falls in a structurally complex region on the long arm of 
chromosome 17, where a stretch of complete linkage disequilibrium (LD) spans 
approximately 2Mb and encompasses several genes [97]. LD describes a state in 
which genetic variants at differing locations are inherited together more often than 
would be expected under normal random inheritance. This usually applies to 
variants located within close proximity to one another and therefore the large 
region of LD on chromosome 17 is a somewhat unusual phenomenon. This 
complexity stems from an ancient 900kb inversion of the MAPT region – believed 
to have originated in European Caucasians approximately 18 to 45 thousand years 
ago [166, 167] – which resulted in the evolution of two completely separate 
haplotype clades, denoted H1 and H2. These haplotypes span the length of the 
MAPT gene and beyond [11, 99, 168] and there is a complete absence of 
recombination between them, with H2 remaining invariant [168, 169]. This 
haplotype is the rarer of the two, with a frequency of up to 30% in Caucasians, 
and is almost completely absent in East Asian, Native American and African 
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populations [97]. The H1 haplotype, on the other hand, is prevalent in all 
populations and represents the ancestral sequence. There is a normal pattern of 
variation and recombination within the H1 clade and several sub-haplotypes exist 
[11, 169].  
 
As described earlier, mutations in MAPT have been shown to cause the tauopathy 
FTDP-17 [98, 170] and, in extremely rare cases, have been shown to cause a 
phenotype similar to that of PSP [105]. In 1999, Hasewaga and colleagues found 
that two FDTP-17-associated missense mutations located within exon 10 (N279K 
and S305N) affected tau function, not by altering the strength of the exon 10 
microtubule-binding domain, but by modifying its inclusion rate [171]. This 
indicated a role for RNA processing in neurodegeneration, with mutations that 
lead to disturbances in protein isoform homeostasis sufficient to cause 
neurodegenerative disease. Since then a number of exon 10 mutations have been 
identified and shown to alter the ratio of 3R-/4R-tau expression. The key 
mutations and their pathological consequences were summarised by Niblock and 
Gallo in a recent review [172]. 
 
Additionally, a recent study has linked the V363I mutation in exon 12 of MAPT 
with frontotemporal dementia, but only in one individual that also carried the A/A 
genotype of the rs9897526 progranulin polymorphism and demonstrated 
homozygosity for the methionine amino acid at codon 129 of the prion protein. 
Individuals from the same family that carried the V363I mutation but not the two 
additional genotypes did not develop FTD by the time of the study [173].  
 
These findings have confirmed that tau dysfunction plays an important role in 
neurodegenerative aetiology, whether directly or in combination with other 
disease modifying factors. In most cases, however, tauopathies are sporadic with 
no known causal mutations and genetic studies have instead focused on 
identifying polymorphisms that modify risk.  
 
1 Introduction 
46 
 
1.6.2 Common MAPT variation and PSP 
 
1.6.2.1 Early association studies 
The first published association of MAPT with PSP was of a dinucleotide repeat 
polymorphism in intron 9, the A0 allele of which was found to be over-
represented in PSP cases [102]. This allele is found on the H1 background and 
after further analysis the association was expanded to include the entire H1 
haplotype – an association that has been consistently replicated in Caucasian 
populations [99, 101, 104, 105, 174]. In addition, H2 was shown to be protective 
against PSP, perhaps explaining why this haplotype appears to be under positive 
selection in the Caucasian population [97]. Further associations of H1 were 
reported in CBD and AD populations and, surprisingly due to the lack of tau 
pathology, in several Parkinson’s disease (PD) studies [11, 175-180]. These will 
be discussed in more detail in section 1.6.2.4. Subsequent high density LD 
mapping identified a number of H1 variant haplotypes and lead to the refinement 
of the PSP association to H1C, one of the more common H1 sub-haplotypes [169, 
181, 182].  
 
1.6.2.2 The H1C haplotype and rs242557  
The H1C haplotype is tagged by the minor A-allele of a single nucleotide 
polymorphism (SNP) denoted rs242557. The frequency of this allele is around 30-
40% in Caucasian populations, which is slightly higher than the frequency of the 
H1C haplotype (23.5%) [181]. This is due to the presence of the A-allele on 
several of the minor MAPT haplotypes, though H1C is the only common 
haplotype to carry this allele. H1C is one of only three major MAPT haplotypes 
that have a frequency greater than 5% (H1B and H1C =23.5%; H2 =17.6%) [181].  
The A-allele of rs242557 appears to drive the association of H1C with PSP [11, 
104, 181-183], with effect sizes of 1.8 and 2.4 reported in UK and US Caucasian 
populations, respectively [181]. Thus, individuals carrying the A-allele are 
approximately twice as likely to develop PSP than those carrying the G-allele.  
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The rs242557 polymorphism is located in a highly conserved region of exon -1, 
approximately 47kb downstream to the MAPT core promoter and 20kb upstream 
to the first coding exon. It is predicted to fall in or near to a cis-acting 
transcription regulatory domain and this therefore suggests that the influence of 
this allele on PSP risk stems from modifications to the regulation of MAPT 
transcription. This will be discussed further in section 1.7. 
 
1.6.2.3 The PSP genome-wide association study   
In 2011, a genome-wide association study (GWAS) [104] added to growing 
evidence supporting the association of rs242557 with PSP risk. The study looked 
at over half a million SNPs in 1,114 pathologically confirmed PSP cases and 
compared them to 3,287 healthy controls (Stage 1) followed by replication with 
an additional 1,051 clinically diagnosed PSP cases (Stage 2). The most strongly 
associated region of the genome was 17q21.31 where, in Stage 1, 56 SNPs 
covering a 1Mb region reached the genome-wide significance threshold of 
p=5x10
-8
. This region contains the MAPT gene and the association was replicated 
in Stage 2. In the combined analysis the most strongly associated SNP in this 
region was rs8070723 (p=1.5x10
-118
), a proxy for the H1/H2 inversion. More in-
depth analysis of the region revealed that most of the associated SNPs mapped 
either directly or closely to the inversion itself. Therefore, as expected, most of the 
associated SNPs became non-significant when rs8070723 was used to control for 
inversion status. Some SNPs, however, did remain and of these rs242557 was the 
most strongly associated (p=8.5x10
-18
), with the A-allele conferring a 1.4-fold 
increase in PSP risk. This confirmed that rs242557 makes an important 
contribution to PSP risk that cannot solely be accounted for by the H1/H2 
inversion. In this, the most comprehensive study on the genetic risk factors of PSP 
completed to date, the H1 MAPT haplotype was shown to increase disease risk by 
5.5-fold, making the magnitude of its effect equivalent to that of the ɛ3/ɛ4 APOE 
genotype in AD. 
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Three other genes were shown to confer increased risk of PSP in the GWAS: 
MOBP, STX6 and EIF2AK3; though little progress has been made regarding their 
role in PSP risk.  
 
1.6.2.4 MAPT haplotypes in other neurodegenerative disorders 
In addition to its strong association with PSP, the rs242557-A allele has been 
associated with various other related neurodegenerative disorders including some 
outside of the tauopathy family. The strongest of these associations (outside PSP) 
is with corticobasal degeneration (CBD), a rare primary tauopathy that shares 
many similarities with PSP, including hallmark 4R-tau pathology [176, 181]. 
Accurate genetic studies of CBD are difficult due to the rarity of the disorder; 
however, one study calculated the effect size of the rs242557-A allele on CBD 
risk to be around 2.2 [181]. Further associations of rs242557-A have been 
reported with Guam amyotrophic lateral sclerosis (ALS-G), parkinsonism 
dementia complex (PDC-G) and dementia (GD), though the effect sizes are much 
smaller (1.03-1.5) despite each displaying significant tau pathology [184].  
 
Investigation of the role of the MAPT haplotypes in Alzheimer’s disease (AD) has 
produced mixed results, though many positive findings have been reported. An 
initial report found an association of the H1C haplotype with AD in two series of 
cases in which age of onset was >65 years [177] and this was independently 
replicated [185]. A recent finding has also associated the G-allele and G/G 
genotype of rs242557 with an increased risk of late-onset AD in a large Han 
Chinese population, with moderate effect sizes of 1.16 and 1.13, respectively 
[186]. This is puzzling as the A-allele is generally believed to be the risk allele of 
rs242557 and therefore this G-allele association may result from the absence of 
the H2 chromosome in Asian populations.  
 
Several studies have failed to replicate these rs242557 associations with AD [187-
189]. One study did, however, find a significant association of the combined 
genetic effects of the rs242557 A/A genotype and the T/T genotype of the 
rs2071746 polymorphism in the heme oxygenase-1 (HO-1) gene. In fact the 
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combined effects of these two genotypes conferred a 6.5-fold increase in AD risk 
for individuals who carry these markers compared to those who do not (p=0.037) 
[190]. The HO-1 gene is involved in the oxidative stress pathway, an intriguing 
finding as increases in oxidative stress have previously been shown to play a 
fundamental role in the aggregation of tau into NFTs and in AD risk [191, 192]. 
Another association study of the MAPT haplotypes in AD reported that the H1 
haplotype was associated with reduced NFT pathology [193]. This was a 
surprising finding and is the opposite of what would be expected based on the 
disease associations of the haplotype identified to date. If this finding is replicated 
in independent studies, it would have important implications for our 
understanding of disease mechanisms in AD. 
 
There is no robust evidence supporting an association of the H1C haplotype with 
sporadic Parkinson’s disease (PD) [194, 195], although one association of 
rs242557 was detected in a Finish population [196]. The H1 haplotype, however, 
has been repeatedly shown to be over-represented in PD cases [189, 194-199]. 
The association of the MAPT gene with PD is surprising, as these patients do not 
exhibit tau pathology. The repeated association of the H1 haplotype strongly 
supports a role for this haplotype in PD; however, the apparent inability to refine 
this association to one of the H1 sub-haplotypes may indicate that the effect on 
PD risk arises as a consequence of the H1/H2 inversion affecting MAPT 
expression, rather than from cis-acting variation from within the gene [175, 183].  
 
Interestingly, the H1 haplotype does not appear to be associated with 
frontotemporal dementia (FTD) [200], suggesting that common variation within 
MAPT does not affect risk and therefore the contribution of this gene to FTD 
arises solely from pathogenic mutations. 
 
1.6.2.5 The effect of rs242557 on CSF tau levels 
An increasing number of studies have investigated the effect of the rs242557 
alleles on tau protein levels in the cerebrospinal fluid (CSF) of patients with 
neurodegenerative disease, again with mixed results. Two studies found an 
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association between rs242557-A and an increase in CSF tau in AD patients, 
though one added the caveat that this association was dependent on both the 
presence of dementia and low CSF β-amyloid levels [201]. This study also 
reported an association of the A-allele with increased phospho-tau levels. The 
second study provided significant evidence for the role of rs242557 in tau 
expression by demonstrating that the association of the A-allele was gene-dosage 
dependent, with an increasing copy number directly leading to proportional 
increases in CSF tau levels. Furthermore, sliding window analysis of the region 
pinpointed the causal variant to lie at or proximal to the rs242557 polymorphism 
[185]. This provides direct evidence that the increase in disease risk is actually 
conferred by rs242557-A, rather than a variant in LD with the polymorphism. 
That being said, one study did not find an association between this polymorphism 
and CSF tau in AD but did report associations with other polymorphisms from the 
MAPT gene [202].  
 
The rs242557 polymorphism has also been shown to increase tau levels in CSF in 
both PSP/CBD and PD cases, though this role was played by opposing alleles 
depending on the disease. In PSP and CBD the A-allele, as expected, conferred 
the increase, whereas the G-allele increased CSF tau levels of PD patients [203]. 
The reasons for these differential associations are unclear but the fact that they 
were detected in the same study using the same methods suggests that they might 
be real. Replications of these findings have yet to be reported, however. 
 
The above sections have provided overwhelming genetic evidence supporting a 
significant role for the rs242557 polymorphism in disease risk. The location of the 
polymorphism within a highly conserved region of the MAPT intron -1 suggests 
that risk may by conferred through changes to MAPT expression. Focus, therefore, 
has shifted to elucidating the functional mechanism behind the rs242557 
association with neurodegenerative disease.  
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1.7 MAPT gene expression 
 
1.7.1 In vivo allele-specific expression studies 
In vivo studies of MAPT haplotypes – primarily allele-specific expression studies 
from post mortem brain tissue – have produced mixed results, with some 
reporting an increase in MAPT transcription from H1 chromosomes compared to 
H2 chromosomes [12, 204] and others not finding any difference at all [111]. One 
group [12] reported a further increase in expression specifically for H1C 
chromosomes compared to non-H1C chromosomes, though this has yet to be 
replicated [111, 204]. An interesting finding from these studies is that, where an 
increase in expression from H1 or H1C was observed, it was accompanied by an 
increase in the number of exon 10+ (i.e. 4R-tau) transcripts relative to exon 10- 
(i.e. 3R-tau) transcripts [12, 204]. This suggests that the H1/H1C association may 
actually exert its effect though two molecular processes – MAPT transcription and 
alternative splicing – and that these processes may be linked. 
 
A recent eGWAS study – a genome-wide association study of quantitative trait 
loci (QTLs) – provided the most comprehensive assessment to date of the effect 
of genetic variation on gene expression in the brain [183]. The authors analysed 
gene expression in tissue samples from the cerebellum and temporal cortex of 400 
autopsied patients with PSP, PD or AD. Overall, an enrichment of cis-acting 
SNPs (SNPs that alter expression of the gene in which they are located) was 
detected amongst disease-associated genes. Decreased MAPT expression was 
associated with a lower risk of AD, PD and PSP, with 78% of identified SNPs 
demonstrating concordant effect sizes between the cerebellum and temporal 
cortex. The rs242557-A allele conferred a significant increase in both PSP risk 
and MAPT expression (cerebellum: p=9.78x10
-3
 to 8.8x10
-13
; temporal cortex: 
p=1.1x10
-8
), with the H2-defining rs3070723 minor allele conferring reductions in 
PSP risk and MAPT expression. This provides further confirmation of the 
detrimental and protective roles of the H1C and H2 haplotypes, respectively. The 
H2 polymorphism was also associated with reduced MAPT levels in PD, 
supporting a potential role for the H1/H2 dichotomy in this disease. 
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Two other genes previously identified in the PSP GWAS study (section 1.6.2.3) 
were also found to confer allelic differences in transcript expression levels in the 
brains of PSP patients. A reduction in SLCO1A2 and an increase in MOBP 
expression were both associated with an increase in PSP risk. Thus, variation 
within the MAPT, SLCO1A2 and MOBP genes has been shown to be associated 
with both an increase in PSP risk and changes in the expression of their respective 
genes in the PSP brain. This suggests that changes in brain expression patterns are 
an important component of PSP aetiology. 
 
1.7.2 In vitro luciferase reporter gene studies 
Several studies have examined the effect of rs242557 and the H1C haplotype on 
in vitro MAPT expression, using varying methodologies and with varying results. 
Two groups [11, 12], including our’s, conducted in vitro luciferase reporter gene 
assays to study the allelic effect of rs242557 on the MAPT core promoter, with 
interesting results that differed on two major points. Firstly, Myers and colleagues 
(our group) [12] reported that the A-allele of rs242557 conferred significantly 
higher MAPT transcription than the G-allele, with the greatest difference observed 
between the A-allele on the H1 promoter background and the G-allele on H2. 
However, Rademakers et al [11] found that the G-allele of rs242557 conferred 
higher expression from the H1 promoter than the A-allele – in direct disagreement 
with the Myers study. Secondly, the results of the Myers study showed that when 
either allele of rs242557 was assayed in conjunction with the MAPT H1/H2 core 
promoters, the general level of transcription was lower relative to the core 
promoter alone. This suggests that the overall effect of the polymorphism is to 
repress transcription, with the G-allele conferring stronger repression and thus 
lower transcription compared to the A-allele. In contrast, the Rademakers study 
demonstrated that each allele of the polymorphism increased expression from both 
the MAPT H1 and SV40 control promoters, suggesting that rs242557 acts to 
enhance transcription and that the G-allele is a stronger enhancer than the A-
allele. 
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These opposing results may potentially be explained by differences in 
methodology, with one major difference being that the Rademakers study cloned 
the region containing rs242557 upstream to the core promoter – altering the 
natural downstream position of the polymorphism which was used in the Myers 
study. It may, therefore, be possible that there are positional effects at play, 
though this phenomenon at present does not appear to have been investigated any 
further. Where both studies are in agreement, however, is that the region 
containing the rs242557 polymorphism appears to affect transcription from the 
MAPT core promoter and that there are allelic differences in this effect, providing 
support to the hypothesis that H1C and rs242557 have an important role to play in 
the regulation of MAPT transcription and that this may underlie the association 
with PSP. 
 
1.7.3 N-terminal exons 2 and 3 
In 2008, Caffrey and colleagues [205] conducted an allele-specific expression 
study to determine whether the H1 and H2 MAPT haplotypes confer differing 
rates of exon 2 and 3 inclusion. They took frontal cortex (FC) and globus pallidus 
(GP) tissue from the brains of 14 H1/H2 individuals and quantified the rate of 
exon inclusion from each chromosome. They found that H2 chromosomes 
expressed two-fold more 2N transcripts (2+3+) than H1 chromosomes in both the 
FC (H2:H1 ratio = 1.96; p<0.0001) and GP (H2:H1 ratio = 1.99; p<0.0001) 
tissues. There were no other transcripts in the FC or GP that demonstrated a 
biologically relevant allelic difference – that is a 20% or 1.2-fold difference – 
suggesting a role for exon 3 in the protection against PSP conferred by H2 
carriers.  
 
Interestingly, this increase in 2N isoform production from H2 chromosomes was 
observed independently of disease status. In addition, there was no significant 
difference in N-terminal transcripts between H1 chromosomes carrying the A-
allele of rs242557 (the H1C sub-haplotype) and those carrying the G-allele. This 
suggests that the splicing of the N-terminal exons may be regulated separately 
from exon 10 and its role in PSP risk – if any – may thus be smaller.  
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In support of these results, a recent study analysed the largest collection of human 
brain samples in the most comprehensive study to date on the regional expression, 
splicing and regulation of MAPT [133]. Significant regional variation in MAPT 
mRNA expression and splicing was detected, with a 1.5-fold difference between 
the highest tau-expressing region (the frontal cortex) and the lowest (the white 
matter; p=5.7x10
-49
). A relative reduction in exon 2 expression was detected in 
white matter compared to other brain regions and this corresponds to a reduction 
in 2N and 1N transcripts specifically in this region; the reason for which is 
unclear.  
 
Overall, the regional tau mRNA expression levels were found to be highly 
correlated with total tau expression levels, though the relationship between 
mRNA and protein isoforms was not determined. At the genetic level, H2 
chromosomes were found 
to express a significantly 
higher proportion of exon 
3-containing transcripts in 
all brain regions and this 
was most significant in the 
frontal cortex (figure 1.10). 
No increase in exon 2 
inclusion was observed in 
any brain region. 
 
 
Figure 1.10 Expression of exon 3 from tau haplotypes in different brain regions.  
Each brain region is presented in a different colour, with the H2 haplotype 
represented by the C/C genotype in the first lane. aveALL is the average across 10 
brain regions: frontal cortex (FCTX); temporal cortex (TCTX); occipital cortex 
(OCTX); hippocampus (HIPP); thalamus (THAL); cerebellum (CRBL); substantia 
nigra (SNIG); putamen (PUTM); medulla (MEDU) and white matter (WHMT). 
Taken from Trabzuni et al (2012) [133]. 
 
1.8 Minigene studies of MAPT alternative splicing 
Over the past decade, the in vitro expression of artificial MAPT constructs has 
provided important information regarding the expression of tau at the molecular 
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level. The value of these tools lies in both their small size and their focused 
investigation of small sections of DNA outside of their normal genomic context. It 
would generally be preferable – and more biologically relevant – to study the 
expression of the full-length MAPT gene but its large size makes this extremely 
difficult. Expression studies using smaller constructs do have some advantages, 
however, particularly for comparing the function of small sections of DNA, or 
variants of the same section, in the absence of variables such as differential cis- 
and trans-acting factors and the promoter driving expression. Indeed, most of the 
published MAPT constructs were created for investigation of splicing regulation 
of the alternative MAPT exons.  
 
In 1993, unique cosmid constructs were created for exon trapping experiments 
designed to assess the inclusion rates of MAPT exons 3-9. This technique 
involved the insertion of the exon into the intronic section of a heterologous exon-
intron-exon genomic fragment to see whether it was spliced in or out. This study 
was the first to demonstrate that MAPT exon 3 is spliced out in the absence of 
exon 2 [206]. Most MAPT constructs, however, were created for the purpose of 
assessing the effect on exon 10 splicing of the recently identified MAPT mutations 
shown to cause FTDP-17. These simple constructs typically comprised exon 9, 10 
and 11 surrounded by small intronic segments with or without the mutation under 
investigation and transcription was driven by a control promoter such as the 
cytomegalovirus (CMV) or simian virus (SV) promoters [207-209].  
 
Focus then shifted to the identification of splicing regulators that modulate the 
alternative splicing of exons 2, 3, 10 and even exon 6. These regulators may act in 
cis and were identified using a series of deletion constructs in which the size of 
the intronic segments around the alternative exon was gradually reduced until the 
sequence containing the regulator was excluded and the splicing pattern changed 
[210-214]. Trans-acting regulators were typically identified by over-expressing or 
knocking down the predicted protein factor in the presence of the MAPT construct 
and determining the effect on splicing pattern of the exon under investigation 
[211, 215-218]. An exon 10 minigene was also used to demonstrate that mRNA 
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secondary structure can affect the inclusion rate of this exon in mature transcripts 
[219].  
 
Minigene constructs have also been created for the purpose of investigating the 
biochemistry of wildtype tau. Published studies include the use of tetracycline-
inducible expression vectors to create cellular models expressing different tau 
isoforms that recapitulate the filamentous tau aggregation indicative of the 
tauopathy brain [220] and the use of 3R- and 4R- tau minigenes to determine a 
20-fold increase in the binding of Fyn tyrosine kinase to 3R isoforms [221]. One 
study also used minigenes to assess the effect of exon 2 and 3 inclusion on the 
function of exon 6-containing N-terminal tau isoforms in microtubule assembly 
[222].  
 
A final use of the MAPT construct involved the trialling of potential corrective 
treatments against aberrant exon 10 splicing. These included so-called trans-
splicing, in which key sections of a MAPT minigene containing sequences 
responsible for aberrant splicing were replaced by the wildtype version [223, 
224]. The use of antisense oligonucleotides to reduce the abundance of exon 10-
containing transcripts was also trialled using a MAPT exon 10 minigene [225]. 
 
Each of the above splicing constructs contain only the short section of the MAPT 
gene under investigation and transcription was always driven by an exogenous 
control promoter to remove confounding by promoter-exon or promoter-intron 
interactions. One study, however, described the design of a minigene that 
expressed all six tau isoforms under the control of the MAPT core promoter 
element. All of the tau exons expressed in the brain were included and alternative 
exons 2, 3 and 10 were surrounded by 150-450bp of intronic sequence (figure 
1.11). The authors used the minigene to create transgenic mouse models and 
showed that the tau N279K mutation confers increased exon 10 inclusion and 
recapitulates FTDP-17 pathology [226]. 
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This minigene was the first of its kind created and its design potentially allows the 
study of mRNA isoform expression at the mRNA and protein levels. It was used 
here to study a specific MAPT mutation, but the basic design could be adapted to 
study the effect of common MAPT variation on the splicing of exons 2, 3 and 10. 
This minigene blueprint could therefore provide an ideal tool for the study of the 
role of the rs242557 polymorphism in the co-transcriptional regulation of MAPT 
alternative splicing.   
 
Figure 1.11 A minigene to study alternative splicing at exons 2, 3 and 10 when 
expression is driven by the endogenous MAPT promoter.  
Adapted from Dawson et al (2007)[226]. 
 
1.9 Project aims 
This project investigated the molecular processes linking a common MAPT 
variant shown to be associated with increased PSP risk with the hallmark 
pathology observed in the brains of patients with this disease. Efforts were 
particularly focused on finding evidence of a co-transcriptional mechanism of 
alternative splicing regulation, which could potentially explain the connection 
between the rs242557 risk polymorphism located within the MAPT promoter 
region and aberrant downstream splicing events.  
 
To this end, minigenes for the expression of all six tau isoforms and representing 
common MAPT variants were constructed and studied in vitro in human 
neuroblastoma cell lines. Investigations were conducted based on the hypothesis 
that the risk allele of the rs242557 polymorphism alters the physical interactions 
between the transcription and splicing machineries – either through 
conformational changes to the mRNA transcript or binding site abolition – which 
concurrently leads to an increase in transcription and a shift towards production of 
the more fibrillogenic exon 10-containing 4R-tau.  
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Accompanying this, two luciferase reporter gene studies aimed to identify the 
regions of the MAPT 5’ and 3’UTRs, and the genetic variants within them, that 
are critical for controlling mRNA transcription and stability respectively. This 
project is the first of its kind to study the co-transcriptional splicing of MAPT 
exons in order to elucidate the role of common promoter variation in 
neurodegenerative disease.  
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2 Methods and Materials  
2.1 Methods 
 
2.1.1 DNA/RNA sample extraction from tissue 
DNA and RNA samples used in all cloning and genetic studies were previously 
extracted from flash frozen brain tissue by Proteinase K/phenol-choloroform 
extraction.  
 
 
2.1.2 DNA/RNA quantification 
The quantity and quality of DNA and RNA samples was determined by UV 
spectrophotometer absorption. The concentration (in ng/μl) of the sample is given 
by the absorption value at 260nm multiplied by 50 (the constant for DNA) or 40 
(the constant for RNA). Sample purity is determined by the ratio of absorption at 
260nm and 280nm, with a ratio greater than 1.8 and 2.0 indicating a pure DNA 
and RNA sample respectively. 
 
2.1.3 Polymerase chain reaction  
 
2.1.3.1 Standard PCR 
 
The polymerase chain reaction (PCR) is a widely used in vitro method for 
amplifying defined sections of DNA from a known template sequence. It is a 
versatile and robust technique that is used in a wide variety of molecular biology 
protocols, including those for genotyping, mutation screening, DNA sequencing, 
cloning and gene expression quantifications. Genomic DNA is the most 
commonly used template, but sequences can also be amplified from plasmid DNA 
and cDNA reverse transcribed from RNA (section 2.1.3.2). The technique 
requires the design of two short oligonucleotides that anneal to the denatured 
DNA template at either end of the target region, creating short stretches of double-
stranded sequence that act as primers for new DNA synthesis. Over repeated 
cycles of priming and synthesis, the concentration of the target sequence is 
exponentially and selectively amplified. 
2 Materials and Methods 
60 
 
The specificity of the PCR product is determined by the design of the two 
oligonucleotide primers (approximately 15-25 nucleotides in length) that anneal 
exclusively to the target region. DNA synthesis occurs when the template and 
primers are subject to a series of heating and cooling steps, called thermal cycling. 
An initial heating step denatures the DNA, allowing the primers to access the 
single-stranded template. On cooling, the primers anneal to their complementary 
sequences at the ends of the target region. A final heating step results in primer 
extension and the synthesis of new DNA that is complementary and specific to the 
target sequence. DNA is synthesised by a heat stable DNA polymerase enzyme in 
the presence of a high concentration of the four deoxynucleoside triphosphate 
DNA components (dATP, dCTP, dGTP and dTTP). Repeated cycles of DNA 
synthesis – with the newly synthesised strands incorporated into the pool of 
template strands after each cycle – results in an exponential increase in the amount 
of product, with 25 cycles producing approximately 10
5
 copies of the target 
sequence. 
 
All primers were designed using the freely available PerlPrimer programme 
(http://perlprimer.sourceforge.net/). The AccuPrime™ Taq DNA High Fidelity 
Polymerase kit was used for all PCR reactions unless otherwise stated. Typical 
25μl reactions comprised 2.5μl of Buffer I (10x), 0.2-0.4μM of forward and 
reverse primers, 2.5 units of Taq DNA polymerase and either 25ng of genomic 
DNA or 5-10ng of plasmid DNA. Additional magnesium chloride (MgCl2; 1-
2mM) and/or DMSO (5-10%) were added as necessary, depending on the 
structure of the primers and target sequence. 
 
Thermal cycling was conducted using a Techne TC-Plus Thermal Cycler. After an 
initial four minute denaturation step at 94°C, 30-35 cycles of the following were 
completed: 30 seconds of denaturation at 94°C, 30 seconds of primer annealing at 
a temperature optimum for the primer pair (usually in the region of 55-65°C) and 
an extension step at 68°C of duration suitable to the size of the target sequence 
(45 seconds per 1 kb of target sequence). A final extension step at 68°C for 7 
minutes completed the protocol. 
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2.1.3.2 Reverse transcription PCR 
A variation of the PCR method, called reverse transcription PCR (or RT-PCR), 
was used for the selective amplification of RNA targets. This method involves an 
initial step in which the RNA template is converted into cDNA before specific 
target amplification by standard PCR. This conversion is facilitated by the reverse 
transcriptase enzyme, an RNA-dependent DNA polymerase that binds to primed 
RNA transcripts and synthesises complementary DNA copies (cDNA). Upon 
enzymatic degradation of the original RNA template, the reverse transcriptase acts 
as a DNA-dependent DNA polymerase and converts the single-stranded cDNA 
into double-stranded cDNA products. 
 
There are three methods by which reverse transcription is achieved and these vary 
in the choice of oligonucleotide primer. The first method uses a primer that binds 
specifically to the target gene and therefore selectively amplifies transcripts 
expressed from this gene. The other two methods provide a means of reverse 
transcribing total RNA and therefore the pool of cDNA produced can be used for 
multiple analyses. With these methods priming is achieved with either random 
hexamers or oligo(dT) primers. Random hexamers are a pool of short 
oligonucleotides, each comprising a six nucleotide sequence generated at random. 
The short length and low specificity of the random hexamers result in the 
universal priming of total RNA transcripts. Oligo(dT) primers comprise stretches 
of 20 T-residues that exclusively bind to the poly-A tail of mature mRNA 
transcripts. With this method only processed transcripts that have been 
polyadenylated are reverse transcribed, with unprocessed nascent transcripts or 
those without a poly-A tail omitted from the reaction. All of the RT-PCR products 
in this project were produced using oligo(dT) priming of RNA samples extracted 
from transfected neuroblastoma cells. 
 
A typical RT-PCR was conducted as follows: 1μg of total RNA was mixed with 
1μl of oligo(dT) primers (50μM) and 1μl of dNTP mix (10μM) and adjusted to a 
total reaction volume of 10μl with RNase-free sterile water. The mixture was 
heated to 65°C for five minutes and immediately cooled on ice. A further 10μl of 
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a mastermix containing 2μl of RT buffer (10x), 4μl of MgCl2 (25mM), 2μl of 
DTT (0.1M), 1μl of RNase OUT enzyme (40U/μl) and 1μl of SuperScript III 
reverse transcriptase (200U/μl) was added to the reaction mixture. The final 20μl 
reaction volume was heated to 42°C for 10 minutes, 53°C for 50 minutes, 85°C 
for 5 minutes and 10°C for 10 minutes; during which reverse transcription 
occurred. A volume of 1μl of E.coli RNase H (2U/μl) was added to the reverse 
transcribed cDNA to digest away the original RNA template. A final incubation at 
37°C for 20 minutes completed the protocol. A volume of 1μl of the cDNA was 
used as the template in a standard PCR to amplify the target sequence.    
 
2.1.3.3 Agarose gel electrophoresis 
Agarose gel electrophoresis provides a method of visualising DNA products. It is 
most commonly used to check the size, specificity and quantity of products 
produced by PCR but can also be used to separate fragments of different size, 
such as a cloned target DNA fragment from its plasmid vector following 
digestion. Samples are loaded onto an agarose gel containing a nucleic acid stain 
that is visible under UV light. The application of an electrical current causes the 
DNA to migrate through the gel matrix and consequently become coated in the 
nucleic acid stain. Larger fragments migrate more slowly than smaller fragments, 
thus allowing size to be determined by comparing migration with that of a DNA 
ladder of known size. 
 
To make a 1% w/vol gel, 1g of agarose powder was melted in 100ml of TAE 
buffer (1x). For visualisation of the DNA fragments under UV light, 5μl of the 
SYBRgreen nucleic acid stain, SafeView, was mixed into the melted agarose. The 
gel was cast around plastic combs to create wells for sample loading. Once set, the 
combs were removed and the gels were placed in the electrophoresis tank. TAE 
buffer (1x) was poured into the tank until the gel was completely submerged. 
DNA samples were mixed with 5x loading dye and loaded onto the gel alongside 
an appropriate size marker, either Hyperladder I or, for smaller products, 
Hyperladder IV. In the presence of an electrical current (typically 80-110 mV), 
the negatively charged DNA migrated through the gel towards the positive 
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electrode at a rate dependent on size. The duration of electrophoresis varied 
depending on the size and percentage of the gel, but typically lasted between 30 
minutes and 1 hour. Bands were visualised under UV light using the MiniBis Pro 
(DNR Bio-Imaging Systems) and size was determined by comparison against the 
DNA ladder. 
 
2.1.3.4 Polyacrylamide gel electrophoresis 
Polyacrylamide gel electrophoresis (PAGE) is a variant of agarose gel 
electrophoresis and is used here to resolve PCR products of particularly small 
and/or similar size. PAGE is traditionally used in Western blotting to resolve 
protein samples or in Sanger sequencing protocols to separate DNA products that 
differ by a single nucleotide; neither of which are possible by agarose gel 
electrophoresis. PAGE is more sensitive than its agarose counterpart and allows 
the visualisation and quantification of products of very low concentration. The 
matrix of the polyacrylamide gel is much smaller than that of the agarose gel, with 
pore size determined by the relative concentrations of acrylamide and bis-
acrylamide included in each gel. Another feature of PAGE is the vertical 
orientation of the electrophoresis tank, with the positive electrode located at the 
bottom of the tank. 
 
Pre-cast polyacrylamide gels (in their plastic cases) were placed vertically in the 
electrophoresis tank with the sample wells at the top. The chamber was filled with 
TBE running buffer (1x) until the gel was completely submerged. PCR products 
were mixed with 5x loading dye and loaded into the vertical wells alongside a size 
marker. Following the application of an electrical current to the top and bottom of 
the gel, the DNA migrated downwards towards the positive electrode at the 
bottom of the tank. The length of the electrophoresis typically lasted between 50 
minutes and 1 hour at 200v. The gel was then removed from its case and carefully 
placed into a small plastic container using clean forceps to prevent the gel from 
tearing. The gel was submerged in a 1:5000 dilution of Syto
®
 60 Nucleic Acid 
Stain in double distilled water and placed, in the dark, on a plate shaker at a low 
number of revolutions. After 30 minutes, the gel was twice washed with double 
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distilled water, returning each time to the plate shaker for 5 minutes. The DNA 
bands were visualised using the Odyssey Infrared Imaging System (LI-COR), 
with DNA bands stained with Styo
®
 60 visible using the 700nm channel. 
 
2.1.4 Molecular biology: cloning 
 
2.1.4.1 Purification of PCR products for use in cloning 
PCR products amplified for ligation into plasmid vectors were purified using the 
QIAquick PCR Purification kit to remove leftover primers, nucleic acids and the 
DNA polymerase enzyme. The purification was conducted according to the 
manufacturer’s instructions. 
 
2.1.4.2 Purification of DNA products by agarose gel electrophoresis 
In instances where two PCR products were produced in one reaction, or to 
separate cloned inserts from their plasmid vector, the DNA products were 
resolved by agarose gel electrophoresis to separate them by size. The desired 
band(s) were excised from the gel using a sterile scalpel and the DNA extracted 
and purified using the QIAquick Gel Extraction kit. This was done according to 
the manufacturer’s protocol. 
 
2.1.4.3 DNA ligation into plasmid vectors: pGEM-T Easy vector 
Each target DNA fragment generated by PCR was routinely cloned into the 
pGEM-T Easy plasmid vector to produce a homogenous population for use in 
further cloning steps. All PCR products synthesised by the Taq DNA polymerase 
enzyme contain a single base (adenosine) overhang at the 5’ end and this 
complements the 5’ thymidine overhang of the linearised pGEM-T Easy vector, 
allowing the direct ligation of PCR products into the vector without the need for 
restriction digestion.  
 
The ligation was facilitated by the T4 DNA ligase enzyme and typical 10μl 
reactions comprised: 50ng of linearised vector, 1-6μl of purified PCR product (at 
a 2-6 molar ratio), 1μl of T4 DNA ligase buffer (10x), 1μl of ATP (100mM) and 2 
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units of T4 DNA ligase (2-3U/μl). Ligation reactions were incubated at 4°C 
overnight before propagation in E.coli and plasmid harvest and purification 
(section 2.1.4.5). The amount of PCR insert included in each ligation reaction was 
calculated using the following formula:  
 
ng insert (purified PCR product) = ng vector x kb insert   x insert:vector ratio 
           kb vector 
 
2.1.4.4 DNA ligation into plasmid vectors: Expression vectors 
To create the expression constructs for in vitro analysis, the cloned DNA inserts 
were removed from the pGEM-T Easy vector by restriction enzyme digestion and 
purified by agarose gel electrophoresis. The purified fragment was then ligated 
into a similarly digested and purified expression vector (in this study pGL4.10 
[luc2] or pMIR-REPORT) using the protocol described in section 2.1.4.3.  
 
2.1.4.5 Propagation of plasmid constructs in E.coli 
After ligation, the vector-insert constructs were transformed into E.coli cells. 
Bacterial cells take up plasmid DNA when subjected to a high temperature – or 
‘heat shocked’. Heating the cells to 42°C for a short interval (30 seconds to 1 
minute) temporarily makes the bacterial cell wall porous, allowing the plasmid 
construct to pass through. Immediate cooling on ice closes the cell wall, trapping 
the plasmid inside where it is replicated as part of the cell division process. Thus, 
a large yield of homogenous plasmid construct is produced following 
transformation of one rapidly-dividing bacterial cell. Successfully transformed 
colonies are primarily identified by continued growth in the presence of a specific 
antibiotic, the resistance to which is conferred solely by the transformed plasmid 
construct.  
 
Typical transformations comprised 50μl-100μl of High Efficiency JM109 or 
HB101 E.coli cells (thawed slowly on ice) and 5μl-10μl of ligation reaction (i.e. 
10% of the cell volume). The transformation mix was incubated on ice for 15 
minutes, "heat shocked" for 30 seconds in a 42°C water bath and returned to the 
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ice for 10 minutes. After the addition of 500μl or 1ml of L-broth (for low or high 
copy number vectors respectively), the cells were incubated at 37°C for 1 hour 
with horizontal agitation at 150rpm. Gentle centrifugation at 3,000 x g formed a 
cell pellet which, after removal of the supernatant, was re-suspended in 100μl of 
L-broth. The full cell suspension was spread on an LB-agar plate containing an 
appropriate selection antibiotic and incubated overnight at 37°C.  
 
Single, well-defined colonies were individually picked using aseptic technique 
and cultured in 3ml of L-broth containing the selection antibiotic. Following 
overnight incubation at 37°C with vigorous horizontal agitation at 250rpm, the 
cultured cells were harvested by centrifugation at 17,000 x g. The cloned plasmid 
DNA was extracted from the bacterial cells using the QIAquick Spin Miniprep kit 
according to the manufacturer’s protocol.  
 
2.1.4.6 Blue-white screening of pGEM-T Easy clones 
As described previously, pGEM-T Easy is a linearised vector that provides a 
single T-overhang for ligation with the target PCR products. The downside to the 
convenience of this method is that during ligation the T4 DNA ligase enzyme also 
catalyses the re-circularisation of empty pGEM-T Easy vectors. Thus, an 
additional method of selection is required to separate colonies that have been 
transformed with vector/insert constructs from those that have taken up re-
circularised empty vectors.  
 
The pGEM-T Easy vector contains the lacZ gene and therefore expresses the β-
galactosidase enzyme. This enzyme, in the presence of IPTG, metabolises X-Gal 
into a blue product. Upon successful ligation of the insert into the pGEM-T easy 
vector, the lacZ gene is disrupted, β-galactosidase is not produced and the X-Gal 
remains unmetabolised. Thus, the addition of IPTG (0.1mM) and X-Gal 
(20μg/ml) to the LB-agar plate, allows the identification of colonies transformed 
with successfully ligated constructs by virtue of their white – not blue – colour.  
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2.1.4.7 Digestion by restriction enzyme 
Restriction enzyme digestion was routinely used to remove DNA fragments from 
purified plasmid vectors following cloning. Restriction endonucleases are 
enzymes that cut double-stranded DNA molecules at a specific recognition 
sequence called a restriction site. Most restriction sites are 6bp in length and are 
palindromic, meaning they can be read in either direction. These sites occur 
naturally throughout the genome but can be artificially added onto the ends of 
target DNA sequences by PCR with primers containing the specific recognition 
sequence on their 5’ ends. Digestion with a restriction enzyme can produce a 
blunt-ended fragment, but more commonly results in so-called ‘sticky ends’, in 
which a 5’ or 3’ single-stranded overhang is produced. Thus, two DNA fragments 
can be joined together using the complementary overhangs produced following 
digestion of each fragment with the same restriction enzyme. This technique is 
used extensively in cloning protocols, as the addition of two different sites onto 
the end of a target sequence facilitates its directional insertion into an expression 
vector containing the same two restriction sites.  
 
In this project, restriction enzyme digestion was used for two main purposes: 
firstly to extract the cloned target DNA from the pGEM-T Easy vector for re-
ligation with an expression vector; and secondly to simply confirm the presence of 
the target DNA insert in a cloned plasmid. For the former purpose, which required 
a high yield of extracted insert, digestions were conducted on a large scale (50μl) 
and comprised: 5-10μg of purified plasmid DNA, 5μl of bovine serum albumin 
(BSA; 10x), 5μl of enzyme-appropriate buffer (10x) and 50 units of restriction 
enzyme. The reactions were incubated overnight at a temperature suitable for 
optimum enzyme activity, which in most cases was 37°C. For the latter purpose – 
to simply confirm the presence of the target DNA – the reaction was scaled down 
to a total volume of 10μl and incubated for 1-2 hours. 
 
In some instances a double digestion was required; for example when a directional 
insertion dictated that the DNA fragment was digested by two different restriction 
enzymes. If the two enzymes were sufficiently active in the same digestion buffer, 
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each was added in half the amount stated above (i.e. the total concentration of 
enzyme in the double digestion did not exceed that in the single digestion). If the 
two enzymes were not compatible with the same buffer, two single digestions 
were conducted with a purification step in between to remove all traces of the first 
enzyme and buffer. This purification was conducted using the QIAquick PCR 
Purification kit according to the manufacturer’s protocol. 
 
2.1.4.8 DNA sequencing 
Final confirmation of cloned plasmid constructs was achieved by sequencing. All 
DNA sequencing was outsourced to a service provider, Source BioScience Ltd. 
 
2.1.5 Cell Culture 
 
2.1.5.1 Neuroblastoma cell culture 
Two human neuroblastoma cell lines, SK-N-F1 and SH-SY5Y, were obtained 
from the European Collection of Cell Cultures (ECACC). SK-N-F1 cells were 
derived from the bone marrow metastasis of a male patient with neuroblastoma. 
These undifferentiated and slow-growing cells have a substrate-adherent, 
epithelial-like phenotype and an aneuploid karyotype. They secrete neuronal 
peptides in culture. SH-SY5Y is a sub-line of the SH-N-SH bone marrow biopsy-
derived line. The parent line was extracted from the bone marrow metastasis of a 
four year old Caucasian female patient with neuroblastoma. SH-SY5Y cells are 
adherent with a neuroblast morphology and a diploid karyotype but have been 
shown to lose neuronal characteristics with increasing passage number. Both cell 
lines grow processes in culture and produce a neuronal phenotype following 
differentiation with retinoic acid.  
 
Cell lines were expanded in F12-MEM cell culture medium supplemented with 
10% foetal calf serum (FCS) and incubated at 37° with 100% relative humidity 
and 5% carbon dioxide. Medium was changed every two to three days and cells 
were passaged when approximately 90% confluent. Briefly, one flask of adherent 
cells was rinsed with 1x phosphate buffered saline (PBS) and detached from the 
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flask surface by incubation with trypsin-EDTA at 37°C for five minutes. The 
detached cells were collected, gently pelleted and resuspended in cell culture 
medium before being diluted and split among three to four new culture flasks. 
These new cultures were propagated as before.  
 
Neuronal differentiation was achieved by replacing the cell culture medium with 
reduced FCS (1%) medium containing 10nM of retinoic acid. The addition of 
retinoic acid halts cell growth and induces the expression of neuronal markers. 
Differentiation medium was changed every two days and cells were fully 
differentiated after five days. 
 
For long term storage of the neuroblastoma cell lines, cells were harvested by 
trypsinisation, pelleted by gentle centrifugation and resuspended in 1ml of 
freezing solution (F12-MEM medium with 10% FCS and 10% DMSO). Cells 
were transferred to cryotubes, slowly frozen to -80°C in an isopropanol bath and 
stored in liquid nitrogen. 
 
2.1.5.2 Transfection of cells with plasmid DNA 
Plasmid DNA constructs were expressed in SK-N-F1 and SH-SY5Y cells 
following lipid transfection. The TransFast transfection reagent is comprised of 
two lipids, a synthetic cationic lipid and L-dioleoyl phosphatidylethanolamine 
(DOPE), a neutral lipid. Plasmid DNA coated in lipid micelles are taken up by 
mammalian cells by endocytosis.  
 
Cells were plated on a suitable cell culture plate and grown to 80% confluency in 
F12-MEM cell culture medium supplemented with 10% FCS. Approximately one 
hour before transfection, the medium was removed and replaced with serum-free 
culture medium. An appropriate amount of endotoxin-free plasmid DNA was 
mixed with TransFast reagent at a charge ratio of 1:1 in serum-free medium. The 
amount of plasmid DNA transfected varied depending on the size of both the 
plasmid and cell culture plate. The mixture was incubated for 15 minutes at room 
temperature with vigorous shaking to ensure the plasmid became fully coated with 
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the lipids. A small volume of fresh serum-free medium was added to the cells 
before addition of the DNA/TransFast mixture. Cells were incubated at room 
temperature for 10 minutes with gentle shaking and then returned to the 37°C 
incubator. After one hour, cells were topped up with 10% culture medium and 
allowed to recover for a further 48-72 hours before analysis. 
 
2.1.5.3 The luciferase reporter gene assay 
The luciferase reporter gene assay provides a simple and high through-put method 
of assessing the ability of short DNA sequences to initiate, regulate or 
differentially alter gene expression. Routinely used to ascertain the comparative 
strengths of different promoters or promoter variants, the assay may also be used 
to determine the regulatory effects on promoter activity of cis-acting elements or 
the effect of the 3’UTR on transcript stability. This is achieved by cloning the 
sequence of interest either upstream or downstream to a luciferase gene in which 
the promoter or the 3’UTR has been removed. When expressed in vitro, the level 
of luciferase produced is directly proportional to the transcriptional activity or 
stability conferred by the cloned sequence. The commonly used reporter gene is 
cloned from the firefly Photinus pyralis which, upon translation, gives rise to the 
luciferase enzyme. This enzyme catalyses the ATP-dependent oxidation of 
luciferin to oxyluciferin, a reaction that produces light at a rate proportional to the 
activity of the enzyme.  
 
The Dual-Glo Luciferase Assay System was used for all reporter gene studies 
described here. This system was chosen due to its incorporation of an internal 
control plasmid, in this case the pRL-TK plasmid which expresses the Renilla 
luciferase gene from a tyrosine kinase control promoter. The Renilla luciferase 
reaction requires a different substrate to its firefly equivalent and therefore its 
independent quantification in the same well allows the normalisation of the firefly 
signal and compensation of well-to-well differences in transfection efficiency 
and/or cell density. Mammalian cells transfected with both the firefly and Renilla 
plasmids are analysed in a two-step assay that individually quantifies the 
luminescence produced by each plasmid. The first step quantifies the level of 
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firefly luciferase and involves the direct addition of the Dual-Glo luciferase 
reagent to the culture medium of the transfected cells. This reagent provides the 
substrate for the firefly luciferase enzyme, producing a stable luminescent signal 
that can be measured by a luminometer (Tecan GENios). The signal lasts for 
approximately two hours and must be measured within this time. The addition of a 
second reagent, the Dual-Glo Stop & Glo reagent, quenches the firefly signal and 
provides the substrate for the Renilla luciferase enzyme. This luminescent signal 
is similarly measured within a two-hour window.   
 
Luciferase assays were conducted on neuroblastoma cells plated on opaque 96-
well plates 48 hours post-transfection with the two luciferase plasmids. The cell 
culture medium was removed and replaced with 20μl of serum-free medium. A 
volume of 20μl of each reagent was sequentially added to each well, with the 
luminescent signal measured ten minutes after the addition of each reagent.  
 
2.1.5.4 TRIzol® method for RNA extraction from cell culture 
The isolation of RNA samples from transfected cells was conducted using the 
TRIzol
®
 method. The TRIzol
® 
Reagent is a monophasic solution of phenol and 
guanidine isothiocyanate developed specifically to maintain the integrity of large 
and small RNA species during cell lysis and cell component dissolution. In this 
project the method was used to extract total RNA from neuroblastoma cells 
transfected with the MAPT minigenes. 
 
The first stage of the method involves cell harvesting and homogenisation. Cells 
were cultured in 6-well, 35mm dishes for 72 hours post transfection. To harvest 
the cells, the culture medium was removed from each well and replaced with 1ml 
of TRIzol
®
 Reagent. Cells were lysed in the dish by vigorous pipetting before 
transferral to a 1.5ml centrifuge tube. 
 
The second stage, phase separation, is essential for the separation of the DNA, 
RNA and protein species in the cell lysate. The homogenised cells were incubated 
at room temperature for 5 minutes to allow the complete dissociation of the 
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nucleoprotein complex. The addition of 0.2ml of chloroform followed by vigorous 
inversion and centrifugation at 12,000 x g for 20 minutes at 4°C, resulted in the 
separation of the mixture into three clearly visible phases. The upper aqueous 
phase contained the isolated RNA. The interphase and lower organic phase 
contained DNA and protein.  
 
To isolate the RNA, the aqueous phase was carefully transferred to a separate 
1.5ml centrifuge tube containing 0.5ml of 100% isopropanol. The RNA was 
precipitated during a 10 minute incubation at room temperature and collected by 
centrifugation at 12,000 x g for 15 minutes at 4°C. The supernatant was removed 
and the RNA pellet washed with 75% ethanol. After centrifugation at 7,500 x g 
for 10 minutes at 4°C, the wash was discarded and the pellet left to air dry for 5 
minutes. The RNA was dissolved in 20μl of RNase-free water and left to 
resuspend for 2 hours at 4°C. 
 
2.1.5.5 RNA purification 
RNA samples extracted from cultured cells were treated with DNaseI to remove 
DNA contaminants. This enzyme selectively digests DNA, leaving the RNA 
molecules intact. This is an important step to ensure future analyses of reverse-
transcribed transcripts are not compromised by amplification of genomic DNA. 
Each 20μl RNA sample was mixed with 1μl of DNaseI enzyme, 2.5μl of DNase 
buffer (10x) and 1.5μl of RNase-free water, and incubated at 37°C for 30 minutes. 
The sample was then purified using the RNeasy MinElute Cleanup kit according 
to the manufacturer’s instructions.  
 
2.1.5.6 DNA extraction from cell culture 
When necessary, DNA was extracted from cultured cells using the CellsDirect 
Cell Resuspension and Lysis Buffers according to the manufacturer’s protocol. 
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2.1.6 Minigene construction  
 
2.1.6.1 Multisite Gateway® cloning by recombination 
The MAPT minigenes were constructed using the Multisite Gateway
®
 Pro Plus kit. 
This technology utilises recombination between two compatible sequences to 
transfer up to four target DNA fragments into one vector in a single step. This 
reduces both the need for multiple cloning steps and the likelihood of sequence 
errors being inserted, as often occurs during cloning in bacterial cells. This 
method is described in detail in chapter 4. 
 
2.1.6.2 Creation of stable isogenic cell models  
The Gateway
®
 technology provides a method of integrating the expression 
constructs into the genome of mammalian cell lines at a pre-determined location. 
This adds reliability and versatility to expression studies by ensuring the contructs 
are not differentially affected by factors related to the insertion site. This method 
is also described in detail in chapter 4. 
 
2.1.7 Cell Biology 
 
2.1.7.1 Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) provides a method of studying the 
association of certain DNA-binding proteins with specific sequences in the 
genome. Such proteins play important roles in numerous cellular processes such 
as gene expression, DNA repair and segregation, cell-cycle progression and 
epigenetic silencing. In this project, the ChIP assay was used to fulfil two project 
aims: firstly to confirm the association of proteins that were predicted to bind to 
specific sequences within the MAPT promoter; and secondly to ascertain whether 
single nucleotide polymorphisms within the predicted binding sites could lead to 
allelic differences in protein binding. 
 
Immunoprecipitation of chromatin from neuroblastoma cells was achieved using 
the MAGnify
™
 ChIP System. Cultured cells were treated with formaldehyde to fix 
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DNA-protein and protein-protein associations by generating crosslinks between 
neighbouring molecules within the chromatin complex. Following cell lysis, 
chromatin was released from the cell nuclei and sheared by sonification to 
produce fragmented DNA of 200-500bp in size. The crosslinked protein of 
interest was selectively immunoprecipitated using a specific ChIP-grade antibody 
conjugated to specially-designed magnetic beads. This conjugation allowed the 
specific isolation of the crosslinked protein of interest from the rest of the nuclear 
chromatin extract. The crosslinking was reversed by heat treatment and the 
protein-associated DNA fragments purified. Target-specific PCR of the purified 
DNA confirmed the presence or absence of the target sequence in the pool of 
DNA fragments that were associated with the protein of interest. The specificity 
of the protocol was determined by the inclusion of the mouse IgG antibody as a 
negative control, as this antibody does not bind to human DNA. The reliability of 
the final PCR was confirmed by the inclusion of an ‘input’ control containing 
chromatin that had been purified but not subject to selective immunoprecipitation. 
 
2.1.8 Genetics 
 
2.1.8.1 Restriction fragment length polymorphism 
A restriction fragment length polymorphism (RFLP) is a single nucleotide 
polymorphism that lies within a restriction enzyme recognition sequence. The two 
alleles can therefore be distinguished based on whether they complete or abolish 
this restriction sequence, as determined by the ability of the restriction enzyme to 
cut at this location. Thus, the presence of a specific allele in a given DNA sample 
is determined by PCR amplification of the surrounding region followed by 
restriction digestion. Resolution of the digestion products by agarose gel 
electrophoresis reveals a banding pattern unique to each allele. PCR product 
containing the allele that abolishes the restriction site will remain uncut, 
producing one solitary band. Product that contains the other allele, however, will 
be cut into two, with two smaller bands visible on the gel. When two variants of 
the target region are present – such as when genotyping human DNA samples – a 
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third banding pattern may be produced for individuals that are heterozygous. In 
these cases all three bands, the uncut and the two cut bands, are present together.  
 
2.1.9 Statistics 
 
2.1.9.1 The Student’s t-test 
The Student’s t-test provides a method of determining whether the means of two 
normally distributed populations are significantly different to one another. The 
test is conducted under the null hypothesis, which states that the difference 
between the two means is zero. The mean, standard deviation and size of each 
population are all used to calculate the test statistic; a measure of the difference 
between the means. The null hypothesis is rejected when the probability of a 
detected difference occurring by chance is less than or equal to 5% (p≤0.05).  
 
2.1.9.2 The Hardy-Weinberg Equilibrium 
The Hardy-Weinberg Equilibrium (HWE) describes the stable inheritance of allele 
and genotype frequencies within a population. It is based on the assumption that 
the population undergoes random mating and is not subject to mutation, 
migration, selection or random drift. The Hardy-Weinberg equation provides a 
means of calculating the deviation of a given population from the genotype 
distributions expected under HWE. The equation (p
2
 + 2pq + q
2
 = 1) calculates the 
expected distribution of genotypes of a given polymorphism based on the 
population allele frequencies. Thus, if p is the frequency of the major allele (A), 
and q is the frequency of the minor allele (a), then p
2
, 2pq and q
2
 provide the 
population frequencies of the AA, Aa and aa genotypes, respectively. This 
expected distribution is compared with the actual distribution observed in the 
population, with a significant difference between the two detected using a Chi-
square test (section 2.1.9.3). The population is said to be in HWE when p>0.05. In 
genetic studies, the Hardy-Weinberg equation is used to identify population 
stratification within a genotyped cohort and can also highlight potential problems 
with the accuracy of the genotyping assay. 
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2.1.9.3 Genetic association: The Chi-square test 
The Chi-square test was used in single locus analyses of genotype and allele 
frequencies in case and control cohorts. It is a non-parametric test of 
independence and uses a contingency table of paired frequencies to calculate the 
Chi-square statistic. This statistic is generated by summing the normalised 
squared difference of each paired allele or genotype count. This, along with the 
degrees of freedom (the number of frequencies minus the number of parameters) 
is used to calculate a p-value, with p≤0.05 the threshold for significance. In 
instances where one of the values in the contingency table is below 5, Fisher’s 
Exact test is used to calculate the significance value. The Chi-Square distribution 
only gives an approximation of statistical significance and this leads to 
inaccuracies when the sample size is too small. Fisher’s Exact test is instead used 
to calculate an accurate significance value. In this project, genotype frequencies 
were tested using dominant and recessive models, with the heterozygote group 
added to one of the homozygote groups in each instance. This allowed the mode 
of inheritance of an associated allele to be determined by ascertaining whether one 
or two copies of the allele are required for association. 
 
2.1.9.4 Genetic association: The odds ratio 
The odds ratio is a measure of the effect size of an association. It is calculated as 
the probability of an event occurring in one group divided by the probability of it 
occurring in the other. An odds ratio of 1.0 indicates that the event is equally 
likely to occur in the two groups. An odds ratio above or below 1.0, however, 
indicates that the event is more likely to occur in one of the groups. For example 
in a case-control study, an associated genetic variant may be calculated as having 
an odds ratio of 2.4. This would mean that an individual with this particular 
genetic variant is 2.4-fold more likely to be in the case group than in the control 
group. An odds ratio of less than 1.0, however, would indicate that the individual 
is more likely to be in the control group and therefore the genetic variant confers 
protection. The further the odds ratio is from a value of 1.0, the greater the effect 
of the association.  
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2.1.10 Bioinformatics resources 
 
2.1.10.1 NCBI  
The National Centre for Biotechnology Information (NCBI; 
http://www.ncbi.nlm.nih.gov/) is a collection of publicly available databases that 
provides a valuable resource for molecular genetics studies. The databases 
facilitate the retrieval of information vital to the progression of such studies, 
including nucleotide sequences and polymorphism frequency data. The resource 
also provides web-based tools such as the basic local alignment search tool 
(BLAST) which can be used to identify unknown sequences through alignment 
with the known sequence database. 
 
2.1.10.2 UCSC Genome Bioinformatics  
The University of California Santa Cruz (UCSC; http://genome.ucsc.edu/) 
genome browser provides comprehensive and visual annotations of assembled 
reference genomes from, among other species, human, chimpanzee and mouse. 
Information available includes: the chromosomal location of genes, polymorphic 
variation, isoform composition, cross-species conservation and tissue-specific 
gene expression. The resource also has an in silico PCR function, which aligns 
potential primer pairs to a reference genome and generates the predicted sequence 
of the product(s), and a Blat tool, which aligns sequences of interest against an 
annotated reference genome. Both of these functions were used extensively 
throughout this project.  
 
2.1.10.3 ClustalW2  
The European Bioinformatics Institute (EBI) provides the web-based ClustalW2 
programme (http://www.ebi.ac.uk/Tools/msa/clustalw2/) which aligns two or 
more protein or DNA sequences, clearly highlighting the differences between 
them. This tool is particularly useful for identifying the single nucleotide 
polymorphisms, deletions, insertions, and repeats in the sequences of genetic 
variants of the same gene or region. In this study, the ClustalW2 tool was used to 
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identify sequence differences between the haplotype variants of each in vitro 
expression construct. 
 
2.2 Materials 
 
2.2.1 PCR reagents 
AccuPrime™ Taq DNA Polymerase High Fidelity (Invitrogen) 
FastStart High Fidelity PCR System (Roche) 
All primers and oligonucleotides were obtained from Sigma-Aldrich 
 
2.2.2 Restriction enzymes 
All restriction enzymes were obtained from New England Biolabs. 
 
2.2.3 Molecular biology reagents 
 
2.2.3.1 Gel electrophoresis reagents 
Tris-acetate-EDTA (TAE) buffer (Qiagen) 
Agarose (Sigma-Aldrich)  
SafeView Nucleic Acid Stain (NBS Biologicals) 
Hyperladder I and Hyperladder IV (Bioline) 
 
2.2.3.2 DNA purification kits 
QIAquick PCR Purification kit – genomic (Qiagen) 
QIAquick Gel Extraction kit – genomic (Qiagen) 
QIAquick Spin Miniprep kit – plasmid mini-preparation (Qiagen) 
Endo-free Plasmid Maxi kit – plasmid maxi-preparation (Qiagen) 
 
2.2.3.3 Plasmid vectors 
pGEM-T Easy – sub-cloning plasmid (Promega) 
pGL4.10 [luc2] – firefly luciferase plasmid (Promega) 
pMIR-REPORT – firefly luciferase plasmid (Promega) 
pRL-TK – Renilla luciferase plasmid (Promega) 
 
2.2.3.4 Ligation reagents 
T4 DNA ligase – single fragment ligation (1-2U/μl; Promega) 
T4 DNA ligase high concentration – multi-fragment ligation (200U/μl; Promega) 
T4 DNA ligase high concentration – splinkerette PCR (500U/μl; New England 
BioLabs) 
ATP (100mM; Sigma-Aldrich) 
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2.2.3.5 Bacterial cells 
JM109 High Efficiency competent cells (>10
8
cfu/μg; Promega)   
HB101 competent cells (Promega) 
 
2.2.3.6 Cloning reagents 
Luria-Bertani (LB) broth (Invitrogen): 
- 20g/L LB broth dissolved in deionised water and sterilised by 
autoclaving at 121ᴼC for 20 minutes. 
LB-agar (Invitrogen):  
- 32g/L LB-agar dissolved in deionised water and sterilised by 
autoclaving at 121ᴼC for 20 minutes. 
 
Ampicillin (Sigma-Aldrich) 
Kanamycin (Sigma-Aldrich) 
Hygromycin B (Invitrogen) 
Zeocin (Invitrogen) 
X-Gal (5-bromo-4-chloro-indolyl-β-D-galactopyranoside; Promega) 
IPTG (isopropyl β-D-1-thiogalactopyranoside; Sigma-Aldrich) 
 
 
2.2.4 Sequencing 
All sequencing was conducted by Source BioScience. 
 
 
2.2.5 Cell culture reagents 
All cell culture reagents were supplied by Sigma-Aldrich unless stated otherwise. 
Neuroblastoma cell culture growth medium (F12-MEM; 1-10%): 
- 44% Ham’s F12 nutrient mixture (F12) 
- 44% Eagle’s minimum essential medium (MEM) 
- 1-10% foetal calf serum (FCS) 
- 2mM L-glutamine 
- 1% non-essential amino acids  
- 20 units/ml penicillin 
- 250ng/ml amphotericin B 
Trypsin-EDTA solution  
Cell freezing solution        
- 10% dimethyl sulphoxide (DMSO) 
- 90% neuroblastoma cell culture growth medium 
Retinoic acid (10μM stock; Tocris) 
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2.2.6 Transfection reagents 
TransFast transfection reagent (Promega) 
Serum-free medium (all Sigma-Aldrich) 
- 49% Ham’s F12 nutrient mixture (F12) 
- 49% Eagle’s minimum essential medium (MEM) 
- 2mM L-glutamine 
- 1% non-essential amino acids  
 
2.2.7 Luciferase assay reagents 
Dual-Glo Luciferase Assay System (Promega) 
 
 
2.2.8 DNA extraction (cells) 
CellsDirection Cell Resuspension and Lysis Buffers (Invitrogen) 
 
 
2.2.9 RNA extraction and purification (cells) 
TRIzol
®
 Reagent (Invitrogen) 
Chloroform 
Isopropanol 
Ethanol 
DNaseI (Invitrogen) 
RNeasy MinElute Cleanup kit (Qiagen) 
 
 
2.2.10 Minigene construction reagents 
Multisite Gateway
® 
Pro Plus Vector Module (Invitrogen) 
Jump-In
™
 TI
™
 Platform Kit (Invitrogen) 
Jump-In
™
 TI
™
 Gateway
®
 Vector Kit (Invitrogen) 
 
 
2.2.11 mRNA analysis reagents 
SuperScript III First Strand Synthesis System for RT-PCR (Invitrogen) 
4-12% Tris-borate-EDTA (TBE) polyacrylamide gels (Invitrogen) 
10% TBE polyacrylamide gels (Invitrogen) 
TBE running buffer (Invitrogen) 
Syto
®
 60 DNA Nucleic Acid Stain (Invitrogen) 
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2.2.12 Chromatin Immunoprecipitation (ChIP) reagents 
MAGnify
™
 Chromatin Immunoprecipitation System (Invitrogen) 
Monoclonal ChIP-grade antibodies: 
- Anti-Pol II (Covance) 
- Anti-hnRNPU clone 366 (Millipore) 
- Anti-β-actin (Abcam) 
- Anti-mouse IgG (negative control; Millipore) 
 
 
2.3 Suppliers 
The suppliers of materials and services used throughout this project are listed 
below: 
 
Abcam plc, 330 Cambridge Science Park, Cambridge CB4 0FL 
Bioline Reagents Ltd, Unit 16 The Edge Business Centre, Humber Road, London 
NW2 6EW 
Covance Inc, Compass House, Manor Royal, Crawley, West Sussex RH10 9PY 
Invitrogen Ltd, 3 Fountain Drive, Ichinnan Business Park, Paisly, UK, PA4 9RF 
Millipore (UK) Ltd, Suite 3 & 5, Building 6, Croxley Green Business Park, 
Watford WD18 8YH 
NBS Biologicals Ltd, 14 Tower Square, Huntingdon, Cambridgeshire PE29 7DT 
New England Biolabs UK Ltd, 73 Knowl Piece, Willbury Way, Hitchin, 
Hertfordshire SG4 0TY 
Promega UK Ltd, Delta House, Chilworth Research Centre, Southamptom, 
SO16 7NS 
Qiagen UK Ltd, Flemming Way, Crawly, West Sussex, RH10 9NQ 
Roche Products Ltd, 6 Falcon Way, Shire Park, Hexagon Place, Welwyn 
Gardeen City, Hertfordshire AL7 1TW 
Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset, BH12 4QH 
Source BioScience plc, 1 Orchard Place, Nottingham Business Park, Nottingham 
NG8 6PX 
Tocris Bioscience, Tocris House, IO Centre, Moorend Farm Avenue, Bristol 
BS11 0QL 
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3 Luciferase reporter gene studies to investigate the effect on 
expression of genetic variation within the untranslated regions 
of the MAPT gene 
 
3.1 Overview 
The 5’ and 3’ regions of a gene, although non-coding, contain important genetic 
information required for the regulation of gene expression. The 5’ region is 
commonly referred to as the gene promoter (or intron -1). This region contains the 
core promoter (often denoted exon 0), which is responsible for initiating 
transcription, and numerous regulatory elements that modulate the rate of 
transcription through enhancement or repression. The 3’ region (often referred to 
as the 3’ untranslated region or 3’UTR) contains binding domains for microRNAs 
and RNA binding proteins along with signal sequences for the polyadenylation, 
degradation, localisation and stabilisation of mRNA transcripts. As a result, the 
3’UTR plays a key role in mRNA stability, processing and translation. It 
therefores follows that genetic variation within these regions has the potential to 
have a profound effect on the normal regulation of gene expression. 
 
The luciferase reporter gene assay is a useful tool in gene expression studies as it 
provides an easily detectable, high throughput method of comparing the 
regulatory potential of unknown DNA sequences. The assay is most commonly 
used to compare the ability of different promoters or promoter variants to drive 
expression of a promoterless luciferase gene in vitro. It can also be used to 
investigate the effect of variation within the 3’UTR on gene expression, achieved 
by cloning the 3’UTR variant downstream to a luciferase gene in which 
expression is driven by a control promoter. 
 
In this study, a series of luciferase reporter gene constructs was designed for the 
in-depth investigation of two highly conserved regions of the MAPT promoter; the 
first containing the MAPT core promoter and the second comprising a predicted 
regulatory domain containing the PSP-associated rs242557 polymorphism. An 
additional series of luciferase constructs was created to determine whether genetic 
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variation within the MAPT 3’UTR can affect mRNA stability and thus gene 
expression levels. This was investigated in two ways: firstly by quantifying 
expression when the full 3’UTR is present, and secondly by splitting the 3’UTR 
into three overlapping fragments to pinpoint the sequences that are most critical 
for maintaining normal gene expression levels.  
 
In both the promoter and 3’UTR studies three variants of each luciferase construct 
were created representing the genetic variation of the H1C, H1B and H2 MAPT 
haplotypes. This allowed for direct comparison between the ‘risk’, ‘neutral’ and 
‘protective’ MAPT variants respectively. 
 
3.2 Background 
The A-allele of the rs242557 polymorphism is strongly associated with an 
increased risk of PSP [104, 181, 227] and defines the MAPT H1 sub-haplotype 
denoted H1C. This polymorphism is located within a highly conserved region of 
the promoter and has been shown to lie within or proximal to a transcription 
regulatory domain [11, 12]. There are, however, conflicting reports regarding the 
exact nature of the domain’s effect on transcription and the first step towards 
unravelling the functional role of the rs242557 polymorphism is to clarify these 
conflicting reports.  
 
As described earlier, two groups used the luciferase reporter gene assay to 
quantify the level of transcription conferred by the allelic variants of the rs242557 
regulatory domain when cloned adjacent to an element containing the MAPT core 
promoter. Although both studies found allelic differences in the activity of the 
regulatory domain, one group reported an significant increase in transcription for 
the G-allele variant [11] while the other reported a significant increase for the A-
allele variant [12]. Both studies quantified the transcriptional activity in human 
neuroblastoma cells and showed that the addition of the SNP domain causes a 
reduction in transcription (i.e. the domain functions as a repressor). The 
Rademakers study [11], however, additionally conducted the assay in mouse 
neuronal cells (N2a) and although the allelic differences in activity remained, in 
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these cells the domain acted as a transcription enhancer. This suggests that the 
cellular environment – including the components of the transcription machinery – 
has an effect on the interaction between the regulatory domain and core promoter. 
Enhancement was also observed when the SNP domain was assayed in 
conjunction with the SV40 immediate early promoter, rather than the MAPT H1 
core promoter, indicating that promoter identity plays an important role in the 
functioning of the domain.  
 
To clarify these findings, an in vitro luciferase reporter gene study was designed 
to incorporate aspects of the two published luciferase studies and to remove some 
of the technical differences that may account for the conflicting results; most 
notably the positioning of the regulatory domain relative to the core promoter and 
the size of the core promoter and rs242557 elements.  
 
An additional aspect of this study includes an in-depth look at the MAPT core 
promoter region. Of particular interest is a highly conserved sequence located 
immediately downstream to the core promoter region. According to database 
annotations (figure 3.1), this 900bp sequence appears to contain a bi-directional 
promoter, with two non-coding transcripts originating from within this region, one 
transcribed in the sense and one in the antisense direction. The sense transcript, 
denoted MAPT-IT1 (LOC100130148), is an intronic transcript of only 3016bp and 
its role is currently unclear. The antisense transcript, denoted MAPT-AS1 
(LOC100128977), may play a role in the regulation of MAPT transcription.  
 
Natural antisense transcripts (NATs) are a group of RNA molecules that have 
sequence complementarity to other RNA transcripts. They can be coding or non-
coding transcripts and form two separate groups depending on whether they are 
transcribed from the same (cis-NATs) or different (trans-NATs) genomic 
locations to their target. There are four proposed models for NAT regulation of 
target gene expression. The first is a knockdown model, in which the binding of 
the NAT to its complementary transcript converts it into a double-stranded 
molecule that is subsequently targeted for degradation, thereby reducing the 
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number of target transcripts available for translation. The second is an RNA 
masking model, in which duplex formation masks certain cis-acting regulatory 
elements residing in either of the transcripts and inhibits protein-RNA interactions 
such as those involved in splicing and mRNA transport. The third is an epigenetic 
model, in which the NAT aids the binding of methylation and/or histone-
modifying complexes to the promoter region of the sense transcript, inhibiting its 
expression. This model is the least understood of the four. The final model is 
based on the observation that transcription cannot occur in two directions 
simultaneously due to collision of the two Pol II elongation complexes. Thus, the 
simple act of transcribing the NAT in the antisense direction impairs transcription 
in the sense direction, reducing the number of transcripts produced [228].  
 
The MAPT-AS1 gene (which expresses a cis-NAT) has only 2 exons but its 
extensive introns result in a DNA sequence spanning over 52kb, overlapping the 
core promoter, the upstream regions of the MAPT promoter and beyond the 
intronless presenilin homologue gene, IMP5. Using the luciferase reporter gene 
assay, the strength of the bi-directional promoter in both the sense and antisense 
directions, as well as its effect on transcription from the MAPT core promoter, 
was quantified in order to determine whether this region plays a role in the 
regulation of MAPT expression. 
 
Figure 3.1 UCSC genome annotations of the region containing MAPT exon 0.  
Two non-coding transcripts denoted MAPT-IT1 and MAPT-AS1 appear to be 
transcribed from the same region located immediately downstream to the core 
promoter at exon 0. 
MAPT core promoter
MAPT-AS1
MAPT-IT1
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The second luciferase study investigated the effect of genetic variation within the 
MAPT 3’UTR on gene expression. As described previously, the 3’UTR is 
responsible for determining the half-life of the mRNA transcript and therefore 
plays an important role in mRNA stability. Stable mRNA transcripts are more 
highly expressed than unstable transcripts as they survive for longer before being 
degraded, producing higher steady-state levels. Thus, genetic variation within the 
3’UTR that alters the stability of the transcript can also modify gene expression 
levels. Tau mRNA is a stable transcript and exhibits a relatively long half-life in 
neuronal cells [229].  
 
The MAPT 3’UTR is approximately 4.4kb in length and contains several regions 
with a high level of sequence conservation. A series of luciferase constructs was 
created containing either the full-length 3’UTR or one of three overlapping 
fragments representing the 5’, middle or 3’ sections of the 3’UTR. The full-length 
constructs were created to determine whether genetic differences in the 3’UTRs of 
the H1B, H1C and H2 MAPT variants affected gene expression and, if so, the 
three deletion constructs would identify which regions are the most critical.  
 
3.3 Patients 
Three patients were identified from an existing cohort of pathologically confirmed 
PSP patients of European descent; one homozygous for the H1B haplotype, one 
homozygous for the H1C haplotype and one homozygous for the H2 haplotype. 
Haplotype and sub-haplotype status was previously confirmed by the genotyping 
of 5 tagging SNPs (rs1467967, rs242557, rs3785883, rs2471738, rs7521) [181] 
and the 238bp intron 9 deletion traditionally used to distinguish H2 from H1 
(table 3.1).  
 
Table 3.1 MAPT haplotype determination of DNA samples. 
The five tagging SNPs and one intron 9 deletion used to confirm haplotype status of 
the three PSP patients. 
Patient rs1467967 rs242557 rs3785883 rs2471738 rs7521 intron9 Haplotype 
P1 G/G G/G G/G C/C A/A ins/ins H1B/H1B 
P2 A/A A/A G/G T/T G/G ins/ins H1C/H1C 
P3 A/A G/G G/G C/C G/G del/del H2/H2 
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During the course of this project the PSP cohort was subject to a clinical review 
and the H2 patient was re-classified as a Parkinson’s disease patient. The change 
in clinical diagnosis does not affect this project as MAPT haplotype status, rather 
than disease status, is of most importance. 
 
3.4 DNA samples 
Post mortem brain tissue was acquired from the Queen Square Brain Bank in 
London. DNA was previously extracted from frontal cortex tissue using standard 
molecular biology protocols. This study was approved by the Joint Ethics 
Committee of the Institute of Neurology and National Hospital for Neurology and 
Neurosurgery. 
 
3.5 Luciferase reporter gene plasmids: Promoter constructs 
 
3.5.1 Design 
The first part of the study comprised an investigation into the influence of the 
rs242557 regulatory domain and its allelic variants on the regulation of MAPT 
transcription. The design of the study was based on that of Myers and colleagues 
[12], where 1.3kb of sequence surrounding the MAPT core promoter and 812bp of 
sequence surrounding the rs242557 polymorphism were cloned from three MAPT 
haplotype variants, H1B, H1C and H2. This study was more inclusive than that 
published by Rademakers et al [11], which incorporated only 182bp of sequence 
surrounding rs242557. In addition, the Rademakers study only looked at the effect 
of rs242557 alleles on the H1 core promoter variant and therefore potential H1/H2 
differences were not investigated. The most intriguing difference between the 
studies, however, was the positioning of the rs242557 domain relative to the 
promoter element. The genomic location of this domain is approximately 46.8kb 
downstream to the MAPT core promoter in intron -1. In the Myers luciferase study 
the SNP domain was cloned immediately downstream to the core promoter 
element, in its more natural position. Rademakers and colleagues, however, chose 
to clone the domain immediately upstream to the promoter element.  
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To ascertain whether the positioning of the SNP domain relative to the core 
promoter could affect its function – and to clarify the conflicting results of the two 
previous studies – two luciferase constructs were created, one with the SNP 
domain cloned upstream to the core promoter element, and one with an identical 
domain situated downstream. Both the core promoter and SNP domain elements 
were identical to the ones described by Myers and colleagues [12]. 
 
The second part of the study involved an additional element comprising the 901bp 
sequence situated immediately downstream to the 1.3kb core promoter element 
and containing the bi-directional MAPT-AS1 NAT promoter. Two luciferase 
constructs were created, with the element inserted alone in the forward and 
reverse orientations, in order to confirm the presence and strength of the bi-
directional promoter. An additional luciferase construct was created, with the 
NAT promoter element cloned immediately downstream to the core promoter 
element in the forward direction – producing an extended promoter element 
encompassing the 2.2kb of highly conserved genomic sequence surrounding the 
major transcription start site at exon 0. 
 
Three versions of each promoter construct were created, representing the genetic 
variation of the H1B, H1C and H2 MAPT haplotypes. 
 
3.5.2 Element sequences and genetic variation 
The three promoter elements – the core promoter (denoted ‘CP’; 1.3kb), the SNP 
domain (denoted ‘SD’; 812bp) and the NAT promoter region (denoted ‘NP’; 
901bp) – show a high degree of sequence conservation between human and mouse 
genomes (figures 3.2 and 3.3).  
 
3.5.2.1 CP: the MAPT core promoter (chr17:43971166-43972505) 
Exon 0 contains the sequences required for the initiation of MAPT transcription 
and falls between nucleotides 582 and 822 (240bp) in the CP element (figure 3.2). 
The H1B and H1C core promoter elements (the full 1.3kb) are identical, as 
confirmed by sequencing, and thus only one CP element representing the H1 
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haplotype was created for comparison with the H2 element. There are eight single 
nucleotide differences between the H1 and H2 CP elements, including two within 
exon 0 and one single nucleotide insertion/deletion polymorphism. There is also 
one five-nucleotide deletion (located between nucleotides 45 and 49) and one ten-
nucleotide insertion (at position 78) on the H2 variant. At the 3’ end of the 
element there is a TG dinucleotide repeat polymorphism that is predicted to form 
a binding domain for the RNA-binding protein TDP-43, a protein known to affect 
gene expression at multiple levels [230, 231]. A multiple sequence alignment 
(performed by ClustalW2) of the two CP element variants is given in Appendix A.  
 
Figure 3.2 BLAT alignment of the CP and NP elements against MAPT  
Alignments performed using the BLAT tool of the UCSC genome browser. Both 
elements are highly conserved and the NP element lies immediately downstream to 
the CP element. 
 
3.5.2.2 The rs242557 ‘SD’ SNP domain (chr17:44019339-44020150) 
The rs242557 polymorphism is located at nucleotide 374 in the 812bp SD 
element. This is the only sequence difference between the H1B and H1C variants, 
with the G-allele present in H1B and the PSP risk-associated A-allele present in 
H1C. There are a further three single nucleotide differences unique to the H2 
sequence, present alongside the rs242557 G-allele. A multiple sequence alignment 
of the three SD element variants is given in Appendix B and potential 
transcription factor binding sites within the SD are annotated in Appendix K. 
 
CP SD
~47kb
rs242557 A/G
Intron -1
NP
Intron -1
NAT 
promoter
Exon 0
3 Luciferase Reporter Gene Studies 
90 
 
 
Figure 3.3 Blat alignment of the SD element against MAPT  
Alignment performed using the Blat tool of the UCSC genome browser. The SD 
element is located approximately 47kb downstream to the CP. The putative 
transcription regulatory domain lies in the centre of the element in a highly 
conserved region and contains the rs242557 polymorphism. 
 
3.5.2.3 The ‘NP’ NAT promoter region (chr17:43972506:43973404) 
The predicted bi-directional promoter is located between nucleotides 340 and 374 
(34bp) in the 901bp NP element. There is one nucleotide difference between the 
H1B and H1C elements – a known C/T polymorphism denoted rs3744457 – 
located just 36bp upstream to the antisense promoter at nucleotide 410. The C-
allele is present on the H1B variant, with the H1C and H2 variants containing the 
T-allele. There are a further three single nucleotide differences unique to the H2 
variant. A multiple sequence alignment of the three NP element variants is given 
in Appendix C. 
 
3.5.3 Promoter element cloning: PCR 
The promoter luciferase constructs were created using the pGL4.10 [luc2] 
luciferase reporter vector (Promega; figure 3.4A) and thus the cloning of the 
promoter elements was designed to facilitate their insertion into this vector. The 
pGL4.10 vector contains the promoterless luc2 firefly luciferase gene located 
downstream to a number of unique restriction enzyme recognition sequences 
together comprising the multiple cloning site (MCS). The MCS was used to 
directionally insert each element into the vector upstream to the firefly luciferase 
CP SD
~47kb
rs242557 A/G
Intron -1
NP
Intron -1
rs242557
SNP 
regulatory 
domain
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gene, thus requiring the attachment of specific restriction enzyme sites onto the 
end of each element. This was achieved by PCR, with the appropriate six-
nucleotide recognition sequences added onto the 5’ ends of the forward and 
reverse primers. The use of different sites at either end of the element allowed 
directional insertion into the pGL4.10 vector, as determined by the order in which 
the two sites appear in the MCS. The restriction sites incorporated into each 
element were selected based on four criteria: firstly, the sites were present in the 
MCS of the pGL4.10 vector; secondly, the sites did not occur naturally within the 
element itself; thirdly, the combination of sites would result in the insertion of the 
element into the MCS in the required 
orientation; fourthly, the chosen sites 
would allow, where required, the 
sequential and directional cloning of two 
different elements into the same pGL4.10 
construct. Figure 3.4B presents schematics 
of the full set of promoter luciferase 
constructs created, with the combination 
of elements included in each one. 
 
Figure 3.4 The pGL4.10 [luc2] promoter 
luciferase constructs 
A: The pGL4.10 [luc2] vector used to 
construct each promoter luciferase 
construct (© Promega)  
B: i) the genomic organisation of the three 
promoter elements; ii) the three constructs 
created to test the function of the SD 
domain on transcription from the CP; iii) 
the three constructs created to test the 
function of the NP domain 
 
To create the upstream and downstream variants of the joint CP and SD 
constructs, two versions of the SD element were required with differing flanking 
restriction sites allowing insertion at either end of the CP element. The NP 
element – unlike the CP and SD elements – was cloned using a single restriction 
site (NheI) incorporated onto both ends. This removed the ability to control the 
direction of the insertion but enabled the creation of two separate pGL4.10 
A
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B iii
luc2CPCP alone
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Together
(2,243bp)
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constructs in one cloning reaction; each with the same NP element inserted in 
either the forward or reverse orientations.  
 
Genetic variants of each element were cloned from the genomic DNA of the three 
PSP patients carrying the H1B, H1C and H2 MAPT haplotype variants (see 
section 3.3). Each element was amplified by PCR using the primers and 
conditions detailed in table 3.2. The restriction enzyme recognition sequences 
attached to the 5’ end of each primer are also included. Typical 25μl PCR 
reactions comprised: 50ng of genomic DNA, 1x FastStart High Fidelity reaction 
buffer with 1.8mM magnesium, dNTPs (each to a final concentration of 10mM), 
forward and reverse primers (each to a final concentration of 0.2μM) and 2.5 units 
of FastStart High Fidelity polymerase mix. PCR occurred during a series of 
heating and cooling steps comprising: an initial denaturation step at 94°C for 5 
minutes, 35 cycles of denaturation at 94°C for 30 seconds, annealing at a 
temperature appropriate for the primer pair (table 3.2) for 30 seconds and 
extension at 72°C for 1-2 minutes, and a final extension at 72°C for 7 minutes. A 
5μl aliquot of the product was resolved by agarose gel electrophoresis and 
successful amplification was confirmed by comparison against a size marker. 
Products from four replicate 25μl PCR reactions were pooled and purified using 
the QIAquick PCR Purification kit. 
 
Table 3.2 The primers used to amplify each promoter element from the genomic 
DNA of the three PSP patients.  
Each primer contains a restriction enzyme site at the 5’ end to allow the sequential 
ligation of each fragment into the multiple cloning site of the pGL4.10 luciferase 
reporter vector. AT: annealing temperature of the primer pair used during PCR. 
Element Size 
(bp) 
Primer 
(F/R) 
5’site Sequence 
(5’-3’) 
AT 
(°C) 
CP 1,342 
F SacI GAGCTC_CAAATGCTCTGCGATGTGTT 
55 
R NheI GCTAGC_GGACAGCGGATTTCAGATTC 
SD upstream 812 
F KpnI GGTACC_TGGGACAGATCCTCAGTG  
60 
R SacI GAGCTC_GGCTGTCGATGAACCCTA 
SD 
downstream 
812 
F NheI GCTAGC_TGGGACAGATCCTCAGTG 
60 
R EcoRV GATATC_GGCTGTCGATGAACCCTA 
NP 901 
F NheI gaGCTAGC_TGCCGCTGTTCGCCATCAG 
60 
R NheI gtGCTAGC_ACCCTCAGAATAAAAGCCAG 
3 Luciferase Reporter Gene Studies 
93 
 
3.5.4 Promoter element cloning: pGEM-T Easy 
The purified PCR products were, in the first instance, cloned into the pGEM-T 
Easy vector (Promega; figure 3.5). This linearised plasmid vector is commonly 
used for the cloning of PCR products as it has a 3’ T-nucleotide overhang that 
complements the 3’ A-nucleotide overhang produced by most DNA polymerases 
during PCR. The pGEM-T Easy vector also contains the α-peptide of the β-
galactosidase gene, allowing the easy 
identification of successful recombinants 
by blue/white screening (described in 
section 2.1.4.6).  
 
Figure 3.5 The pGEM-T Easy vector  
This vector was used to clone PCR 
products (© Promega) 
 
Ligation reactions (10μl) were incubated overnight at 4°C and comprised: 50ng of 
linearised pGEM-T Easy vector, 100-150ng of purified PCR product, 10mM 
ATP, 1x T4 DNA ligase buffer and 1-2 units of T4 DNA ligase enzyme. Half of 
the ligation mixture was transformed into 50μl of High Efficiency JM109 E.coli 
cells and incubated overnight at 37°C on LB-agar plates containing 50μg/ml of 
ampicillin, 0.1mM of IPTG and 20μg/ml of X-Gal. White colonies were manually 
picked and cultured overnight at 37°C in 3ml of L-broth containing 50μg/ml of 
ampicillin. Cultures were subject to continuous horizontal agitation at 250rpm 
during incubation. Plasmid DNA was extracted from the bacterial cells using the 
QIAprep Spin Miniprep kit. Positive clones were identified by sequencing with 
the SP6 and T7F primers that anneal at either side of the insertion site (SP6: 
TATTTAGGTGACACTATAG; T7F: TAATACGACTCACTATAGGG). 
  
3.5.5 Promoter element cloning: pGL4.10 [luc2] 
The cloned promoter elements were removed from the pGEM-T Easy vector by 
restriction enzyme digestion using the unique recognition sequences inserted onto 
the ends of each element. Each 50μl digestion comprised: 5μg of purified plasmid 
DNA, 1x digestion buffer, 1x bovine serum albumin (BSA) and 25 units of each 
restriction enzyme. An aliquot of the pGL4.10 vector was similarly prepared for 
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insertion of the promoter element by digestion with the same enzyme(s). The 
enzyme and buffer combinations for the digestion of each element are given in 
table 3.3. 
 
Table 3.3 The restriction enzymes and digestion buffer used to remove the cloned 
promoter element from the pGEM-T Easy plasmid vector.  
An aliquot of the pGL4.10 luciferase vector was similarly prepared for the insertion 
of each digested element. 
 
The digestion products were resolved by agarose gel electrophoresis to separate 
the empty pGEM-T Easy vector from the newly liberated element. The latter was 
excised from the gel using a sharp, sterile scalpel and purified using the QIAquick 
Gel Extraction kit. The digested pGL4.10 vector was similarly purified. 
 
The digested element was then ligated into the pGL4.10 vector by overnight 
incubation at 4°C with T4 DNA ligase. Each 10μl ligation reaction comprised: 
50ng of digested pGL4.10 vector, 100-150ng of digested promoter element, 
10mM of ATP, 1x T4 DNA ligase buffer and 1-2 units of T4 DNA ligase enzyme. 
JM109 E.coli cells were transformed with the full ligation mixture and selected on 
LB-agar plates containing 50μg/ml of ampicillin. Plasmid DNA was isolated from 
five to ten colonies as before using the QIAquick Spin Miniprep kit. A 1μl aliquot 
of the purified DNA was screened by digestion to ascertain the successful 
insertion of the promoter element. Final confirmation of the luciferase construct 
was achieved by sequencing with primers that anneal at either side of the insertion 
site: 
RVp3: TAGCAAAATAGGCTGTCCCC 
Luc-R: ATGTGCGTCGGTAAAGGCG  
 
 
Plasmid Product 
size (bp)
5’ Enzyme 3’ Enzyme Restriction 
buffer
Incubation 
temp (°C)
pGEM-T/CP 1,342 SacI NheI NEB1 37
pGEM-T/SD-up 812 KpnI SacI NEB1 37
pGEM-T/SD-down 812 NheI EcoRV NEB2 37
pGEM-T/NP 901 NheI NheI NEB2 37
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Some of the luciferase constructs required the insertion of a second promoter 
element immediately adjacent to the CP. To create these constructs, a second 
round of cloning was undertaken in which the pGL4.10/CP construct was digested 
with a pair of enzymes matching those on the ends of the second element. The 
additional element was inserted using the digestion-ligation method described 
above. The digestion components for the second round of cloning are given in 
table 3.4.  
 
Table 3.4 The restriction enzymes, digestion buffer and incubation temperature 
used to digest a second element for insertion into the CP luciferase construct. 
 
 
3.6 Luciferase reporter gene plasmids: 3’UTR constructs 
 
3.6.1 Design 
The second part of the study investigated the role of genetic variation within the 
MAPT 3’UTR on gene expression. In addition to the full-length version, a set of 
deletion constructs were created to identify the regions of the 3’UTR that are most 
critical for maintaining the normal pattern of gene expression. It was not possible 
to amplify the full 3’UTR in one PCR reaction as the forward and reverse primers 
required to achieve this were incompatible. Instead, the 3’UTR was split into three 
separate fragments of 1,179bp, 1,828bp and 1,981bp in size, with the second 
fragment overlapping the first and third fragments by 312 and 314 nucleotides 
respectively. The three deletion constructs each comprised one of the overlapping 
fragments. 
 
The full-length 3’UTR contains two naturally-occurring restriction sites that 
appear within the region only once. The deletion constructs were designed such 
that each overlapping region contained one of these unique recognition sequences. 
The AatII enzyme cuts in the overlap between fragments 1 and 2, with XbaI 
Plasmid To insert 5’ Enzyme 3’ Enzyme Restriction 
buffer
Incubation 
temp (°C)
pGL4.10/CP SD-up KpnI SacI NEB1 37
pGL4.10/CP SD-down NheI EcoRV NEB2 37
pGL4.10/CP NP-sense NheI NheI NEB2 37
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cutting in the overlap between fragments 2 and 3. Thus, these two enzymes were 
used to ligate the three fragments together, creating the full-length construct. 
Figure 3.6B presents the design of the four 3’UTR constructs. As with the 
promoter plasmids, three sets of 3’UTR constructs were created to represent the 
genetic variation of the H1B, H1C and H2 MAPT variants. 
 
Figure 3.6 The pMIR-REPORT 3’UTR luciferase constructs 
A: the pMIR-REPORT vector used to create each 3’UTR luciferase construct (© 
Promega). B: i) The section of the 3’UTR included in each deletion fragment; ii) The 
four luciferase constructs created to test the stability of the MAPT 3’UTR. 
 
 
3.6.2 Fragment sequences and genetic variation 
The full-length MAPT 3’UTR is 4,370bp in length and is located at 
chr17:44101545-44105914. The three deletion fragments are denoted Fr1, Fr2 and 
Fr3 and multiple sequence alignments (performed by ClustalW2) highlighting the 
genetic differences between the H1B, H1C and H2 variants of each fragment are 
given in appendices D, E and F.  
 
3.6.2.1 Fragment 1 (Fr1) 
The 5’ end of the 3’UTR is contained in Fragment 1 (1,179bp). The three variants 
share 14 nucleotide differences; nine are H1/H2 differences including two 
insertion/deletion polymorphisms (one single nucleotide and one dinucleotide), 
four are H1B/H1C single nucleotide changes and one nucleotide at position 234 
differs in all three variants (H1B-del, H1C-A, H2-T). Six of these sequence 
differences are in the region of Fr1 that overlaps with Fr2. 
 
A
3’UTRLuciferaseCMV
B i
3’UTR (4.3kb)
Fr1
Fr2
Fr3
1,187bp
1,828bp
1,981bp
B ii
Fr1LuciferaseCMV
Fr2LuciferaseCMV
Fr3LuciferaseCMV
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3.6.2.2 Fragment 2 (Fr2) 
The middle section of the 3’UTR is contained in Fragment 2 (1,828bp). In 
addition to the six sequence differences in the region overlapping Fr1, there are a 
further 13 nucleotide variations between the three variants. The H1B and H1C 
variants differ by two nucleotides including one insertion/deletion polymorphism. 
The H2 variant differs from the H1 fragments by 11 nucleotides, including one 
dinucleotide and one trinucleotide deletion. 
 
3.6.2.3 Fragment 3 (Fr3) 
The 3’ section of the 3’UTR is contained in Fragment 3 (1,981bp). The H1B and 
H1C variants have five nucleotide differences including one deletion. The H2 
variant contains nine differences including two trinucleotide deletions. There are a 
total of 14 nucleotide differences between the three variants. 
 
3.6.3 3’UTR fragment cloning: PCR 
The 3’UTR constructs were created using the pMIR-REPORT luciferase vector 
(Promega; figure 3.6A), a commonly used plasmid vector containing the firefly 
luciferase gene under the control of the highly active cytomegalovirus (CMV) 
promoter. The 3’UTR of the luciferase gene has been removed and replaced with 
a multiple cloning site, allowing the insertion of the MAPT 3’UTR downstream to 
the luciferase gene. The three deletion fragments were individually cloned into 
pMIR-REPORT and these constructs were then used to create the full-length 
construct. 
 
As with the promoter constructs, the 3’UTR fragments were inserted into the 
MCS of the pMIR-REPORT vector by restriction enzyme digestion and ligation. 
Thus, specific restriction enzyme recognition sequences were, again, inserted onto 
the ends of each fragment by PCR. As the full-length 3’UTR was formed using 
naturally-occurring restriction sites, the recognition sequences introduced onto the 
ends of the fragments were required solely for the creation of the individual 
deletion constructs. Thus, the same two sites, SacI and HindIII, were added onto 
5’ and 3’ ends, respectively, of each fragment.  
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The three fragments were amplified from the same genomic DNA samples used in 
the promoter study (see section 3.3). PCR was conducted as described earlier, 
with the primer sequences and reaction conditions given in table 3.5. A 5μl aliquot 
of the PCR product was resolved by agarose gel electrophoresis and successful 
amplification was confirmed by comparison against a size marker. Products from 
four replicate PCR reactions were pooled and purified using the QIAquick PCR 
Purification kit. 
 
Table 3.5 The primers, restriction sites, magnesium concentration (Mg), annealing 
temperature (AT) and number of PCR cycles used to amplify the three 3’UTR 
deletion fragments. 
 
3.6.4 3’UTR fragment cloning: pGEM-T Easy 
The Fr1, Fr2 and Fr3 PCR products, as with the promoter constructs, were first 
cloned into the pGEM-T Easy vector using the protocol described above in 
section 3.5.4.  
 
3.6.5 3’UTR fragment cloning: pMIR-REPORT 
To create the individual deletion constructs the cloned fragments were excised 
from their pGEM-T Easy vector in a double restriction digest comprising: 5μg of 
the plasmid DNA, 25 units each of SacI and HindIII enzymes, 1x NEB2 buffer 
and 1x BSA. The pMIR-REPORT vector was similarly prepared. The digestion 
mixture was incubated overnight at 37°C and the products resolved by agarose gel 
electrophoresis. The digested fragments were excised and purified using the 
QIAquick gel extraction kit, as before.  
 
The fragments were individually ligated into the pMIR-REPORT vector by 
overnight incubation at 4°C with T4 DNA ligase. Ligation, transformation in 
JM109 E.coli cells, ampicillin selection, liquid culture and miniprep DNA 
purification were all conducted as described above. An aliquot of the purified 
Element
Primer 
(F/R)
5'site Sequence (5'-3')
Mg 
(mM)
AT 
(°C)
Elongation 
time
PCR 
cycles
Size 
(bp)
F SacI GAGCTC_CCTGGGGCGGTCAATAA
R HindIII AAGCTT_AGGCAGTGATTGGGCTCTC
F SacI GAGCTC_GTAGGGGGCTGAGTTGAG
R HindIII AAGCTT_ACCAGAAGTGGCAGAATTGG
F SacI GAGCTC_CAGACTGGGTTCCTCTCCAA
R HindIII AAGCTT_GCCAGCATCACAAAGAAG
35
35
1.8
1.8
1.8
1.5 mins 1179
2 mins 1828
2 mins 1981
35Fr1 65
60
65
Fr2
Fr3
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plasmid DNA was screened by digestion to confirm the presence of the promoter 
element. Final confirmation was achieved by sequencing with primers that anneal 
at either side of the insertion site (M13-F: TGTAAAACGACGGCCAGT; M13-
R: AGGAAACAGCTATGACCAT). 
 
To create the full-length construct, a further two rounds of cloning were required. 
The first inserted the Fr2 fragment into the Fr1 luciferase construct by 
digestion/ligation using the AatII (which cuts in the Fr1/Fr2 overlapping region) 
and HindIII (which cuts at the end of each fragment) enzymes. Fr3 was similarly 
inserted into the Fr1/Fr2 luciferase construct using the XbaI (which cuts in the 
overlap between Fr2 and Fr3) and HindIII enzymes. Final confirmation was, 
again, achieved by sequencing with the M13 F/R primers. 
 
3.7 Cell lines 
Each luciferase construct was assayed in vitro in two different human 
neuroblastoma cell lines, SH-SY5Y and SK-N-F1. These neuronal cell lines 
express tau endogenously, though only foetal tau (the shortest 0N3R isoform) is 
expressed when the cells are in an undifferentiated state. The addition of retinoic 
acid to the culture medium causes the cells to differentiate, producing a neuronal 
phenotype with the expression of all six adult tau isoforms that more closely 
resembles in vivo neuronal conditions. These particular cell lines were chosen for 
their MAPT haplotype status; the SH-SY5Y cells are H1 homozygous, whereas 
SK-N-F1 cells are H1/H2 heterozygous. In addition to genetic differences, the cell 
lines also show distinct morphologies in culture (figure 3.7). Comparison between 
the two lines will highlight any differences in luciferase activity that are due to 
endogenous differences in transcriptional regulation. Unfortunately there are no 
H2 homozygous cell lines currently available for comparison. 
 
 
Figure 3.7 The two 
neuroblastoma cell lines. 
SH-SY5Y (A) and SK-N-F1 
(B) cells have distinct 
morphologies in culture.  
 
A SH-SY5Y (H1/H1) B SK-N-F1 (H1/H2)
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3.8 Transfection 
Transfection was conducted 24 hours after the cells were transferred into a 96-
well opaque cell culture plate, when approximately 80% confluent. Each 
promoter/3’UTR construct (containing the firefly luciferase gene) was transiently 
transfected into three replicate wells. The empty pMIR-REPORT luciferase vector 
was included in triplicate on all plates for normalisation (see section 3.10). 
Transfection in mammalian cells is inhibited by endotoxins commonly found in 
mini-preparations of plasmid DNA. Thus, an endotoxin-free maxi preparation of 
each luciferase construct was made specifically for transfection. 
 
Each well was transfected with 200ng of the firefly construct and 50ng of a 
Renilla luciferase plasmid under the control of the tyrosine kinase promoter (pRL-
TK). Co-transfection with the Renilla plasmid provides an internal control for the 
correction of differences in transformation efficiency. A volume of 1.5ul of 
TransFast transfection reagent (1mM) and 40ul of serum-free culture medium was 
added to each well (giving a 1:1 charge ratio of DNA to transfection reagent) and 
transfection occurred during a one hour incubation at 37°C.  
 
3.9 Luciferase reporter assay 
The luciferase assay was conducted 48 hours post-transfection using the Dual-Glo 
Luciferase Reporter Assay System (Promega). A volume of 20μl of Dual Glo 
Luciferase Reagent was added to 20μl of fresh serum-free culture medium in each 
well. This reagent induces a luciferase signal from the firefly luciferase reporter 
only (i.e. from the pGL4.10 and pMIR-REPORT constructs), which was 
quantified after a ten-minute room temperature incubation using the Tecan 
GENios luminometer and XFLUOR4 (version V 4.30) software. The 
luminescence reading was taken with an integration time of 1000ms and a gain 
setting of 150. A volume of 20μl of Dual Glo Stop & Glo Reagent was then added 
to each well. This reagent quenches the firefly luciferase signal and immediately 
induces the Renilla luciferase signal from the control plasmid. The Renilla signal 
was quantified with the same GENios settings after a ten-minute room 
temperature incubation.  
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3.10 Luciferase assay results 
The relative luciferase activity is given by the ratio of firefly to Renilla signal 
emitted from each well and accounts for any changes in signal caused by well-to-
well differences in cell density and/or transformation efficiency. The relative 
luciferase activity of each promoter construct was then normalised against the 
average relative luciferase activity of the three pMIR-REPORT positive control 
wells included on each plate. This allows direct comparison of luciferase activity 
from multiple plates and cell lines. The normalised results for each construct were 
averaged across the three replicate wells. Each construct was assayed in a 
minimum of three independent experiments and the mean relative luciferase 
activity across the replicates was calculated. A significant difference (defined as 
p≤0.05) in relative luciferase activity between two constructs was detected using a 
two-tailed Student’s t-test. 
  
3.11 The funtional effect of the rs242557 domain on transcription from the 
MAPT core promoter 
 
3.11.1 ‘Upstream’ vs ‘Downstream’ positioning of the rs242557 element 
affects its function 
The first step in unravelling the functional role of the rs242557 polymorphism in 
PSP risk was to confirm the nature of the effect, if any, of the rs242557-
containing regulatory domain (SD) on transcription from the core promoter (CP). 
In an attempt to clarify previous conflicting reports regarding the allelic effects of 
the polymorphism, two luciferase constructs were created in which the SD 
element was inserted either upstream or downstream to the CP element. These 
constructs, along with an additional construct containing the CP element alone, 
were assayed in undifferentiated SK-N-F1 (denoted ‘F1’) and SH-SY5Y (‘SH’) 
neuroblastoma cells. Comparative luciferase activity was initially assayed in 
neuronally differentiated cells treated with retinoic acid for five days but did not 
differ significantly from that quantified in undifferentiated cells (data not shown). 
The relative luciferase activities of each construct 48 hours post transfection in 
undifferentiated cells is given in figure 3.8. The results are presented by haplotype 
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set – H1B, H1C and H2 – with the error bars representing the standard error of the 
mean from three biological replicates. The key findings are summarised below. 
 
3.11.1.1 The SD element functions as a repressor of transcription when 
inserted downstream to the CP 
The addition of the SD element downstream to the CP produced the strongest and 
most consistent effect on transcription. For all three haplotype variants in both cell 
lines the downstream addition of the SD element significantly repressed 
transcription from the core promoter. This repression was strongest for the H2-G 
variant (F1: 6.7-fold reduction; SH: 11.8-fold; p<0.0001 for both) and weakest for 
the H1C-A variant (F1: 1.8-fold reduction, p=0.0447; SH: 3.7-fold, p=0.0145) 
(figure 3.8). 
 
3.11.1.2 The function of the SD is determined by the cellular conditions 
when inserted upstream to the CP 
The effect of the upstream addition of the SD element on transcription differed 
depending on the cell line in which it was assayed. In F1 cells, the element 
functioned as an enhancer, with a general trend of increased transcription 
observed for all three variants. This increase reached statistical significance for 
the H2-G variant (2.2-fold, p=0.0007) and trended towards significance for the 
H1B-G variant (1.6-fold, p=0.0602). The H1C-A allele of the SD did not 
significantly alter transcription when inserted upstream to the CP (p=0.2284).  
 
In SH cells, however, the picture was very different. For the H2-G variant, the 
ability to modify transcription from the CP was lost when the SD was moved from 
the downstream to the upstream position, with no difference in activity observed 
between the CP and upstream constructs (p=0.7981). For the H1B-G and H1C-A 
variants, however, the SD element continued to function as a repressor, but only 
the H1C-A variant was close to achieving a statistically significant reduction in 
CP transcription (H1B-G: 1.5-fold, p=0.3337; H1C-A: 3.2-fold, p=0.0687) (figure 
3.8). 
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Figure 3.8 Promoter luciferase results 1 
 
A: The luciferase construct variant 
assayed in each instance, separated by 
haplotype. 
 
B: The relative luciferase activity of 
each construct in SK-N-F1 cells, 
separated by haplotype. 
 
C: The relative luciferase activities in 
SH-SY5Y cells. 
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3.11.1.3 The function of the H1C-A SD variant is unaffected by a change in 
positioning in SH-SY5Y cells 
In general, the relative luciferase activities of the upstream constructs were 
consistently and significantly higher than their downstream counterparts – a 
difference that can be solely attributed to the positioning of the SD. The only 
occurrence for which this was not true was with the H1C-A variant in SH cells, 
where the constructs conferred equal levels of transcriptional repression 
(p=0.5400). This suggests that the A-allele variant of the SD is not affected by its 
positioning relative to the H1 core promoter in this cell line.  
 
3.11.2 The allelic variants of the rs242557 element differentially affect 
transcription from the core promoter 
A simpler picture is produced when, rather than comparing positional variants 
within a haplotype set, the activity of the allelic variants of the same construct are 
considered. Figure 3.9 provides a different presentation of the results discussed 
above and given in figure 3.8. This time the results are split by construct, with the 
H1B, H1C and H2 variants presented on the same bar graph. Unlike the positional 
comparisons, the allelic differences in transcriptional activity were consistent in 
both cell lines. There was no significant difference in relative luciferase activity 
between the two CP variants (F1: p=0.7765; SH: p=0.5375), suggesting that 
unregulated MAPT transcription from H1 and H2 chromosomes is of equal 
strength. The H1C-A variant of the SD domain conferred a significantly different 
level of activity when added to the CP than the H1B-G and H2-G variants in both 
the upstream and downstream positions. When cloned upstream to the CP, the 
H1C-A variant conferred 1.2- to 2.1-fold lower transcriptional activity compared 
to H1B-G (F1: p=0.0805; SH: p=0.0282) and 1.5- to 2.9-fold lower compared to 
H2-G (F1: p=0.0037; SH: p=0.0278). In the downstream position the allelic 
differences were more pronounced, with a 1.7- to 2.7-fold and 3.6- to 4.1-fold 
increase in transcriptional activity conferred by the H1C-A variant compared to 
the H1B-G (F1: p=0.0140; SH: p=0.0060) and H2-G (F1: p=0.0006; SH: 
p<0.0001) variants, respectively.  
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Figure 3.9 Promoter luciferase results 2 
 
A: The luciferase construct variant 
assayed in each instance, separated by 
construct. 
 
B: The relative luciferase activity of 
each haplotype variant in SK-N-F1 
cells, separated by construct. 
 
C: The relative luciferase activities in 
SH-SY5Y cells. 
 
*  p≤0.05  
**  p≤0.01  
***  p≤0.001 
****  p<0.0001 
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Thus, regardless of the positioning of the SD element, the H1C-A variant of the 
domain conferred significantly different activity than the H1B-G and H2-G 
variants, producing increased activity in the downstream and reduced activity in 
the upstream positions. As the positioning of the SD is the only difference 
between the upstream and downstream constructs, these results present a viable 
explanation for the discrepancies in the direction of the allelic effect of rs242557 
reported by Myers and Rademakers; Myers and colleagues, who reported an 
increase in activity for the A-allele, cloned their element downstream to the CP 
element whereas Rademakers et al cloned theirs upstream and reported a decrease 
for the A-allele. 
 
3.11.3 The relationship between the function of the SD and the strength of its 
interaction with the CP changes depending on the cell line  
The differential behaviour of the SD constructs in each cell line is an intriguing 
finding, but perhaps becomes clearer when considered in conjunction with the 
comparative strengths of the different SD allelic variants. As described 
previously, the strongest and most consistent effect on transcription was observed 
when the SD was cloned in its more natural downstream position. This was the 
only finding that was consistent for all haplotype variants in both cell lines. There 
were, however, allelic differences in the strength of the repression and thus the SD 
variants can be classified based on the magnitude of their effect on the core 
promoter: H1C-A (weakest repression), H1B-G (moderate) and H2-G (strongest).  
 
The behaviour of the SD element has also been shown to be affected both by 
changes in positioning and by variation in cell type. When these three things are 
taken together – the function of the SD, the strength of the allelic variant and the 
in vitro cellular conditions – an intriguing pattern begins to emerge which shows 
the importance of both the interaction between the CP and SD and the cellular 
environment.  
 
In F1 cells, the strongest repressor in the downstream position – H2-G – becomes 
the strongest enhancer of transcription in the upstream position. Similarly, the 
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weakest downstream repressor – H1C-A – has no significant effect on 
transcription in the upstream position. The H1B-G moderate repressor becomes a 
moderate enhancer when moved upstream. This indicates that although the nature 
of the interaction between the SD and CP in F1 cells changes depending on the 
positioning of the two elements, the relative strengths of the allelic interactions do 
not significantly change (figure 3.10). 
 
Figure 3.10 A schematic representation of the relationship between the positioning 
of the SD, haplotype-specific variation within it and SD function in SK-N-F1 cells.  
The strongest allelic SD repressor in the downstream position became the strongest 
enhancer in the upstream position. 
 
In SH cells this relationship is inverted, with the H1C-A variant – the weakest 
downstream repressor – becoming the strongest upstream repressor. Similarly, the 
H2-G variant, which conferred the strongest downstream repression, was unable 
to exert influence on the CP from an upstream position. In therefore appears that, 
in these cells, it is the relative strength of the interaction, and not the nature of it, 
that is most affected by the change in positioning (figure 3.11).  
 
Figure 3.11 A schematic representation of the relationship between the positioning 
of the SD, haplotype-specific variation within it and SD function in SH-SY5Y cells.  
The strongest allelic SD repressor in the downstream position became the weakest 
repressor in the upstream position. 
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3.11.4 Evidence for an interaction between the MAPT core promoter and the 
rs242557 domain 
During the construction of the promoter luciferase constructs, a CP clone was 
identified that had serendipitously mutated during the cloning process. This H1 
CP construct – denoted H1X – had two single nucleotide errors inserted into the 
sequence during PCR or cloning in E.coli bacteria. The first error was an A to G 
transition at position 120 (A120G) at the 5’ end of the CP element, over 460 
nucleotides upstream to the start of exon 0 in a relatively unconserved region of 
the element. It was therefore unlikely that this error would affect transcription 
from the CP element. The second error, however, was a G to T transition at 
position 596 (G596T) and is located within exon 0 – the major transcription start 
site. The wildtype G nucleotide at this position is highly conserved. The A120G 
and G596T errors are highlighted in red in the ClustalW2 sequence alignment of 
H1 and H1X presented in Appendix G. To determine whether transcription rate 
was affected by these transitions, the H1X CP luciferase construct was assayed 
alongside the wildtype H1 version and the results are presented in figure 3.12. 
There was no difference in luciferase activity conferred by the two H1 CP variants 
in either of the cell lines (F1: p=0.8177; SH: p=0.9606), indicating that the G 
nucleotide at position 596 is not essential for the initiation and maintenance of 
transcription rate.  
 
To determine whether this error altered the interaction between the CP and SD 
elements, the H1C-A SD element was inserted downstream to the H1X CP and 
assayed against the wildtype version (figure 3.12). The activity of the mutated 
construct (H1X-A) was 4- to 6-fold lower than the activity of the wildtype H1-A 
construct (F1: p=0.0026; SH: p=0.0002), reducing to a level equivalent to the 
activity of the H2-G wildtype variant. This is an intriguing finding and suggests, 
firstly, that a single nucleotide error in exon 0 can affect transcription rate, not by 
modulating the efficiency of transcription initiation at exon 0 but by altering the 
interaction between the SD regulatory domain and the core promoter; and 
secondly, that this altered interaction has a gain-of-function effect, serving to 
strengthen the normally reduced repression conferred by the H1C-A variant to 
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match that of the H2-G variant. The reason for this is unclear; however these 
findings provide evidence of a direct interaction between the core promoter and 
regulatory domain. 
 
Figure 3.12 Promoter luciferase results 3  
A: Schematics of the H1 and H1X versions of the CP luciferase construct and the 
H1-A and H1X-A versions of the downstream SD luciferase construct. B: The 
relative luciferase activity of each H1 variant in SK-N-F1 cells, separated by 
construct. C: The relative luciferase activities in SH-SY5Y cells. ** p≤0.01; *** 
p≤0.001. 
 
3.11.5 Biological interpretation 
This part of the study has confirmed previous reports that the rs242557 
polymorphism falls within a cis-acting regulatory domain that is capable of 
modifying transcription from the MAPT core promoter. It has also shown that the 
position of the domain relative to the core promoter can potentially alter its 
function, thereby providing an explanation for the opposing results reported from 
similar studies by Myers and Rademakers. Most interesting of all, however, is the 
finding that the function of the regulatory domain can be differentially influenced, 
not only by genetic variation within the domain and its positioning, but by the 
cellular environment. This would suggest that the domain’s influence on MAPT 
transcription results from a delicate balance between the proximity and orientation 
of its cis-acting signal, genetic variation within it and trans-acting binding factors 
expressed by the cell line. This relationship will be explored further in chapter 5.    
SH-SY5YCSK-N-F1BA
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The luciferase reporter assay is, of course, an artificial means of assessing the 
ability of short DNA sequences to initiate and/or modify transcription and 
therefore it is difficult to draw any biological conclusions from these results. In 
particular, these results have shown the importance of the positioning of the SD 
for both strength and function and therefore the removal of the intervening 47kb 
of intronic sequence between the two elements – as occurs in the genome – is 
highly likely to affect their interaction. It is hypothesised that the two elements 
interact through changes in confirmation that form a ‘loop’ structure and bring the 
regulatory domain into close proximity to the core promoter. Transcription factors 
bound to the regulatory domain may then interact with those bound to the core 
promoter, thus altering the rate of transcription. If this is the case, the distal 
location of the regulatory domain would be a vital factor in its normal functioning 
and thus the luciferase constructs described here would not be biologically 
representative. 
    
That being said, this study has confirmed that, at the basic sequence level, the 
rs242557 polymorphism lies within a stretch of sequence that can regulate 
transcription from the MAPT core promoter in cis, even when located proximally. 
More importantly, it has consistently shown that the alleles of the rs242557 
polymorphism differentially affect this regulation, regardless of positioning and in 
vitro cellular conditions.  
 
3.12 Functional assessment of the NAT promoter region, individually and in 
conjunction with the MAPT core promoter 
 
3.12.1 Sense vs antisense 
There are well characterised examples of antisense-mediated transcriptional 
regulation occurring via each of the four models described in section 3.2 [228], 
though the effect on transcription of the overlapping sense gene varies depending 
on the model. Expression of the antisense transcript is often correlated – either 
positively or inversely – with expression of the sense gene, though this is not 
always the case. The relationship between sense and antisense transcription can 
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hint at the mechanism connecting the two, as well as provide clues as to the 
biological consequences of the non-coding natural antisense transcript (NAT). 
 
The second part of this luciferase study takes a more in-depth look at the highly 
conserved region located immediately downstream to the core promoter element 
described above. The 900bp region includes a 34 nucleotide sequence that is 
predicted to act as a bi-directional promoter for two non-coding transcripts, one 
transcribed in the sense (MAPT-IT1) and one in the antisense (MAPT-AT1) 
direction. To test whether this region (the NP element) is capable of initiating 
transcription in the sense and antisense directions, two luciferase constructs were 
created, one with the NP element inserted upstream to the promoterless luciferase 
gene in the forward or ‘sense’ direction (NP-S) and the second in which the 
element has been ‘flipped’ and lies in the reverse or ‘antisense’ direction (NP-A). 
Three variants of each construct representing the H1B, H1C and H2 haplotypes 
were assayed in undifferentiated SK-N-F1 and SH-SY5Y cells and the results are 
presented in figure 3.13. The key findings are summarised below. 
 
3.12.1.1 The NP element contains a promoter capable of initiating 
transcription in both the sense and antisense directions 
A small level of transcription was detected when the NP element was cloned 
upstream to the luciferase gene in both the sense and antisense directions, thereby 
confirming the presence of a bi-directional promoter within this element. The H1 
variants conferred a higher level of activity in the sense direction than in the 
antisense direction (approximately 1.7- to 2.5-fold higher) and this reached or 
trended towards statistical significance in both the F1 (H1B: p=0.0039; H1C: 
p=0.0784) and SH (H1B: p=0.0437; H1C: p=0.0625) cell lines. The consistent 
relationship between sense and antisense transcription from the NP indicates a 
positive correlation between the two. This is particularly evident when 
comparisons are made between the two cell lines, as an increased level of sense 
transcription in F1 cells was accompanied by a proportional increase in NP-
antisense transcription.  
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The H2 variants, however, behaved differently depending on the cellular context. 
In the F1 line (which has one endogenous H2 chromosome), the comparison 
between the sense and antisense constructs resembled that of the H1 variants, with 
2-fold greater activity in the sense direction. This did not reach statistical 
significance (p=0.1140); most likely as a result of the large standard error 
produced by the sense construct. 
 
Figure 3.13 Promoter luciferase results 4 
A: The NP-sense (top) and NP-antisense (bottom) luciferase constructs differ only 
by the orientation of the NP element. B: The relative luciferase activities of the three 
haplotype variants of the sense (NP-S) and antisense (NP-A) constructs in SK-N-F1 
cells. C: The relative luciferase activities in SH-SY5Y cells. * p≤0.05; ** p≤0.01  
 
 
In SH cells (which do not possess an endogenous H2 chromosome), however, the 
activity level of the H2-sense construct was reduced and equalled that of the H2-
antisense construct (p=0.8156), which itself was barely above background levels. 
This suggests that there is something specifically produced by the endogenous H2 
chromosome of the F1 cells that upregulates transcription of the H2 NP variant in 
the sense direction. The absence of an endogenous H2 chromosome in the SH 
cells appears to affect sense transcription but not antisense transcription, perhaps 
suggesting that they are regulated by different mechanisms. It is more likely, 
however, that the overall level of antisense transcription is too low in SH cells for 
any difference in H2 antisense expression to be detected.  
 
3.12.1.2 The NP element modifies expression from the core promoter 
Following confirmation that the NP element contains a second transcription start 
site, the effect of this element on transcription from the core promoter was 
SH-SY5YCSK-N-F1BA
luc2NP
luc2
NP
** *
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investigated. It was hypothesised that the addition of the NP element to the CP 
construct would cause either an increase – perhaps through the additive effects of 
transcription from two sense promoters – or a decrease – through antisense-
mediated repression – in luciferase activity compared to the CP alone. To test this, 
the NP element was inserted downstream to the CP in the sense orientation; 
producing an extended promoter fragment covering the full 2.2kb of highly 
conserved sequence located between chr17:43971166 and chr17:43973404. The 
three haplotype variants were assayed alongside the CP alone and NP-sense 
luciferase constructs and the results are presented in figure 3.14.  
 
The results show that the addition of the NP element to the core promoter does 
indeed alter significantly the activity level of the CP, though this was dependent 
on the cell line. In the F1 cell line, CP transcription rate was significantly 
increased following the addition of the NP element (H1B: p=0.0295; H1C: 
p=0.0469; H2: p=0.0478). In SH cells, however, the effect of the NP was to 
significantly decrease CP activity (H1B: p=0.0308; H1C: p=0.0237; H2: 
p=0.0001). This, once again, indicates the importance of trans-acting factors and 
endogenous cellular conditions in gene expression. 
 
Indeed, the cellular context does appear to differentially alter the activity of the 
NP variants. When comparing the rate of transcription conferred by the NP in the 
sense direction with that of the core promoter element, there are clear differences 
in expression between the two cell lines which can only be attributed to 
differences in the endogenous conditions. Although transcription levels are low 
across the board, the activities of the NP elements are much higher in F1 cells, 
with NP-sense reaching 53-71% of the level of transcription from the core 
promoter – the major transcription start site. In fact, although NP-sense 
transcription is clearly lower than CP transcription, this difference does not quite 
reach statistical significance for any of the three variants in this cell line (H1B: 
p=0.2292; H1C: p=0.0795; H2: p=0.0708). In SH cells, however, the NP-sense 
elements can only manage 5-14% of the activity of the core promoter and this 
difference is statistically significant in all cases (H1B: p=0.0056; H1C: p=0.0047; 
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H2: p=0.0001). Thus, in F1 cells, the increase in activity observed when the NP-
sense element is added to the CP may result from the combination of the two 
highly active sense promoters. In SH cells, however, although the level of NP-
sense transcription was much lower than observed in F1 cells and, therefore as 
expected, the combined effects of the two sense promoters was also much lower, 
the overall repression of transcription from the CP was a surprising finding. 
 
The differential activity of the joint CP and NP-sense constructs in the two cell 
lines is difficult to explain and is not concordant with any of the four models of 
antisense-mediated transcriptional regulation outlined in section 3.2. This is likely 
due to the bi-directional nature of the antisense promoter, with additional sense 
transcription from this promoter complicating the picture. It is likely that the 
significant differences in NP promoter activity observed between the two cell 
lines is an important part of the mechanism linking the activities of these three 
promoters. Indeed, at this stage, the only viable explanation for these opposing 
results may be that the reduced NP activity in SH cells causes the accumulation of 
RNA Pol II transcription complexes at this site that block upstream Pol II 
complexes elongating from the CP, thus reducing overall expression. This would 
be less of a problem in F1 cells, where NP activity is much higher; therefore 
additive transcription from the two sense promoters would increase overall 
expression. This cannot be proved using the luciferase assays described here as 
CP, NP-sense and NP-antisense transcription cannot be distinguished when 
expressed from a single luciferase construct. 
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Figure 3.14 Promoter luciferase results 5 
 
A: The luciferase construct variant 
assayed in each instance, separated by 
construct. 
 
B: The relative luciferase activity of 
each construct variant in SK-N-F1 
cells, separated by haplotype. 
 
C: The relative luciferase activities in 
SH-SY5Y cells. 
 
*  p≤0.05  
**  p≤0.01  
***  p≤0.001 
****  p<0.0001 
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3.12.2 The effect of genetic variation on transcriptional regulation by the NP 
As the main aim of this project was to look at the effect of genetic variation on tau 
gene expression, it was important to assess whether polymorphisms in the NP 
element could affect its function. Therefore, the relative luciferase activities of the 
three haplotype variants of the NP-sense, NP-antisense and CP+NP-sense 
combined constructs are presented together in figure 3.15. Only one significant 
difference was observed; between the H1B and H2 variants of the NP-sense 
construct in SH cells (p=0.0313). Thus, at first glance it does not appear that 
genetic variation within the NP domain affects either its independent function or 
its effect on transcription from the CP. However, a consistent, though non-
significant, pattern emerged between the H1B and H1C variants of all three 
constructs in both cell lines.  
 
First noticed with the NP-sense construct, the H1C variant conferred consistently 
lower activity than the H1B variant, as observed across numerous independent 
replications in both cell lines. This was intriguing as, if there was truly no 
difference between the two variants, the high variability of the luciferase 
technique would normally result in the H1C variant being slightly higher than the 
H1B variant in some of the replications. This was never the case; neither was such 
variability observed with the NP-antisense constructs, where the H1C variant was 
consistently higher than the H1B variant, at least in the F1 cell line (the 
expression level of this construct is too low to detect subtle haplotype differences 
in SH cells). When the same consistency in H1B/H1C expression occurred with a 
third NP construct – NP-sense together with the CP – a coincidence seemed 
unlikely. A comparison of the sequences of the two NP haplotype variants 
revealed a single nucleotide difference – a known C/T polymorphism denoted 
rs3744457. Furthermore, this polymorphism lies just 36bp downstream to the 3’ 
end of the NP-sense promoter (and therefore 36bp upstream to the 5’ end of the 
NP-antisense promoter), suggesting it may play a role in regulating NP 
transcription. 
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Figure 3.15 Promoter luciferase results 6 
 
A: The luciferase construct variants 
assayed, separated by construct. 
 
B: The relative luciferase activity of each 
haplotype variant in SK-N-F1 cells, 
separated by construct. 
 
C: The relative luciferase activities in SH-
SY5Y cells. 
 
*  p≤0.05  
**  p≤0.01  
***  p≤0.001 
****  p<0.0001 
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3.12.3 The C/C genotype of rs3744457 is over-represented in PSP 
To determine whether rs3744457 plays a role in PSP risk, the polymorphism was 
genotyped in two DNA cohorts, one consisting of 125 clinically diagnosed PSP 
patients and one consisting of 127 neurologically normal control individuals. 
These cohorts were pre-existing and DNA was previously extracted from brain 
tissue using standard methods. 
 
The sequences of the NP luciferase constructs show that the H1B haplotype 
contains the C-allele of rs3744457, with the H1C and H2 haplotypes carrying the 
T-allele. The global population frequency of the minor C-allele, as reported by the 
1000 Genomes project, is 0.43, which 
is similar to that of the rs242557-A 
allele (0.42); however, these 
polymorphisms are not in LD with 
each other, nor with the H1/H2 
inversion polymorphism (figure 3.16).  
 
Figure 3.16 An LD plot of the six 
tagging SNPs commonly used to define 
the MAPT haplotypes and the 
rs3744457 polymorphism.  
The numbers represent the R’squared measure of correlation between the 
polymorphisms; the higher the number the greater the correlation. The plot was 
created from the genetic information of 55 PSP patients.  
 
The rs3744457 polymorphism is a restriction fragment length polymorphism 
(RFLP), with the C-allele abolishing one of two NlaIII recognition sites (CATG) 
contained within the NP element (901bp). Thus, an element carrying the T-allele 
will be cut twice by the NlaIII enzyme (at nucleotides 412 and 690) whereas an 
element carrying the C-allele will be cut only once (at nucleotide 690).  
 
The NP region was amplified from the DNA of each patient in the PSP and 
control cohorts using the method described in section 3.5.3. PCR products were 
incubated overnight at 37°C with 3 units of NlaIII enzyme, 1x NEB4 buffer and 
1x BSA and the digestion products were resolved by agarose gel electrophoresis 
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using a 2% gel. Figure 3.17 gives examples of the banding pattern that identified 
each genotype.   
 
Figure 3.17 Genotyping of the rs3744457 
polymorphism 
The banding pattern produced by NlaIII 
digestion of NP PCR products amplified from 
the DNA of individuals carrying the three 
rs3744457 genotypes. Each cohort was 
independently genotyped on two separate 
occasions and genotypes were consistent with 
Hardy-Weinberg equilibrium. 
 
 
 
As mentioned previously, during the course of this project the PSP cohort was 
subject to clinical review and 23 of the patients were re-classified with non-PSP 
diagnoses. These included PD (N=11), CBD (N=3), multiple system atrophy 
(N=6), parkinsonism (N=1) and PSP in conjunction with other neurodegenerative 
conditions (N=2). Thus two separate analyses were conducted, one using only 
patients classified as purely having PSP (N=102), and one using all patients 
diagnosed with a neurodegenerative condition (N=125). Table 3.6 gives details of 
the genotype and allele frequencies of each cohort. The frequency of the minor C-
allele in the control population was lower than the global frequency reported by 
the 1000 Genomes project (0.26 v 0.43); however it more closely matched the 0.3 
frequency reported by HapMap (NIH) specifically for populations of European 
descent.  
 
Table 3.6 Genotype and allele frequencies of the rs3744457 polymorphism.  
Frequencies of the PSP only cohort, the PSP cohort including other 
neurodegenerative disorders (‘All’) and the neurologically normal control cohort 
following genotyping by RFLP. All genotyping was in Hardy-Weinberg equilibrium. 
 
690bp
413bp
277bp
211bp
C/C C/TT/T
PSP cases N Freq
T/T 48 0.47
C/T 41 0.40
C/C 13 0.13
Total 102 1.00
T 137 0.67
C 67 0.33
Total 204 1.00
HWE p=0.369862
Controls N Freq
T/T 69 0.54
C/T 50 0.4
C/C 8 0.06
Total 127 1.00
T 188 0.74
C 66 0.26
Total 254 1.00
HWE p=0.790851
All cases N Freq
T/T 57 0.45
C/T 51 0.41
C/C 17 0.14
Total 125 1.00
T 165 0.66
C 85 0.34
Total 250 1.00
HWE p=0.309442
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A statistically different distribution of allele or genotype frequency between the 
case and control cohorts was detected using a two-sided Fisher’s Exact test and 
defined as p≤0.05. Comparisons of the C- and T-allele frequencies are given in 
figures 3.18A and 3.18B. There was a slight over-representation of the C-allele in 
both case cohorts versus the controls, but this did not reach statistical significance 
(PSP vs controls: p=0.3523, OR=0.71 [95% CI: 0.39-1.31]; All versus controls: 
p=0.2800, OR=0.68 [CI: 0.37-1.26]). This may be due to the small size of the 
cohorts producing insufficient statistical power to detect subtle shifts in 
frequency, as the p-value edged closer to significance with the ‘All’ cohort, which 
was slightly larger than the PSP cohort (N=125 vs N=102).  
 
Figure 3.18 Results of the rs3744457 genotyping in PSP and control cohorts 
The frequencies (%) of the C- and T-alleles in the PSP (A) and ‘All’ (B) cohorts 
versus controls; and the frequencies (%) of the C/C and C/T+T/T genotype groups 
in the PSP (C) and ‘All’ (D) cohorts versus controls. The p-value (Fisher’s) and odds 
ratio (OR) produced from a Fisher’s Exact of cases versus controls are given in each 
instance. 
 
Testing a recessive mode of inheritance for the C-allele, a slight over-
representation of the C/C genotype in the case cohorts was again observed 
(figures 3.18C and 3.18D) and this time the p-value for the ‘All’ comparison fell 
N C T Fisher's OR (CI)
PSP 204 67 (0.33) 137 (0.67)
Controls 254 66 (0.26) 188 (0.74)
p=0.3523
0.71 
(0.39-1.31)
N C T Fisher's OR (CI)
All 250 85 (0.34) 165 (0.66)
Controls 254 66 (0.26) 188 (0.74)
p=0.2800
0.68
(0.37-1.25)
A
B
N C/C C/T + T/T Fisher's OR (CI)
PSP cases 102 13 (0.13) 89 (0.87)
Controls 127 8 (0.06) 119 (0.94)
p=0.1464
0.43 
(0.16-1.17)
N C/C C/T + T/T Fisher's OR (CI)
All cases 125 17 (0.14) 108 (0.86)
Controls 127 8 (0.06) 119 (0.94)
p=0.0970
0.43
(0.14-1.07)
C
D
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below the p=0.10 threshold that indicates a trend towards significance (PSP vs 
controls: p=0.1464, OR=0.43 [CI: 0.16-1.17]; All vs controls: p=0.0970, OR=0.40 
[CI: 0.14-1.01]).  
 
These results are interesting and suggest that the rs3744457 polymorphism may 
be worth analysing in a larger PSP cohort. Due to the rarity of PSP it is difficult to 
collect enough samples to create a cohort large enough to allow confidence in the 
results. It is unfortunate that this polymorphism was not genotyped as part of the 
PSP genome-wide association study published by Hoglinger et al in 2010 [104], 
as this was the largest genetic study of PSP to date and pooled data from 
numerous independent cohorts.  
 
It has been shown here, however, that the rs3744457 C/C genotype is slightly 
over-represented in PSP cases and this may therefore indicate an important role in 
tau gene expression and PSP risk for two factors that are yet to be investigated 
thoroughly. The first is the confirmed presence of a secondary sense promoter 
lying immediately downstream to the major core promoter at exon 0. This 
promoter is believed to express the MAPT-IT1 transcript of which little is 
currently understood. The second is the role of antisense transcription and the 
MAPT-AS1 transcript in the regulation of tau gene expression, again of which 
little is understood. It was shown earlier in section 3.12.1 that the cellular 
conditions can potentially alter the regulatory effect of this region on transcription 
from the core promoter. Can genetic variation also alter its activity? Does the 
rs3744457 C-allele alter the expression of either the sense or antisense transcripts 
and if so does this play a role in PSP risk? Are these transcripts capable of 
modulating either transcription rate and/or alternative splicing in vivo? These 
questions, however, are outside of the scope of this project. 
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3.13 The role of the 3’UTR in MAPT expression 
The second luciferase study looked at the role of the MAPT 3’UTR in gene 
expression. This region of the gene is vital for determining mRNA transcript 
stability and has the potential to modulate protein expression by increasing or 
decreasing the half-life of the transcript. Thus, genetic variation within the 3’UTR 
that changes mRNA stability could directly influence tau gene expression and 
contribute to PSP risk. To test this hypothesis and to identify the most critical 
regions of the 3’UTR for determining stability, a set of luciferase constructs were 
created in which either the full-length 3’UTR or one of three overlapping 
fragments (the deletion constructs) were cloned immediately downstream to the 
luciferase gene. Luciferase expression driven by the highly active CMV promoter 
was quantified in undifferentiated SK-N-F1 and SH-SY5Y as described 
previously.   
 
The first findings to be discussed concern the full-length 3’UTR (~4.4kb) and the 
effect of genetic variation on overall mRNA stability. This will be followed by an 
assessment of the deletion constructs (~1.2-2.0kb) and their individual 
contribution to gene expression. Finally, the three haplotype variants of each 
deletion fragment will be compared.    
 
3.13.1 The MAPT 3’UTR increases stability of the luciferase transcripts 
The relative luciferase activity of the three haplotype variants of the full-length 
3’UTR did not differ significantly in either cell line (figure 3.19); indicating that 
haplotype variation within this region does not contribute to the increased risk of 
PSP conferred by the H1C haplotype. In general, the activities of the 3’UTR 
constructs were much higher than their promoter counterparts, though there were 
sizeable differences in overall expression between the two cell lines. In F1 cells, 
the normalised luciferase activities of the three variants were 4- to 5-fold higher 
than the activities of the CP constructs in this cell line. In SH cells, however, 
activities were 8- to 9-fold higher from the H1 variants and 14-fold higher from 
the H2 variant than their CP counterparts. This, again, highlights the importance 
of the cellular context in these types of studies.  
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Figure 3.19 3’UTR luciferase results 1 
The full-length 3’UTR construct (A) and the 
relative luciferase activities of the three 
haplotype variants in SK-N-F1 (B) and SH-
SY5Y cells (C). 
 
All results – both promoter and 3’UTR – 
were normalised against the activity of an 
empty CMV-driven pMIR-REPORT vector 
and thus this increase cannot be attributed to 
the higher activity of the viral promoter in 
SH cells. Thus, although at the basic 
sequence level genetic variation within the 
3’UTR does not differentially affect tau 
gene expression, the difference in stability 
observed between the two cell lines opens 
the possibility for allelic differences in the interaction of the 3’UTR with 
differentially expressed endogenous factors.  
 
It has been shown that actively transcribed genes adopt a loop formation in which 
factors within the polyadenylation complex at the 3’ end of the transcribed gene 
interact with promoter-associated transcription factors to reduce aberrant 
transcription and promote mRNA transcription in the sense direction [232]. In 
particular, the poly(A)-associated factor, Ssu72, has been shown to play an 
important role in this, with mutations preventing loop formation in the FMP27 
gene. Interestingly, these Ssu72 mutations also caused an increase in Pol II 
density at and antisense transcription from the FMP72 promoter. This would 
therefore suggest that the 3’UTR plays a role in determining the activity and 
directionality of the promoter. Thus, it would be interesting to combine the 
promoter and 3’UTR luciferase studies to determine the effect of the full-length 
MAPT 3’UTR on transcription from both the CP and NP elements. This may add 
an additional layer of complexity to the regulation of MAPT transcription but 
could also potentially reveal haplotype differences that are dependent on the 
interaction of the 3’UTR with the promoter and therefore were undetectable when 
3’UTRLuciferaseCMV
SK-N-F1B
A
SH-SY5YC
3 Luciferase Reporter Gene Studies 
 
124 
 
the 3’UTR was assayed alone. Due to time constraints, this unfortunately falls 
outside the scope of this project. 
 
3.13.2 H1/H2 differences in determining transcript stability 
The relative luciferase activities of the three deletion constructs are given in figure 
3.20 alongside that of the full-length constructs. Results are separated by 
haplotype and cell line and appear to reveal H1/H2 differences in the 
determination of overall luciferase expression. For the H1 variants, the Fr1 
fragment conferred a marked increase in expression compared to its full-length 
counterpart; an increase that reached or trended towards statistical significance in 
both the F1 (H1B: p=0.0083; H1C: p=0.0083) and SH (H1B: p=0.0058; H1C: 
p=0.0634) cell lines.  
 
The reason for this increase may lie with the utilisation of the three 
polyadenylation signals (AATAAA) present in the MAPT 3’UTR. 
Polyadenylation is one of the final steps in the production of the mature mRNA 
transcript. The addition of a string of A-residues to the 5’ end of the transcript 
initiates transcription termination, facilitates export of the mature transcript from 
the nucleus and subsequent subcellular localisation, prevents transcript 
degradation in the cytoplasm, and is required for translation of the mRNA 
transcript into protein. Each process, however, is not solely dependent on 
polyadenylation and requires additional regulation from RNA binding factors 
such as microRNAs (miRNAs).  
 
The first MAPT poly(A) site is present at the 5’ end of Fr1 and its usage results in 
mature transcripts with a short 3’UTR of around 220 nucleotides. The other two 
signals are located at the 3’ end of Fr3, producing transcripts containing almost 
the full-length 3’UTR (~4130 and 4280 nucleotides respectively). It is therefore 
likely that these sites have different roles to play in the 3’UTR-mediated 
regulation of transcript expression. Thus, the absence of the Fr3 polyadenylation 
signals results in transcripts that exclusively contain the shorter 3’UTR and this 
may therefore lead to an increase in overall expression through the loss of the Fr3-
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mediated regulation of some or all of the polyA-dependent processes listed above. 
For the H2 Fr1 variant, although a relatively small increase in expression was 
observed, it did not quite reach statistical significance in either cell line, though 
came close in F1 cells (F1: p=0.0841; SH: p=0.3137; figure 3.20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 3’UTR luciferase results 2 
A: The luciferase construct variant assayed in each instance; B: The relative 
luciferase activity of each construct in SK-N-F1 cells, separated by haplotype; C: 
The relative luciferase activities in SH-SY5Y cells. A two-tailed Student’s t-test 
compared the relative activity of each deletion construct to that of the full-length 
construct (* p≤0.05). 
A 3’UTR
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As Fr1 expression is the most consistently altered compared to that of the full-
length construct, it is likely that the key sequences for determining the overall 
level of expression are contained on Fr2, Fr3 or both. Again there appears to be 
H1/H2 differences in how this is achieved. For the H2 variants, the overall 
stability of the mRNA transcripts appears to result from a balance between the 
stabilising and de-stabilising functions of the three individual fragments, with no 
single fragment consistently matching the expression of the full-length construct 
and therefore appearing dominant. For the H1 variants, however, Fr2 could be 
considered the dominant fragment, as the expression levels of the Fr2 H1 deletion 
constructs conferred expression that was consistently similar to their full-length 
counterparts in both the F1 (H1B: p=0.6004; and H1C: p=0.8939) and SH (H1B: 
p=0.1691; and H1C: p=0.9397) cell lines. Fr2 expression from the H2 variant was 
reduced compared to full-length expression and this reached or trended towards 
significance in both cell lines (F1: p=0.0238; SH: p=0.0877). 
 
Fr3 expression was the most variable, behaving differently depending on the cell 
line. In F1 cells, none of the three haplotype variants conferred expression levels 
that were significantly different from that of their full-length counterparts (H1B: 
p=0.6477; H1C: p=0.2170; H2: p=0.1758). In SH cells, however, expression 
significantly increased for the H1C and H2 variants, but not for the H1B variant 
(H1B: p=0.3855; H1C: p=0.0035; H2: p=0.0104).  
 
As mentioned earlier, Fr3 contains two of the three MAPT poly(A) sites and 
therefore the differential behaviour of this fragment in the two cell lines may 
result from differences in the recognition of the sites by the endogenous 
polyadenylation machinery. A useful tool for determining poly(A) site usage is 3’ 
RACE, in which priming at the poly(A) tail of mature transcripts, followed by 
extension and sequencing, allows the identification of the sequence lying 
immediately upstream to the poly(A) tail. Thus the relative usage of the two Fr3 
poly(A) sites – and the Fr1 site – in each cell line could be determined, though 
this is, again, outside the scope of this project. 
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Taken together, these results suggest that the Fr2 deletion fragment contains the 
key sequences for determining the expression level of H1 MAPT transcripts. This 
was the only fragment for which expression did not significantly deviate from that 
of the full-length 3’UTR, regardless of H1 sub-haplotype status and cell line. Fr2 
comprises the middle section of the 3’UTR (between nucleotides 1179-3007) and 
contains a string of A-residues that, when translated into mRNA forms a U-rich 
binding domain for the ELAV-like protein, HuD. It has been shown that HuD 
regulates the stability of some tau mRNA transcripts by anchoring them to 
microtubules and protecting them from decay [233]. This not only leads to an 
increase in stability, but ensures the correct subcellular localisation of the mature 
transcripts, a process that requires association with functioning microtubules. This 
is particularly important in neuronal cells, where local translation of MAPT 
transcripts occurs at large distances from the cell body and is vital for maintaining 
cellular polarity, which, in turn, is important for generating synapses and for 
neuronal plasticity during development.  
 
In fact, HuD expression has been shown to increase during development – first 
appearing following cessation of the cell cycle – and therefore regulates the 
stability of tau mRNA during neuronal differentiation. Inhibition of HuD 
expression in PC12 cells results in a decrease in the number of tau transcripts and 
a failure to respond to neuronal differentiation [233]. Interestingly, the H2 Fr2 
variant contains a triplet deletion (GAA) that reduces the A-rich stretch from 24 
nucleotides, as occurs in the H1 variants, to 21 nucleotides, likely weakening the 
HuD binding site and accounting for the lower stability conferred by the H2 Fr2 
variant. 
 
In consideration of the changes in HuD expression during development, it would 
have been desirable to compare the 3’UTR constructs in neuronally differentiated 
cell lines, but unfortunately the luciferase reporter assay was not a suitable 
technique in this instance. As the increase in expression from the 3’UTR 
constructs was so high – particularly in SH cells – the luciferase signal was close 
to the maximum limit of the Tecan GENios plate reader. Thus if, as expected, 
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expression increased further upon differentiation of the cells, the GENios limit for 
differentiating the signals would be exceeded.   
 
3.13.2.1 The H1C variant of Fr3 confers significantly increased expression 
compared to the H1B and H2 variants 
Although there was no difference in overall expression between the three full-
length haplotype variants, the variability in individual function of the three 
deletion constructs may suggest a role for genetic variation. Thus, the 3’UTR 
luciferase results described above and in figure 3.20 by haplotype are presented 
by construct in figure 3.21. The main influence of genetic variation was on the 
expression of Fr3. In both cell lines, the H1C variant conferred significantly 
increased expression compared to the H1B variant (F1: p=0.0135; SH: p=0.0360) 
and reached or trended towards a significant increase compared to the H2 variant 
(F1: p=0.0034; SH: p=0.0600). A significant H1/H2 difference was also observed 
for Fr2 in F1 cells, with the H2 variant conferring significantly lower expression 
than the H1B (p=0.0220) and H1C (p=0.0051) variants, likely due to the triplet 
deletion in the HuD binding site. 
 
It may therefore be that the H1C variant of the MAPT 3’UTR can affect gene 
expression by modulating Fr3-mediated processes, perhaps through alterations to 
poly(A) site preference. This is, of course, pure speculation and the H1C 
difference does disappear when the Fr3 region is assayed as part of the full-length 
3’UTR construct. The genetic difference, however, may come to prominence 
when assayed in conjunction with the MAPT promoter, allowing the formation of 
a gene loop that apparently plays an important role in promoting transcriptional 
activity in the sense direction (as described in section 3.13.1)  [232].  
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Figure 3.21 3’UTR luciferase results 3 
A: The three luciferase deletion construct variants; B: The relative luciferase 
activity of each construct in SK-N-F1 cells, separated by construct; C: The relative 
luciferase activities in SH-SY5Y cells.  * p≤0.05; ** p≤0.01.  
 
3.14 Discussion 
This chapter has described three luciferase reporter gene studies that investigated 
the effect of genetic variation within the 5’ and 3’ UTRs on transcription and 
mRNA stability. The most important finding described here was the consistently 
different regulation of transcription conferred by a cis-acting distal transcription 
regulatory domain containing the A-allele of the rs242557 polymorphism; the 
variant strongly associated with an increase in PSP-risk. It was also shown that 
this differential regulation of transcription by the allelic variants of rs242557 
remained regardless of the positioning of the domain relative to the core promoter 
or differences in endogenous cellular conditions. These factors are, however, 
important in determining the strength and function of the interaction between the 
domain and the core promoter and therefore the genomic location of this domain 
and polymorphism is likely key to its regulation of tau transcription in vivo. The 
SK-N-F1 SH-SY5YBA C
Fr1LuciferaseCMV
Fr2LuciferaseCMV
Fr3LuciferaseCMV
*
**
**
**
*
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H1 mutant constructs demonstrated that a single nucleotide mutation within exon 
0 was sufficient to abolish the differential effect of the A-allele variant of the 
regulatory domain. This provided evidence of a physical interaction between the 
two elements, which again signifies the importance of the distal location of the 
domain.  
 
The second luciferase study confirmed the presence of a secondary bi-directional 
promoter located immediately downstream to the core promoter. Transcriptional 
activity in both the sense and antisense directions was differentially affected by 
the endogenous cellular conditions, as was the effect of this additional activity on 
transcription from the core promoter. Not only was overall transcription from the 
bi-directional promoter increased in SK-N-F1 cells compared to SH-SY5Y cells 
in both directions, H2 transcription in the sense direction was apparently affected 
by the lack of a H2 chromosome in the SH line; failing to produce the 2-fold 
greater level of activity compared with that in the antisense direction that was 
observed in F1 cells. It is therefore likely that transcription from this promoter is 
dependent upon factors that are specific to the H1/H2 polymorphism and the cell 
type.  
 
Although there were no significant differences in either sense or antisense 
transcription conferred from the three haplotype variants, a polymorphism was 
identified that appeared to have a subtle but consistent allelic effect on activity. 
Following genotyping in PSP and control cohorts, the C-allele and C/C genotype 
were found to be slightly over-represented in PSP patients, though statistical 
significance was not reached. Investigation by more sensitive methods – such as 
allele-specific quantitative RT-PCR of endogenous MAPT-IT1 and MAPT-AS1 
expression from heterozygous cell lines – would allow differential activity of the 
allelic variants to be detected. This polymorphism is certainly worth investigating 
in larger PSP cohorts and its potential functional consequences bring into play 
non-coding RNAs, antisense transcription and chromatin modifications in MAPT 
expression and PSP risk.  
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The final luciferase study aimed to identify genetic variation within the 3’UTR of 
the MAPT gene that differentially affected mRNA stability and thus gene 
expression. Although no such genetic variation was detected when the full-length 
3’UTR was assayed, when split into three individual fragments the expression 
level conferred by the 3’ end of the 3’UTR (Fr3) was shown to be increased for 
the H1C variant. Fr3 expression was also the most affected by a change in cellular 
conditions, suggesting that this fragment may play an important role in regulating 
expression of the tau transcripts during development. It may therefore be that the 
increase in expression conferred by the H1C variant of this fragment is only of 
significance in neuronally differentiated cells, or when assayed in conjunction 
with MAPT promoter elements. As the luciferase assay was not suitable to 
investigate this hypothesis, more sensitive in vivo methods such RNA-FISH may 
prove to be more valuable in this instance. This method could also be used to 
quantify alternative poly(A) site usage and the effect on sub-cellular localisation 
of MAPT transcripts.  
 
In conclusion, the investigations described here have identified three H1B/H1C 
genetic differences that could account for the increase in in vivo expression 
reported for H1C chromosomes [12] and thus contribute to the increased risk of 
PSP conferred by this MAPT haplotype variant. The first – and strongest – is the 
rs242557 A-allele which was shown to confer increased transcriptional activity by 
weakening repression of the MAPT core promoter when cloned in its natural 
downstream position. The second is the rs3744457 C-allele and/or C/C genotype 
which may have a subtle effect on the transcription of two non-coding RNAs. The 
regulation of transcription by non-coding RNAs, particularly natural antisense 
transcripts, is a growing field of investigation but has been shown to play an 
important role in gene transcription. Thus, determining the function of these 
transcripts and the allelic effects of rs3744457 on their expression may further 
unlock the role of common genetic variation in MAPT transcription and PSP risk. 
The final genetic finding was the discovery that the H1C variant of Fr3 (the 3’ 
end) of the 3’UTR conferred significantly increased luciferase expression 
compared to the H1B and H2 variants. Although this increase was lost in the full-
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length constructs, the variability of Fr3 expression in the two cell lines suggests 
this region may play an important role in differential tau expression during 
development. 
 
After confirming the first part of this project’s hypothesis: that common genetic 
variation can affect the transcriptional activity of the tau promoter; the next stage 
was to determine the effect on the alternative splicing of downstream exons, and 
this is described in chapter 4. 
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4 Design, construction and validation of MAPT minigenes for 
the investigation of the effect of the rs242557 polymorphism on 
MAPT transcription and alternative splicing 
 
4.1 Overview 
To further investigate the link between the rs242557 polymorphism and the 
regulation of MAPT expression, a set of MAPT minigenes were created. The 
minigene blueprint comprised the 11 protein coding exons expressed in the adult 
brain, the key intronic sequences surrounding the alternatively spliced exons and 
the 3’untranslated region (3’UTR). Interchangeable promoter elements allowed 
the comparison of MAPT expression when driven by the MAPT core promoter 
with or without the addition of the rs242557 regulatory domain. Different versions 
of the minigenes were created representing the genetic variation of the common 
MAPT haplotypes. Each haplotype set included the minigene variant under the 
control of the MAPT core promoter alone, the MAPT core promoter in conjunction 
with the rs242557 regulatory domain, and the cytomegalovirus (CMV) promoter 
as an independent control. 
 
Each minigene variant was, in the first instance, transiently transfected into two 
neuroblastoma cell lines and the in vitro expression profiles determined. Platform 
cell lines were also created for the integration of the minigenes into the genome of 
each cell line to create stably-expressing isogenic cell models. This chapter details 
the design, construction and validation of these minigene cell models. 
 
4.2 Background 
Minigenes are artificially constructed versions of a gene in which most of the non-
essential sequences have been removed. They are traditionally used in splicing 
studies to identify the key cis- and trans-acting factors responsible for regulating 
the splicing of constitutive and alternative exons [234]. Minigenes are 
significantly smaller than their full-length counterparts, making them easier to 
manipulate in mutagenesis studies and allowing transfection and study in in vitro 
cell models.  
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To date, most tau minigenes have been created for the specific purpose of 
studying the splicing of exon 10 and as such have consisted of part or all of the 
region spanning exons 9-11 under the control of a either the MAPT core promoter 
or an independent control promoter [11, 12, 207, 209]. These minigenes allow the 
study of exon 10 splicing at the mRNA level but not at the protein level and not in 
conjunction with the N-terminal splicing events at exons 2 and 3. 
 
In 2007, Dawson et al [226] created a transgenic mouse model to investigate the 
effect of the N279K MAPT mutation – previously associated with FTDP-17 – on 
exon 10 inclusion (figure 4.1 (A)). Using a mixture of genomic and cDNA 
fragments of human tau, they created a chimeric minigene (denoted T-279) that 
contained all 14 tau exons and expressed mRNA that was alternatively spliced at 
exons 2, 3 and 10 (figure 4.1 (B)). The promoter consisted of a 5,049bp fragment 
of the human tau promoter and the N279K mutation was introduced into exon 10 
by site-directed mutagenesis. Two control models were created, one wildtype 
version without the mutation (T-WT) and one in which the tau promoter was 
swapped for the CMV promoter (C-279). In adult mice, the T-WT wildtype 
minigene expressed approximately equal amounts of 3R and 4R human tau 
mRNA, as observed in the healthy human adult brain (figure 4.1 (C)). The T-279 
and C-279 versions, however, almost exclusively expressed mRNA containing 
exon 10, showing a direct effect of the N279K mutation on exon 10 splicing.  
 
Interestingly, in foetal mice the T-279 model replicated the wildtype expression 
pattern of an equal 3R- and 4R-tau ratio, whereas the C-279 model demonstrated 
the same 4R-tau exclusivity seen in the adult mice. In a separate analysis, all three 
minigene models were found to constitutively include exons 2 and 3 (2N tau) in 
adult mice, with the 1N and 0N tau isoforms completely absent. The reason for 
this remains unclear. At the protein level, expression of human tau from the 
minigenes was found to be extremely low (approximately 1-2% of endogenous 
murine tau expression) and therefore the expression of exons 2, 3 and 10 in tau 
protein were not quantified here. Despite the low level of human protein 
expression, pathological aggregates resembling those found in the tauopathy brain 
were detected in the T-279 – but not the C-279 or T-WT – mouse brain post 
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mortem. Together, these findings revealed four things: firstly, that the tau 
promoter plays a role in the regulation of exon 10 inclusion; secondly, that this 
regulation changes during development; thirdly, that the N279K mutation causes a 
change in exon 10 splicing and fourthly, that an increase in tau expression is not 
sufficient to cause tau pathology unless there is an accompanying shift in 3R- and 
4R-tau ratio. 
 
Figure 4.1 A published minigene study of  tbe MAPT N279K mutation 
Taken from Dawson et al. J Neurosci (2007). A: The tau minigene used to create 
transgenic mouse models for the study of the effect of the N279K exon 10 mutation 
on tau expression. B: The mRNA transcribed from the minigene. The numbered 
arrows represent the location of primers used to analyse exon 2 and 3 (primers 1 
and 2) and exon 10 (primers 3 and 4) inclusion. C: RT-PCR results of minigene 
cDNA extracted from mouse brain. ‘non-TG’ = non-transgenic control mouse; 
Human = human tau cDNA from healthy adult brain; C-279 = the mutated Tg 
mouse with the CMV promoter; T-279 = the mutated Tg mouse with the tau 
promoter; T-WT = the wildtype Tg mouse with the tau promoter. 
 
This study by Dawson et al was the first to show that the tau promoter can 
influence splicing at exon 10 and has demonstrated a direct effect of a known 
disease-causing mutation on this process. It has yet to be shown, however, 
whether common variation that is known to increase risk, rather than cause 
disease, can have a similar effect on tau splicing. In addition, it has yet to be 
determined whether the increase in tau transcription reported for the PSP-
associated H1/H1C haplotypes can actually cause the pathology-associated 
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alteration in tau splicing ratio directly, rather than the two phenomena simply 
occurring concurrently. Thus, in this study the basic design of the Dawson 
minigene was adapted to create in vitro mammalian cell models to determine 
whether the rs242557 promoter polymorphism can directly affect the splicing 
events at exons 2, 3 and 10. Their construction is described here. 
 
4.3 Multisite Gateway® Pro Technology  
Multisite Gateway
®
 Technology (Invitrogen) presents a highly efficient method 
for the simultaneous transfer of several heterologous DNA sequences into a 
chosen vector system in a defined order and orientation [235-237]. The 
technology is typically used to bring together separate elements of a gene for 
expression analysis in vitro. DNA transfer is facilitated using a modified version 
[238] of the bacteriophage lambda site-specific recombination system [239]. 
Briefly, lambda utilises specific recombination sequences – called attachment or 
att sites – to integrate itself into the genome of its E.coli host and to switch 
between its lytic and lysogenic pathways [240]. Recombination reactions are 
catalysed by a mixture of enzymes that bind to the att sites, bring the two target 
sequences together, and facilitate DNA strand exchange by cleavage and covalent 
re-attachment. Recombination is reversible, with different sets of proteins 
catalysing the lytic and lysogenic pathways, and conservative, as there is no gain 
or loss of nucleotides and DNA synthesis is not required. Although strand 
exchange occurs within a core region common to all att sites, the new site formed 
post-recombination is a hybrid that combines the differing flanking sequences 
donated by the two parental sites [239].  
 
The basic Gateway
®
 technology utilises four att recombination sites, modified 
from the wildtype lambda site to improve efficiency and specificity, to transfer the 
target DNA in a two-step reaction. In step one, attB sites recombine with attP 
sites to produce the hybrid attL and attR sites in a reaction termed the ‘BP’ 
reaction. This reaction is used for the transfer of the target DNA sequence 
(typically a PCR product flanked by attB sequences) into a ‘donor’ vector 
(pDONR) containing attP sequences to produce ‘entry clones’ (figure 4.2A). In 
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step two, the ‘LR’ reaction catalyses a reversal of the BP reaction, with 
recombination between attL and attR sites, giving rise to attB and attP sites. This 
reaction is used to transfer the target DNA sequence from the entry clone (now 
flanked by the newly formed attL sequences) into the ‘destination’ vector 
(pDEST) containing attR sequences. This ‘expression clone’ is now ready for in 
vitro expression analysis (figure 4.2B). The BP and LR reactions are catalysed by 
proprietary mixtures of different recombination proteins, ensuring each reaction is 
unidirectional. 
Figure 4.2 The two-step recombination process using Gateway
®
 technology  
A. The BP reaction transfers the target DNA fragment into a pDONR vector to 
produce an ‘entry clone’; B. The LR reaction transfers the target DNA from the 
entry clone into a destination vector to produce the final ‘expression clone’. Taken 
from the Invitrogen Gateway
®
 Technology with Clonase™ II manual. 
 
A modified version of the Gateway
®
 protocol, called Multisite Gateway
®
, allows 
the simultaneous and directional transfer of up to four different target sequences 
into one destination vector. This is made possible by specific modifications to the 
attB and attP sequences that increase specificity and give the sites an orientation. 
Up to five modified attB sites (attB1-B5) in two orientations are used in the 
Multisite Gateway
®
 BP reaction, depending on the number of DNA sequences to 
be transferred. The att sites are not palindromic and therefore their orientation 
relative to the target DNA sequence determines the type of hybrid site produced 
following recombination. When the orientation of the attB site (illustrated by the 
direction of the arrowhead in figure 4.3) points towards the target DNA sequence, 
the modified sites are denoted attB1-B5 and recombination with donor vectors 
containing similarly modified attP1-P5 sites results in the production of entry 
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clones with attL sites (attL1-L5). Specificity among the attB variants is 
maintained as attB1 sites will only recombine with attP1 sites to produce attL1 
sites, attB2 with attP2 to produce attL2 etc. Conversely, when the orientation of 
the attB site points away from the target DNA sequence the sites are denoted with 
an ‘r’ (attB1r-B5r) and recombination with attP1r-P5r sites produces attR sites 
(attR1-R5). Thus, up to four different entry clones can be created, each containing 
a target DNA sequence flanked by different attL and attR variants. 
 
Figure 4.3 The Multisite Gateway
®
 process  
Four target DNA sequences are combined in one expression clone. Taken from 
Invitrogen’s ‘Multisite Gateway Pro’ manual. 
 
In the Multisite Gateway
®
 LR reaction, recombination occurs simultaneously 
between the four pDONR entry clones. Specificity is again maintained as attL1 
sites will only recombine with attR1 sites etc. Thus, by flanking the initial target 
DNA sequences with specific combinations of the attB/attBr variants, the order 
and orientation of the multiple fragments in the final expression clone can be 
controlled. Figure 4.3 outlines the experimental process and the att site 
combinations required for the simultaneous transfer of the maximum four DNA 
sequences, as required here for construction of the MAPT minigenes. The 
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simultaneous transfer of two or three fragments is also possible using this system, 
but the combination of attB sites on the ends of each fragment must be altered. 
 
4.4 Jump-In™ TI™ (Targeted Integration) Gateway® System  
The Jump-In TI System (Invitrogen) presents a method by which expression 
clones generated using the Gateway
® 
or Multisite Gateway
®
 Technology can be 
irreversibly inserted into specific locations in the mammalian genome, creating 
stably expressing isogenic cell lines. The technology uses the PhiC31 and R4 
integrase enzymes to stably insert target DNA sequences into a specific, 
predetermined location in the genome of mammalian cells. The ‘targeted 
integration’ process involves, in step one, creating a platform cell line by inserting 
the unique R4 attP sequence into the genome of the chosen cell line and 
determining the site of integration. In step two, the expression clone is integrated 
into the platform cell line at the predetermined genomic locus in a process called 
‘retargeting’ (Figure 4.4).  
 
Platform creation involves the PhiC31-mediated integration of a ‘platform’ vector 
into the genome of the chosen cell line. This is possible, firstly, due to the 
presence of naturally occurring PhiC31 ‘psuedo-attP’ sites in the mammalian 
genome and, secondly, the ability of the PhiC31 integrase enzyme to catalyse 
recombination between two non-identical sites. Thus, in the presence of PhiC31 
integrase, recombination occurs between PhiC31 attB sequences located on the 
platform vector and the endogenous pseudo-attP sites, resulting in the insertion of 
the platform vector into the genome of the cell line. PhiC31 integrase lacks a 
corresponding excisionase enzyme, making this insertion unidirectional. 
 
The platform vector also contains the unique attP target sequence of the R4 
integrase. R4 target sites do not occur naturally in the mammalian genome and 
will therefore only be present at the insertion site of the platform vector. The 
hygromycin resistance gene and a promoterless zeocin, blasticidin or neomycin 
resistance gene are also included in the platform vector and are required for the 
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selection of successful recombinants during the two-step targeted integration 
process described below.  
 
In step one, cells successfully transformed with the R4 platform vector are 
selected by their resistance to the antibiotic Hygromycin B. Each resistant cell 
colony is isolated and expanded to produce new monoclonal cell lines, each with 
the R4 platform vector inserted into the genome at one or more of the naturally 
occurring pseudo-attP sites. The site(s) of integration of each new cell line is 
determined by cell harvest and DNA extraction followed by Splinkerette PCR 
(see section 4.10.2). Cell lines with more than one integration site are immediately 
discarded, as are those in which the platform vector has been inserted into a 
critical region of the genome, for example within a gene. In this instance, the 
insertion may disrupt normal cell function and make subsequent expression 
analyses unreliable and misleading. The use of a platform vector allows the effect 
of the insertion on normal cell functioning to be monitored in the absence of any 
influence conferred by the expression clone and provides a single, unique attP 
integration site for the subsequent retargeting step.   
 
In step two, the Gateway
®
 expression clone is integrated into the predetermined 
genomic locus by virtue of the newly inserted R4 attP target site in the platform 
cell line. The destination vector used to create the expression clone (see section 
4.3) contains the attB target sequence for the R4 integrase and an independent 
promoter element (EF1α) that is required for antibiotic selection following 
integration. In the presence of R4 integrase, recombination occurs between the R4 
attB site in the expression clone and the R4 attP site in the platform cell line, 
inserting the expression clone into the genome of the cell line at the 
predetermined site of the platform vector. This integration event results in the 
insertion of the EF1α promoter element upstream to the promoterless zeocin, 
blasticidin or neomycin resistance gene present in the platform vector, giving 
successful recombinants resistance to the zeocin, blasticidin or neomycin 
antibiotic as appropriate and providing a new agent for selection.  
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This two-step targeted integration process leads to the production of an isogenic 
cell model in which DNA sequences of interest are stably expressed from a 
predetermined genomic location and can be differentiated from the platform or 
wildtype cell line by virtue of their antibiotic resistance. The main advantage of 
this system, however, is that once a platform cell line has been selected, it can be 
used for the integration of all subsequent expression clones generated using 
Gateway
®
 Technology, creating a series of isogenic cell models in which the 
integration of the expression clone is always into the same genomic locus. This 
removes the possibility of gene expression being differentially influenced by the 
insertion site of the expression clone, increasing reliability and reproducibility of 
subsequent expression studies. 
Figure 4.4 The Gateway
® 
two-step targeted integration process  
The Gateway
®
 expression clone is integrated into the genome of a chosen 
mammalian cell line to create stably-expressing cell models. Taken from Invitrogen’s 
‘Jump-In TI’ manual. 
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4.5 Cell lines 
Two human cell lines were chosen to create the stable cell models. The SK-N-F1 
and SH-SY5Y cell lines are both derived from neuroblastomas and were 
described in sections 2.1.5.1 and 3.7. As the two cell lines are morphologically 
different, the effect of cell type – particularly the difference in endogenous MAPT 
haplotype status – on minigene expression can be investigated. 
 
4.6 MAPT minigenes: design 
 
4.6.1 The minigene blueprint 
The MAPT minigenes were created for the specific purpose of studying the effect 
of the rs242557 polymorphism on the co-regulation of MAPT transcription and 
alternative splicing. A unique objective of this project was to investigate the effect 
at both the transcript and protein levels and to allow this a number of elements 
had to be incorporated into the minigene design.  
 
To ensure expression of the full tau protein in vitro, the minigene had to include: a 
promoter with a start site for the initiation of transcription, the Kozak sequence 
((gcc)gccRccAUGG) for the initiation of translation, all MAPT protein-coding 
exons to produce full-length tau protein, the splicing signals at the 5’ and 3’ ends 
of introns 1, 2, 3, 9 and 10 to ensure the expression of all six tau isoforms, and the 
3’ untranslated region (UTR) which plays a major role in the post-transcriptional 
processing of tau mRNA. Exons 4A, 6 and 8 were not included as they are not 
widely expressed in the adult brain [149]. To minimise the size of the minigene, 
introns 4-8 and 11-12 were completely excluded as their neighbouring exons are 
constitutively included in tau mRNA and are therefore not subject to alternative 
splicing. It was necessary to have a method of distinguishing the tau mRNA and 
protein produced by the minigene from the species produced endogenously by the 
cell lines. For this reason a 27 nucleotide tagging sequence – unique to the 
minigene and recognised by the non-native FLAG antibody – was inserted 
downstream to the final coding exon, upstream to the stop codon. Panel A in 
figure 4.5 presents a schematic of the basic MAPT blueprint. 
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4.6.2 The minigene promoter elements 
The rs242557 polymorphism falls within a transcription regulatory domain and 
therefore three minigenes, each under the control of a different promoter but 
otherwise identical, were necessary to fully ascertain the contribution of rs242557 
to the regulation of minigene expression:  
 
1. The first promoter comprised the MAPT core promoter (the ‘CP’ element 
described in chapter 3) with the rs242557 regulatory domain (the ‘SD’ 
element) cloned immediately downstream. By comparing minigene 
expression conferred by the H1B-G, H1C-A and H2-G variants of this 
promoter construct, the differential effect of each rs242557 allele on 
alternative splicing could be determined. The downstream positioning of 
the SD domain in this promoter construct was preferred over the upstream 
version (see chapter 3) as it more closely resembles the endogenous 
genomic organisation. 
  
2. The second promoter acted as a control from within the MAPT gene and 
simply comprised the core promoter alone. By comparing minigene 
expression conferred with and without the addition of the SD, the 
contribution of the rs242557 domain to both transcription rate and 
alternative splicing could be determined. 
 
3. The third promoter was cloned from the cytomegalovirus (CMV) and 
provided an independent control. Comparison of the minigene expression 
profiles of the three haplotype variants when driven by the same CMV 
promoter would highlight any changes in expression that were due solely 
to genetic variation elsewhere in the minigene and not to the promoter 
itself. Further comparison with the MAPT promoter-driven minigenes 
would confirm whether sequences specific to the native MAPT core 
promoter play a role in regulating the pattern of MAPT alternative splicing. 
 
The minigenes were created using the Multisite Gateway
®
 technology (see section 
4.3), with four entry clones containing different sections of the minigene 
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recombining in the LR reaction to produce the complete construct. Thus, by 
isolating the promoter element on the first of the four entry clones, different 
versions could be swapped into the minigene simply by exchanging the promoter 
entry clone in the final LR reaction. With the other three entry clones comprising 
the body and the 3’UTR of the minigene and remaining the same each time, three 
separate minigenes were created for each haplotype variant in which only the 
promoter element varied.  
 
4.6.3 Adaptations for the Multisite Gateway® protocol 
To fulfil the requirements for the Multisite Gateway
® 
system all of the 
components of the minigene must be contained within four DNA fragments. Due 
to its size, large sections of the MAPT gene - including most of the introns and 
some of the exons – were excluded from the minigene to facilitate its study in 
vitro. This meant that the minigene was made up of numerous smaller elements 
distributed across the gene – typically at large distances from each other – making 
it impossible to clone all of the required elements in just four PCR reactions. 
Figure 4.5B details the nine separate elements (not including the promoter and 
3’UTR) that made up the body of the minigene, with each element amplified in 
one PCR reaction from either genomic DNA or reverse transcribed cDNA. A 
series of cloning steps joined the individual minigene elements together to 
produce two larger fragments that were compatible with the Multisite Gateway
®
 
protocol. 
  
1
4
5
 
Figure 4.5 The 
minigene blueprint 
 
A: The basic 
design 
 
B: The separate 
PCR elements 
required to 
construct the 
minigene. 
Elements 5 and 9 
were amplified 
from cDNA, the 
rest from genomic 
DNA 
 
C: The PCR 
elements were 
grouped into four 
larger fragments 
to meet the 
requirements of 
the Multisite 
Gateway
®
 protocol 
(Invitrogen) 
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The composition of the final minigene fragments was carefully considered to take 
advantage of the modular design of the Gateway
®
 system. As described 
previously, one of the main advantages of this system is the flexibility it provides 
in the study of genetic variation, as variants of one of the DNA fragments can be 
swapped in while the other three remain the same. It is also possible – with some 
adjustments to the protocol – to leave one or even two fragments out completely, 
allowing a more focused investigation of certain sections of the minigene. 
Another consideration was the final size of each fragment, as the closer the four 
fragments are in size, the more efficient the final recombination reaction will be. 
For these reasons, and in consideration of the hypothesis under investigation, the 
first fragment comprised the promoter element alone to allow the straightforward 
swap-in of the three different promoters. The second fragment contained the 
alternatively spliced exons 2 and 3 and the third contained the 3R/4R-determining 
exon 10. Placing exons 2 and 3 on a separate fragment to exon 10 creates the 
possibility of studying the N-terminal (exons 2 and 3) and C-terminal (exon 10) 
alternative splicing events separately if necessary at a later date. The fourth 
fragment contained the full-length 3’UTR. Figure 4.5C details the minigene 
elements included in each fragment. 
 
4.7 MAPT minigenes: Target DNA fragment construction 
 
4.7.1 Fragment 1 (F1): the promoter elements 
 
4.7.1.1 Promoter 1 (F1-242): The MAPT core promoter in conjunction with 
the rs242557 regulatory domain 
The first promoter element comprised the MAPT H1 or H2 core promoter (CP) in 
conjunction with the distal regulatory domain containing the rs242557 
polymorphism (the SD element). The construction of this promoter was described 
in section 3.5, when it was cloned into the pGL4.10 [luc2] vector as part of the 
luciferase reporter gene study of the MAPT promoter elements. To recap, the H1B 
and H1C variants comprised the H1 core promoter with either the rs242557 G-
allele (H1B-G) or A-allele (H1C-A) variant of the SD cloned immediately 
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downstream. The rs242557 polymorphism in the SD represented the only 
sequence difference between these two constructs, allowing a direct examination 
of the effect of this polymorphism on minigene expression. The H2 variant 
comprised the H2 core promoter with the G-allele variant of the SD domain, with 
several sequence differences in both the CP and SD separating this variant from 
its H1 counterparts. The luciferase reporter study revealed that the H1C-A variant 
conferred an approximate 2-fold increase in transcriptional activity in comparison 
to the H1B-G variant, with a corresponding 4-fold increase over the H2-G variant 
observed. Thus, the study of this promoter variant in the wider context of the 
minigene allowed the determination of the effect of the increased transcription 
rate of H1C-A on the inclusion/exclusion rate of exons 2, 3 and 10.  
 
To make these constructs – denoted from here onwards as F1-242 – compatible 
with the Gateway system, attB1 and attB5r recombination sequences (the 
combination required for fragment 1) were introduced onto the 5’ and 3’ ends 
respectively. This was achieved by PCR, with the pGL4.10 luciferase construct 
used as the template to amplify the full element in one reaction. The appropriate 
attB sequences were added onto the 5’ end of the forward (attB1) and reverse 
(attB5r) primers, producing a 2,218bp PCR product containing the promoter 
element flanked by the attB1 site at the 5’ end and the attB5r site at the 3’ end. A 
full description of the attB PCR protocol is given in section 4.7.4. 
 
4.7.1.2 Promoter 2 (F1-CP): The MAPT core promoter alone 
The second promoter was the 1,342bp core promoter (CP) element containing the 
major MAPT transcription start site (exon 0) and is described in section 3.5. The 
H1 variant doubled as the promoter element for both the H1B and H1C minigene 
variants, whereas the H2 variant was included on the H2 minigene only. The 
inclusion of this promoter element in the investigation allowed the effects of the 
rs242557 domain of the F1-242 variant to be separated from the effects conferred 
by the core promoter alone. It also allowed the examination of basic differences 
between the unregulated H1 and H2 core promoters independently of the 
rs242557 regulatory domain and, as the H1B and H1C core promoters are 
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identical, provided a means of detecting any changes in alternative splicing 
pattern that resulted from genetic variation elsewhere in the minigene.  
 
As with the F1-242 constructs, the required attB1 and attB5r sequences were 
introduced onto the ends of the H1 and H2 CP elements (denoted from here 
onwards as F1-CP) by PCR, using the pGL4.10 luciferase constructs described in 
section 3.5.5 as the template. The total size of the F1-CP attB PCR product was 
1,400bp. 
 
 
Figure 4.6 The cloning process for the construction of the three minigene promoters.  
CP = the H1 MAPT core promoter; SD = the rs242557 regulatory domain; CMV = 
the cytomegalovirus immediate early promoter. 
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4.7.1.3 Promoter 3 (F1-CMV): The cytomegalovirus promoter 
The third promoter element was an extrinsic, non-mammalian control promoter 
originating from the cytomegalovirus (CMV). Placing the minigene variants under 
the control of the same CMV promoter allowed the detection of differences in 
alternative splicing and mRNA processing due solely to the genetic variation in 
the body of the minigene and 3’UTR (i.e. in Fragments 2, 3 and 4 only). Of 
greater interest, however, is the assessment of the role of promoter identity in the 
regulation of tau alternative splicing, achieved by determining whether a viral 
promoter can recapitulate the pattern of expression conferred by the intrinsic 
MAPT promoter. If differences are observed, this would indicate that elements 
specific to the MAPT promoter region play a role in alternative splicing, pointing 
towards co-transcriptional regulation as a likely mechanism for the control of tau 
isoform expression. 
 
The CMV promoter is highly active – significantly higher than the MAPT 
promoter – and is commonly used in expression studies as either a control 
promoter or in instances where the promoter is not under investigation, for 
example in many miRNA studies. There are therefore many plasmid vectors 
available containing the CMV immediate early promoter element, one of which is 
the pMIR-REPORT vector used in the 3’UTR luciferase reporter gene study and 
described in section 3.6.3. Thus, the CMV promoter element was amplified by 
PCR using the pMIR-REPORT vector as the template. The full sequence of the 
CMV immediate early promoter element is given in Appendix H.  
 
As with the F1-242 and F1-CP constructs, the attB1 and attB5r sequences were 
added onto the 5’ and 3’ ends of the construct (denoted from here onwards as F1-
CMV) respectively by PCR. The total size of the F1-CMV attB PCR product was 
623bp. The processes involved in producing each of the three F1 promoter 
variants are presented in Figure 4.6.  
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4.7.2 Fragment 2 and Fragment 3 
 
4.7.2.1 Fragment 2 (F2) composition 
Fragment 2 comprised protein-coding exons 1, 2 and 3 with surrounding 5’ and 3’ 
segments from introns 1, 2 and 3. The intronic sequences are necessary as they 
contain vital signals required for the regulation of alternative splicing events. The 
minimum sequence lengths of these and all introns present in the minigene were 
based upon the findings of Yu et al, who demonstrated that 569bp of the 5’ 
sequence and 725bp of the 3’ sequence of intron 10 was required to maintain the 
correct pattern of splicing in their exon 10 construct [210]. In the absence of 
similar information for the other MAPT introns, these sizes were set as a minimum 
inclusion length for intronic segments throughout the minigene. This marks an 
important departure from the Dawson minigene, where as little as 172bp of 
intronic sequence was included.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 The cloning process for the construction of Fragment 2 
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Exons 1, 2 and 3 were contained within three separate elements (denoted 1-3), 
with each element amplified from genomic DNA by PCR. One set of primers per 
element was sufficient to capture the 3’ segment of the upstream intron, the exon 
and the 5’ segment of the downstream intron. An additional fourth element 
contained only the 3’ segment of intron 3. The composition of each element in 
Fragment 2 is presented in figure 4.7. 
 
4.7.2.2 Fragment 3 (F3) composition 
Fragment 3 contained the remaining protein-coding exons and the intron 9 and 10 
segments surrounding exon 10. As exons 4, 5, 7, 9, 11, 12 and 13 are 
constitutively present in MAPT mRNA, the surrounding intronic segments 
containing the splicing signals were deemed unnecessary. Thus, to reduce the size 
of the minigene – and therefore increase transformation efficiency – introns 4, 5, 
7, 11 and 12 were excluded in their entirety.  
 
Figure 4.8 The cloning process for the construction of Fragment 3 
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The exons were amplified in two groups by PCR using cDNA reverse transcribed 
from RNA as the template. The RNA samples were extracted from the brain tissue 
of the same three patients from whom the genomic DNA elements have been 
cloned, thus encompassing the same genetic variation. Exons 4, 5, 6 and 9 were 
amplified in one PCR to form element 5. Element 9 was initially designed to 
similarly include exons 11, 12 and 13; however the primers required to achieve 
this in one PCR reaction were incompatible and therefore only exons 12 and 13 
were incorporated into this element. Exon 11 was instead amplified from genomic 
DNA in a PCR reaction that also incorporated the 3’ segment of intron 10. Exon 
10 and the remaining intronic segments were amplified from genomic DNA to 
form the final two elements. The exact composition of elements 5-9 are presented 
in figure 4.8. 
 
4.7.2.3 Fragment 2 and 3 construction 
As described above, elements 1-9 were created by PCR from a starting template 
of either genomic DNA or reverse transcribed cDNA. To create Fragment 2, 
elements 1-4 were ligated together, as were elements 5-9 to create Fragment 3. To 
facilitate this, specific restriction enzyme recognition sequences were introduced 
onto the 5’ and 3’ ends of each element during PCR. Fragments 2 and 3 were each 
constructed in the pGEM-T Easy vector (section 3.5.4) and therefore the 
combinations of restriction sites were chosen to allow the sequential and 
directional insertion of each element into the multiple cloning site (MCS) of this 
vector (figures 4.7 and 4.8). Each six-nucleotide restriction sequence was attached 
onto the 5’ end of the forward or reverse primer and was thus incorporated onto 
the appropriate end of the element during PCR. The primer sequences, restriction 
sites and PCR conditions required for the amplification of each element are given 
in table 4.1.  
 
The element 9 reverse primer contained the FLAG-tag motif in addition to the 
required ApaI restriction site. The FLAG-tag motif is 27 nucleotides in length and 
provides a method of distinguishing the minigene tau protein from the 
endogenous species through its reactivity with the FLAG antibody. The 
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positioning of the motif between the restriction site and the element 9 target 
sequence at the 5’ end of the reverse primer resulted in its incorporation onto the 
3’ end of element 9, immediately downstream to the final coding exon. The stop 
codon at the end of exon 13 was moved to the end of the FLAG motif to ensure 
the tag is transcribed and translated. The sequence of the FLAG-tag motif is: 
GATTACAAGGATGACGACGATAAGTAA. 
 
The PCR products were purified using the QIAquick PCR Purification kit and 
individually ligated into the pGEM-T Easy vector using the cloning method 
described in section 3.5.4 Positive clones were identified by blue/white β-
galactosidase screening and confirmed by sequencing. 
 
To construct Fragment 2, component elements 2, 3 and 4 were cut out of their 
pGEM-T Easy vectors and inserted into the vector containing element 1. This was 
done by digestion of each clone with the appropriate pair of enzymes (table 4.1), 
followed by a single multi-fragment ligation reaction between the linearised 
pGEM-T/element 1 vector and the three digested elements. A 6:1 ratio of 
insert:vector was used for this reaction, with optimal efficiency achieved by 
calculating the exact amount of each insert required to provide an equimolar ratio 
of DNA ends. This calculation takes into account the size of each element and 
uses the following formula to convert μg of DNA to pmol of ends: 
 
μg DNA x   pmol    x   106pg    x   1    x   2  x   kb element   =  pmol DNA ends 
           660pg         1μg           N                     1000bp 
 
Where: N is the number of nucleotides (in kb), 660pg/pmol is the average 
molecular weight of a single nucleotide pair, 2 is the number of ends in a linear 
DNA molecule, and kb/1000bp is a conversion factor for kilobases to base pairs 
(Promega BioMath calculator, “Linear DNA: Micrograms to Picomoles of DNA 
Ends”). 
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A total of 25ng of digested pGEM-T/element 1 vector  (0.018 pmol ends) and 
52ng, 23ng and 45ng of digested elements 2, 3 and 4 (each 0.108 pmol ends) were 
included in the 20μl ligation reaction, which was incubated overnight at 16°C with 
40 units of T4 DNA ligase, 1x T4 DNA ligase buffer and 10mM ATP. Half of the 
ligation mix was transformed into 100μl of JM109 E.coli cells and incubated 
overnight on LB-agar plates containing 50μg/ml of ampicillin. Positive clones 
were screened by digestion and confirmed by sequencing. 
 
To construct Fragment 3, elements 6, 7, 8 and 9 were similarly inserted into the 
vector containing element 5. The enzymes used to digest each element are given 
in table 4.1. The large discrepancy in size between element 7 (1,764bp) and the 
other four elements (368-843bp) meant a multi-fragment ligation was unsuitable 
in this instance, as optimal efficiency occurs when each element is similar in size. 
Thus, the elements were inserted one at a time over four rounds of cloning to 
produce the final Fragment 3. Each single-fragment ligation comprised 150ng of 
digested element, 50ng of linearised pGEM-T/element(s) vector, 2 units of T4 
DNA ligase, 1x T4 DNA ligase buffer and 10mM ATP and was incubated 
overnight at 4°C. A volume of 50μl of JM109 cells were transformed with 5μl of 
ligation mix and incubated overnight on LB-agar plates containing 50μg/ml of 
ampicillin. Positive clones were screened by digestion and confirmed by 
sequencing following each round of cloning. 
  
1
5
5
 
Promoter 3’UTR
FL
A
G
E13E12E11E10E9E7E5E1 E2 E4E3
Intron -1 Intron 1 Intron 2 Intron 3 Intron 9 Intron 10
3’UTRElement 9Element 1 Element 2 Element 3 Element 4Promoter Element 5 Element 6 Element 7 Element 8
 
DNA template Primer RE site Sequence (5'-3') Length (bp) AT (°C) Mg (mM) Size (bp) Double digestion, buffer
Forward NheI GCTAGCCCTGGTGGTGTTGAATATGA 26
Reverse XhoI CTCGAGAAGAGGCGAAGTCAATTTGG 26
Forward XhoI CTCGAGCACAGGGAAGGGACAATTCA 26
Reverse SacII CCGCGGCTTGACTGACACAGATGGGA 26
Forward SacII CCGCGGAAAGCCTTCAAAGCTGACAA 26
Reverse SphI GCATGCGCCCTGTCTGATTGATTCCC 26
Forward SphI GCATGCCCCGTGAGCCCATTG 21
Reverse AatII GACGTCCTGGTGTATGTGTCAGCAAA 26
Forward HpaI GTTAACCTGAAGAAGCAGGCATTGGA 26
Reverse XbaI TCTAGACTTCCCGCCTCCCGGCT 26
Forward XbaI TCTAGAGTGAGAGTGGCTGGCTG 23
Reverse NcoI CCATGGTAACGCACCCAGACGA 22
Forward NcoI CCATGGAAGACGTTCTCACTGATCTGG 27
Reverse SphI GCATGCCACTTTGGTTTGGCTCTTTG 26
Forward SphI GCATGCCTCGAGCTTACTGAGACACTA 27
Reverse AatII GACGTCCTGGTTTATGATGGATGTTGCCTA 30
Forward AatII gtcattacatattGACGTCGAGGTGGCCAGGTG 33
Reverse ApaI
GGGCCCTTACTTATCGTCGTCATCCTTGTA
ATCCAAACCCTGCTTGG
47
Genomic
Genomic
Genomic
Genomic
Genomic
Genomic
cDNA
NcoI/SphI, NEB2
SphI/AatII, NEB4
AatII/ApaI, NEB4
Genomic
cDNA
XhoI/AatII, NEB4
XhoI/SacII, NEB4
SacII/SphI, NEB4
SphI/AatII, NEB4
XbaI/ApaI, NEB4
XbaI/NcoI, NEB4
Element 9
63
65
65
65
65
Element 1
Element 2
Element 3
Element 4
1.8
Element 5
Element 6
Element 7
Element 8
60
368
63
65
2.5
1.8
1.8
1.8
2.5
1.8
2.5
60 1.8
1201
1449
1474
1247
527
629
1764
843
 
 
Table 4.1 The primers, restriction enzyme sites, PCR conditions and digestion conditions for the cloning and ligation of each minigene element. 
PCR products were cloned into the pGEM-T Easy vector to product Fragments 2 (elements 1-4) and 3 (elements 5-9).  
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4.7.2.4 Gateway modifications 
Once Fragments 2 and 3 had been constructed in the pGEM-T Easy vector, it was 
necessary to add the appropriate attB sequences onto the 5’ and 3’ ends. As with 
Fragment 1, this was done by PCR with the attB sequences added onto the 5’ end 
of the forward and reverse primers. Fragment 2 was flanked by attB5 and attB4 
sequences, with attB4r and attB3r sites incorporated onto the ends of Fragment 3. 
The total size of the F2 and F3 attB PCR products was 5,398bp and 4,086bp 
respectively. 
 
Full schematics of the processes involved in the creation of Fragments 2 and 3 are 
given in figures 4.7 and 4.8, respectively. 
 
4.7.3 Fragment 4 (F4): the 3’UTR 
Fragment 4 constituted the MAPT 3’UTR which was previously cloned in the 
pMIR-REPORT vector for investigation in the luciferase reporter gene study 
described in section 3.12. As such, the full-length construct was used as the 
template in the attB PCR reaction to introduce the attB3 and attB2 sequences onto 
the 5’ and 3’ ends of the fragment, respectively. The total size of the F4 attB PCR 
product was 4,428bp. A schematic of the preparation of Fragment 4 for inclusion 
in the Multisite Gateway
®
 protocol is given in figure 4.9. 
 
4.7.4 attB PCR 
The standard PCR protocol had to be modified to take into account the addition of 
27-31 nucleotides of attB sequence – which does not anneal to the target DNA in 
the initial PCR cycles – to the primers and the large size (up to 5.4kb) of the target 
fragments. The AccuPrime High Fidelity polymerase enzyme blend (Invitrogen) 
is designed for the amplification of large products from plasmid DNA and 
provides increased specificity for PCR conducted with suboptimal primers. Each 
25μl PCR reaction comprised: 100ng of purified plasmid construct, 0.25μl of 
AccuPrime Taq, 1x AccuPrime Buffer I, dNTPs (each to a final concentration of 
10mM), the forward and reverse primers (each to a final concentration of 0.2μM), 
with magnesium and DMSO added as necessary. Each reaction was heated to 
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94°C for 4 minutes followed by 10 cycles of 94°C for 30 seconds, a suitable 
annealing temperature for 30 seconds and 68°C for 1-5 minutes depending on the 
product size. A further 20 cycles of 94°C for 30 seconds and 68°C for 1.5-5.5 
minutes was followed by a final extension at 68°C for 7 minutes. The primer 
sequences and PCR conditions used for the amplification of each fragment are 
given in table 4.2. The attB PCR products were resolved by agarose gel 
electrophoresis and purified by QIAquick Gel Extraction kit. 
 
Figure 4.9 The cloning process for the construction of Fragment 4 containing the 
MAPT 3’UTR 
 
4.7.5 Entry clone creation and the BP reaction  
The first stage of the Gateway
®
 process involves the insertion of each fragment 
into one of four pDONR vectors to create an ‘entry clone’. This requires the 
proprietary BP Clonase™ II enzyme which catalyses recombination between the 
attB-flanked PCR fragments and the pDONR vector carrying the corresponding 
attP sites. There are several versions of the pDONR vector that differ only by the 
attP site variants they carry (attP1-5/attP1r-P5r). All pDONR vectors carry the 
kanamycin resistance gene for the selection of positive recombinant clones and 
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are approximately 4,770bp in size. A schematic of the original pDONR 221 vector 
is given in figure 4.11A. 
 
Each 10μl ‘BP’ reaction comprised: 2μl of BP Clonase II, 150ng of pDONR 
vector and 150ng of purified attB PCR product. BP reactions were incubated 
overnight at 25°C and then at 37°C for 10 minutes with an additional 1μl of 
Proteinase K. The full recombination mixture was transformed in 100μl of HB101 
E.coli cells and positive recombinants were selected on LB agar plates containing 
kanamycin. The pDONR vector contains the ccdB cassette situated between the 
two attP sites. This cassette produces a protein that interferes with E.coli DNA 
gyrase, thereby suppressing the growth of most strains of E.coli, including HB101 
cells. On successful recombination with the attB fragments, the ccdB cassette is 
removed from the entry clone and therefore only cells that have taken up a 
recombinant vector will grow, providing a second means of selection in addition 
to kanamycin resistance. Bacterial strains that contain the F’ episome, including 
the JM109 cells used previously, are resistant to the effects of the ccdB cassette 
and are thus unsuitable in this instance.  
 
Successful entry clone formation was confirmed by sequencing with the M13 
forward and reverse primers that anneal at either side of the recombination site (F: 
GTAAAACGACGGCCAG; R: CAGGAAACAGCTATGAC). A midi 
preparation of the final entry clones produced the larger yields required for the 
next stage of the Gateway
®
 protocol. 
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Promoter 3’UTR
FL
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G
E13E12E11E10E9E7E5E1 E2 E4E3
Fragment 1 Fragment 2 Fragment 3 Fragment 4
attB5rattB1 attB4attB5 attB3rattB4r attB2attB3
 
Primer att B variant att B sequence (5'-3') Target-specific sequence (5'-3')
Length 
(bp)
AT 
(°C)
Mg 
(mM)
DMSO 
(% )
Size 
(bp)
F att B1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTC CAAATGCTCTGCGATGTGTT 51
R att B5r GGGGACAACTTTTGTATACAAAGTTGT GGCTGTCGATGAACCCTA 45
F att B1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTC CAAATGCTCTGCGATGTGTT 51
R att B5r GGGGACAACTTTTGTATACAAAGTTGT GGACAGCGGATTTCAGATTC 47
F att B1 GGGGACAAGTTTGTACAAAAAAGCAGGCTTC CTCTGCTTATATAGACCTC 50
R att B5r GGGGACAACTTTTGTATACAAAGTTGT AGTTATTAATAGTAATCAATTACGGGG 53
F att B5 GGGGACAACTTTGTATACAAAAGTTGTC CCTGGTGGTGTTGAATATGA 48
R att B4 GGGGACAACTTTGTATAGAAAAGTTGGGTG CTGGTGTATGTGTCAGCAAA 50
F att B4r GGGGACAACTTTTCTATACAAAGTTGTCCAG CTGAAGAAGCAGGCATTGGA 51
R att B3r GGGGACAACTTTATTATACAAAGTTGT TCACTTATCGTCGTCATCCTTGTAATC 54
F attB3r GGGGACAACTTTGTATAATAAAGTTGTC CCTGGGGCGGTCAATAA 45
R att B2 GGGGACCACTTTGTACAAGAAAGCTGGGTA GCCAGCATCACAAAGAAG 48
F1-242
F1-CP
F1-CMV
F2
F3
F4
2218
1400
623
5398
4086
4428
57 1.5 -
60 1.5 -
51 1.5 -
60 3.5 -
56 1.5 5
55 1.5 5
 
 
Table 4.2 The primer sequences and PCR conditions for the introduction of the attB sequence variants onto the 5’ and 3’ ends of the four large 
minigene fragments (F1-F4). 
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Figure 4.10 contains schematics of each BP reaction, detailing the pDONR vector 
used to create each clone, the combination of attB and attP sites involved and the 
attR and attL sites formed post-recombination. Three entry clones were produced 
for each fragment, representing the three MAPT haplotype variants. 
 
Figure 4.10 The creation of entry clones using the BP reaction 
The four entry clones are created by individual recombination reactions between the 
attB PCR products and specific pDONR vectors. Modified from Invitrogen’s 
‘Mulitsite Gateway Pro’ manual. 
 
4.8 Final minigene construction  
 
4.8.1 The LR reaction 
The four fragments were joined together to produce the complete minigene in a 
final one-step recombination reaction denoted ‘LR’. The four entry clones each 
contain one of the minigene fragments flanked by a different combination of 
attR1-5 and attL1-5 variant sites and this specificity is vital in ensuring the 
fragments are incorporated into the minigene in the correct order and orientation. 
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The final minigene is formed by the simultaneous transfer of the four fragments 
into a ‘destination’ vector (pDEST) to produce the expression clone. There are 
different versions of the pDEST vector available but only the R4 pDEST vector 
(figure 4.11B) allows the integration of the expression clone into the genome of a 
platform cell line, as desirable in this investigation.  
Figure 4.11 The basic blueprint of the Gateway
®
 vectors 
A: Variants of the pDONR™221 vector were used to create the Gateway® entry 
clones. The attP sites recombine with the attB sites at the ends of the minigene PCR 
fragments to produce the individual entry clones required to create the final 
expression clone. B: The R4 destination vector used to create the final minigene or 
‘expression clone’. Modified from Invitrogen’s ‘Mulitsite Gateway Pro’ manual. 
 
The proprietary LR Clonase™ II enzyme simultaneously catalyses recombination 
between the attR and attL sites present in the four entry clones and the R4 pDEST 
vector. To achieve the highest efficiency in the ‘LR’ reaction, an equimolar ratio 
of each entry clone was required. This was calculated based on the total size of the 
clone and ensured the same number of DNA molecules were present for each. Ten 
femtomoles (fmoles) of each entry clone was required for the LR reaction and the 
ng conversion for each fragment is given in table 4.3. The formula for converting 
femtomoles (fmoles) of DNA into nanograms (ng) of DNA is: 
ng   =   x  fmoles    x   N   x   660fg    x   1ng . 
                                           fmoles       10
6
fg 
where x is the number of fmoles and N is the size of the DNA in bp. 
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Table 4.3 The size of each entry clone and the amount (in ng) required to ensure an 
equimolar ratio (10fmol) of each component in the final LR reaction. 
Sizes include the pDONR vector.  
 
The DNA mixtures were incubated overnight at 25°C with 20fmoles of R4 
pDEST vector and 2μl of LR Clonase™ II proprietary enzyme mix (adjusted to a 
final volume of 10μl with 1x TE buffer, pH 8.0). HB101 E.coli cells were 
transformed with half of the recombination mixture and selected on LB-agar 
plates containing ampicillin. Resistance to this selection antibiotic is only 
conferred by the bacterial cells that have taken up the pDEST vector and therefore 
those that have only taken up the component entry clones will not grow. 
Additional selection was provided by the presence/absence of the ccdB cassette 
(described in section 4.7.5) in the pDEST vector. For a four fragment LR reaction, 
approximately 50-100 colonies were produced each time. Ten clones per LR 
reaction were purified by miniprep and successful minigene formation was 
confirmed as described in the following section. 
 
4.8.2 Confirmation of final minigene expression clones 
The presence of the completed minigene in the expression clone was determined 
by restriction enzyme digestion of the purified plasmid DNA with the SphI 
enzyme. This enzyme cuts at multiple sites in the minigene and in the pDEST 
vector, producing a specific banding pattern that only occurs when all four 
fragments are present in the correct order and orientation (figure 4.12). Final 
endotoxin-free maxi preparations of expression clones exhibiting the correct SphI 
banding pattern were fully sequenced using a set of primers that annealed at 
approximate 800bp intervals along the minigene. The full sequences of the H1B 
and H1C minigenes are given in appendices I (CP variants) and J (CP+rs242557 
Entry clone
Size (bp) 10fmol (ng) Size (bp) 10fmol (ng) Size (bp) 10fmol (ng)
F1-242 6,919 14.2 - - - -
F1-CP - - 6,107 8.9 - -
F1-CMV - - - - 5,330 3.7
F2 10,114 35.2 10,114 35.2 10,114 35.2
F3 8,751 26.6 8,751 26.6 8,751 26.6
F4 9,144 28.8 9,144 28.8 9,144 28.8
CP + rs242557 CP alone CMV
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variants), with a multiple sequence alignment (ClustalW2) highlighting the 
genetic differences between them. 
 
Figure 4.12 Confirmation of 
the successful minigene 
construction.  
Digestion with restriction 
enzyme SphI produces a 
banding pattern that only 
occurs when all four 
fragments have been 
transferred into the R4 
pDEST vector in the correct 
order and orientation. 
 
4.8.3 The H2 minigene variants 
Due to problems with the cloning of Fragment 3, it was not possible to produce 
H2 variants of the three minigenes. For unknown reasons, multiple and varied 
attempts to insert element 7 into Fragment 3 at the pGEM-T Easy stage all 
resulted in failure. It is unclear why this would occur for the H2 variant only, as 
the cloning processes for the H1B and H1C variants were completed successfully 
and efficiently. It was thus deemed more appropriate to focus on the H1 
minigenes. It is also questionable as to whether the H2 variant would provide a 
fully informative model in this instance, as the design of the system would result 
in the H2 minigenes eventually being inserted into the genome of the cell lines in 
the same orientation as the H1 variants. As described previously, the genomic 
location containing the MAPT gene was subject to an ancient inversion, with the 
H2 variant subsequently lying in the opposite orientation to the H1 variants. This 
makes it highly likely that the endogenous H2 MAPT gene is subject to different 
positional effects and chromatin modifications than the H1 variant. Thus, although 
it would be interesting to determine expression differences purely at the sequence 
level, comparison between the H1 and H2 minigene variants may not be fully 
informative in this model. The H2 versions of Fragments 1, 2 and 4 were all 
completed and may by ‘swapped in’ to the H1 minigenes at a later date if deemed 
appropriate. 
 
 
4 MAPT Minigene Construction 
164 
 
4.9 Transient expression of the minigene variants 
 
4.9.1 Transfection  
To confirm that the minigenes were capable of correctly expressing tau in vitro, 
each minigene was transiently transfected into the SK-N-F1 and SH-SY5Y cell 
lines. Cells were plated onto a 6-well culture plate and allowed to grow until 
approximately 80% confluent. An 18μl volume of TransFast transfection reagent 
was used to transfect 6μg of plasmid DNA with a TransFast:DNA charge ratio of 
1:1. Cells were incubated post-transfection for 72 hours before harvest. 
 
4.9.2 mRNA analysis 
 
4.9.2.1 Reverse transcription-PCR 
Total RNA was extracted from transfected cells using the TRIzol reagent 
(Invitrogen) and following the manufacturer’s protocol. The RNA sample was 
incubated with DNase I for 30mins at 37°C to remove DNA contaminants before 
purification using the RNeasy MinElute Cleanup kit (Qiagen). One microgram of 
total RNA was reverse transcribed into cDNA using the Superscript III 
transcriptase and oligo(dT) primers. These primers comprise a string of T-
nucleotide residues, ensuring only polyadenylated mRNA transcripts are reverse 
transcribed. The reverse transcription reactions were incubated at 42°C for 10 
minutes, then at 53°C for 50 minutes. The transcriptase was inactivated during a 5 
minute incubation at 85°C, followed by a final cooling step at 4°C for 10 minutes. 
 
4.9.2.2 Exon 10 inclusion 
The presence of exon 10 in the minigene mRNA was determined by PCR of the 
reverse transcribed cDNA. The forward primer annealed to exon 9 of MAPT, with 
a FLAG-tag-specific reverse primer ensuring only the minigene cDNA – and not 
endogenous tau – was amplified in the PCR reaction (F: 
AAGATCGGCTCCACTGAGAA and R: TTACTTATCGTCGTCATCCTTG). 
An amplicon of 585bp was produced when exon 10 was present in the minigene 
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mRNA and this represented the 4R-tau isoform. An amplicon of 492bp 
represented exon 10 exclusion and 3R-tau.  
 
A volume of 1μl of cDNA template was amplified by 35 cycles of PCR using 
standard conditions and an annealing temperature of 55°C. The PCR products 
were resolved by polyacrylamide gel electrophoresis, with 6μl of product loaded 
onto a pre-cast 4-12% gradient TBE polyacrylamide gel and run at 200v for 50 
minutes. To visualise the bands, the gel was stained with a 1:5000 dilution of 
SYTO
® 
60 red fluorescent DNA stain (Invitrogen) for thirty minutes, followed by 
two 5 minute washes with double distilled water. The stained gel was then 
visualised with the LI-COR Odyssey scanner, using the 700nm channel, the DNA 
gel setting, a 0.8mm focus offset and an intensity setting of either 1.5 or 3.0. The 
ratio of 4R-tau product (upper band) to 3R-tau product (lower band) was 
quantified using the ImageJ software (NIH).  
 
The final outcome measure was an internal ratio between the 4R- and 3R-tau 
products and it was therefore vital that the PCR reaction did not reach the point of 
saturation. When saturation is reached, one or both of the amplification products 
stop increasing at an exponential rate, potentially altering the ratio between the 
two. To determine the saturation point for the minigene cDNA templates, a PCR 
was conducted as described above, with 37 cycles of denaturation, annealing and 
extension. A 5μl aliquot of product was removed after 28, 30, 32, 34, 36 and 37 
cycles and resolved by polyacrylamide gel electrophoresis as described above. 
The 4R:3R-tau ratio of aliquots from the exponential stage of the PCR should not 
differ significantly. A significant reduction or increase in ratio indicates that the 
PCR saturation point has been reached. This must also be considered when 
scanning the polyacrylamide gel using the LI-COR system, as a high intensity 
setting could similarly saturate the SYTO
®
60 fluorescent signal and significantly 
alter the tau ratio. To optimise the Odyssey intensity settings, the gel was scanned 
twice at intensities of 1.5 and 3.0 and the tau ratios compared.  
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The PCR was performed on cDNA templates from SK-N-F1 (figure 4.13) and 
SH-SY5Y cells transfected with the H1C-CP and H1C-CMV minigene variants. 
The results show that, in all cases, 34 to 36 cycles of PCR was sufficient to allow 
accurate quantification without reaching the saturation point. The optimal 
Odyssey intensity setting, however, differed depending on the minigene variant. 
The CP-H1C ratios were consistent at both intensity settings. The 4R-tau signal of 
the CMV-H1C minigene, however, appeared to reach saturation at the 3.0 
intensity level, resulting in a general decline of the 4R:3R-tau ratio. This is likely 
due to the marked increase in expression conferred by the CMV promoter in 
comparison to the CP promoter. Thus, the RT-PCR results from the CMV 
minigene variants were always quantified with the 1.5 intensity setting.  
 
Figure 4.13 Polyacrylamide gel images of the exon 10 PCR optimisation.  
cDNA was reverse-transcribed from undifferentiated SK-N-F1 cells transfected with 
the H1C variants of the CP and CMV minigenes. Aliquots of the PCR reaction were 
taken at 30, 32, 34, 36 and 37 cycles. The 4R/3R tau ratio (upper band divided by 
lower band) was quantified using the ImageJ software. 
 
4.9.2.3 Mis-splicing events at exon 9 
The exon 10 PCR optimisation revealed that both the 4R and 3R PCR products 
resolve as doublets and not, as expected, as single bands (figure 4.13). To 
determine the reason for this, the 4R and 3R PCR bands were purified and cloned 
into the pGEM-T Easy vector using standard protocols described previously in 
37 37363634 34323230 3028Cycles
1.5int
4R/3R ratio
37 37363634 34323230 3028Cycles
3.0int
4R/3R ratio
H1C-CP H1C-CMV
1.58 1.66 1.54 1.51 3.22 3.17 3.16
1.55 1.65 1.71 1.54 4.23 3.15 2.73 2.21
SK-N-F1
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section 3.5.4. Random selections of 36 clones were sequenced and the results 
show the occurrence of a mis-splicing event at the exon 9/intron 9 border in 23 of 
the 36 clones (64%). In these clones, the splice site at the exon/intron boundary 
was skipped, with splicing occurring 24bp downstream in intron 9. This caused 
the insertion of 26bp of intron 9 into the mRNA sequence between exons 9 and 
10. All of the clones that were spliced correctly were 4R isoforms and accounted 
for 52% of the total number of 4R clones sequenced (N=23). None of the 3R 
clones sequenced were spliced correctly (N=12).  
 
The reason for this mis-splicing event appears to lie in the design of the minigene. 
Exons 4, 5, 7 and 9 were cloned together in one element amplified from cDNA 
(element 5, figure 4.5). This was done purposely to remove the intervening 
intronic elements and reduce the size and transfection efficiency of the minigene. 
The 5’ region of intron 9 was amplified from genomic DNA (element 6 in figure 
4.5) and attached to the 3’ end of exon 9 via restriction enzyme digestion and 
ligation. This resulted in the introduction of the XbaI sequence (TCTAGA) at the 
exon/intron boundary and appears to have weakened the splicing signal at this 
site. The full signal consists of the AG dinucleotide located at the 3’ end of exon 9 
and the GTG triplet at the 5’ end of intron 9. The AGGTG motif is repeated 21bp 
downstream at the site of the mis-splicing event, suggesting that intron 9 contains 
a second, cryptic splice site (figure 4.14B). The purpose of this second site is 
currently unknown but comparative analysis of cDNA from untransfected cells 
suggests that the use of this site, if at all, is extremely rare in endogenous tau. 
 
4.9.2.4 Exon 2 and 3 inclusion 
The inclusion of exons 2 and 3 was determined in three separate PCR reactions 
using forward primers annealing in exons 1, 2 and 3. As with exon 10, the reverse 
primer in each PCR annealed to the minigene-specific FLAG-tag motif. The exon 
1 PCR should amplify all six tau isoforms, though the six products resolve as four 
separate bands due to the small difference in size – 6bp – of the 1N3R and 0N4R, 
and 2N3R and 1N4R products. The exon 2 PCR should similarly produce four 
products visible as three bands, with 2N3R and 1N4R again resolving together. 
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The 2N3R and 2N4R products should be easily distinguishable by the exon 3 
PCR. The expected product sizes for each PCR are given in table 4.4. 
 
The PCRs were performed as described previously for the exon 10 PCR, with an 
annealing temperature of 55°C and 35 cycles of denaturation, annealing and 
extension. An aliquot of 6μl of PCR product was resolved by polyacrylamide gel 
electrophoresis, stained with SYTO
®
60 fluorescent stain and visualised by LI-
COR Odyssey, as described previously. The results are presented in figure 4.15.  
 
When performed on minigene cDNA, PCR product was detected for all three sets 
of primers, confirming the presence of exons 1, 2 and 3. The exon 1 and exon 2 
PCRs, however, produced fewer bands than expected, with the largest band 
representing the 2N4R product notably absent in each case. The 2N4R isoform is 
the rarest of the six tau isoforms and therefore its absence is not necessarily 
surprising. The exon 3 PCR, however, revealed that this isoform is present, albeit 
in low abundance.  
 
 
 
  
1
6
9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 The minigene transcript mis-splicing events. 
A: The basic blueprint of the MAPT minigene; B: The insertion of a restriction site into the exon 9/intron 9 5’splice site causes the preferential 
usage of a cryptic splice site located 21 nucleotides downstream; C: The skipping of the exon4-9 element results in the transcripts representing 
the six tau isoforms being shortened. 
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Primer Sequence (5'-3') AT (°C) 0N3R 1N3R 2N3R 0N4R 1N4R 2N4R
Ex1-F CATGCACCAAGACCAAGA
FLAG-R ATCCTTGTAATCCAAACCCTG
Ex2-F CTCTGAAACCTCTGATGCTAAG
FLAG-R ATCCTTGTAATCCAAACCCTG
Ex3-F AGCACCCTTAGTGGATGAG
FLAG-R ATCCTTGTAATCCAAACCCTG
1089/574 1176/661 1095/580 1182/667 1269/754 
55 - 999/484 1086/571 - 1092/577 1179/664 
55 1002/487 
1131/616 
Exon 1
Exon 2
Exon 3 55 - - 1038/523 - -
 
Table 4.4 The primer sequences, PCR annealing temperature and expected product sizes of the Exon 1, Exon 2 and Exon 3 PCRs with the 
FLAG reverse primer.  
The expected product sizes without element 5 (exons 4-9) are given in red. 
 
 
600bp
400bp
1000bp
800bp
500bp
H1B-CP H1B-242-G H1C-242-A H1C-CMV
e1 e1 e1e2 e2 e2 e2 e3e3e3e3
 
Figure 4.15 Optimisation of the exon1, exon 2 and exon 3 PCRs.  
PCR with forward primers annealing in exon 1 (ex1), exon 2 (ex2) and exon 3(ex3), produces products ~500bp smaller than expected, as 
visualised by PAGE.  
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An important and intriguing finding, however, concerns the sizes of the products 
of each minigene N-terminal PCR, as all were approximately 500bp smaller than 
expected. This is roughly the same size as the exon 4-9 element of the minigene, 
suggesting that the splice site at the intron 3/exon 4 boundary has been skipped 
and exons 4, 5, 7 and 9 have been completely spliced out of the minigene mRNA. 
This was confirmed by the purification, cloning and sequencing of the PCR 
products (figure 4.14C). The complete absence of exons 4-9 in these transcripts 
was somewhat puzzling, as the exon 10 PCR described above – with a forward 
primer annealing in exon 9 – yielded product, confirming that exon 9 must be 
present in some of the transcripts even though there were no bands representative 
of this in the exon 1, 2 and 3 PCR products. In addition, the cloning and 
sequencing of these products appear to show that the bands observed for the exon 
1 and 2 PCRs almost exclusively represent the 3R-tau isoforms, suggesting that 
the mis-splicing event at exons 4-9 favours the exclusion of exon 10.  The reason 
for this is unclear; however, further analyses of the N-terminal splicing events 
conferred by the minigenes will be described in chapter 5. 
   
4.9.3 Protein analysis 
The mis-splicing events described above, specifically the use of the cryptic splice 
site in intron 9, causes a shift in opening reading frame and thus a change in 
protein translation. A truncated form of the tau protein may still be expressed but 
the absence of the FLAG-tag at the C-terminal end prevents its detection using the 
minigene-specific FLAG antibody. It was therefore not possible to study minigene 
expression at the protein level in this study. 
 
4.9.4 Suitability of the minigenes for use in this project 
Despite the mis-splicing events at the intron 3/exon 4 and exon 9/intron 9 
boundaries, the minigene is expressed at the mRNA level in vitro and is 
alternatively spliced at exons 2, 3 and 10 in a consistent and highly replicable 
pattern. The mis-splicing events are common to all six variants of the minigene, 
with each affected in the same way. The aim of this project is, firstly, to link the 
promoter and transcription to the regulation of tau alternative splicing and, 
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secondly, to assess the effect of the rs242557 polymorphism on the splicing of 
exon 10. The transient transfections have shown that minigene mRNA is 
alternatively spliced at exon 10 and therefore the effect of the promoter and the 
genetic variation within it on exon 10 splicing can still be determined. Thus, the 
core themes of this project can still be tested at the mRNA level by determining 
whether small changes in sequence can affect the splicing pattern. Any biological 
interpretation of the results, however, must be made with extreme caution.  
 
4.10 Cell models 
 
4.10.1 Generating the R4 platform cell line 
Transient expression is highly variable, with factors such as the passage and 
growth rate of the cells, the large size of the minigene plasmid (~20kb) and 
variance in transfection efficiency having an effect on the overall level of 
minigene expression. As described in section 4.4, the use of the Gateway
®
 system 
to create the minigenes provides a means of integrating them into the genome of 
chosen cell lines to produce stably-expressing cell models. This should remove 
most of the variability, increase minigene expression and produce more consistent 
results.  
 
The platform cell lines were created by co-transfecting the pJTI/Zeo platform 
vector with a vector containing the PhiC31 integrase gene (pJTI/PhiC31). The 
pJTI/Zeo vector contains the Hygromycin B resistance gene for initial selection, 
the R4 attB sequence and a promoterless zeocin resistance gene for selection 
during the retargeting stage (see figure 4.4). The PhiC31 integrase is required for 
integration of the platform vector at pseudo-PhiC31 attP sites that occur naturally 
in the mammalian genome. A 6μg amount of each plasmid was co-transfected into 
SK-N-F1 and SH-SY5Y cells plated at approximately 80% confluency onto 6-
well culture plates. After recovering from transfection, cells were transferred to a 
100mm culture dish and recombinant colonies were selected using 50μg/ml of the 
antibiotic Hygromycin B. Well-defined colonies were visible after 1-2 weeks of 
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selection. These colonies were manually picked and individually expanded under 
selection to form new, isogenic platform cell lines.  
 
Genomic DNA was isolated from each platform cell line using the CellsDirect 
Resuspension and Lysis Buffers according to the manufacturer’s protocol. Briefly, 
10,000 to 30,000 cells were pelleted and washed with 500μl of PBS before 
resuspension in a mixture of 20μl of Resuspension Buffer and 2μl of Lysis Buffer. 
Following incubation at 70°C for 10 minutes, 3μl of cell lysate was analysed by 
nested PCR using primers specific to the pJTI/Zeo platform vector. A final 
product size of 397bp indicated successful integration. 
 
PCR1   F: GCCAGACCCTGAATTTGTGT  
            R: GTTCTTTCCTGCGTTATCCC  
PCR2:  F: CCCAAAGCGATACCACTTG  
            R: AAGTTCGTGGACACGAC  
 
4.10.2 Splinkerette PCR 
The site of integration was determined by splinkerette PCR (spPCR). This method 
was initially developed by Potter and Luo [241] to identify unknown genomic 
DNA sequences located between a known restriction site and a target gene and is 
commonly used to map the integration site of viral DNA sequences in the mouse 
genome. The process requires the attachment of unique, double-stranded 
‘splinkerette’ linkers onto the ends of genomic DNA fragments digested with a 
specific restriction enzyme. The fragment containing the integrated target DNA is 
then amplified by PCR using a forward primer that anneals to the target gene and 
a reverse primer specific to the splinkerette linker. Sequencing of the PCR product 
and subsequent genome mapping allows the site of integration to be identified. A 
schematic of the process involved and the oligonucleotide sequences of the 
splinkerette linker and PCR primers used to determine the integration of the 
pJTI/Zeo platform vector are given in figure 4.16. 
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SpPCR was performed following ‘Splinkerette Protocol S1’ published by Potter 
and Luo [241] and using the BstYI restriction enzyme. This enzyme cuts at either 
side of the PhiC31 attB site in the pJTI/Zeo vector and at regular intervals 
throughout the human genome. Digestion of genomic DNA with this enzyme 
produces a four-nucleotide 3’ overhang (GATC) which anneals to a compatible 5’ 
overhang on the splinkerette linker. The splinkerette overhang is 
unphosphorylated; increasing specificity by ensuring only the 3’ recessed end on 
the bottom strand is capable of ligation. The presence of a stable hairpin loop 
prevents the splinkerette from binding to genomic DNA at anywhere other than 
the compatible sticky ends and reduces the background produced by non-specific 
and end-repair priming. 
 
The genomic DNA isolated from each platform cell line (described in section 
4.10.1) was purified by ethanol precipitation to remove all traces of the 
CellsDirect buffers. One microgram of purified DNA was digested with BstYI in 
a total reaction volume of 35μl, including 3.5μl of NEB buffer 4, 3.5μl of BSA 
(10x) and 10 units of enzyme. Following overnight incubation at 60°C, the BstYI 
enzyme was inactivated by heating to 80°C for 20 minutes. The full digestion 
volume was added to 6μl of double-stranded splinkerette linker, 600 units of T4 
DNA ligase (NEB), 5μl of ligase buffer (10x) and 2μl of water. The double-
stranded splinkerette linkers were created by heating the two oligonucleotides 
(figure 4.16B) to 95°C for 3 minutes in the presence of NEB buffer 2 and 
allowing natural cooling to room temperature. The final ligation reaction volume 
of 50μl was incubated at room temperature for 3 hours to facilitate the annealing 
of the splinkerette linkers to the genomic DNA.  
 
The nested PCR reactions were optimised using Phusion Taq polymerase 
(Finnzymes) and the reaction mixtures are detailed below in table 4.5. The primer 
sequences are given in figure 4.16C. 
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Round 1 PCR Volume 
(μl)
Round 2 PCR Volume 
(μl)
Ligation reaction 10 Round 1 PCR 0.5
Water 1.5 Water 11
Phusion MasterMix (2x) 12.5 Phusion MasterMix (2x) 12.5
p1 (10μM) 0.5 p2 (10μM) 0.5
s1 (10μm) 0.5 s2 (10μm) 0.5
Total 25 Total 25  
Table 4.5 The composition of the nested PCR reactions conducted to confirm the 
presence of the pJTI/Zeo platform vector in the genome of the cell line. 
 
The round 1 reaction was heated to 98°C for 75 seconds, followed by two cycles 
of 98°C for 20 seconds and 64°C for 15 seconds. A further 30 cycles of 98°C for 
20 seconds, 68°C for 15 seconds and 72°C for 2 minutes was followed by a final 
extension at 72°C for 7 minutes. 
 
The round 2 reaction was heated to 98°C for 75 seconds, followed by 30 cycles of 
98°C for 20 seconds, 68°C for 15 seconds and 72°C for 90 seconds. Final 
extension occurred at 72°C for 7 minutes. A 5μl aliquot of the round 2 PCR 
product was resolved by agarose electrophoresis to confirm the presence of a 
single band (Figure 4.16D). The remaining PCR product was purified using the 
QIAquick PCR purification kit and sequenced using a primer that anneals to the 
pJTI vector (F: TCCCGTGCTCACCGTGACCAC). The resulting sequence was 
mapped to the human genome using the Blat tool (UCSC). 
 
Two platform lines were identified from each of the SK-N-F1 and SH-SY5Y 
parental lines, with details of the integration sites given in table 4.6. Each parental 
line produced one platform line with an integration site that did not disrupt a gene 
and one that did. The undisrupted lines were favoured as their sites of integration 
are less likely to disrupt normal cell functioning; however, the positioning outside 
of an active area of the genome may cause low minigene expression levels. 
Comparison between the two platform lines will highlight any minigene 
expression differences caused by the insertion site. 
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Figure 4.16 The splinkerette PCR method  
A: The process involved in identifying the insertion site of the pJTI/Zeo platform 
vector into the genome of mammalian cell lines; B: The sequence and structure of 
the ‘splinkerette’ linker; C: The two sets of primers used in a nested PCR to confirm 
the presence of the platform vector in the genome of the cell line; D: An agarose gel 
image of the nested PCR products. The ringed cell clones contained single insertions 
of the platform vector. Adapted from Potter et al (2010) [241]. 
 
Clone Cell line Match (bp) Chr Location Gene Insertion Function Expressed in brain?
F4 SK-N-F1 21 4 45328896 - - - -
F2 SK-N-F1 36 19 44564015
ZNF223
Zinc finger protein 223
Intron 1 Zinc finger protein No (thymus and ovary)
S20 SH-SY5Y 596 3 65179876 - - - -
S19 SH-SY5Y 119 18 40535992
RIT2
Ras-like without CAAX 2
Intron 2 RAS family of GTPases Yes
 
 
Table 4.6 The Gateway
®
 TI platform cell lines. 
Four platform cell lines were identified; two each from the SK-N-F1 and SH-SY5Y 
parent lines. 
 
4.10.3 Retargeting 
The final stage in the creation of the cell models involved the insertion of each 
minigene into the chosen platform cell lines in a process called ‘retargeting’ (see 
section 4.4.). Due to the mis-splicing events, however, the decision was taken to 
delay the creation of the stable models. Simple alterations to the minigenes at 
exons 4-9 should correct the mis-splicing events occurring in this region (see 
4 MAPT Minigene Construction 
177 
 
section 4.11 below) and it was therefore considered preferable to make these 
corrections before integrating the minigenes and creating the stable cell lines. 
This, unfortunately, falls outside the timeline of this project and therefore the final 
stage in the creation of the stable cell models was not completed.  
 
4.11 Discussion 
This chapter has described the design, assembly and validation of minigenes to 
study the role of promoter variation in tau alternative splicing. The use of 
Invitrogen’s Gateway® technology provided the flexibility to study the specificity 
of the MAPT promoter – and in particular the effect of the rs242557 
polymorphism – on the inclusion rate of exon 10. Six minigenes were created, 
three representing the genetic variation of the MAPT H1B haplotype and three 
similarly representing H1C. The three minigenes in each haplotype set differed 
only by their promoter, with expression controlled by either the MAPT core 
promoter alone, the core promoter in conjunction with an allelic variant of the 
rs242557 regulatory domain or the CMV promoter. 
 
The minigenes were created using a mixture of genomic DNA and cDNA 
fragments cloned from two PSP patients confirmed as having the H1B and H1C 
variants of the MAPT gene. A series of intricate and varied cloning strategies were 
used to join together multiple individual elements into complete minigenes of 
14.1-15.7kb in size. Following transient transfection in SH-SY5Y and SK-N-F1 
cells, in vitro expression and alternative splicing of minigene mRNA transcripts 
was confirmed and found to be consistent between all minigene variants in 
multiple independent transfections. 
 
Two mis-splicing events, however, were identified and can be traced to the 
inclusion of a cDNA element in the minigene design. The decision to amplify 
constitutive exons 4, 5, 7 and 9 from cDNA in a single element reduced the size of 
the minigene by excluding unnecessary intronic sequences. This ultimately 
reduced the number of cloning steps required to construct the minigene – reducing 
the number of opportunities for sequence errors to be introduced – and increased 
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the efficiency of in vitro transfection – thereby increasing the number of cells 
expressing the minigene. It seems, however, that the complete removal of introns 
4, 5, 6, 7 and 8 altered the splicing signals at the intron 3/exon 4 and exon 9/intron 
9 boundaries. Exons often contain splicing regulatory elements, called exonic 
splicing enhancers (ESEs) or repressors (ESRs). Grouping together the four exons 
may have produced competition between the exonic signals, leading to confusion 
and failure of the splicing machinery to recognise the exon/intron boundaries. 
This was certainly not helped by the unavoidable insertion of an attB sequence at 
the intron 3/exon 4 boundary, although the sequence is designed such that the AG 
exon recognition sequence is reformed at the boundary following recombination. 
The attB insertion may, however, disrupt the intronic polypyrimidine tract or 
increase its distance from the AG exon recognition sequence, therefore weakening 
the splicing signal. The signal at the exon 9/intron 9 boundary was similarly 
weakened by the unavoidable insertion of a restriction site into the exon/intron 
recognition motif. 
 
The minigene design – particularly the inclusion of cDNA elements – was based 
on that described by Dawson et al in the creation of their transgenic mouse 
models. Although the authors did not report any mis-splicing issues with their 
minigene, they did observe extremely low protein expression, quantified at 
approximately 1-2% of the endogenous murine tau level. This was unexpected 
and suggests that a mis-splicing event leading to a shift in reading frame may have 
occurred during mRNA processing, thereby affecting tau protein expression. In 
addition, the N-terminal exons of their minigene mRNA were not alternatively 
spliced, with exons 2 and 3 constitutively present. This may be due to the 
inclusion of shorter intronic segments (approximately 200bp) surrounding these 
exons, confirming that a minimum length of intronic sequence is required to 
produce the correct pattern of exon 2 and 3 splicing. Unlike in this study, Dawson 
and colleagues did not require the presence of a C-terminal FLAG-tag motif to 
distinguish the minigene human tau from the endogenous murine tau. They 
therefore had more flexibility in the placement of their PCR primers and did not 
need to amplify the full-length mRNA in order to quantify the inclusion rate of 
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exons 2 and 3. Thus the inclusion of these exons in the context of exon 10 splicing 
was not reported and any mis-splicing events at the exon 4-9 cDNA segment may 
not have been detected.    
 
A few changes to the minigene should correct the mis-splicing events at exons 4-9 
and facilitate tau protein expression. Ideally, the exon 4-9 element would be 
replaced with four separate elements each comprising one of the exons 
surrounded by approximately 600bp of upstream and downstream intronic 
sequence. This would move the restriction sites and attB sequence to the intronic 
junction between two elements, away from the critical exon/intron boundaries. 
The restriction enzyme-based construction of the minigene, however, makes this 
correction unfeasible. The sheer number of unique restriction enzymes required – 
with each not cutting internally in the new inserts but cutting at exactly the right 
points in the current minigene to remove and replace the exon 4-9 element – is 
simply too high. Even when going back several cloning steps to insert the new 
elements into the individual component Fragments 2 and 3 (figures 4.7 and 4.8), 
this approach is not possible and the resulting increase in overall minigene size 
would likely reduce transfection efficiency too far. A more feasible approach, 
however, may be to insert only two of the new elements; the ones containing exon 
4 and exon 9. This will keep the size of the final minigene down and ensure the 
two critical boundaries – the intron 3/exon 4 and exon 9/intron 9 boundaries – are 
preserved. Although exons 5 and 7 would be entirely excluded, this should not 
affect the inclusion rate of exons 2, 3 and 10 at both the mRNA and protein level 
and the size of the minigene should not increase by too much. A schematic of how 
this correction may be achieved is given in figure 4.17. 
 
The second aspect of this project was the creation of stable cell models by 
integrating each minigene into the same location in the genome of the SH-SY5Y 
and SK-N-F1 cell lines. Although two platform cell lines were created per cell 
type and the sites of integration verified, the decision was taken to delay the 
creation of the integrated cell models until the mis-splicing events of the 
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minigenes have been corrected. This will increase the value and versatility of the 
models for use in future investigations of MAPT expression. 
 
Despite the mis-splicing events, the minigene variants still express tau mRNA in 
vitro and demonstrate a highly replicable pattern of splicing at alternative exons 2, 
3 and 10. Thus, they are a valid tool for studying the role of the tau promoter and 
the rs242557 allelic variants on the splicing pattern of these exons. This 
investigation will be described in detail in Chapter 5. 
  
1
8
1
 
Figure 4.17 Correction of 
the mis-splicing events at 
exons 4-9. 
 
A: Removal of the exon 4-9 
element would allow the 
insertion two new elements 
containing exons 4 and 9 
with surrounding intronic 
segments.  
 
B: The new exon 4 element 
could be inserted into the 
3’ end of Fragment 2, with 
the new exon 9 element 
inserted into the 5’ end of 
Fragment 3. This would 
result in the problematic 
attB sequence falling 
outside of the intron/exon 
boundary. 
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5 The role of the tau promoter and rs242557 polymorphism in 
the alternative splicing of MAPT exons 2, 3 and 10 
 
5.1 Overview 
It is evident that transcription and alternative splicing are not independent 
processes and an increasing number of genes have been shown to demonstrate co-
regulation [1-5]. The luciferase reporter gene study of the MAPT promoter region 
(chapter 3) confirmed that the rs242557 polymorphism lies within a transcription 
regulatory domain and that its two alleles differentially alter the strength of this 
regulation, regardless of the positioning of the domain relative to the core 
promoter and the endogenous cellular environment. Thus, if MAPT transcription 
and alternative splicing are co-regulated, it would follow that the allelic variants 
of the rs242557 regulatory domain could also differentially affect the inclusion 
rate of the alternatively spliced MAPT exons.  
 
To test this hypothesis and determine the influence of the promoter and the 
rs242557 polymorphism on MAPT alternative splicing, the six MAPT minigenes 
were expressed in vitro in neuroblastoma cells, as described in chapter 4. To 
recap, two minigenes were created representing the genetic variation of the H1B 
and H1C MAPT haplotypes. Three versions of each minigene were produced, 
differing only by the promoter element driving expression. The three promoter 
elements comprised: the MAPT H1 core promoter, the CMV promoter and the H1 
core promoter in conjunction with the allelic variants of the rs242557-containing 
regulatory domain. Each minigene was expressed in SK-N-F1 and SH-SY5Y 
neuroblastoma cells in undifferentiated and neuronally differentiated states. The 
relative inclusion rates of exon 10 and of exons 2 and 3 in minigene mRNA 
transcripts were quantified, as was the differential binding of specific transcription 
and splicing factors to the alleles of the rs242557 polymorphism.  
 
5.2 Background 
There are two main models supporting the co-transcriptional regulation of 
alternative splicing: physical coupling and kinetic coupling (section 1.2.3). 
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Physical coupling describes the physical interactions between components of the 
transcription and splicing machineries and in this scenario genetic variation that 
disrupts the normal functioning of one could directly modulate the functioning of 
the other. We have shown that the two allelic variants of the rs242557-containing 
regulatory domain differ in the strength of their effect on transcription from the 
MAPT core promoter. This may result from a change in mRNA conformation that 
changes the relative proximity of the regulatory domain to the core promoter, 
restricting or increasing the interaction between the two. Transcriptional changes 
may also result from an allelic modification to a transcription factor binding site 
that increases or reduces binding affinity. In either case, these differences would 
likely change the composition of the transcription complex, which in turn would 
alter its physical interaction with the splicing machinery. 
 
Kinetic coupling refers to the specific linking of transcription rate to splice site 
recognition, with a faster rate of transcription increasing the likelihood that a weak 
alternative splice site is outcompeted for spliceosome assembly by a stronger 
downstream constitutive splice site. Thus, the rate of alternative exon skipping 
would increase in this scenario. This model is unlikely to provide the mechanism 
linking the rs242557-A allele with an increase in PSP risk, as this allele (to the 
best of our knowledge) confers an increase in MAPT transcription rate. The 
kinetic model would therefore suggest that rs242557-A confers an increase in 
MAPT exon 10 skipping (i.e. an increase in 3R-tau), which is not consistent with 
the increase in 4R-tau observed in the PSP brain.  
 
Although the allelic differences in rs242557-mediated transcriptional regulation 
may also affect the inclusion rates of exons 2 and 3, previous evidence suggests 
that the N-terminal and C-terminal alternative exon splicing events are regulated 
by different mechanisms (section 1.7.2) [205]. Thus, although we would expect to 
see differences in the splicing of exons 2 and 3 between the MAPT and CMV 
promoter-driven minigenes, the rs242557-regulatory domain – and its allelic 
variants – is not expected to contribute to splicing in this region. 
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5.3 In vitro expression of the minigene variants 
 
5.3.1 Overview 
The six minigene variants were expressed in SK-N-F1 (F1) and SH-SY5Y (SH) 
neuroblastoma cells as described in section 4.9. This section also describes the 
methods of mRNA analysis used to determine the inclusion rate of exon 10 and of 
exons 2 and 3 in the minigene transcripts. Unless otherwise stated, these methods 
were used in all comparative analyses of minigene mRNA transcripts described in 
this chapter. 
 
5.3.2 Neuronal differentiation 
The addition of retinoic acid to low-serum cell culture medium suspends cell 
growth and induces morphological changes including the formation of long 
neuronal processes (figure 5.1). Most significant, however, are the changes in 
gene expression that result as a consequence of differentiation, with numerous 
proteins and neuronal markers upregulated. In particular, tau expression is 
significantly altered in differentiated cells with all six isoforms expressed, 
concurrent with a shift from exclusive 3R expression to an approximately equal 
ratio of 4R:3R transcripts. Thus, the changes in endogenous cellular conditions 
achieved through differentiation would likely influence minigene transcript 
processing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 SH-SY5Y and SK-N-F1 cells undergo morphological changes after 
treatment with retinoic acid. 
 
 
SH-SY5Y SK-N-F1
Undifferentiated
Retinoic Acid
(4 days)
5 MAPT Alternative Splicing 
185 
 
Cells were cultured for 24 hours in 10% cell culture medium (see section 2.2.5) 
and then rinsed with 1x PBS to remove all traces of the serum. The PBS was then 
replaced with cell culture medium containing 1% foetal calf serum (1% medium) 
and supplemented with 10nM of retinoic acid. Medium was changed every 2 days 
and minigene transfection was conducted after five days of treatment. Cells were 
allowed to recover from transfection with 10% cell culture medium for 24 hours 
before retinoic acid treatment was resumed for a further 48 hours. 
 
5.4 Minigene quantification of exon 10 inclusion 
 
5.4.1 mRNA analysis 
The six minigene variants were transfected in differentiated and undifferentiated 
F1 and SH cells as described previously. After 72 hours, total RNA was extracted, 
reverse transcribed and the rate of exon 10 inclusion determined by PCR with 
primers annealing to exon 9 and the 3’ FLAG-tag motif, again as described 
previously in chapter 4. Exon 10 inclusion was measured as an internal ratio and 
defined as the number of exon 10+ transcripts divided by the number of exon 10- 
transcripts (i.e. the 4R:3R-tau mRNA ratio); values that were determined by the 
relative intensities of the RT-PCR products when visualised by polyacrylamide 
gel electrophoresis (PAGE; section 2.1.3.4). Quantification of band intensity was 
conducted using the ImageJ software (NIH), which calculated the area under the 
intensity peak produced by each band (figure 5.2C). The 4R:3R ratios conferred 
by the minigene variants are presented on a bar graph with results averaged from 
4-8 independent transfections in 2-4 biological replicates. The error bars represent 
the standard deviation from the mean and a significant difference in 4R:3R ratio 
was detected by a Student’s t-test and defined as p≤0.05 (section 2.1.9.1). 
 
5.4.2 Exon 10 splicing in undifferentiated cells is heavily influenced by the 
in vitro cell model 
Figure 5.2 presents the 4R:3R-tau ratios of the six minigenes when expressed in 
undifferentiated F1 cells. Each of the promoter variants (CP, CP+rs242557 and 
CMV) demonstrated significantly different rates of exon 10 inclusion, 
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independently of haplotype status, and this indicates the importance of promoter 
identity in the regulation of exon 10 splicing in this cell line. The CMV promoter 
variants produced the highest 4R:3R ratios, with four times as many 4R 
transcripts than 3R transcripts expressed (H1B ratio = 4.05; H1C = 4.21). The CP 
minigenes produced the lowest ratios but still expressed twice as many 4R 
transcripts than 3R transcripts (H1B = 2.13; H1C = 2.18). This is surprising as 
undifferentiated cells generally express only 3R-tau endogenously and even in 
differentiated cells the ratio of 4R:3R-tau is approximately 1.0. Thus, the 
preference of the minigenes for 4R expression suggests that additional cis-acting 
factors involved in the regulation of exon 10 splicing are absent from the 
minigene construct, likely as a consequence of the exclusion of large sections of 
the MAPT promoter region.  
 
Figure 5.2 The exon 10 quantification of minigene transcripts expressed in 
undifferentiated SK-N-F1 cells.  
Ai: The 4R:3R mRNA ratio produced by each minigene variant; Aii: An example of 
a polyacrylamide gel image used to quantify the 4R and 3R RT-PCR products; B: 
The individual results of the H1B (Bi) and H1C (Bii) haplotypes; C: The 
quantification was achieved by calculating the area under the intensity peak using 
the ImageJ software (NIH); D: Significant differences in ratio were detected by 
Student’s t-test. * p≤0.05; ** p≤0.01; *** p≤0.001; **** p<0.0001 
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rs242557
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CP 1B 3 4 2.13 0.40 - 0.0246 0.0002
CP 1C 3 6 2.18 0.42 - 0.0022 <0.0001
rs242557-G 1B 3 6 3.07 0.59 0.0246 - 0.0117
rs242557-A 1C 3 6 3.30 0.58 0.0022 - 0.0174
CMV 1B 3 5 4.05 0.39 0.0002 0.0117 -
CMV 1C 3 5 4.21 0.42 <0.0001 0.0174 -
0.8970
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The CP+rs242557 minigene variants produced three times as many 4R than 3R 
transcripts (H1B-G = 3.07; H1C-A = 3.30). Although there was no significant 
difference in 4R:3R ratio between the two rs242557 allelic variants, these 
constructs produced a significantly higher ratio than their CP counterparts (H1B: 
p=0.0246; H1C: p=0.0022) and a significantly lower ratio than their CMV 
counterparts (H1B: p=0.0117; H1C: p=0.0174), as presented in figure 5.2B. This 
confirms that the rs242557 domain has the ability to regulate exon 10 splicing, 
acting to increase the proportion of 4R transcripts expressed by the core promoter 
in this cell line. Figure 5.3 presents the 4R:3R-tau ratios in undifferentiated SH 
cells and in this instance the picture was very different. In general, the proportion 
of 4R transcripts produced by each minigene was much higher in this cell line and 
there was little difference in 4R:3R ratio between either the promoter or haplotype 
variants. 
 
Figure 5.3 The exon 10 quantification of minigene transcripts expressed in 
undifferentiated SH-SY5Y cells.  
Ai: The 4R:3R mRNA ratio produced by each minigene variant; Aii: An example of 
a polyacrylamide gel image used to quantify the 4R and 3R RT-PCR products; B: 
The individual results of the H1B (Bi) and H1C (Bii) haplotypes; C: The 
quantification was achieved by calculating the area under the intensity peak using 
the ImageJ software (NIH); D: Significant differences in ratio were detected by 
Student’s t-test. * p≤0.05. 
 
700bp
500bp
600bp
*
Ai
Aii
Bi
Bii
C
Biological 
replicates
N
Mean 
4R:3R ratio
Standard 
Deviation
H1B vs H1C vs CP
vs 
rs242557
vs CMV
CP 1B 2 4 7.19 1.51 - 0.1826 0.6485
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CMV 1B 3 4 6.78 0.80 0.6485 0.2553 -
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Student's T-test (2t) p-values
0.8961
0.9235
0.2672
D
5 MAPT Alternative Splicing 
188 
 
Indeed, only one significant difference in ratio was detected between the 
CP+rs242557-A and CMV versions of the H1C minigene, with the former variant 
producing a significantly smaller proportion of 4R transcripts (Figure 5.3 Bii: 
p=0.011).  
 
An interesting finding, however, concerns the behaviour of the CP variants in the 
two cell lines. As mentioned earlier, the 4R:3R ratio was notably increased across 
the board in SH cells compared to F1 cells. For the CP variants, however, this 
increase was greater (3.2- to 3.4-fold) than for the CP+rs242557 and CMV 
variants (1.7- to 2.0-fold), which the results of the promoter luciferase study in 
chapter 3 shows cannot be attributed to differences in CP transcriptional activity 
in the two cell lines (figure 3.8 in chapter 3). The reason for this is unclear, but 
may, once again, highlight the important contribution of endogenously expressed 
trans-acting factors in the regulation of tau gene expression.  
 
5.4.3 Neuronal differentiation induces allelic differences in the contribution 
of rs242557 to splicing regulation of exon 10 
The significance of the cellular context in tau isoform expression is exemplified in 
vivo by the well-established changes in exon 10 splicing that take place during 
development. Foetal tau consists exclusively of the 0N3R isoform, with exon 10 
constitutively spliced out. In the adult brain, however, exon 10 skipping is 
downregulated and the overall expression of 3R- and 4R-tau isoforms is 
approximately even. To determine whether minigene splicing was similarly 
affected by developmental changes in the cellular environment, comparative 
analyses were conducted in F1 and SH cells that had been neuronally 
differentiated by treatment with retinoic acid (section 5.3.2).  
 
Figure 5.4 presents the 4R:3R-tau ratios produced by each minigene variant when 
expressed in differentiated F1 cells. The most important finding is the emergence 
of an allelic difference in 4R:3R ratio between the two CP+rs242557 variants, 
with the H1C-A variant producing a significantly higher proportion of 4R 
transcripts than the H1B-G variant (4.88 versus 2.81 (1.7-fold increase); 
p=0.0103). Comparison of the allelic variants to their CP minigene counterparts 
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(figure 5.4B) also reveals interesting allelic differences. The addition of the H1B-
G allele variant of the rs242557 domain conferred a reduction in the proportion of 
4R transcripts produced, thereby significantly reducing the 4R:3R ratio 
(p=0.0366). The H1C-A allele variant, however, appears to increase the 
proportion of 4R transcripts produced and thus confers an overall increase in 
4R:3R ratio compared to the minigene containing the CP alone (p=0.0295) – 
concordant with the findings from the analyses in undifferentiated cells. 
 
Figure 5.4 The exon 10 quantification of minigene transcripts expressed in 
differentiated SK-N-F1 cells treated with retinoic acid for 5 days.  
Ai: The 4R:3R mRNA ratio produced by each minigene variant; Aii: An example of 
a polyacrylamide gel image used to quantify the 4R and 3R RT-PCR products; B: 
The individual results of the H1B (Bi) and H1C (Bii) haplotypes; C: Significant 
differences in ratio between minigene variants were detected by Student’s t-test; D: 
Comparison of 4R:3R-tau ratios in undifferentiated and differentiated (prefixed 
with ‘d’) cells for H1B (Di) and H1C (Dii) haplotype variants. * p≤0.05; ** p≤0.01. 
 
Panel D in figure 5.4 presents individual comparisons of the H1B (Di) and H1C 
(Dii) promoter variants in undifferentiated versus differentiated F1 cells. As 
expected, the 4R:3R ratio produced by the CMV variant does not change 
following differentiation. The CMV promoter is a viral promoter and is therefore 
unlikely to be as sensitive to changes in the endogenous environment of human 
cells as the tau promoter variants. Minigene expression driven by the intrinsic 
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MAPT CP promoter, by contrast, exhibited a significant increase in the proportion 
of mRNA transcripts containing exon 10; a finding which was also expected as 
this is consistent with the changes in endogenous tau expression produced 
following differentiation. This was also the case with the minigene containing the 
A-allele variant of the rs242557 domain.  
 
The H1B-G minigene, however, did not behave as expected, with the 4R:3R 
mRNA ratio unaltered following neuronal differentiation. This was surprising, as 
the PSP-associated H1C-A variant would be expected to be the one to deviate 
from the general trend. This may be explained by considering the potential 
function of the rs242557 domain in exon 10 splicing regulation. If the role of the 
domain is to suppress exon 10 inclusion following the upregulation of tau 
expression in differentiated neurons, then the H1C-A variant would be the one 
that does not respond to retinoic acid treatment, failing to regulate the increase in 
exon 10 inclusion conferred by the CP following differentiation. In section 3.11 it 
was shown that the A-allele variant of the rs242557 domain conferred 
significantly weaker repression of transcription from the CP compared to its G-
allele counterpart. Together these results suggest an overall loss-of-function for 
the A-allele variant of the regulatory domain, causing a weakening of its 
repressive effect on the CP in terms of both transcription rate and exon 10 
inclusion. 
 
Figure 5.5 presents comparative 4R:3R-tau ratios produced by the minigenes 
when expressed in differentiated SH cells. The rs242557 allelic difference in ratio 
detected in F1 cells was replicated in this second cell line (figure 5.5.Ai), with a 
1.5-fold increase in ratio conferred by the H1C-A variant. Although statistical 
significance was not quite reached, it was extremely close to the threshold (6.61 
versus 4.27; p=0.0556).  
 
Another important finding was the emergence of a significant difference in exon 
10 splicing between the two tau promoter types following differentiation (figure 
5.5Bi and Bii) – a finding that was absent in undifferentiated SH cells. Both allelic 
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variants of the rs242557 domain acted to reduce the 4R:3R ratio produced by the 
CP alone, though the H1C-A variant was notably less efficient at this (H1B: 2.6-
fold reduction, p=0.0900; H1C: 1.6-fold reduction, p=0.0135).  
 
Figure 5.5 The exon 10 quantification of minigene transcripts expressed in 
differentiated SH-SY5Y cells treated with retinoic acid for 5 days.  
Ai: The 4R:3R mRNA ratio produced by each minigene variant; Aii: An example of 
a polyacrylamide gel image used to quantify the 4R and 3R RT-PCR products; B: 
The individual results of the H1B (Bi) and H1C (Bii) haplotypes; C: Significant 
differences in ratio between minigene variants were detected by Student’s t-test; D: 
Comparison of the 4R:3R-tau ratios in undifferentiated and differentiated (prefixed 
with ‘d’) cells for the H1B (Di) and H1C (Dii) haplotype variants. # p<0.09; * 
p≤0.05; ** p≤0.01. 
 
Comparison of minigene expression in undifferentiated and differentiated SH 
cells (figure 5.5D) again shows that 4R expression is upregulated from the CP 
minigenes following differentiation, as occurs in vivo. For the rs242557 variants, 
however, the 4R:3R ratio conferred by the H1B-G variant is significantly reduced 
following differentiation (p=0.0195), while the ratio conferred by the H1C-A 
variant does not change (p=0.4781). It would, again, appear that the allelic 
difference in 4R:3R ratio stems from the inability of the H1C-A variant to fully 
respond to retinoic acid treatment, demonstrating a weaker ability to suppress 
exon 10 inclusion compared to the H1B-G variant in differentiated cells. The 
reason for this is unclear, but one hypothesis may be that the A-allele of rs242557 
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causes a change in the conformation of the mRNA transcript, blocking access of 
neuronal-specific trans-acting protein factors. The weakening or abolition of the 
binding site of such a factor by the presence of the A-allele may be another 
potential hypothesis. 
 
5.5 Quantification of minigene exon 2 and exon 3 alternative splicing 
 
5.5.1 Distinguishing the 0N, 1N and 2N isoforms 
In section 4.9.2.4, a method was described for analysing the alternative splicing 
events at exons 2 and 3 in combination with splicing at exon 10. This method 
proved unsatisfactory, as the mis-splicing out of the exon 4-9 minigene element 
produced a PCR bias that resulted in the selective amplification of the shorter, 
mis-spliced transcripts. Correctly spliced transcripts containing the exon 4-9 
element – known to be present due to the successful use of an exon 9 primer in the 
exon 10 quantification – were not detectable using this method. An additional 
issue with this method was the inability to separate the six tau isoforms due to 
small size differences (6bp) between some of the transcripts. Thus, although it is 
desirable to study the alternative splicing events along the full length of the 
minigene transcripts – as would have been possible by Western blot if minigene-
expressed protein analysis was viable – it was instead decided to focus on the 
splicing of exons 2 and 3 independently of exon 10.   
 
This approach was also not without problems, as the ability to distinguish 
minigene tau transcripts from those expressed endogenously was reliant on the use 
of a reverse primer annealing to the FLAG-tag motif at the 3’ end of the transcript 
– downstream to exon 10. To selectively amplify the N-terminal section of 
correctly spliced transcripts and exclude those missing the exon 4-9 element, a 
reverse primer annealing to exon 4 was required. To enable this, a nested PCR 
was performed on the minigene cDNA, with the first round of amplification using 
primers annealing to exon 1 and the FLAG-tag motif, as described previously in 
section 4.9.2.4. The only change in conditions was the reduction in the number of 
PCR cycles from 35 to 29 to reduce the level of background after the second 
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amplification. A 1μl aliquot of the exon 1-FLAG PCR product was used to set up 
a second PCR, using the same forward primer in exon 1 (F: 
CATGCACCAAGACCAAGA) and a reverse primer in exon 4 (R: 
TCCAATGCCTGCTTCTTC). PCR was conducted during 30 cycles of 
denaturation, annealing at 55°C and elongation for 1 minute.  
 
To ensure that the nested PCR selectively amplified transcripts expressed from the 
minigene – particularly in the absence of a FLAG-tag primer in the second PCR – 
a control PCR was conducted on reverse-transcribed endogenous tau transcripts 
from untransfected cells. As endogenous tau does not contain a FLAG-tag motif, 
the first amplification of the nested PCR was conducted with a reverse primer 
annealing in exon 12 (R: GTCCAGGGACCCAATCTTCGA) at an annealing 
temperature of 55°C. The rest of the PCR conditions and the second PCR was the 
same as for the minigene cDNA. In undifferentiated cells, this control PCR 
produced only one product representing 0N transcripts, as this is the only tau 
isoform expressed endogenously in this state. The minigene PCR products 
consistently deviated from this banding pattern, indicating that the nested method 
was indeed specifically amplifying the minigene transcripts. 
 
All nested PCR products were resolved by agarose gel electrophoresis (section 
2.1.3.3) and visualised bands were individually quantified using the ImageJ 
software. In all instances results were pooled from four independent transfections 
in four biological replicates. 
 
5.5.2 Promoter identity affects N-terminal splicing in differentiated F1 cells 
The minigene nested PCR products were slightly larger than expected, as 
observed by comparison of the 0N isoform band (~100bp) with that produced 
from the endogenous tau transcripts (~60bp; figure 5.6). As described in section 
4.9.2.4, one of the Gateway attB sequences used to create the minigene lies within 
the 3’splice site at the intron 3/exon 4 boundary, and it therefore appears that the 
attB insertion causes the intronic sequences of the splicing motif to shift 
approximately 40bp upstream to the exon boundary. Thus all nested PCR products 
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amplified from minigene transcripts were approximately 40bp larger than 
expected.  
 
The most notable finding from the results of the nested PCR was the preferential 
expression of 2N mRNA containing both exons 2 and 3 (278bp with attB 
insertion). The 0N mRNA was also detected (ex2-/3-; 104bp); however, although 
an appropriately-sized 1N band (ex2+/3-; 191bp) was detected, it was of too low 
abundance to be accurately quantified. As mentioned previously, 2N isoforms are 
the least abundant in the adult brain and therefore its over-expression here may 
result from the splicing issues at exon 4, with exon 3 inclusion increasing the 
likelihood of the transcript being correctly spliced at exons 4-9. Although far from 
a perfect model, the preference for 2N and 0N expression – and the attB insertion 
– was the same for all six minigene variants. Thus, a preliminary quantification of 
promoter and genetic influences on the ratio of 2N/0N isoform expression could 
still be determined. Figures 5.6 and 5.7 present these ratios from minigenes 
expressed in undifferentiated and differentiated F1 cells, respectively. Error bars 
represent the standard deviation from the mean and significance was detected 
using the Student’s t-test, as previously. 
 
In undifferentiated F1 cells, there were no significant differences in 2N/0N tau 
ratio between any of the minigene variants (figure 5.6), suggesting that the 
rs242557 domain does not play a role in regulating N-terminal splicing events 
when this cell line is in the undifferentiated state. 
 
Promoter identity had a greater influence on N-terminal exon splicing when F1 
cells were neuronally differentiated by treatment with retinoic acid (figure 5.7), 
with the MAPT promoter variants (CP and CP+rs242557) conferring a 
significantly lower 2N/0N ratio than their CMV counterparts. There were no 
differences in 2N/0N ratio between the H1B/H1C haplotype and rs242557 allelic 
variants, nor between the two MAPT promoter types. 
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Figure 5.6 The 2N/0N mRNA ratio of N-terminal tau isoform expression in 
undifferentiated F1 cells.  
A: Comparison of the 2N/0N ratio between H1B and H1C haplotype variants 
presented i: by bar graph; ii: by an agarose gel image of resolved nested PCR 
products; B: Comparison of the promoter variants of i: H1B and ii: H1C minigene 
variants; C: Significant differences in ratio were detected by Student’s t-test. 
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Figure 5.7 The 2N/0N mRNA ratio of N-terminal tau isoform expression in 
differentiated F1 cells.  
A: Comparison of the 2N/0N ratio between H1B and H1C haplotype variants 
presented i: by bar graph; ii: by an agarose gel image of resolved nested PCR 
products; B: Comparison of the promoter variants of i: H1B and ii: H1C minigene 
variants; C: Significant differences in ratio were detected by Student’s t-test. * 
p≤0.05; ** p≤0.01 
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The results of the 2N/0N mRNA quantifications in F1 cells suggest that tau 
promoter identity is important in the splicing of N-terminal exons – but only when 
cells are differentiated. As the splicing pattern produced by the minigenes does 
not resemble that observed in vivo, it is difficult to make any biological 
interpretations relating to the upregulation or downregulation of specific isoforms. 
It can, however, be determined that the rs242557 regulatory domain does not play 
a role in N-terminal splicing regulation in this cell line, as the 2N/0N ratio 
produced by the CP+rs242557 variants did not differ from that of the CP variants 
in either undifferentiated or differentiated state. 
 
5.5.3 The N-terminal exon splicing events conferred by the minigenes in SH 
cells   
Analysis of the N-terminal exon 2 and 3 splicing events from minigenes expressed 
in SH cells produced some surprising and intriguing results. In undifferentiated 
SH cells, differences were detected between the promoter variants, with the 
highest 2N/0N ratio conferred by the CMV minigene variants and the 
CP+rs242557 allelic variants conferring the lowest (figure 5.8A). There was also 
an allelic difference in ratio between the CP+rs242557 H1B-G and H1C-A 
variants that almost reached statistical significance (p=0.0787), with H1C-A 
conferring a lower ratio than its G-allele counterpart. There were no differences 
between the CP (p=0.1326) and CMV (p=0.5055) haplotype variants, suggesting 
that the rs242557 allelic difference is directly due to the promoter element and not 
genetic variation elsewhere in the minigene.  
 
There was, however, evidence of a role for promoter identity, with the two tau 
promoter types conferring significantly lower 2N/0N ratios than their CMV 
counterparts (figure 5.8B; CP H1B: p=0.0306; CP H1C: p=0.0492; rs242557-A: 
p=0.0043; vs CMV). There was also a significant difference between the two 
MAPT promoter types, with the addition of the rs242557 domain reducing the 
expression of 2N tau conferred by the unregulated CP minigene (figure 5.8B; CP 
vs CP+rs242557; H1B: p=0.0445; H1C: p=0.0500). 
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Figure 5.8 The 2N/0N mRNA ratio of N-terminal tau isoform expression in 
undifferentiated SH cells.  
A: Comparison of the 2N/0N ratio between H1B and H1C haplotype variants 
presented i: by bar graph; ii: by an agarose gel image of resolved nested PCR 
products; B: Comparison of the promoter variants of i: H1B and ii: H1C minigene 
variants. # p<0.08; * p≤0.05; ** p≤0.01 
 
In differentiated SH cells a clear haplotype difference was observed between all 
three promoter variants, with the H1C minigenes, firstly expressing a much lower 
abundance of transcripts overall, which, secondly, consisted almost exclusively of 
the 2N mRNA (figure 5.9). The reason for this is unclear, but the H1C-specific 
shift in N-terminal splicing suggests that the H1C minigene backbone contains an 
element that influences this ratio in SH cells, regardless of the nature of the 
promoter element. As 0N mRNA was undetectable for the H1C minigenes, 
internal ratios were not calculated in this instance. It is fair to say that 
quantification of the minigene N-terminal exon splicing events was erratic in the 
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SH cell line and these results are difficult to fathom. Further replications must be 
undertaken before anything can be read into these contradictory findings.   
 
Figure 5.9 The nested PCR 
products of N-terminal 
exon 2 and 3 splicing 
events in differentiated SH 
cells. 
 
 
 
Overall, however, these quantifications have shown that MAPT promoter identify 
plays a role in the regulation of N-terminal exon splicing in F1 cells when in the 
differentiated – but not undifferentiated – state; perhaps indicating its importance 
in regulating the significant changes in exon 2 and 3 splicing that take place 
during development.  
 
5.6 Differential binding of factors to the rs242557 allelic variants 
 
5.6.1 Overview 
Chromatin immunoprecipitation (ChIP) provides a method of determining 
whether specific proteins bind to a known DNA sequence (section 2.1.7.1). It was 
used here to determine whether the allelic variants of the rs242557 domain 
differentially bind specific transcription and splicing factors. These factors were 
chosen for investigation based on experimental evidence produced previously in 
the laboratory [JF Anaya, PhD thesis, UCL 2012, [242]].  
 
This work included electrophoretic mobility shift assays (EMSAs) and DNA 
affinity purification, which were used to identify a number of proteins that bind to 
the rs242557 region and to determine the comparative strength of their binding to 
the two alleles. The top candidates for differential binding – that is the proteins 
that demonstrated the largest difference in binding strength to the two alleles – 
were further analysed in vitro. Expression of each candidate protein was 
individually knocked down by siRNA treatment of SH cells and the effect on 
expression of the SD-downstream promoter luciferase constructs (described in 
100bp
200bp
300bp
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section 3.5) was determined. Out of the candidates analysed, knockdown of 
hnRNP U had the greatest differential effect on the activity of the rs242557 allelic 
variants, with the H1C-A construct conferring a significant reduction in activity 
compared to the H1B-G 
construct following hnRNP U 
knockdown (figure 5.10). 
 
Figure 5.10 The effect of siRNA 
knockdown on promoter 
luciferase activity. 
The relative luciferase activity 
of the CP H1 and CP+SD 
allelic variants in SH-SY5Y 
cells treated with an siRNA 
targeted against hnRNP U. Results were normalised against the activity of 
each construct in cells treated with a control (scrambled) siRNA. JFAnaya, 
PhD thesis, UCL 2012. *** p≤0.001 
 
Heterogeneous ribonucleoproteins (hnRNPs) are a family of RNA-binding 
proteins that are expressed ubiquitously and have been implicated at all levels of 
gene expression, including in mRNA splicing, stability, transport and translation. 
The hnRNP U protein is a component of ribonucleoprotein particles and is 
thought to have an additional role in the regulation of transcription through its 
association with histone acetylase and the transcriptional activator CBP/p300 
[243]. This is supported by its apparent physical association with the 
phosphorylated CTD of RNA Pol II (see section 1.2.2.2) [243, 244]. It has also 
been suggested that hnRNP U forms a complex with β-actin to regulate Pol II-
mediated transcription during the initial activation phases. Indeed, antibodies 
against hnRNP U and β-actin have been shown to block transcription of Pol II-
transcribed genes [243]. The association of hnRNP U to the rs242557 domain – a 
transcription regulatory domain – would therefore further support the hypothesis 
that MAPT transcription and splicing processes are co-regulated.  
 
The allelic minigene variants were not suitable for use in these ChIP experiments, 
as the minigene rs242557 domain could not be separated from its endogenous 
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counterpart. Thus, ChIP was performed on endogenous chromatin extracted from 
untransfected cells of determined genotype. 
 
5.6.2 rs242557 genotyping 
The rs242557 genotype status of five human cell lines was determined: SK-N-F1, 
SH-SY5Y, BE(2)-M17, SK-N-MC and HEK293. This polymorphism is an RFLP 
(section 2.1.8.1), with the A-allele abolishing a restriction site of the ApaLI 
enzyme. Thus, the rs242557 genotype of each cell line was determined by the 
PCR amplification of a 384bp fragment containing the polymorphism followed by 
digestion with ApaLI.  
 
DNA was extracted from cultured cells as described in section 2.1.5.6. A volume 
of 3μl formed the template in a PCR with specially-designed primers (F: 
ACAGAGAAAGCCCCTGTTGG; R: ATGCTGGGAAGCAAAAGAAA). PCR 
was performed as described previously using the FastStart High Fidelity PCR 
System and comprised 35 cycles of denaturation, annealing at 60°C and 
elongation for 1 minute. PCR products were digested overnight at 37°C with 25 
units of ApaLI enzyme, NEB4 buffer (1x) and BSA (1x) in a total reaction 
volume of 50μl. Digestion products were visualised by agarose gel electrophoresis 
and genotypes were called based on the banding pattern observed. Cell lines 
homozygous for the A-allele produced one band of 384bp, whereas those 
homozygous for the G-allele produced two bands of 188 and 196bp that resolved 
together as one band. Heterozygous cell lines were identified by the appearance of 
two bands of 384 and ~190bp. The banding patterns produced are presented in 
figure 5.11. 
 
Figure 5.11 Genotyping of the rs242557 
polymorphism. 
The banding pattern produced by the 
ApaL1 digestion of rs242557-containing 
PCR amplicons of 384bp. SH: SH-SY5Y; 
F1: SK-N-F1; HEK: HEK293. 
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Three of the cell lines were homozygous for the G-allele, with SH-SY5Y 
homozygous for the A-allele. Although these genotypes are informative, a 
heterozygous line (A/G) was desirable as it would have avoided confounding due 
to general differences between the cell lines. Unfortunately, the only heterozygous 
line identified was HEK293, which is not a neuronal line and therefore was not 
deemed suitable in this instance. Thus, the SH-SY5Y (A/A) and SK-N-F1 (G/G) 
neuroblastoma cell lines were chosen for ChIP as, in addition to carrying 
opposing rs242557 genotypes, they have also been used throughout this project 
and therefore results produced here would further inform the transcription and 
splicing findings described thus far.  
 
5.6.3 Chromatin immunoprecipitation (ChIP) 
ChIP was performed using the MAGnify
™
 System (Invitrogen). Chromatin was 
extracted from cultured SH and F1 cells at four time points during retinoic acid-
induced differentiation: before treatment (day 0) and after 1, 3 and 5 days of 
treatment. Comparison over this time course provided a more detailed analysis of 
the changes in protein binding during the different stages of neuronal 
differentiation. 
 
Endogenous chromatin was fixed, extracted and sonicated into 100-500bp 
fragments according to the manufacturer’s protocol. Each IP was conducted with 
chromatin from approximately 200,000 cells and samples were diluted 
accordingly in the presence of protease inhibitors (1x). Three investigative IPs 
were preformed on each chromatin sample using antibodies against RNA Pol II, 
hnRNP U and β-actin. There are various commercially-available antibodies that 
react against Pol II in specific phosphorylation states. Although hnRNP U is 
believed to bind to phosphorylated Pol II, the evidence for this is not absolute and 
it is not clear which residues of the Pol II CTD must be phosphorylated to enable 
hnRNP U binding. Thus, a phospho-independent Pol II antibody was used in these 
ChIP experiments to detect all Pol II molecules bound to the rs242557 domain, 
regardless of phosphorylation state. A final IP using the mouse IgG antibody was 
included as a negative control as this should not react against human proteins. 
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Each IP was conducted with 1μg of antibody, with the exception of the β-actin IP, 
for which 2μg was used. The IP, reverse cross-linking and DNA purification steps 
were conducted according to the manufacturer’s protocol. For each IP, a positive 
‘input’ control was included, in which the chromatin sample was subject to the 
same reverse cross-linking and DNA purification steps but did not undergo the 
antibody IP.  
 
The binding of the three factors to the rs242557 domain was determined by PCR 
using 3μl of each purified IP product. The primers and PCR conditions used to 
genotype the rs242557 polymorphism in the cell lines were also used here and are 
described in section 5.6.2. A product of size 384bp indicated the binding of the 
factor to the rs242557 domain. A second PCR was conducted on each IP product 
using primers annealing to the GAPDH gene (AT=60°C; F: 
TACTAGCGGTTTTACGGGCG; R: TCGAACAGGAGGAGCAGAGAGCGA)  
 
GAPDH is a highly active housekeeping gene that is constitutively expressed in 
most cell and tissue types [245]. Thus, this PCR acted as a measure of the 
efficiency of the IP, as transcription-associated proteins should bind to this gene 
regardless of differentiation state or cell type. For each PCR, two positive controls 
were included consisting of genomic DNA extracted from untransfected F1 and 
SH cells. All PCR products were resolved by agarose gel electrophoresis using a 
2% gel. The results of the rs242557 and GAPDH PCRs are presented in figures 
5.12 and 5.13 respectively.  
 
5.6.4 RNA Pol II and hnRNP U associate with the rs242557 domain in a 
manner dependent on differentiation state 
The ChIP results reveal that RNA Pol II and hnRNP U are detectable at the 
rs242557 domain (figure 5.12). This is a significant finding as the association of 
these two factors at the PSP-associated rs242557 domain has not been 
investigated before. If hnRNP U only binds to phosphorylated – and therefore 
elongating – Pol II, these findings may shed light on both the mechanism by 
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which the rs242557 domain influences transcription and the observed allelic 
differences in this influence.  
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Figure 5.12 ChIP results of rs242557 binding.  
ChIP was performed on cultured F1 (A) and SH (B) cells harvested following 0, 1, 3 
and 5 days of retinoic acid treatment. Four IPs were performed on each chromatin 
sample using antibodies against: RNA Pol II, hnRNP U, β-actin and mouse IgG. The 
positive input control completed the ChIP protocol but skipped the IP stage. Two 
PCR controls comprised genomic DNA from SH (g-SH) and F1 (g-F1) cells.  
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Figure 5.13 Comparative ChIP results of GAPDH binding.  
ChIP was performed on cultured F1 (A) and SH (B) cells harvested following 0, 1, 3 
and 5 days of retinoic acid treatment.  
 
 
The rs242557 ChIP results from the F1 cells (carrying the G/G genotype) show 
that Pol II is associated at all points of the differentiation process, increasing 
steadily from day 0 to a maximum concentration at day 3 (figure 5.12A). 
5 MAPT Alternative Splicing 
205 
 
Increasing Pol II binding is concurrent with a decrease in hnRNP U binding, 
leading to almost complete dissociation of the hnRNP U factor by day 3. Thus, if 
hnRNP U is an indicator of active transcription, this would suggest that 
transcriptional pausing and Pol II accumulation is enhanced at the rs242557 
domain during the later stages of differentiation. It may be, therefore, that the 
rs242557 domain represses MAPT transcription by inducing Pol II pausing. 
 
In SH cells (carrying the A/A genotype) the pattern of Pol II and hnRNP U 
binding is slightly different (figure 5.12B). Neither factor was associated with the 
region at day 0, suggesting transcriptional pausing does not occur at this region in 
undifferentiated cells. This may be due to low basal tau levels when cells are in 
their undifferentiated form, with Pol II resident at the CP. Following induction of 
tau expression during differentiation, transcription complexes may proceed to the 
rs242557 domain. Indeed, as with F1 cells, Pol II binding at the rs242557 domain 
increased over time but in SH cells, the association of hnRNPU remained, albeit at 
lower relative levels. Thus, it would appear that the weaker transcriptional 
repression conferred by the A-allele of rs242557 (figure 3.9) results from a 
reduced ability to induce transcriptional pausing and therefore higher levels of 
elongating Pol II are detected at this allelic variant.  
 
β-actin does not appear to be associated with either of the rs242557 allelic 
variants, Pol II or hnRNP U. It must be emphasised, however, that these results 
are preliminary and technical difficulties have currently prevented independent 
replication. In particular the β-actin IP needs further optimisation as the hit-and-
miss GAPDH results (figure 5.13) suggest the lack of product from the rs242557 
PCR may be a consequence of failure of the IP.  
 
5.6.5 GAPDH binding confirms Pol II association with hnRNP U 
Pol II and β-actin were highly associated with GAPDH in both cell lines, though 
hnRNP U binding decreased over the course of the differentiation process (figure 
5.13). This appears to confirm the previous reports that hnRNP U associates with 
elongating Pol II. Accumulation of Pol II indicates transcriptional pausing and the 
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results presented here describe an inverse relationship between Pol II 
accumulation and hnRNP U binding, suggesting the latter factor has a low 
affinity, if any, for inactive Pol II. Reactivity with anti-mouse IgG was detected in 
four of the GAPDH PCRs. This could indicate contamination; however, sporadic 
positive results from this IP have been widely reported and are generally 
considered technical artefacts. 
 
5.7 The ability of the rs242557 regulatory domain to initiate transcription 
in undifferentiated and neuronally differentiated cells  
Following the finding that Pol II accumulates at the rs242557 domain, it was 
important to determine whether transcription could originate from the rs242557 
domain itself. In other words, does the rs242557 domain contain sequences that 
are capable of initiating transcription independently of the core promoter? To 
answer this question, two pGL4.10 luciferase constructs were created, each 
containing one of the allelic variants of the rs242557 domain (the ‘SD’ H1B and 
H1C elements from chapter 3). The constructs were created using the NheI- and 
EcoRV-flanked SD elements and the cloning techniques described in chapter 3. 
Constructs were transfected into F1 and SH cells and luciferase activity was 
quantified as described previously.  
 
As the ChIP results revealed that the association of Pol II and hnRNP U to the 
rs242557 domain changes during the course of differentiation, the SD constructs 
were assayed in both undifferentiated and differentiated (5 days) cells to see if 
transcriptional activity – if any – changed with the differentiation state. The CP 
H1 construct described in section 3.5.5 was included for comparison. Each assay 
was conducted in triplicate and the results are presented in figure 5.14. The error 
bars represent the standard deviation from the mean. Significant differences in 
activity between the two differentiation states were detected by Student’s t-test, as 
previously.  
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Figure 5.14 Promoter luciferase results 7 
The relative luciferase activity conferred by the H1 core promoter (CP) and the 
allelic variants of the SD in undifferentiated and neuronally differentiated (dark 
green; prefixed with ‘d’) F1 (A) and SH (B) cells. * p≤0.05 
 
The rs242557 domain did not confer transcription in F1 cells in either 
differentiation state (figure 5.14A), suggesting the active Pol II associated with 
this domain in the ChIP experiments originated from upstream regions of the 
MAPT gene and not the domain itself. Activity levels did appear slightly higher in 
SH cells (figure 5.15B), which may suggest this region is capable of initiating a 
low level of transcriptional activity, but only in certain cellular conditions. The 
activity of the H1 core promoter did not increase following differentiation of 
either cell line, presumably due to the over-expression of the construct required by 
the luciferase technique. 
 
As a final investigation, the CP+rs242557-A and CP+rs242557-G luciferase 
constructs – previously assayed in undifferentiated cells in chapter 3 – were 
assayed again, this time in F1 and SH cells in both undifferentiated and 
differentiated states. The results were intriguing and are presented in figure 5.15. 
In F1 cells, differentiation did not significantly alter the activity of either of the 
rs242557 allelic variants; again presumably due to construct over-expression 
potentially masking subtle differences. In SH cells, however, the activity of the 
CP+rs242557-A variant, significantly reduced following differentiation 
(p=0.0044), suggesting the difference in ability of the allelic variants to modulate 
transcription rate, though still present (p=0.0854), is muted in differentiated cells. 
It must be noted, however, that these analyses were conducted on results gained 
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from one single experiment, with at least two further biological replicates needed 
before firm conclusions can be drawn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 Promoter luciferase results 8 
The relative luciferase activity of the allelic variants of the CP+rs242557 construct in 
undifferentiated and neuronally differentiated (dark green; prefixed with ‘d’) F1 
(A) and SH (B) cells. ** p≤0.01 
 
 
5.8 Discussion 
This chapter has described an investigation into the role of the rs242557 
polymorphism in the regulation of MAPT alternative splicing. The MAPT 
minigene variants were expressed in vitro in order to quantify the rate of exon 2, 3 
and 10 inclusion in mRNA transcripts produced from different promoter and 
haplotype variants. 
 
The rs242557 polymorphism was not found to play a role in the N-terminal  exon 
splicing events in F1 cells. In undifferentiated cells, the ratio of 2N and 0N 
expression did not differ significantly between the six minigene variants. In 
differentiated F1 cells, however, promoter specificity did play a role, with a 
reduction in the proportion of 2N isoforms expressed from the tau promoter-
driven minigenes compared to the CMV minigenes. The addition of the rs242557 
domain to the CP did not affect 2N/0N ratio and this was in concordance with 
previously reported evidence suggesting N-terminal splicing events are regulated 
by a different mechanism to that at exon 10 [133, 205]. This picture was 
complicated in SH cells, where significant differences in 2N/0N ratio between the 
three promoter variants, and between the two rs242557 variants were detected. It 
is difficult to take any biological interpretations from these results and further 
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replications are required before conclusions can be drawn. If these cell line 
differences prove to be real, it would indicate that cell-specific trans-acting 
factors have a significant influence on the inclusion rate of exons 2 and 3. Recent 
evidence has assigned a protective role for exon 3 against neurodegeneration and 
therefore these findings may help to explain why certain subgroups of neurons are 
vulnerable to tau aggregation, where others are not. 
 
Despite the over-expression of transcripts containing exon 10, the quantification 
of the 4R:3R ratio from minigene mRNA revealed that the rs242557 
polymorphism plays a role in exon 10 splicing in differentiated cells, with the 
rs242557-A allele conferring increased exon 10 inclusion in both cell lines. This 
was accompanied by the ChIP results, which revealed an association of the 
hnRNP U factor with the A-allele domain in differentiated SH cells that was 
absent with the G-allele domain of differentiated F1 cells. When combined, these 
results provide some intriguing insights into the potential mechanism behind the 
association of rs242557 with the over-expression of 4R-tau in PSP. Putting all of 
the evidence together, the role of the rs242557 domain in exon 10 splicing may be 
characterised as follows: 
 
1. Early in the differentiation process, as MAPT transcription is upregulated, 
the abundance of phosphorylated Pol II molecules increases 
2. hnRNP U associates with elongating phospho-Pol II and recruits/interacts 
with the splicing machinery to promote exon 10 inclusion. 
3. As differentiation progresses, the rs242557 domain induces increased Pol 
II pausing, leading to a decrease in transcription rate and Pol II 
accumulation.  
4. hnRNP U dissociates from accumulated, and therefore paused, Pol II, 
altering the recruitment/interaction with the spliceosome and leading to a 
decrease in exon 10 inclusion. 
 
The evidence presented by the ChIP results suggests that the A-allele of the 
rs242557 domain is inefficient at inducing Pol II pausing during differentiation, 
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with a proportion of the Pol II molecules remaining active and associated to 
hnRNP U, promoting higher levels of exon 10 inclusion. This may therefore link 
the increase in transcriptional activity conferred by the CP+rs242557-A luciferase 
construct with the relative increase in exon 10 inclusion produced by the 
CP+rs242557-A minigene. These results, along with the other evidence reported 
in this project, will be discussed in more detail in chapter 6.  
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6 Discussion 
 
6.1 Summary of results 
The role of common haplotype variation in MAPT expression was investigated at 
multiple levels: firstly, by quantifying the level of transcription conferred by 
MAPT promoter elements containing the genetic variation of the H1B, H1C and 
H2 haplotypes; secondly, by determining the rate of alternative exon inclusion 
conferred by minigenes representing the H1B and H1C haplotypes; and thirdly, by 
identifying protein factors that differentially bind to the key polymorphism that 
differentiates H1B from H1C.  
 
The project began with three luciferase reporter gene studies designed to 
investigate the effect of genetic variation within the 5’ and 3’ UTRs on gene 
expression. Particular emphasis was placed on the role of a highly conserved 
distal domain containing the rs242557 polymorphism that has been strongly 
associated with PSP. The allelic variants of this domain were repeatedly shown, 
using reporter gene vectors in cell culture, to differentially alter the transcriptional 
activity of the MAPT core promoter, regardless of their relative positioning and 
the in vitro cell model in which they were expressed. The nature of the effect did, 
however, change depending upon whether the rs242557 domain was placed 
upstream or downstream to the core promoter, with the former position resulting 
in a significantly increased transcription rate compared to the latter and an 
inversion in the direction of the allelic effect on domain function. Thus, the 
genomic organisation of the two elements is likely to be a key factor in the 
functioning of this domain in vivo.  
 
This was further exemplified by the comparative luciferase activity of the H1 
mutant constructs containing a single nucleotide error inserted into the 
transcription start site (exon 0) of the core promoter element. The results provided 
evidence of a physical interaction between the two elements by demonstrating that 
a single alteration to the conserved sequence of one of the elements affects the 
functioning of the other.  
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The second luciferase study investigated the function of a bi-directional promoter 
located immediately downstream to the MAPT core promoter element. The results 
confirmed that this promoter was capable of initiating transcription in both the 
forward (sense) and reverse (antisense) directions and revealed that this 
transcriptional activity was up to 2.5-fold higher in the sense direction than the 
antisense direction. The transcriptional activities of the H1 haplotype variants did 
not differ significantly from one another in either direction and the fold-difference 
between sense and antisense transcription was consistent in both cell lines. The 
H2 variant, however, behaved differently in the two cell lines, with sense 
transcription equalling antisense transcription in SH cells.  
 
The study of an extended promoter fragment, containing both the core promoter 
and bi-directional promoter in their natural genomic orientation, revealed that the 
addition of the bi-directional promoter modifies the transcriptional activity of the 
core promoter. Expression in F1 and SH cell lines produced opposing results, with 
the bi-directional promoter conferring increased activity in F1 and decreased 
activity in SH cells compared to the CP alone. The reason for this significant 
difference, however, could not be determined using the luciferase reporter gene 
assay. 
 
During the course of the investigation into the bi-directional promoter, a 
polymorphism was identified that appeared to have a subtle but consistent allelic 
effect on activity. The C-allele – which was found to tag the H1B haplotype – 
conferred marginally increased sense and marginally decreased antisense 
transcription compared to the T-allele of the H1C haplotype. The C/C genotype of 
this polymorphism – denoted rs3744457 – was found to be slightly over-
represented in PSP patients compared to control individuals but this did not quite 
reach statistical significance in these small cohorts. 
 
The final luciferase study identified the region of the MAPT 3’UTR that was most 
influenced by genetic variation. The insertion of the full-length MAPT 3’UTR 
downstream to a CMV promoter-driven luciferase gene conferred a significant 
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increase in luciferase expression compared to the empty luciferase vector, 
presumably due to increased stability of the luciferase transcripts. Comparison of 
the H1B, H1C and H2 variants of the full-length 3’UTR did not reveal genetic 
differences in the regulation of luciferase expression. When split into three 
overlapping fragments, however, genetic variation in the 2kb section at the 3’ end 
of the 3’UTR was shown to differentially affect luciferase expression, with the 
H1C variant conferring significantly increased expression compared to its H1B 
and H2 counterparts.  
 
Focus then shifted to studying the effect of allelic promoter variation on MAPT 
alternative splicing. This was achieved through the construction of MAPT 
minigenes containing all of the exons, intronic segments and regulatory elements 
required to produce the six tau isoforms expressed in the human adult brain. 
Although the minigenes were far from perfect – exhibiting aberrant splicing at 
two important sites – and due to time constraints the planned isogenic cellular 
models could not be completed, these minigenes proved a valuable tool for 
determining the role of promoter identity and common genetic variation on the 
regulation of MAPT alternative splicing events.  
 
In neuronally differentiated cells, the quantification of exon 10 splicing events 
revealed, firstly, that promoter identity plays a role in exon 10 splicing, with the 
two MAPT promoter variants (the core promoter (CP) alone and the core promoter 
in conjunction with the rs242557 domain) conferring significantly reduced exon 
10 inclusion (4R-tau) compared to their CMV promoter-driven counterparts. An 
allelic difference between the two rs242557 domain variants was also observed, 
with the H1C minigene containing the A-allele variant producing a significantly 
higher proportion of 4R (exon 10+) transcripts than the H1B minigene containing 
the G-allele variant. The absence of differences between the haplotype variants of 
the CP and CMV minigenes confirmed that this difference in exon 10 inclusion 
was driven by the rs242557 polymorphism. Thus, the polymorphism that drives 
the strong association of the H1C haplotype with increased PSP risk – and has 
been shown to differentially modulate MAPT transcription rate – was here shown 
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to additionally drive a change in MAPT alternative splicing towards preferential 
4R-tau expression following neuronal differentiation. 
 
Quantification of the splicing events at the N-terminus of the minigene transcripts 
was less reliable, but did reveal a potential influence of promoter identity in the 
regulation of exon 2 and 3 inclusion. For unknown reasons, the minigenes 
produced a bias towards 2N tau (ex2+/ex3+) expression, with 1N tau (ex2+/ex3-) 
virtually undetectable. Biological interpretations relating to individual N-terminal 
isoforms could not, therefore, be made; however, the effect of promoter variation 
on overall N-terminal splicing – here defined as the 2N/0N ratio – could be 
determined and significant differences between MAPT promoter-driven minigenes 
and CMV promoter-driven minigenes were detected in differentiated F1 cells. 
This was not accompanied by rs242557-mediated allelic differences, which 
suggests that N-terminal and C-terminal splicing events are regulated by different 
mechanisms. 
 
The final investigation of this project identified differential binding of two major 
protein factors to the alleles of the rs242557 polymorphism. Chromatin 
immunoprecipitation (ChIP) was performed on extracts from cells homozygous 
for the A-allele (SH) and G-allele (F1) of rs242557 and reactivity of antibodies 
against phospho-independent RNA Pol II and RNA-binding factor hnRNP U was 
determined at four stages of neuronal differentiation. These results revealed that 
RNA Pol II accumulates at the rs242557 domain in increasing concentration as 
differentiation progresses, with hnRNP U found to exhibit an inverse relationship 
with Pol II concentration. Pol II accumulation at the A-allele variant of the 
rs242557 domain appeared to be lower than at the G-allele variant, with a 
corresponding increase in hnRNP U reactivity. 
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6.2 General discussion 
 
6.2.1 The role of antisense transcription in MAPT gene expression 
The luciferase reporter gene assay was used to confirm the presence of a bi-
directional promoter located downstream and proximal to the MAPT core 
promoter. In general, the level of expression conferred from this promoter in the 
sense direction was significantly higher than that in the antisense direction in both 
cell lines. Overall, however, it exhibited significantly higher activity in F1 cells 
than in SH cells, as demonstrated by comparing the sense transcription conferred 
by the bi-directional promoter alone with that from the MAPT core promoter 
alone. As described previously, there is no difference in core promoter activity in 
the two cell lines; however, for the bi-directional promoter the level of activity in 
F1 cells was equal to 71% of the activity of the core promoter, significantly higher 
than the 14% observed in SH cells. This cellular difference in relative promoter 
strength is likely to be behind the difference in the bi-directional transcription-
mediated regulation of core promoter expression observed in the two cell lines. 
 
The hypothesis that a low level of activity from the bi-directional promoter blocks 
elongating transcription complexes from the core promoter is an intriguing one 
and preliminary evidence from the ChIP experiments described in section 5.6.3 
may support this theory. Figure 6.1 presents a PCR analysis of the bi-directional 
promoter region (~150bp) using the DNA products from the Pol II, hnRNP U and 
β-actin IPs conducted in chapter 5. Both Pol II and hnRNP U were detected at the 
bi-directional promoter in F1 cells, again demonstrating an inverse relationship. 
This indicates that Pol II accumulation does occur at this secondary promoter and 
may therefore cause the transcriptional arrest of Pol II complexes originating from 
the core promoter. The accumulation of Pol II is fairly low, however, in F1 cells 
and the additional activity of the highly active secondary sense promoter 
presumably masked this transcriptional arrest when quantification was conducted 
using the luciferase assay, leading to the relative increase in luciferase expression 
observed in F1 cells. Due to technical issues stemming from the difficulty in 
amplifying this GC-rich region by PCR, comparative results from SH cells are not 
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yet available; Pol II accumulation would, however, be expected to be much higher 
in this cell line to account for the repressive effect on CP expression observed in 
the luciferase study. 
 
Figure 6.1 ChIP results of the binding of RNA Pol II, hnRNP U, β-actin and mouse 
IgG to the bi-directional promoter.  
ChIP was performed on cultured F1 cells harvested following 0, 1, 3 and 5 days of 
retinoic acid treatment. The positive input control completed the ChIP protocol but 
skipped the IP stage. Two PCR controls used SH and F1 genomic DNA (g-SH/g-F1)  
 
The presence of a bi-directional promoter – transcribing non-coding transcripts in 
both the sense and antisense directions – immediately downstream to the MAPT 
core promoter element indicates that the regulation of expression of this gene is 
very complex. The methods used in this project did not allow a detailed 
investigation into the effect of either of the non-coding transcripts on core 
promoter expression. There are, however, well-characterised examples of 
antisense-mediated transcriptional regulation that allow us to speculate on how 
antisense transcription may play a role in MAPT expression.  
 
There are three different kinds of naturally occurring sense-antisense transcript 
pairs: a head-to-head model in which the 5’ ends of the transcripts overlap, a tail-
to-tail model in which the 3’ ends of the transcripts overlap and a complete 
overlap model in which one gene is completely overlapped by the other (figure 
6.2) [228]. The MAPT promoter region demonstrates a head-to-head organisation 
(figure 6.2A), with the antisense promoter lying approximately 1kb downstream 
to the core promoter. The picture is, however, slightly more complicated than this 
due to the bi-directional nature of the antisense promoter and further regulation by 
the sense-transcribed non-coding transcript is likely to play an additional – but as 
yet unknown – role in the regulation of transcription in either direction.  
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Figure 6.2 The three kinds of antisense pairs  
A: head-to-head; B: tail-to-tail; C: 
completely overlapping. Taken unchanged 
from Lapidot et al (2006) [228]. 
 
 
In humans, 15% of protein-coding genes 
have an associated antisense transcript and 
approximately 22% of all transcripts 
genome-wide are involved in transcriptional overlap – which is significantly 
higher than observed in species such as rat (5%), chicken (5%) and nematode 
(0.5%) – and this suggests that these transcripts contribute to the great complexity 
of human gene expression [246]. The main models proposed for this role were 
touched upon briefly in section 3.7 and include: transcriptional interference and 
Pol II collision, duplex formation leading to RNA editing or RNAi-mediated 
degradation, and chromatin re-modelling to induce gene silencing [228]. The most 
interesting model, however, that may provide a mechanism for the antisense-
mediated regulation of MAPT expression involves RNA masking. 
 
RNA masking describes a scenario in which the overlapping sections of the two 
transcripts form a double-stranded duplex that masks a cis-acting regulatory 
sequence located on the sense transcript. If the masked sequence is, for example, a 
splice site or splicing regulator, duplex formation would cause a shift in splicing 
ratio towards the preferential expression of one isoform over another and therefore 
antisense transcription would be positively correlated with one splice variant and 
inversely correlated with the other. A real example of this is given by the gene 
encoding the α-thyroid hormone receptor (erbA) which is overlapped in the 
antisense direction by the RevErb gene. Expression of RevErb strongly correlates 
with an increase in the expression ratio of the erbAα1/erbAα2 splice variants 
[247]. The MAPT bi-directional promoter element (the ‘NP’ element) was not 
included in the minigene models, and therefore its potential effect on MAPT 
splicing was not determined.  
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The creation of such MAPT minigenes would allow this determination, and a 
specific motif located within the overlapping region of the CP and NP transcripts 
makes this approach appealing. The 3’ end of the core promoter element contains 
a TG dinucleotide repeat polymorphism – a motif at which the RNA-binding 
factor TDP-43 is known to bind [230]. TAR DNA-binding protein 43 (TDP-43) 
belongs to the hnRNP class of proteins and binds to both DNA and RNA. This 
protein has multiple functions in transcriptional repression, pre-mRNA splicing 
and translational repression [230, 248, 249] and is well characterised in 
neurological disease. So-called TDP-43 proteinopathies exhibit major neuronal 
and glial inclusions of TDP-43 and include frontotemporal lobar degeneration 
(FTLD-TDP), FTLD with motor neuron disease (FTLD-MND) and amyotrophic 
lateral sclerosis (ALS) [250, 251]. TDP-43 inclusions have also been detected in 
the limbic system of some PSP patients [252].  
 
Given the functions of TDP-43 in transcription and splicing and its association 
with neurodegeneration, the location of a potential binding site between the major 
core promoter and secondary antisense promoter in the MAPT gene is intriguing. 
Preliminary data from our group has shown that TDP-43 does indeed bind to this 
motif, with the strength of binding determined by the length of the TG repeat 
[Roberto Simone; personal communication]. Knockdown of the protein by siRNA 
causes a significant increase in expression from the CP luciferase construct 
[Roberto Simone; personal communication]. Thus, if the NP-antisense transcript 
(commonly denoted MAPT-AS1) forms a duplex with the CP-expressed MAPT 
transcript, the repressive TDP-43 motif would be masked (figure 6.3). This could 
potentially lead to an increase 
in MAPT transcription which, 
in turn could alter the co-
regulated splicing ratio of 
MAPT alternate exons.  
Figure 6.3 Potential masking of MAPT transcripts 
Antisense transcripts expressed by the bi-directional promoter (NP) may form a 
duplex with transcripts expressed from MAPT core promoter (CP). The TG 
dinucleotide motif (TG; red box) would therefore be masked and transcriptional 
repression by TDP-43 would be inhibited.  
CP NP
TDP
X
TG
5’
5’3’
3’
6 Discussion 
 
219 
 
It has to be said, however, that a role for TDP-43 in MAPT splicing has yet to be 
determined, with a recent study failing to show an effect on exon 2, 3 and 10 
splicing following the siRNA knockdown of TDP-43. This is concordant with 
initial results gained from the MAPT minigenes described here, which detected an 
overall increase in minigene transcription following TDP-43 siRNA knockdown, 
but not an accompanying shift in exon 10 splicing ratio (data not shown). 
 
It may therefore be unlikely that antisense-mediated transcriptional regulation 
plays a role in the regulation of MAPT exon 10 splicing, though a more detailed 
investigation into the function of this antisense transcript – and the non-coding 
sense transcript, MAPT-IT1 – will further inform our understanding of the 
complex mechanisms regulating MAPT transcription. 
 
6.2.2 The ability of the MAPT 3’UTR to regulate gene expression  
The pMIR-REPORT luciferase study conducted in undifferentiated F1 and SH 
cells did not identify differences in luciferase expression conferred by genetic 
variants of the MAPT 3’UTR. Recent work by Tan-Wong and colleagues has 
shown that the 3’UTR region of a gene can influence transcription by directly 
interacting with the promoter. This is dependent upon factors that associate to 
both the 5’ and 3’ ends of the gene, with the formation of a ‘gene loop’ 
conformation bringing the two ends together (figure 6.4).  
 
Figure 6.4 Ssu72 enables 
interaction of the 3’UTR 
and promoter through 
the adoption of a gene 
loop conformation.  
Adapted from Tan-Wong 
et al (2012)[232]. 
 
 
 
 
This mechanism was found to determine the directionality of transcription from 
bi-directional promoters in which non-coding transcripts were produced in the 
antisense direction and protein-coding mRNA was produced in the sense 
6 Discussion 
 
220 
 
direction. The adoption of a gene loop formation enforced transcription in the 
sense direction and reduced aberrant transcription of non-coding antisense 
transcripts. The key protein involved in this regulation was the polyadenylation 
factor, Ssu72, which associates to both the 5’ and 3’ ends of genes. Mutation of 
Ssu72 was shown to prevent gene loop formation across the FMP27 gene and was 
concurrent with an increase in promoter-associated antisense transcripts and Pol II 
density [232].  
 
To date, gene loop formation has only been demonstrated with certain bi-
directional promoters, a description that does not include the uni-directional 
MAPT core promoter. Loss of the 3’ polyadenylation site from a mammalian gene 
has, however, been shown to directly influence the recruitment of transcription 
factors, with a subsequent reduction in gene expression [253]. The pMIR-
REPORT vector used in the MAPT 3’UTR luciferase study expresses the firefly 
luciferase gene under the control of the CMV promoter. Thus, it is unlikely that 
gene loop formation would occur between a human 3’UTR and a viral promoter 
and therefore potential effects on expression of MAPT promoter-3’UTR 
interactions are presumably absent in these assays. Genetic variation within the 
MAPT 3’UTR that differentially affects its interaction with the MAPT promoter 
region cannot, therefore, be ruled out.   
 
Another finding from this luciferase study was the significantly increased 
expression conferred by the H1C variant of the Fr3 fragment when compared to 
its H1B and H2 counterparts. The multiple sequence alignment of the three Fr3 
variants (Appendix F) reveals a H1C-specific T/A polymorphism lying just 8bp 
upstream to a putative polyadenylation motif (ATAAAA; in green below). If the 
T to A transition on the H1C haplotype strengthens the signal from this putative 
site – leading to its recognition by the polyadenylation machinery – the 3’UTR of 
transcripts produced from this variant would be shortened by approximately 
442bp. As transcripts with shorter 3’UTRs are generally more stable than those 
with longer 3’UTRs, this may account for the increased expression conferred by 
the Fr3 luciferase construct in both cell lines. 
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Fr3 Multiple Sequence alignment (1433/39-1492/99) 
H1B CGTGTCCCATCTACAGACCTGCAGCTTCATAAAACTTCTGATTTCTCTTCAGCTTTGAAA 1499 
H1C CGTGTCCCATCTACAGACCAGCGGCTTCATAAAACTTCTGATTTCTCTTCAGCTTTGAAA 1498 
H2  CGTGTCCCATCTACAGACCTGCGGCTTCATAAAACTTCTGATTTCTCTTCAGCTTTGAAA 1492 
    *******************:**.************************************* 
 
 
6.2.3 The MAPT minigenes  
The main component of this project was the design, construction and in vitro 
investigation of MAPT minigenes representing the genetic variation of two 
common MAPT haplotypes: H1B and the PSP risk-associated H1C. The 
completed minigenes conferred two transcript mis-splicing events – one major 
and one relatively minor. The minor splicing event occurred at the exon 9/intron 9 
boundary and was caused by a weakening of the 5’ splicing signal due to the 
insertion of a restriction site necessary for minigene construction. This resulted in 
the preferential use of a secondary, intronic splice site – located 26bp upstream to 
the native site – in a portion of the transcripts.  
 
It is difficult to tell what effect this had on the exon 10 splicing ratio, as both 4R 
and 3R mRNA transcripts were produced despite the change in splice site 
utilisation. It may be that this cryptic splice site is somehow involved in exon 10 
splicing and its over-use in transcripts expressed by the minigenes may be 
responsible for the over-expression of exon 10-containing 4R transcripts that was 
a feature of all six of the minigene variants regardless of the differentiation status 
of the in vitro cell lines – an unexpected finding given the exclusive 3R 
expression observed endogenously in undifferentiated cells. This would seem 
unlikely, however, as the use of this secondary splice site results in the insertion 
of 26 nucleotides of intronic sequence into the RNA message, which causes a shift 
in the open reading frame during protein translation. It is for this reason that 
protein analyses could not be undertaken using the MAPT minigenes produced 
here. 
 
The major mis-splicing event resulted in the complete removal of exons 4-9 from 
the minigene transcripts and stemmed from the original minigene design. 
Although the attB sequence at the intron 3/exon 4 boundary was designed to re-
6 Discussion 
 
222 
 
capitulate the 3’ splice site, the increased distance between the exon boundary and 
the intronic splicing elements (such as the Py tract) appear to have resulted in 
inefficient splice site recognition.  
 
The importance of intronic sequences in exon recognition was highlighted in a 
study by Dewey and colleagues, who showed that the length of the intron between 
two exons determines the strength of the splicing signal by dictating the number 
of splicing enhancer elements contained within the exon. Longer introns require a 
higher number of enhancers in order to maintain the splicing signal over a greater 
distance. Thus, the decision to completely remove the introns between exons 4, 5, 
7 and 9 likely caused an accumulation of exonic splicing signals within a short 
stretch of sequence [256], presumably confusing the splicing machinery and 
resulting in its failure to recognise the element as an exon. 
 
Although the Dawson study did not report a similar problem with their minigenes, 
they were not able to conduct protein analyses due to the low level of minigene-
expressed tau protein. Their study was conducted on a murine tau background, 
awarding greater flexibility in the analysis of the minigene mRNA as they did not 
have to rely on a FLAG-tag motif to separate human minigene tau from 
endogenous murine tau. As a result, their mRNA analyses were much clearer. 
This is encouraging in terms of the stable cellular models that were planned for 
this project, as stable integration into the genome of the cell line should increase 
yield and add confidence to the splicing studies – particularly those at the N-
terminal exons. Before this, however, the problem of the exon 4-9 element and the 
intron 9-mediated frameshift must be corrected and an outline of how this could 
be achieved was discussed in section 4.11.      
 
One important observation regarding the in vitro expression of the minigenes was 
that the mis-splicing events were common to all six minigenes, with the 
consequences on expression the same and highly replicable in each instance. It 
was therefore agreed that these minigenes could still fulfil the purpose for which 
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they were initially designed – to study the effect of promoter identity and genetic 
variation of the alternative splicing events at exons 2, 3 and 10. 
 
6.2.4 The role of promoter identity in the regulation of MAPT N-terminal 
splicing events 
The design of the MAPT minigenes made the quantification of the N-terminal 
splicing events difficult. As aberrant splicing events inhibited full-length protein 
expression – preventing Western blot analysis that would have allowed the 
adequate separation of the six tau isoforms formed by exon 2, 3 and 10 alternative 
splicing – quantification was only possible at the mRNA level. The shortcomings 
of the mRNA analysis method meant the N-terminal exon splicing ratio was 
quantified independently of exon 10 inclusion; however, the aberrant splicing 
event that resulted in the exclusion of exons 4-9 seemed to occur preferentially in 
1N transcripts. Therefore the refinement of the analysis to detect only the 
transcripts that were spliced correctly produced an over-representation of the 2N 
isoforms – the isoform that is actually the least expressed in vivo. In the absence 
of quantifiable 1N isoforms, the 2N/0N ratio was used to investigate a potential 
role for promoter identify and the rs242557 domain on N-terminal splicing 
regulation.  
 
A role for promoter identity was observed in differentiated F1 cells, though 
additional regulation by the rs242557 domain was not apparent. This is 
concordant with the results of a previous study, which failed to find an association 
between rs242557 and exon 2 and 3 inclusion [205]. This was largely concordant 
in undifferentiated SH cells, though the behaviour of the variants in differentiated 
SH cells – in which all three H1C variants puzzlingly exhibited constitutive exon 
3 inclusion – does not inspire confidence in the accuracy of the N-terminal 
splicing ratios quantified from these cells.  
 
There have been reports of an association between the MAPT H2 haplotype and 
increased exon 3 inclusion, leading to suggestions that this exon contributes to the 
protective role attributed to H2 against PSP [133]. Indeed, one study reported a 2-
6 Discussion 
 
224 
 
fold increase in the number of H2 transcripts containing exon 3 compared with H1 
transcripts. There were also suggestions of an additional increase in 1N isoforms 
of the H2 transcript, though this was not deemed biologically relevant. Exactly 
how exons 2 and 3 may confer protection against neurodegeneration is currently 
unclear, though some studies have indicated potential mechanisms. 
 
Investigations into the effect of the N-terminal exons on tau protein folding and 
aggregation suggests that tau forms a paperclip-like conformation in solution, 
which brings together the N- and C-termini as the C-terminus is associating with 
the microtubule binding repeat domains. As this conformation is similar to the 
aberrant tau epitope that is detected in early-stage AD, it has been suggested that 
the stabilisation of the paperclip confirmation may be pathologically significant 
[258]. The N-terminal may also be key to maintaining tau solubility, as N-
terminal fragments have been shown to inhibit the polymerisation of tau into 
insoluble aggregates [259]. Increased exon 3 inclusion (and thus exon 2 inclusion 
due to their incremental relationship) in H2 MAPT transcripts may protect against 
neurodegeneration by altering the conformation of the tau protein and preventing 
its aggregation into insoluble filaments. Further clarification of the role of the N-
terminal inserts and the effect of genetic variation on their inclusion rate is likely 
to be achieved in the near future as focus increasingly shifts from the study of 
exon 10 to exon 2 and 3 splicing. 
 
Unfortunately the absence of H2 versions of the minigenes prevented a H1/H2 
comparison of N-terminal exon splicing events that would be highly informative 
and is currently of great interest in the field. Thus, although these minigene 
quantifications reveal a role for the MAPT promoter in the regulation of exon 2 
and 3 alternative splicing, little else pertaining to the mechanism and the 
relationship with exon 10 splicing can be determined here.  
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6.2.5 Evidence for a role of rs242557 in the co-regulation of MAPT 
transcription and exon 10 splicing 
 
6.2.5.1 rs242557 and transcription 
This project has provided evidence of a role for the rs242557 polymorphism in the 
co-regulation of MAPT transcription and exon 10 splicing, gained from analysis 
using multiple methods. The first method was the luciferase reporter gene assay, 
which clarified previous reports into the differential regulatory effect of the 
rs242557 alleles on MAPT transcription by demonstrating that the function of the 
domain and the direction of the allelic effect is dependent upon both the 
positioning of the rs242557 domain relative to the core promoter (CP) and the 
cellular environment in which the luciferase construct was assayed. This, 
combined with analyses of mutant CP constructs, indicated that the genomic 
positioning of the rs242557 domain – approximately 47kb downstream to the 
MAPT core promoter – is vital to its regulatory function in vivo and hinted at a 
physical interaction between the two domains.  
 
This physical interaction may result from the formation of a loop structure which 
brings the core promoter and rs242557 domain into close proximity. This would 
allow proteins bound to either element to interact and for the rs242557 domain to 
modulate the activity of the transcription machinery assembled at the core 
promoter – similar to the ‘gene loop’ mechanism described for 3’UTR-mediated 
transcriptional regulation (section 6.2.2; figure 6.4). Although the direction of the 
regulation by the rs242557 domain changed depending on both its positioning 
relative to the core promoter and the cell model, the A-allele demonstrated 
consistently weaker regulation of transcription than its G-allele counterpart 
regardless of these factors. Furthermore, a single nucleotide error at position 596 
of the core promoter element (in exon 0) – in which the wildtype G nucleotide 
was substituted for a T nucleotide – compensated for the altered regulation by the 
A-allele domain variant and caused a strengthening of domain function to match 
that of the G-allele variant.  
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This would suggest that the A-allele exerts a gain-of-function effect on the 
domain, which is abolished by the exon 0 mutation. One hypothesis could be that 
the A-allele of the rs242557 polymorphism forms (or strengthens) a binding site 
for an unknown protein factor that, in turn, recruits an additional unknown protein 
factor to exon 0 and together these proteins weaken the regulatory signal from the 
rs242557 domain (figure 6.5).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 A potential mechanism for the differential regulation of CP expression by 
the rs242557-G and rs242557-A domain variants.  
A: The rs242557 domain carries out its regulatory effect on CP transcription by 
adopting a loop confirmation that brings the two elements into close proximity. 
Proteins bound to the rs242557 domain (factor 1; yellow rectangle) interact with 
components of the transcription machinery assembled at the core promoter (such as 
RNA Pol II, red oval) to regulate transcription rate;  
B: The A-allele of rs242557 completes a binding site for an additional DNA binding 
factor (factor 2; orange hexagon). This factor recruits a third factor to the CP 
(factor 3; blue circle). Factors 1, 2 and 3, interact and weaken the regulatory 
function of the rs242557 domain; 
C: A single G to T transition within exon 0 of the core promoter element abolishes 
the binding site of factor 2, restoring the strength of rs242557-mediated regulation. 
 
In a bid to identify factors that may differentially bind to the A- and G-allele 
variants of the rs242557 domain – and therefore explain the differences in 
transcriptional regulation conferred by these variants – ChIP was performed on 
extracts from A/A homozygous (SH) and G/G homozygous (F1) cell lines using 
antibodies against phospho-independent Pol II and hnRNP U epitopes. Both 
proteins were found to associate with the region containing rs242557 and 
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demonstrated an inverse relationship in regards to one another. The hnRNP U 
factor was chosen for investigation as EMSA and siRNA knockdown-mediated 
luciferase reporter gene studies had previously indicated that the two alleles of the 
rs242557 polymorphism differentially associate with this protein [JF Anaya, PhD 
thesis, UCL 2012; [242]]. The ChIP experiments supported these results and 
showed for the first time that hnRNP U – a known splicing factor – associates 
with Pol II at the MAPT promoter region. 
 
It has been shown in other genes that hnRNP U binds to the phosphorylated CTD 
(carboxy terminal domain) of Pol II [243, 244] and could therefore potentially be 
used as an indicator of active and elongating transcription complexes. This would 
explain the apparent inverse relationship between Pol II and hnRNP U 
concentration that was observed over the differentiation time course. Pol II 
abundance increased during differentiation, with the consequential decrease in 
hnRNP U binding indicating transcriptional pausing and Pol II accumulation at 
the rs242557 domain.  
 
In general, there was a higher level of Pol II accumulation at the G-allele variant 
compared to the A-allele variant of the rs242557 domain. Furthermore, by day 3 
of differentiation, hnRNP U was undetectable at the G-allele variant, suggesting a 
lowering of transcription rate that is concurrent with the general repressive effect 
of the rs242557 domain that occurs when it is cloned downstream to the core 
promoter, as demonstrated by the promoter luciferase reporter gene study. The A-
allele variant of the domain remained associated with hnRNP U throughout 
differentiation, although the abundance of the RNA-binding factor reduced as Pol 
II accumulation increased. This indicates that whatever it is that induces 
transcriptional pausing at the rs242557 domain (cis- or trans-acting factors) is 
weakened by the presence of the A-allele and therefore a higher proportion of Pol 
II complexes fail to pause at the rs242557 domain and continue to elongate. This 
is, again, concordant with the promoter luciferase assay results that reported a 
reduced capacity of this domain variant to repress transcription from the core 
promoter.  
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In summary, therefore, the combination of the luciferase reporter gene studies and 
the ChIP experiments have revealed two potential mechanisms that may explain 
both the role of the rs242557 domain in regulating transcription from the core 
promoter and the allelic differences in this regulation. Although the luciferase 
quantification of the effect of the rs242557 domain on expression could not 
determine the specific function of the domain, as either enhancement or repression 
was observed depending on its relative positioning and the in vitro cellular 
environment, the ChIP results support a repressive role for this domain and is in 
agreement with the highly consistent effect on luciferase expression produced in 
both cell lines when the domain was cloned in its more natural position 
downstream to the core promoter. Thus, if the rs242557 domain does, indeed, 
function as a repressor of transcription and the A-allele variant weakens this 
function, then this raises the question of its role in the alterations in exon 10 
splicing ratio produced from the MAPT minigenes containing this domain variant.  
 
6.2.5.2 rs242557 and alternative splicing: model 1 
Figure 6.6A presents a possible mechanism in which transcriptional pausing at the 
rs242557 domain facilitates splicing factor recruitment and spliceosome 
assembly. In this model, cis- and/or trans-acting factors (orange hexagon in figure 
6.6A) at the rs242557 domain (purple oblong) blocks the progression of the 
transcription complex (represented by Pol II; red oval). This causes the Pol II 
accumulation and dissociation of hnRNP U (blue triangle) observed in the ChIP 
experiments, followed by splicing factor recruitment and assembly of the 
spliceosome (green oval) on the nascent transcript. As elongation resumes, the 
nascent transcript is spliced as it emerges from the transcription machinery. The 
appropriate inclusion of alternate exons 2, 3 and 10 may be dependent on the 
recruitment of specific components to the spliceosome, which itself may be 
dependent on the length of transcriptional pausing.  
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Figure 6.6 A potential mechanism for the repressive effect of the rs242557 domain 
(purple oblong) on transcription.  
A: In the default mechanism, the G-allele domain variant may act as a ‘speed 
bump’, causing a reduction in transcription rate and accumulation of Pol II (red 
oval). The reduction in transcription rate could lead to hnRNP U (blue triangle) to 
dissociate from the transcription complex, facilitating spliceosome assembly (green 
oval).  B: In the altered mechanism, the A-allele domain variant may be inefficient 
at reducing transcription rate, resulting in sub-optimal spliceosome assembly (cut 
out green circle) and altered interactions between the spliceosome and hnRNP U 
(blue flattened triangle). 
 
One problem with this mechanism is that spliceosome formation occurs during 
transcription elongation and not when the transcription complex is stationary. As 
it is currently unclear as to what stage of elongation hnRNP U associates with Pol 
II, it may be that transcription is not completely blocked; rather it is simply 
slowed down, with the rs242557 acting as a ‘speed bump’. This reduction in 
transcription rate may be necessary for the specific recruitment and assembly of 
the spliceosome on the nascent transcript, which may, in turn, determine the 
pattern of alternate exon inclusion by ensuring vital interactions between the 
splicing and transcription components can take place. 
 
Under this hypothesis, the rs242557-A domain would appear to be inefficient at 
reducing the elongation rate of the transcription complex, with a proportion of 
complexes remaining associated with hnRNP U and passing straight through the 
domain (figure 6.6B). This may result in sub-optimal splicing factor recruitment 
and spliceosome assembly, presumably due to the transcription complex being at 
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the domain for a shorter amount of time and/or a modifying signal caused by the 
continued association of hnRNP U.  
 
Matching this with endogenous exon 10 splicing patterns, Pol II accumulation 
would appear to cause a shift in isoform expression from default constitutive exon 
10 exclusion (3R-tau), as observed in undifferentiated cells, towards increased 
exon 10 inclusion (4R-tau), as observed in neuronally differentiated cells. It is 
difficult, however, to reconcile a reduction in transcription rate with an increase in 
exon 10 inclusion, as the kinetic model of co-transcriptional splicing (section 
1.2.3.3) dictates that a lower rate of transcription elicits greater exon exclusion – 
in this case increased 3R expression – due to competition from stronger 
downstream splice sites.  
 
6.2.5.3 rs242557 and alternative splicing: model 2 
A second potential mechanism centres on the secondary structure of the nascent 
pre-mRNA transcript. In silico evidence suggests that a single change from a G 
nucleotide to an A nucleotide at rs242557 can potentially cause a significant 
change in mRNA conformation. Figure 6.7 shows the strikingly different RNA 
secondary structures predicted to form when the G-allele (6.7A) or the A-allele 
(6.7B) is present. These predictions were created using the RNAfold web server 
(University of Vienna) and the full 812bp sequences of the rs242557 SD elements 
(Appendix B).  
 
Figure 6.7 In silico predictions of 
differences in rs242557 RNA 
conformation.  
The G-allele (A) and A-allele (B) 
variants of the 812bp rs242557 domain 
may confer significantly different 
secondary RNA structures, as predicted 
by the RNAfold web server. 
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These predictions are, of course, artificial and change significantly when the input 
sequences are extended by just a few nucleotides. They do show, however, that 
one nucleotide change can significantly alter RNA conformation and this may be 
important when considering co-transcriptional mechanisms of alternative splicing.   
 
Figure 6.8 presents a mechanism by which the folding of the nascent transcript as 
it emerges from the transcription complex facilitates the recruitment and assembly 
of the splicing machinery (panel A). In this model, the alterations to the secondary 
structure caused by the A-allele of rs242557 could affect the assembly of the 
spliceosome, perhaps by masking – or exposing – binding sites for certain splicing 
factors (panel B). In addition to this, the reduced ability of the A-allele to lower 
transcription elongation rate may contribute to the production of differential RNA 
secondary structures, as a faster elongation rate would imply a smaller window for 
RNA folding before assembly of the spliceosome. 
 
 
Figure 6.8 Folding of the nascent pre-mRNA transcript into a specific secondary 
structure may influence splicing factor recruitment and spliceosome assembly.  
A: The default secondary structure produced in the presence of the G-allele of 
rs242557, combined with a reduced elongation rate, facilitates optimal spliceosome 
assembly; B: The A-allele of rs242557, combined with an increased elongation rate, 
alters the secondary structure of the nascent transcript and results in sub-optimal 
splicing factor recruitment. The continued association of hnRNP U to Pol II as a 
result of the increased elongation rate may further alter the composition and 
functioning of the spliceosome. 
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6.2.5.4 rs242557 and the co-transcriptional regulation of alternative 
splicing 
The above sections have outlined partial mechanisms that could potentially 
explain some of the findings described here relating to the role of rs242557 in 
MAPT transcription and alternative splicing. Figure 6.9 brings together some of 
these ideas and speculates as to how these individual mechanisms may impact 
upon each other.  
 
Figure 6.9 A potential mechanism of MAPT co-transcriptional splicing.  
This mechanisms brings together the individual mechanisms proposed in this 
chapter. The G-allele (A) and A-allele (B) have multiple effects on transcription that 
together influence splicesome assembly. A thorough description of this figure is 
given in the text of this section. 
 
Starting with the gene loop theory from section 6.2.4.1 – in which proteins bound 
to the rs242557 regulatory domain physically interact with proteins bound to the 
core promoter to reduce the overall rate of transcription – the binding of an 
additional transcription factor to rs242557-A may contribute to the reduced Pol II 
accumulation observed at this domain variant. The binding of an extra protein – 
and its physical interactions with the core promoter – presumably alters the 
conformation of this domain, making it easier for the transcription complex to 
pass through. Thus, the insufficient reduction in elongation rate of the 
transcription complex – combined with competing signals from the additional 
transcription factor and the continued association of hnRNP U with Pol II – would 
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likely alter the recruitment and assembly of the spliceosome on nascent 
transcripts. This, in turn, may modify the ability of the spliceosome to recognise 
certain splicing signals at intron-exon boundaries and cause a shift in the inclusion 
rate of certain alternate exons. 
 
This mechanism is, of course, purely speculative and infers several relationships 
that are currently unproven. It does, however, bring together the individual data 
described in this project and provides an initial hypothesis which future studies 
can investigate. As research continues into the regulation of MAPT expression, 
this hypothesis will be proved or disproved, embellished or fragmented. Either 
way, the results presented here have provided valuable insight into the molecular 
consequences of the PSP risk allele, rs242557-A, and has, for the first time 
provided evidence that MAPT transcription and alternative splicing are co-
regulated and that promoter identity plays a vital role in determining the outcome 
of this co-regulation. By establishing the regulatory potential of the rs242557 
domain at the basic sequence level, a platform is provided for further 
investigation.  
 
6.2.6 Cellular differences in gene expression 
One overarching theme of this project has been the differential behaviour of many 
of the luciferase and minigene constructs when assayed in the two neuroblastoma 
cell lines, SK-N-F1 and SH-SY5Y. This may be because cancer cells, by their 
very nature, are abnormal and the two cell lines likely have different abnormalities 
that lead to differences in the way gene expression is regulated. There is evidence, 
however, that suggests that these two cell lines may be at different points in the 
differentiation pathway, despite the common belief that both are in the 
undifferentiated state. Several findings have indicated that, while the SH cells 
appear truly undifferentiated, the F1 cell line may in fact be at least one day into 
the differentiation pathway. The evidence for this includes: 
 
1. N-terminal exon splicing analysis on RNA extracts from untransfected 
F1 cells shows that the 1N isoform is expressed in this cell line (figure 
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5.8Aii) in addition to the 0N isoform that was present alone in SH cells 
(figure 5.9). It is widely accepted that 0N3R is the only isoform 
expressed when cells are in their undifferentiated state [132].  
 
2. Exon 10 splicing quantifications in undifferentiated F1 cells showed 
that promoter identity was already beginning to influence minigene 
expression, with the CP+rs242557 minigenes showing significantly 
different 4R:3R tau mRNA ratios than their CP and CMV 
counterparts. In SH cells promoter specificity was not detected until 
cells were in their differentiated state. 
 
3. Expression of the promoter luciferase and minigene constructs was 
generally higher in F1 cells than in SH cells, consistent with the 
upregulation of MAPT expression that occurs during differentiation. 
All assays, particularly minigene quantifications, demonstrated greater 
consistency in F1 cells, and this suggests that gene expression is more 
tightly regulated in this cell line than in SH cells, where replicate 
assays were more inconsistent. 
 
4. The rs242557 ChIP experiments performed on SH cell extracts show 
that neither Pol II nor hnRNP U is detectable at day 0 and first appear 
at day 1, with Pol II reaching a maximum concentration at day 5 
(figure 5.12B). In F1 cells, however, Pol II and hnRNP U are already 
present at ‘day 0’ and Pol II accumulation reaches a maximum at day 3 
(figure 5.12A), indicating that the cells have reached the end of the 
differentiation pathway. This would suggest that F1 cells are actually 
1-2 days into the differentiation pathway in the so-called 
‘undifferentiated’ state. 
 
If ‘undifferentiated’ F1 cells are, indeed, one day into the neuronal differentiation 
pathway, this may account for the differences in expression observed in some of 
the assays and this must be taken into account when considering the results. If 
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nothing else, these differences show the significance of the endogenous cellular 
environment on gene expression and demonstrate the important of choosing the 
right cellular model for in vitro expression studies. 
 
6.3 Conclusions 
This project has presented evidence that MAPT transcription and splicing 
processes are co-regulated and has confirmed a role for the rs242557 regulatory 
domain in these processes. The A-allele of this polymorphism is highly associated 
with the tauopathies, in particular with PSP and CDB, and it has been shown here 
that this allele – at the basic sequence level – has the ability to modify both the 
rate of transcription conferred by the core promoter and the inclusion rate of the 
alternatively spliced disease-associated exon 10.  
 
Initial chromatin immunoprecipitation experiments have provided a potential link 
between the MAPT transcription rate and splicing and have shown that RNA Pol 
II differentially accumulates at the allelic variants of the rs242557 domain. The 
apparently reduced Pol II accumulation at the A-allele presumably contributes to 
– or is a consequence of – the increased transcription rate conferred by this 
domain variant. An inverse relationship between Pol II accumulation and hnRNP 
U – a known splicing factor – and the increased association of this factor at the A-
allele variant compared to the G-allele variant is likely to contribute to the 
differences in exon 10 inclusion detected in transcripts expressed from the two 
minigene variants. 
 
To conclude, although this project has encountered several problems that have 
restricted the interpretation of the data produced, a minigene model has been 
created that has, for the first time, linked rs242557 to exon 10 splicing, and found 
evidence of co-transcriptional regulation of MAPT alternate exon inclusion. 
Perhaps most importantly, by bringing together elements that have previously 
been individually associated with PSP risk – the rs242557 allelic variants, an 
increase in MAPT expression and increased exon 10 expression – many exciting 
new avenues for future research have been opened.  
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6.4 Future directions 
 
6.4.1 Correction of the MAPT minigenes  
The first thing that must be done is to correct the mis-splicing events displayed by 
the MAPT minigenes. Section 4.11 describes a potential way of achieving this, 
though the resultant minigenes would be without exons 5 and 7. This is more 
preferable than the current model, however, and should allow improved mRNA 
quantifications and additional protein analyses.  
 
Following these corrections, the creation of the isogenic cell models will increase 
assay yield and replicability. In chapter 4, the creation of platform cell lines was 
described, with two monoclonal lines selected from each of the F1 and SH cell 
types for minigene integration: one in which integration occurred within an active 
gene and one in which integration occurred in an non-critical, though inactive, 
region of the genome. These integrated models have two major advantages: 
firstly, that each minigene will be inserted into the same place in the genome and, 
secondly, that minigene expression should be significantly higher than observed 
with transient transfection. Such integration should remove confounding factors 
such as well-to-well differences in cell density and transfection rate and positional 
effects due to differential insertion sites. A comprehensive description of the 
method for creating these isogenic cell models is given in sections 4.4 and 4.10 
and will not be repeated here. 
 
6.4.2 Further analyses using the MAPT minigenes 
 
6.4.2.1 H2 minigenes 
One frustrating aspect of this project was the failure to complete the H2 minigene 
variants. As described in section 4.8.3, this was due to problems with the cloning 
of minigene fragment 3. This minigene variant would, however, add significant 
value to the project as H1/H2 differences in alternative exon splicing and tau 
protein expression, if present, are likely to be more pronounced than those 
detected between the two H1 sub-haplotypes. Such analyses are particularly 
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desirable following recent evidence describing the contribution of increased exon 
3 inclusion to the protective role of H2 against PSP and neurodegeneration [133, 
205].  
 
As three of the four H2 minigene fragments – including the promoter variants – 
have been completed, a potential solution (if completion of the final fragment 
continues to be problematic) could be to create H2 minigenes using one of the H1 
variants of fragment 3. This is obviously less desirable than a complete H2 
minigene – particularly as fragment 3 contains exon 10 – but as the focus of this 
project was to investigate the effect of genetic variation within the promoter 
region, such hybrid minigenes should still prove informative and add significant 
value to the findings already drawn from this project. 
 
Completion of the H2 isogenic cell models as planned would allow comparison 
with the H1 variants at the basic sequence level but, as described in section 4.8.3, 
would not take into account the positional effects conferred by the inversion 
polymorphism at the MAPT genomic location. There may be some value, 
therefore, in altering the design of the H2 minigene to allow its insertion into the 
platform cell line in the opposite orientation to the H1 models. This could be 
achieved by altering the combination of attB sequences inserted onto the ends of 
each minigene fragment, to reverse the orientation of the final minigene in the 
integrated cell models. Comparison between two H2 models, in which the H2 
minigene has been inserted in opposite directions, may shed some light on the 
impact of the inversion, independently of H2-specific sequences, on MAPT 
expression. 
 
6.4.2.2 Alternative mRNA analysis 
In addition to the mRNA analysis methods used in this project, there are alternate 
methods of mRNA quantification that may prove valuable in the analysis of 
transcripts expressed from the MAPT minigenes. Real-time quantitative PCR 
(qPCR) in conjunction with reverse transcription provides an accurate method of 
quantifying the abundance of a specific transcript. Furthermore, the relative 
6 Discussion 
 
238 
 
abundance of two different isoforms of a transcript can be determined in one PCR 
by designing two probes, labelled with different colour fluorophores, that each 
bind specifically to one isoform. Thus, to quantify the proportion of minigene 
transcripts containing, for example, exon 10, two forward primers could be 
designed: one overlapping the exon 9/exon 10 boundary to detect 4R isoforms and 
the other overlapping the exon 9/exon 11 boundary to detect 3R-tau isoforms.  
 
This method could also be used to quantify the splicing at the N-terminal exons – 
though only after the appropriate corrections to the minigenes have been made. 
Indeed, commercial TaqMan probes are available for the quantification of 
individual tau transcript isoforms. 
 
6.4.2.3 Protein analyses 
Quantification of tau protein expression from the minigene variants is a vital 
investigation. Not only will it determine whether the exon 10 inclusion rate in tau 
mRNA directly translates into 4R/3R tau protein isoform expression – as has been 
suggested to be the case [133] – but Western blotting will allow the analysis of all 
six protein isoforms in one assay; something which cannot be achieved by mRNA 
analysis.  
 
A primary antibody targeting the FLAG-tag motif would detect the presence – and 
relative abundances – of all of the protein isoforms correctly expressed by the 
minigene variants and would distinguish them from endogenously expressed tau 
protein. This would determine whether the allelic differences in exon 10 inclusion 
detected in minigene mRNA translate into allelic differences in minigene protein 
isoform expression, not to mention the significant clarification the resolution of all 
six isoforms would give to the N-terminal exon splicing investigation.  
 
Commercial antibodies are available that target specific phosphorylation sites on 
the tau protein, with reactivity only detected when the site is phosphorylated. Such 
antibodies will allow information to be gained on the phosphorylation status of the 
minigene-expressed protein isoforms, potentially bringing together the two major 
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areas of tau research – molecular processing and protein phosphorylation. In this 
instance, however, care must be taken to normalise the minigene tau blots against 
equivalent endogenous tau blots, as these phospho-specific antibodies will not 
distinguish between the two. 
 
6.4.2.4 Alternative promoters 
Although the modular nature of the MAPT minigenes has proved unsatisfactory in 
certain respects, one significant advantage to their design is the ability to easily 
swap in different promoters or promoter variants. Thus, the minigene blueprint 
can be used to investigate the role of other regions of the MAPT promoter, such as 
predicted regulatory elements or highly conserved stretches of sequence currently 
of unknown function. The minigene analysis methods optimised in this project 
and described above could be used in all of the investigations described below. 
 
Recent work by our group has revealed the presence of a potential promoter 
element located downstream to both the main core promoter and the adjacent bi-
directional promoter [R. Simone, personal communication]. This region has 
already been cloned and adapted to form a Gateway
®
 entry clone and can 
therefore be incorporated into a MAPT minigene. It would be interesting to 
confirm whether this sequence is a promoter element, whether it can express full-
length tau, and whether its transcripts are alternatively spliced. It may be that the 
MAPT gene has a second transcription start site in addition to the major core 
promoter, with this promoter perhaps limited to producing certain isoforms, for 
example 3R-tau. If so, the activity of this promoter would likely change during 
development and neuronal differentiation. The absence of this putative promoter – 
or similar elements elsewhere in intron -1 – in the current minigenes could 
potentially account for the over-expression of 4R-tau transcripts from these 
constructs. 
 
Another valuable investigation would be to study the effect of genetic variation 
within the core promoter on minigene expression. In section 6.2.1 a TG repeat 
polymorphism located at the 3’ end of the CP element was described (figure 6.2). 
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Work within our group has shown that TDP-43 binds to this region and that the 
strength of this binding is dependent upon the length of the dinucleotide repeat. 
Luciferase reporter gene assays have, in turn, associated repeat length with 
luciferase activity and there are early indications that this polymorphism is linked 
significantly to PSP risk [Roberto Simone, personal communication]. It would 
therefore be interesting to create a series of minigenes, each with expression 
driven by a CP element that differs only by the number of TG repeats it contains. 
If, as expected, repeat length is correlated with minigene expression as a result of 
differential TDP-43 binding, splicing of the alternate exons may also be affected. 
Indeed, TDP-43 is involved in multiple levels of gene expression and is a known 
splicing factor; however, there is no evidence to date that this protein is involved 
in the splicing of MAPT transcripts. Knockdown of endogenous TDP-43 should 
neutralise any differences in binding resulting from the repeat length of the 
minigene variants. Such analyses would form the most comprehensive study to 
date on the role of TDP-43 in MAPT expression and would greatly enhance our 
current understanding in this area of research.  
 
6.4.2.5 Trans-acting factors 
Once the stable minigene cell models have been established, they will provide a 
platform for the study of specific trans-acting factors on MAPT expression. As 
described above, one such factor of interest is the TDP-43 protein. Other factors 
that were identified in this project are hnRNP U and, potentially, β-actin. 
Common methods for assessing the role of trans-acting factors in gene expression 
comprise either knockdown or over-expression of the factor of interest, followed 
by quantification of the effect on expression of the target gene. These two 
methods are complementary and should elicit opposing effects; for example 
increased expression following knockdown should correlate with decreased 
expression following over-expression of the same factor, and vice versa.  
 
The most widely used method for protein knockdown is RNA interference 
(RNAi), which prevents the translation of target mRNA transcripts into protein. 
This involves the transfection of synthetic small interfering RNA molecules 
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(siRNAs) that are approximately 20 nucleotides in length and demonstrate 
complementarity to the target transcript, in this case the mRNA transcripts of the 
trans-acting factor. The binding of these siRNAs to the target transcript produces 
short stretches of double-stranded RNA that are subsequently targeted for 
degradation, thus preventing translation of the target transcript into protein. Over-
expression is simply achieved by transfecting the cell model with an appropriate 
plasmid vector containing the gene for the trans-acting factor under investigation. 
 
A slight variation of this method could be used to investigate the role of micro 
RNAs (miRNAs) in MAPT minigene expression. MicroRNAs are expressed 
endogenously and behave similarly to siRNAs by binding to specific target 
transcripts and suppressing their translation, thus negatively regulating gene 
expression. MicroRNAs bind to the 3’UTRs of genes, as discussed in section 
3.13, and therefore factors such as genetic variation and alternative polyA site 
usage could affect the extent of their regulation of target gene expression.  
 
A recent study has linked a specific miRNA, denoted miR-132, to PSP by 
identifying a relative reduction in the abundance of this miRNA in the brains of 
PSP patients compared to healthy controls. Furthermore, knockdown of miR-132 
in murine Neuro2a cells was shown to cause an increase in expression of the 
splicing factor polypyramidine tract-binding protein 2 (PTBP2), which plays a 
role in MAPT splicing. This, in turn, caused a significant reduction in the 
production of 4R-tau isoforms [157]. Thus, increased levels of miR-132 in the 
brains of PSP patients could potentially contribute to the over-expression of 4R-
tau characteristic of this disease by modulating the expression of a trans-acting 
factor. This could be confirmed in human cells by knockdown and/or over-
expression of miR-132 in the minigene cellular models followed by quantification 
of the effect on 4R/3R mRNA and protein ratios. If an effect is observed, 
correlations with PTPB2 expression levels may add weight to the proposed 
mechanism.  
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Such a study could provide the first replication of the miR-132/PTPB2/PSP 
findings in human cells and, potentially, investigate a role for the promoter in this 
type of regulation. If alterations to miR-132 expression differentially affect 
minigenes containing different promoter elements, this may add credence to the 
gene loop theory described in section 6.2.2, where the 3’UTR and promoter of a 
gene physically interact. Comparisons between the MAPT promoter- and CMV 
promoter-driven minigenes would particularly inform this investigation.  
 
6.4.3 Investigation of the gene loop theory in the 3’UTR-mediated 
regulation MAPT expression 
To further investigate the gene loop theory of 3’UTR-mediated gene expression, 
versions on the MAPT minigenes could be created in which the full-length 3’UTR 
is replaced by one of the deletion fragments – either the 5’, middle or 3’ end of the 
3’UTR – as described in section 3.13. It would be interesting to see whether the 
pattern and/or rate of tau isoform expression differs when specific sections of the 
3’UTR are absent, or indeed, whether such differences depend on the identity of 
the promoter element included in the minigenes. Again, comparisons between the 
MAPT core promoter and CMV promoters would be of significant value in this 
instance.  
 
If specific promoter/3’UTR fragment combinations were shown to differentially 
affect minigene expression, it may be prudent to scan the relevant sequences for 
potential trans-acting protein binding sites that may be involved in gene loop 
formation (using tools such as those provided by the UCSC genome browser). 
Ssu72 binding would be of particular interest due to its reported involvement in 
gene loop-mediated regulation of the FMP27 gene (section 6.2.2) [232]. An effect 
of Ssu72 knockdown/overexpression on expression of the minigenes would 
indicate a role for Ssu72 – and potentially gene loop formation – in MAPT 
expression. Immunoprecipitation of the Ssu72 protein from the cell chromatin 
extracts described in chapter 5 (used above in the experiment presented in figure 
6.1), would confirm – or disprove – the binding of this protein to the predicted 
target regions of the MAPT promoter/3’UTR. 
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Moving away from the minigene model, chromosome conformation capture (3C) 
provides a high throughput method of analysing the natural organisation of 
chromosomes within a cell and has previously been used to identify a loop 
structure at the β-globin locus in erythroid cells [260]. It could therefore be used 
to confirm – or refute – the ‘gene loop’ hypothesis of MAPT regulation. 
 
6.4.4 Natural antisense transcription and the bi-directional promoter 
The luciferase reporter gene study of the MAPT bi-directional NAT promoter (the 
‘NP’ element, chapter 3) showed this region to be capable of initiating 
transcription in both the sense and antisense orientations as well as altering 
transcription from the core promoter. It would be interesting to determine whether 
this region – in conjunction with the core promoter – could also affect alternative 
splicing at exons 2, 3 and 10. This, as before, could be done by altering the 
promoter element of the MAPT minigene. Added value may be gained from 
comparing expression of such minigenes in F1 and SH cell models. It was shown 
in section 3.12.1.2 that the addition of the NP element to the core promoter 
increases relative luciferase expression in F1 cells but reduces expression in SH 
cells, though the mechanism behind this could not be determined. As the cell line 
differences must result from differences in the expression of trans-acting factors, 
it is reasonable to suggest that this may also affect splicing, either directly 
(through interactions with the spliceosome) or indirectly (through the 
modifications to transcription rate). 
 
Initial work by our group has shown that siRNA knockdown of the antisense 
transcript originating from the NP region increases the relative luciferase activity 
conferred by the CP and CP+NP constructs described in chapter 3 (data not 
shown). In complement, its overexpression reduces luciferase activity. These 
methods could also be applied to the minigene model to assess whether there is an 
effect on MAPT expression and, in particular, alternative splicing. 
 
If so, would the two alleles of the rs3744457 polymorphism (section 3.12.3) 
differentially affect this function? The luciferase and genotyping analyses of this 
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polymorphism suggest that an effect, if any, would be very subtle and therefore 
minigene methods may not be sensitive enough in this instance. A more 
informative experiment may be to quantify the expression of the non-coding 
antisense transcript in two cell lines, each homozygous for one allele of the 
polymorphism (i.e. C/C or T/T). This could be done using the quantitative RT-
PCR method described above on cellular RNA extracts.  
 
If allelic differences in non-coding antisense transcript expression are observed 
endogenously, this may support and expand any findings relating to MAPT 
isoform expression gained from the NP minigene variants. Further insight may 
also be gained from looking at the differential binding of factors to the alleles of 
rs3744457. The EGR family of zinc finger transcription factors – namely EGR1 
and EGR2 – have predicted binding sites in the region containing rs3744457, with 
the C-allele abolishing or weakening EGR binding. Thus, ChIP experiments using 
antibodies against EGR1 and EGR2 may identify a trans-acting factor that 
differentially binds to the alleles of rs3744457, implicating this polymorphism and 
the domain in which it sits in the expression of two MAPT non-coding transcripts.  
 
6.4.5 Chromatin immunoprecipitation (ChIP) 
The ChIP experiments described in this project must be repeated in two further 
biological replicates before conclusions can be reasonably drawn. In particular, 
the β-actin IP must be optimised before its contribution to the Pol II-hnRNP U 
association can be analysed. Additional IPs may also prove valuable, and these 
have been indicated in the above sections as appropriate. The main extension to 
the rs242557 ChIP experiments, however, must be to properly quantify the PCR 
products produced following each IP in each cell line. This will provide a better 
and more accurate comparison of factor binding to the alleles of rs242557. This 
could be done by quantifying the intensity of the bands produced following 
resolution by agarose gel electrophoresis, as achieved using the ImageJ software 
for the exon 10 and N-terminal exon minigene quantifications, or by real-time 
quantitative PCR, as described previously. 
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6.5 Final comments 
The aetiology of PSP has yet to be fully determined, though small pieces of the 
puzzle have been and continue to be revealed. This project aimed to link three 
factors known to be altered in PSP, with the hope of describing a basic 
mechanism to which future studies can build upon. To a certain extent, this has 
been achieved. The A-allele of rs242557, known to significantly increase PSP 
risk, was shown to reduce the strength of a transcriptional repressor domain, 
thereby inducing a significantly higher level of core promoter activity than the G-
allele variant; a phenomenon also reported in conjunction with PSP. This increase 
in transcriptional activity was shown to be accompanied by a significant increase 
in relative 4R-tau mRNA transcripts which, if translated into a similar increase at 
the protein level, would account for the increased 4R-tau expression observed in 
the PSP brain.  
 
Perhaps the most valuable aspect of this project, however, was the creation of 
MAPT minigenes. Following a few tweaks to correct erroneous splicing events, 
the MAPT minigene cell models have the potential to inform a wide variety of 
studies at multiple levels of expression. As interest grows in the role of MAPT 
exons 2 and 3 in neurodegeneration, these corrected models could prove a 
valuable tool. Mutation screening, regulatory studies, microRNA analysis, non-
coding RNA function, alternative poly(A) site usage, gene loop formation, 
differential trans-acting factor binding and, of course, genetic analyses are all 
possible using these models. Discussions have already taken place regarding their 
use for screening potential therapeutic agents aimed at reducing 4R transcript 
levels.  
 
Other groups are taking different approaches to clarifying the role of rs242557 in 
PSP and these studies should complement the work described here. In particular, 
Richard Wade-Martins and colleagues have described a viral method of delivering 
the whole of the MAPT gene (the H1 variant) when cloned into a bacterial 
artificial chromosome (‘infectious’ BAC or iBAC) construct [261]. They are 
currently investigating the effect of the rs242557 alleles – replacing the wildtype 
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G-allele of the iBAC with the A-allele by site-directed mutagenesis – on MAPT 
alternative splicing, though the results of this project have yet to be published. 
Once completed, this study should hopefully support and further inform the 
results described here. 
 
Another emerging method uses TALE-like effector nuclease (TALEN) 
technology to edit the genome of patient-derived induced pluripotent stem cells 
(iPS cells). This provides another method of producing isogenic cell models that 
are free of confounding from, among other things, different genetic and epigenetic 
backgrounds [262].  
 
Gene expression analyses using minigene methods are often considered too 
artificial, with in vivo methods preferred due to their greater and more immediate 
biological relevance. The recent publication by Trabzuni and colleagues suggests, 
however, that reported H1/H2 differences in MAPT transcription rate detected by 
in vivo analyses are, in fact, likely to be artefactual [133]. This is due to the 
discovery of in-probe polymorphisms in the expression arrays that are commonly 
used in this type of study. It has been shown here that cell type and differentiation 
status have a significant influence on gene expression and current analysis 
methods using brain tissue appear to lack sufficient resolution to account for this. 
Indeed, recent in vivo expression analyses of 4R-tau expression in six brain 
regions counters the results of the Trabzuni study, not only by reporting 
significant differences in expression between specific brain regions, but by 
finding a general trend for increased 4R-tau expression for H1 chromosomes 
compared to H2 chromosomes [134]. Perhaps the only way to resolve these 
conflicting reports regarding haplotype-specific MAPT expression is to look in 
individual cell populations by methods such as laser cell capture. 
 
This study has, however, demonstrated the value of in vitro methods and shown 
how functional analysis at the basic sequence level can be used to build a 
mechanism that can further inform in vivo experiments. This is particularly true 
when investigating the role of common variation on gene expression as the effect 
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is often too subtle for accurate quantification in vivo. This project has shown the 
significant influence common variation can have on gene expression and has 
provided a blueprint for a cellular model that can investigate such variation at 
multiple levels. The models described here have the potential to significantly 
impact upon our understanding of the role of MAPT expression in neurodegerative 
disease. 
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Appendix A 
CP: the MAPT core promoter (chr17:43971166-43972505) 
In the below multiple sequence alignment of the two CP elements, sequence 
matches are denoted *, with sequence differences highlighted in red. Exon 0 is 
highlighted in green. 
CP_H1 CAAATGCTCTGCGATGTGTTAAGCACTGTTTGAAATTCGTCTAATTTAAGATTTTTTTTT 60 
CP_H2 CAAATGCTCTGCGATGTGTTAAGCACTGTTTGAAATTCGTCTAA-----GATTTTTTTTT 55 
      ********************************************     *********** 
 
CP_H1 CTGACGTAACGGTTAGAT----------TCACGTTTCTTTTTTTTTAAGTACAGTTCTAC 110 
CP_H2 CTGACGTAACGGTTAGATACATCATAGATCACGTTTCTTTTTTTTTAAGTACAGTTCTAC 115 
      ******************          ******************************** 
 
CP_H1 TGTATTGTAACTGAGTTAGCTTGCTTTAAGCCGATTTGTTAAGGAAAGGATTCACCTTGG 170 
CP_H2 TGTATTGTAACTGAGTTAGCTTGCTTTAAGCCGATTTGTTAAGGAAAGGATTCACCTTGG 175 
      ************************************************************ 
 
CP_H1 TCAGTAACAAAAAAGGTGGGAAAAAAGCAAGGAGAAAGGAAGCAGCCTGGGGGAAAGAGA 230 
CP_H2 TCAGTAACAAAAAAGGTGGGAAAAAAGCAAGGAGAAAGGAAGCAGCCTGGGGGAAAGAGA 235 
      ************************************************************ 
 
CP_H1 CCTTAGCCAGGGGGGCGGTTTCGGGACTACGAAGGGTCGGGGCGGACGGACTCGAGGGCC 290 
CP_H2 CCTTAGCCAGGGGGGCGGTTTCGGGACTACGAAGGGTCGGGGCGGACGGACCCGAGGGCC 295 
      *************************************************** ******** 
 
CP_H1 GGCCACGTGGAAGGCCGCTCAGGACTTCTGTAGGAGAGGACACCGCCCCAGGCTGACTGA 350 
CP_H2 GCCCACGTGGAAGGCCGCTCAGGACCTCTGTAGGAGAGGACACCGCCCCAGGCTGACTGA 355 
      * *********************** ********************************** 
 
CP_H1 AAGTAAAGGGCAGCGGACCCAGCGGCGGAGCCACTGGCCTTGCCCCGACCCCGCATGGCC 410 
CP_H2 AAGTAAAGGGCAGCGGACCCAGCGGCGGAGCCACTGGCCTTGCCCCGACCCCGCATGGCC 415 
      ************************************************************ 
 
CP_H1 CGAAGGAGGACACCCACCCCCGCAACGACACAAAGACTCCAACTACAGGAGGTGGAGAAA 470 
CP_H2 CGAAGGAGGACACCCACCCCCGCAACGAGACAAAGACTCCAACTACAGGAGGTGGAGAAA 475 
      **************************** ******************************* 
 
CP_H1 GCGCGTGCGCCACGGAACGCGCGTGCGCGCTGCGGTCAGCGCCGCGGCCTGAGGCGTAGC 530 
CP_H2 GCGCGTGCGCCACGGAACGCGCGTGCGCGCTGCGGTCAGCGCCGCGGCCTGAGGCGTAGC 535 
      ************************************************************ 
 
CP_H1 GGGAGGGGGACCGCGAAAGGGCAGCGCCGAGAGGAACGAGCCGGGAGACGCCGGACGGCC 590 
CP_H2 GGGAGGGGGACCGCGAAAGGGCAGCGCCGAGAGGAACGAGCCGGGAGACGCCGGACGGCC 595 
      ************************************************************ 
 
CP_H1 GAGCGGCAGGGCGCTCGCGCGCGCCCACTAGTGGCCGGAGGAGAAGGCTCCCGCGGAGGC 650 
CP_H2 GAGCGGCAGGGCGCTCGCGCGCGCCCACTGGTGGCCGGAGGAGAAGGCTCCCGCGGAGGC 655 
      *****************************.****************************** 
 
CP_H1 CGCGCTGCCCGCCCCCTCCCCTGGGGAGGCTCGCGTTCCCGCTGCTCGCGCCTGCGCCGC 710 
CP_H2 CGCGCTGCCCGCCCCCTCCCCTGGGGAGGCTCGCGTTCCCGCTGCTCGCGCCTGCGCCGC 715 
      ************************************************************ 
 
CP_H1 CCGCCGGCCTCAGGAACGCGCCCTCTTCGCCGGCGCGCGCCCTCGCAGTCACCGCCACCC 770 
CP_H2 CCGCCGGCCTCAGGAACGCGCCCTCTTCGCCGGCGCGCGCCCTCGCAGTCACCGCCACCC 775 
      ************************************************************ 
 
CP_H1 ACCAGCTCCGGCACCAACAGCAGCGCCGCTGCCACCGCCCACCTTCTGCCGCCGCCACCA 830 
CP_H2 AACAGCTCCGGCACCAACAGCAGCGCCGCTGCCACCGCCCACCTTCTGCCGCCGCCACCA 835 
      *.********************************************************** 
Appendices 
271 
 
 
CP_H1 CAGCCACCTTCTCCTCCTCCGCTGTCCTCTCCCGTCCTCGCCTCTGTCGACTATCAGGTA 890 
CP_H2 CAGCCACCTTCTCCTCCTCCGCTGTCCTCTCC-GTCCTCGCCTCTGTCGACTATCAGGTA 894 
      ******************************** *************************** 
 
CP_H1 AGCGCCGCGGCTCCGAAATCTGCCTCGCCGTCCGCCTCTGTGCACCCCTGCGCCGCCGCC 950 
CP_H2 AGCGCCGCGGCTCCGAAATCTGCCTCGCCGTCCGCCTCTGTGCACCCCTGCGCCGCCGCC 954 
      ************************************************************ 
 
CP_H1 CCTCGCCCTCCCTCTCCGCAGACTGGGGCTTCGTGCGCCGGGCATCGGTCGGGGCCACCG 1010 
CP_H2 CCTCGCCCTCCCTCTCCGCAGACTGGAGCTTCGTGCGCCGGGCATCGGTCGGGGCCACCG 1014 
      **************************.********************************* 
 
CP_H1 CAGGGCCCCTCCCTGCCTCCCCTGCTCGGGGGCTGGGGCCAGGGCGGCCTGGAAAGGGAC 1070 
CP_H2 CAGGGCCCCTCCCTGCCTCCCCTGCTCGGGGGCTGGGGCCAGGGCGGCCTGGAAAGGGAC 1074 
      ************************************************************ 
 
CP_H1 CTGAGCAAGGGATGCACGCACGCGTGAGTGCGCGCGTGTGTGTGTGCTGGAGGGTCTTCA 1130 
CP_H2 CTGAGCAAGGGATGCACGCACGCGTGAGTGCGCGCGTGTGTGTGTGCTGGAGGGTCTTCA 1134 
      ************************************************************ 
 
CP_H1 CCACCAGATTCGCGCAGACCCCAGGTGGAGGCTGTGCCGGCAGGGTGGGGCGCGGCGGCG 1190 
CP_H2 CCACCAGATTCGCGCAGACCCCAGGTGGAGGCTGTGCCGGCAGGGTGGGGCGCGGCGGCG 1194 
      ************************************************************ 
 
CP_H1 GTGACTTGGGGGAGGGGGCTGCCCTTCACTCTCGACTGCAGCCTTTTGCCGCAATGGGCG 1250 
CP_H2 GTGACTTGGGGGAGGGGGCTGCCCTTCACTCTCGACTGCAGCCTTTTGCCGCAATGGGCG 1254 
      ************************************************************ 
 
CP_H1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG------GAGGGGTCCGATAACGACCC 1310 
CP_H2 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGGAGGGGTCCGATAACGACCC 1312 
      ********************************************************** 
 
CP_H1 CCGAAACCGAATCTGAAATCCGCTGTCC 1338 
CP_H2 CCGAAACCGAATCTGAAATCCGCTGTCC 1340 
     **************************** 
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Appendix B 
SD: the rs242557 SNP domain (chr17:44019339-44020150) 
In the below multiple sequence alignment of the three SD elements, sequence 
matches are denoted *, with sequence differences highlighted in red. The 
rs242557 polymorphism is highlighted in green. 
SD_H1B TGGGACAGATCCTCAGTGGAACATGACTCTGTAACGAGAGCATTTTGTTTTGTCAAAATG 60 
SD_H1C TGGGACAGATCCTCAGTGGAACATGACTCTGTAACGAGAGCATTTTGTTTTGTCAAAATG 60 
SD_H2  TGGGACAGATCCTCAGTGGAACATGACTCTGTAACGAGAGCATTTTGTTTTGTCAAAATG 60 
       ************************************************************ 
 
SD_H1B AGAACATATTATTGCCTTTCATCTGATTGTAAACATAATACATGTTTATAAAACAGTATA 120 
SD_H1C AGAACATATTATTGCCTTTCATCTGATTGTAAACATAATACATGTTTATAAAACAGTATA 120 
SD_H2  AGAACATATTATTGCCTTTCATCTGATTGTAAACATAATACATGTTTATAAAACAGTATA 120 
       ************************************************************ 
 
SD_H1B ATGAGACAAAAATGTAGACACTAATAAGGGAAAATCTCCCTAATTGTATTTCTCTTCACA 180 
SD_H1C ATGAGACAAAAATGTAGACACTAATAAGGGAAAATCTCCCTAATTGTATTTCTCTTCACA 180 
SD_H2  ATGAGACAAAAATGTAGACGCTAATAAGGGAAAATCTCCCTAATTGTATTTCTCTTCACA 180 
       *******************.**************************************** 
 
SD_H1B GAGAAAGCCCCTGTTGGGCATATATACTCTAGTTTGTTTATTTGTTTGACTACACATATA 240 
SD_H1C GAGAAAGCCCCTGTTGGGCATATATACTCTAGTTTGTTTATTTGTTTGACTACACATATA 240 
SD_H2  GAGAAAGCCCCTGTTGGGCATATATACTCTAGTTTGTTTATTTGTTTGACTACACATATA 240 
       ************************************************************ 
 
SD_H1B TGTATTCTTTTCTTATGTATAAAAATTCTGAACATGCACATTTCTGCAACTACTGTTTTC 300 
SD_H1C TGTATTCTTTTCTTATGTATAAAAATTCTGAACATGCACATTTCTGCAACTACTGTTTTC 300 
SD_H2  TGTATTCTTTTCTTATGTATAAAAATTCTGAACATGCACATTTCTGCAACTACTGTTTTC 300 
       ************************************************************ 
 
SD_H1B ACTTGATGATGCATGGACCTCTCTAGAGTGTACGTTTCTTCTTCCTTACAAAGCAGTTGG 360 
SD_H1C ACTTGATGATGCATGGACCTCTCTAGAGTGTACGTTTCTTCTTCCTTACAAAGCAGTTGG 360 
SD_H2  ACTTAATGATGCATGGACCTCTCTAGAGTGTACGTTTCTTCCTCCTTACAAAGCAGTTGG 360 
       ****.************************************ ****************** 
 
SD_H1B CTTCGCCCAGGGTGCACCAGGACACGGTTTTGGCTCTGTCCCCAGGGTGTCACGGGACCA 420 
SD_H1C CTTCGCCCAGGGTACACCAGGACACGGTTTTGGCTCTGTCCCCAGGGTGTCACGGGACCA 420 
SD_H2  CTTCGCCCAGGGTGCACCAGGACACGGTTTTGGCTCTGTCCCCAGGGTGTCACGGGACCA 420 
       *************.********************************************** 
 
SD_H1B GGGGATGATCTCACAGGGTCTGCCATCTGCCCTGCCTGGCCGGAGGCTGCATCGAGAGGG 480 
SD_H1C GGGGATGATCTCACAGGGTCTGCCATCTGCCCTGCCTGGCCGGAGGCTGCATCGAGAGGG 480 
SD_H2  GGGGATGATCTCACAGGGTCTGCCATCTGCCCTGCCTGGCCGGAGGCTGCATCGAGAGGG 480 
       ************************************************************ 
 
SD_H1B CCAAGGGGCACCACGTGTCGTGGGTACTGTCAAACAAGAGCCTTCAGAGCCTTCCACAGT 540 
SD_H1C CCAAGGGGCACCACGTGTCGTGGGTACTGTCAAACAAGAGCCTTCAGAGCCTTCCACAGT 540 
SD_H2  CCAAGGGGCACCACGTGTCGTGGGTACTGTCAAACAAGAGCCTTCAGAGCCTTCCACAGT 540 
       ************************************************************ 
 
SD_H1B CTTTCTTTTGCTTCCCAGCATTGCTTCCCCGCTGGTGGACTCTGAATCTAGAACTAGCTC 600 
SD_H1C CTTTCTTTTGCTTCCCAGCATTGCTTCCCCGCTGGTGGACTCTGAATCTAGAACTAGCTC 600 
SD_H2  CTTTCTTTTGCTTCCCAGCATTGCTTCCCCGCTGGTGGACTCTGAATCTAGAACTAGCTC 600 
       ************************************************************ 
 
SD_H1B CAGGCGCCTCTCCAAATTCAGACGGGAGCTGGGGCACTATTATAATGCAAATCTAGGCAA 660 
SD_H1C CAGGCGCCTCTCCAAATTCAGACGGGAGCTGGGGCACTATTATAATGCAAATCTAGGCAA 660 
SD_H2  CAGGCGCCTCTCCAAATTCAGACGGGAGCTGGGGCACTATTATAATGCAAATCTAGGCAA 660 
       ************************************************************ 
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SD_H1B AGCCCTCCCAATACCAGGATCCAGAATGGGGTGGGGCCCTTTGCCCTGAAAAGCTGTTTA 720 
SD_H1C AGCCCTCCCAATACCAGGATCCAGAATGGGGTGGGGCCCTTTGCCCTGAAAAGCTGTTTA 720 
SD_H2  AGCCCTCCCAATACCAGGATCCAGAATGGGGTGGGGCCCTTTGCCCTGAAAAGCTGTTTA 720 
       ************************************************************ 
 
SD_H1B GTTTGAAAATACAAACAGGAGACAGAAAAGTTTGGCTAAATTAATGGATAAAGTTTTAAC 780 
SD_H1C GTTTGAAAATACAAACAGGAGACAGAAAAGTTTGGCTAAATTAATGGATAAAGTTTTAAC 780 
SD_H2  GTTTGAAAATACAAACAGGAGACAGAAAAGTTTGGCTAAATTAATGGATAAAGTTTTAAC 780 
       ************************************************************ 
 
SD_H1B GATGGTAACCATAGTAGGGTTCATCGACAGCC 812 
SD_H1C GATGGTAACCATAGTAGGGTTCATCGACAGCC 812 
SD_H2  GATGGTAACCATAGTAGGGTTCATCGACAGCC 812 
       ******************************** 
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Appendix C 
NP: the NAT promoter region (chr17:43972506:43973404) 
In the below multiple sequence alignment of the three NP elements, sequence 
matches are denoted *, with sequence differences highlighted in red. The 
predicted bi-directional promoter is highlighted in green. 
NP_H1B CTGCCGCTGTTCGCCATCAGCTCTAAGAAAGACGTGGATCGGGTTCTAGAAAAGATGACT 60 
NP_H1C CTGCCGCTGTTCGCCATCAGCTCTAAGAAAGACGTGGATCGGGTTCTAGAAAAGATGACT 60 
NP_H2  CTGCCGCTGTTCGCCATCAGCTCTAAGAAAGACGTGGATCGGGTTCTAGAAAAGATGACT 60 
       ************************************************************ 
 
NP_H1B CCCTGCACGCCCCTCCCTGCACCTCCCGAGCAGTGATTCCGACAGGGCCTTCACTGCCCC 120 
NP_H1C CCCTGCACGCCCCTCCCTGCACCTCCCGAGCAGTGATTCCGACAGGGCCTTCACTGCCCC 120 
NP_H2  CCCTGCACGCCCCTCTCTGCACCTCCCGAGCAGTGATTCCGACAGGGCCTTCACTGCCCC 120 
       *************** ******************************************** 
 
NP_H1B TGATTTTAGGCGGGGGCCGGCCCCCTCCCCTTTTCCTCCTTCAGAAACCCGTAGGGGACA 180 
NP_H1C TGATTTTAGGCGGGGGCCGGCCCCCTCCCCTTTTCCTCCTTCAGAAACCCGTAGGGGACA 180 
NP_H2  TGATTTTAGGCGGGGGCCGGCCCCCTCCCCTTTTCCTCCTTCAGAAACCCGTAGGGGACA 180 
       ************************************************************ 
 
NP_H1B TTTGGGGGCTGGGAGAAATCGAGGAGATGGGGAGGGGTCCACGCGCTGTCACTTTAGTTG 240 
NP_H1C TTTGGGGGCTGGGAGAAATCGAGGAGATGGGGAGGGGTCCACGCGCTGTCACTTTAGTTG 240 
NP_H2  TTTGGGGGCTGGGAGAAATCGAGGAGATGGGGAGGGGTCCACGCGCTGTCACTTTAGTTG 240 
       ************************************************************ 
 
NP_H1B CCCTTCCCCCTGCGCACGCCTGGCACAGAGACGCGAGCAGCGCCGTGCCTGAGAACAGTG 300 
NP_H1C CCCTTCCCCCTGCGCACGCCTGGCACAGAGACGCGAGCAGCGCCGTGCCTGAGAACAGTG 300 
NP_H2  CCCTTCCCCCTGCGCACGCCTGGCACAGAGACGCGAGCAGCGCCGTGCCTGAGAACAGTG 300 
       ************************************************************ 
 
NP_H1B CGCGGATCCCACTGTGCACGCTCGCAAAGGCAGGGTTCACCTGGCCTGGCGATGTGGACG 360 
NP_H1C CGCGGATCCCACTGTGCACGCTCGCAAAGGCAGGGTTCACCTGGCCTGGCGATGTGGACG 360 
NP_H2  CGCGGATCCCACTGTGCACGCTCGCAAAGGCAGGGTTCACCTGGCCTGGCGATGTGGACG 360 
       ************************************************************ 
 
NP_H1B GACTCGGCGGCCGCTGGTCCCCGTTCGCGGGCACGCACAGCCGCAGCCACGCACGGATGG 420 
NP_H1C GACTCGGCGGCCGCTGGTCCCCGTTCGCGGGCACGCACAGCCGCAGCCATGCACGGATGG 420 
NP_H2  GACTCGGCGGCCGCTGGTCCCCGTTCGCGGGCACGCACAGCCGCAGCCATGCACGGATGG 420 
       ************************************************* ********** 
 
NP_H1B GCGCGGGGCTGCAGGTGCATCTCGGGGCGGATTTCTTTCTCAGCGCTCGGAGCGCAGGGC 480 
NP_H1C GCGCGGGGCTGCAGGTGCATCTCGGGGCGGATTTCTTTCTCAGCGCTCGGAGCGCAGGGC 480 
NP_H2  GCGCGGGGCTGCAGGTGCATCTCGGGGCGGATTTCTTTCTCAGCGCTCGGAGCGCAGGGC 480 
       ************************************************************ 
 
NP_H1B GCCCGGCGTGTGCGCTCCCTGCCGGAGGCGCGGGGCTGGCGCGCAGGGCTCGCCCCTCAC 540 
NP_H1C GCCCGGCGTGTGCGCTCCCTGCCGGAGGCGCGGGGCTGGCGCGCAGGGCTCGCCCCTCAC 540 
NP_H2  GCCCGGCGTGTGCGCTCCCTGCCGGAGGCGCGGGGCTGGCGCGCAGGGCTCGCCCCTCAC 540 
       ************************************************************ 
 
NP_H1B TGCGGCAGTGGGTGTGGACCCTGGTGGGCGAGGAAGGGGGAGGATAGGCTGTGCCTCCTC 600 
NP_H1C TGCGGCAGTGGGTGTGGACCCTGGTGGGCGAGGAAGGGGGAGGATAGGCTGTGCCTCCTC 600 
NP_H2  TGCGGCAGTGGGTGTGGACCCTGGTGGGCGAGGAGGGGGGAGGATAGGCTGTGCCTCCTC 600 
       **********************************.************************* 
 
NP_H1B CCACTCCCGCCCCCAGCCCCCCTTTTTTTCCCCCTCGGAACGCGAGGTGCCATCTTTTTT 660 
NP_H1C CCACTCCCGCCCCCAGCCCCCCTTTTTTTCCCCCTCGGAACGCGAGGTGCCATCTTTTTT 660 
NP_H2  CCACTCCCGCCCCCACCCCCCCTTTTTTTCCCCCTCGGAACGCGAGGTGCCATCTTTTTT 660 
       *************** ******************************************** 
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NP_H1B CGGCGTGTCACGTCTTTACGGTGCCATGCCAAACCGGGTGGCCGGGCTTCATAGGACAGG 720 
NP_H1C CGGCGTGTCACGTCTTTACGGTGCCATGCCAAACCGGGTGGCCGGGCTTCATAGGACAGG 720 
NP_H2  CGGCGTGTCACGTCTTTACGGTGCCATGCCAAACCGGGTGGCCGGGCTTCATAGGACAGG 720 
       ************************************************************ 
 
NP_H1B GCGGGGCCTGGCATTAAAGGGAGGGGGACAATCAGCGCTGAAATCTTGGCGTTTTGCTGC 780 
NP_H1C GCGGGGCCTGGCATTAAAGGGAGGGGGACAATCAGCGCTGAAATCTTGGCGTTTTGCTGC 780 
NP_H2  GCGGGGCCTGGCATTAAAGGGAGGGGGACAATCAGCGCTGAAATCTTGGCGTTTTGCTGC 780 
       ************************************************************ 
 
NP_H1B TGCGGGCGTGAGCACTGGGGGCGTTCGCCCAGCACCTTCTTCGGGGGCTCTTTGCTTTGT 840 
NP_H1C TGCGGGCGTGAGCACTGGGGGCGTTCGCCCAGCACCTTCTTCGGGGGCTCTTTGCTTTGT 840 
NP_H2  TGCGGGCGTGAGCACTGGGGGCGTTCGCCCAGCACCTTCTTCGGGGGCTCTTTGCTTTGT 840 
       ************************************************************ 
 
NP_H1B CTGTAGAGGTTACGTGATCTGCGCTCCCAGCCCTGGTTTCTGGCTTTTATTCTGAGGGT 899 
NP_H1C CTGTAGAGGTTACGTGATCTGCGCTCCCAGCCCTGGTTTCTGGCTTTTATTCTGAGGGT 899 
NP_H2  CTGTAGAGGTTACGTGATCTGCGCTCCCAGCCCTGGTTTCTGGCTTTTATTCTGAGGGT 899 
       *********************************************************** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
276 
 
Appendix D 
3’UTR Fragment 1 (Fr1): chr17:44101545-44102731 
In the below multiple sequence alignment of the three Fr1 variants, sequence 
matches are denoted *, with sequence differences highlighted in red. The region 
of Fr1 that overlaps with Fr2 is highlighted in blue, with the AatII internal 
restriction site underlined and italicised.  
Fr1_H1B CCTGGGGCGGTCAATAATTGTGGGGAGGAGAGAATGAGAGAGTGTGGAAAAAAAAAGAAT 60 
Fr1_H1C CCTGGGGCGGTCAATAATTGTGGAGAGGAGAGAATGAGAGAGTGTGGAAAAAAAAAGAAT 60 
Fr1_H2  CCTGGGGCGGTCAATAATCGTGGAGAGGAGAGAATGAGAGAGTGTGGAAAAAAAAAGAAT 60 
        ****************** ****.************************************ 
 
Fr1_H1B AATGACCCGGCCCCCGCCCTCTGCCCCCAGCTGCTCCTCGCAGTTCGGTTAATTGGTTAA 120 
Fr1_H1C AATGACCCGGCCCCCGCCCTCTGCCCCCAGCTGCTCCTCGCAGTTCGGTTAATTGGTTAA 120 
Fr1_H2  AATGACCCGGCCCCCGCCCTCTGCCCCCAGCTGCTCCTCGCAGTTCGGTTAATTGGTTAA 120 
        ************************************************************ 
 
Fr1_H1B TCACTTAACCTGCTTTTGTCACTCGGCTTTGGCTCGGGACTTCAAAATCAGTGATGGGAG 180 
Fr1_H1C TCACTTAACCTGCTTTTGTCACTCGGCTTTGGCTCGGGACTTCAAAATCAGTGATGGGAG 180 
Fr1_H2  TCACTTAACCTGCTTTTGTCACTCGGCTTTGGCTCGGGACTTCAAAATCAGTGATGGGAG 180 
        ************************************************************ 
 
Fr1_H1B TAAGAGCAAATTTCATCTTTCCAAATTGATGGGTGGGCTAGTAATAAAATATTT-AAAAA 239 
Fr1_H1C TAAGAGCAAATTTCATCTTTCCAAATTGATGGGTGGGCTAGTAATAAAATATTTAAAAAA 240 
Fr1_H2  TAAGAGCAAATTTCATCTTTCCAAATTGATGGGTGGGCTAGTAATAAAATATTTTAAAAA 240 
        ****************************************************** ***** 
 
Fr1_H1B AAACATTCAAAAACATGGCCACATCCAACATTTCCTCAGGCAATTCCTTTTGATTCTTTT 299 
Fr1_H1C AAACATTCAAAAACATGGCCACATCCAACATTTCCTCAGGCAATTCCTTTTGATTCTTTT 300 
Fr1_H2  AAACATTCAAAAACATGGCCACATCCAACATTTCCTCAGGCAATTCCTTTTGATTCTTTT 300 
        ************************************************************ 
 
Fr1_H1B TTCTT-CCCCCTCCATGTAGAAGAGGGAGAAGGAGAGGCTCTGAAAGCTGCTTCTGGGGG 358 
Fr1_H1C TTCTT-CCCCCTCCATGTAGAAGAGGGAGAAGGAGAGGCTCTGAAAGCTGCTTCTGGGGG 359 
Fr1_H2  TTCTTCCCCCCTCCATGTAGAAGAGGGGGAAGGAGAGGCTCTGAAAGCTGCTTCTGGGGG 360 
        ***** *********************.******************************** 
 
Fr1_H1B ATTTCAAGGGACTGGGGGTGCCAACCACCTCTGGCCCTGTTGTGGGGGTGTCACAGAGGC 418 
Fr1_H1C ATTTCAAGGGACTGGGGGTGCCAACCACCTCTGGCCCTGTTGTGGGGGTGTCACAGAGGC 419 
Fr1_H2  ATTTCAAGGGACTGGGGGTGCCAACCACCTCTGGCCCTGTTGTGGGGGTGTCACAGAGGC 420 
        ************************************************************ 
 
Fr1_H1B AGTGGCAGCAACAAAGGATTTGAAACTTGGTGTGTTCGTGGAGCCACAGGCAGACGATGT 478 
Fr1_H1C AGTGGCAGCAACAAAGGATTTGAAACTTGGTGTGTTCGTGGAGCCACAGGCAGACGATGT 479 
Fr1_H2  AGTGGCAGCAACAAAGGATTTGAAACTTGGTGTGTTCGTGGAGCCACAGGCAGACGATGT 480 
        ************************************************************ 
 
Fr1_H1B CAACCTTGTGTGAGTGTGACGGGGGTTGGGGTGGGGCGGGAGGCCACGGGGGAGGCCGAG 538 
Fr1_H1C CAACCTTGTGTGAGTGTGACGGGGGTTGGGGTGGGACGGGAGGCCACGGGGGAGGCCGAG 539 
Fr1_H2  CAACCTTGTGTGAGTGTGACGGGGGTTGGGGTGGGGCGGGAGGCCACGGGGGAGGCCGAG 540 
        ***********************************.************************ 
 
Fr1_H1B GCAGGGGCTGGGCAGAGGGGAGAGGAAGCACAAGAAGTGGGAGTGGGAGAGGAAGCCACG 598 
Fr1_H1C GCAGGGGCTGGGCAGAGGGGAGAGGAAGCACAAGAAGTGGGAGTGGGAGAGGAAGCCACG 599 
Fr1_H2  GCAGGGGCTGGGCAGAGGGGAGAGGAAGCACAAGAAGTGGGAGTGGGAGAGGAAGCCACG 600 
        ************************************************************ 
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Fr1_H1B TGCTGGAGAGTAGACATCCCCCTCCTTGCCGCTGGGAGAGCCAAGGCCTATGCCACCTGC 658 
Fr1_H1C TGCTGGAGAGTAGACATCCCCCTCCTTGCCGCTGGGAGAGCCAAGGCCTATGCCACCTGC 659 
Fr1_H2  TGCTGGAGAGTAGACATCCCCCTCCTTGCCGCTGGGAGAGCCAAGGCCTATGCCACCTGC 660 
        ************************************************************ 
 
Fr1_H1B AGCGTCTGAGCGGCCGCCTGTCCTTGGTGGCCGGAGGTGGGGGCCTGCTGTGGGTCAGTG 718 
Fr1_H1C AGCGTCTGAGCGGCCGCCTGTCCTTGGTGGCCGGGGGTGGGGGCCTGCTGTGGGTCAGTG 719 
Fr1_H2  AGCGTCTGAGCGGCCGCCTGTCCTTGGTGGCCGGGGGTGGGGGCCTGCTGTGGGTCAGTG 720 
        **********************************.************************* 
 
Fr1_H1B TGCCACCCTCTGCAGGGCAGCCTGTGGGAGAAGGGACAGCGGGTAAAAAGAGAAGGCAAG 778 
Fr1_H1C TGCCACCCTCTGCAGGGCAGCCTGTGGGAGAAGGGACAGCGGGTAAAAAGAGAAGGCAAG 779 
Fr1_H2  TGCCACCCTCTGCAGGGCAGCCTGTGGGAGAAGGGACAGCGGGTAAAAAGAGAAGGCAAG 780 
        ************************************************************ 
 
Fr1_H1B CTGGCAGGAGGGTGGCACTTCGTGGATGACCTCCTTAGAAAAGACTGACCTTGATGTCTT 838 
Fr1_H1C CTGGCAGGAGGGTGGCACTTCGTGGATGACCTCCTTAGAAAAGACTGACCTTGATGTCTT 839 
Fr1_H2  CTGGCAGGAGGGTGGCACTTCGTGGATGACCTCCTTAGAAAAGACTGACCTTGATGTCTT 840 
        ************************************************************ 
 
Fr1_H1B GAGAGCGCTGGCCTCTTCCTCCCTCCCTGCAGGGTAGGGGGCCTGAGTTGAGGGGCTTCC 898 
Fr1_H1C GAGAGCGCTGGCCTCTTCCTCCCTCCCTGCAGGGTAGGGGGCCTGAGTTGAGGGGCTTCC 899 
Fr1_H2  GAGAGCGCTGGCCTCTTCCTCCCTCCCTGCAGGGTAGGGGACCTGAGTTGAGGGGCTTCC 900 
        ****************************************.******************* 
 
Fr1_H1B CTCT--GCTCCACAGAAACCCTGTTTTATTGAGTTCTGAAGGTTGGAACTGCTGCCATGA 956 
Fr1_H1C CTCT--GCTCCACAGAAACCCTGTTTTATTGAGTTCTGAAGGTTGGAACTGCTGCCATGA 957 
Fr1_H2  CTCTCTGCTCCACAGAAACCCTGTTTTATTGAGTTCTGAAGGTTGGAACTGCTGCCATGA 960 
        ****  ****************************************************** 
 
Fr1_H1B TTTTGGCCACTTTGCAGACCTGGGACTTTAGGGCTAACCAGTTCTCTTTGTAAGGACTTG 1016 
Fr1_H1C TTTTGGCCACTTTGCAGACCTGGGACTTTAGGGCTAACCAGTTCTCTTTGTAAGGACTTG 1017 
Fr1_H2  TTTTGGCCACTTTGCAGACCTGGGACTTTAGGGCTAACCAGTTCTCTTTGTAAGGACTTG 1020 
        ************************************************************ 
 
Fr1_H1B TGCCTCTTGGGAGACGTCCACCCGTTTCCAAGCCTGGGCCACTGGCATCTCTGGAGTGTG 1076 
Fr1_H1C TGCCTCTTGGGAGACGTCCACCCGTTTCCAAGCCTGGGCCACTGGCATCTCTGGAGTGTG 1077 
Fr1_H2  TGCCTCTTGGGAGACGTCCACCCGTTTCCAAGCCTGGGCCACCGGCATCTCTGGAGTGTG 1080 
        ****************************************** ***************** 
 
Fr1_H1B TGGGGGTCTGGGAGGCAGGTCCCGAGCCCCCTGTCCTTCCCACGGCCACTGCAGTCACCC 1136 
Fr1_H1C TGGGGGTCTGGGAGGCAGGTCCCGAGCCCCCTGTCCTTCCCACGGCCACTGCAGTCACCC 1137 
Fr1_H2  TGGGGGTCTGGGAGGCGGGTCCCGAGCCCCCTGTCCTTCCCACGGCCACTGCAGTCACCC 1140 
        ****************.******************************************* 
 
Fr1_H1B C-GTCTGCGCCGCTGTGCTGTTGTCTGCCGTGAGAGCCCAATCACTGCCTA 1186 
Fr1_H1C CTGTCTGCGCCGCTGTGCTGTTGTCTGCCGTGAGAGCCCAATCACTGCCTA 1188 
Fr1_H2  CTGTCTGCCCCGCTGTGCTGTTGTCTGCCGTGAGAGCCCAATCACTGCCTA 1191 
        * ****** ****************************************** 
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Appendix E 
Fragment 2 (Fr2): chr17:44102418-44104245 
In the below multiple sequence alignment of the three Fr2 variants, sequence 
matches are denoted *, with sequence differences highlighted in red. The regions 
of Fr2 that overlaps with Fr1 (5’ end) and Fr3 (3’ end) are highlighted in blue, 
with the AatII and XbaI internal restriction sites underlined and italicised.  
Fr2_H1B TAGGGGGCCTGAGTTGAGGGGCTTCCCTCT--GCTCCACAGAAACCCTGTTTTATTGAGT 57 
Fr2_H1C TAGGGGGCCTGAGTTGAGGGGCTTCCCTCT--GCTCCACAGAAACCCTGTTTTATTGAGT 58 
Fr2_H2  TAGGGGGCCTGAGTTGAGGGGCTTCCCTCTCTGCTCCACAGAAACCCTGTTTTATTGAGT 59 
        ******************************  **************************** 
 
Fr2_H1B TCTGAAGGTTGGAACTGCTGCCATGATTTTGGCCACTTTGCAGACCTGGGACTTTAGGGC 117 
Fr2_H1C TCTGAAGGTTGGAACTGCTGCCATGATTTTGGCCACTTTGCAGACCTGGGACTTTAGGGC 118 
Fr2_H2  TCTGAAGGTTGGAACTGCTGCCATGATTTTGGCCACCTTGCAGACCTGGGACTTTAGGGC 119 
        ************************************ *********************** 
 
Fr2_H1B TAACCAGTTCTCTTTGTAAGGACTTGTGCCTCTTGGGAGACGTCCACCCGTTTCCAAGCC 177 
Fr2_H1C TAACCAGTTCTCTTTGTAAGGACTTGTGCCTCTTGGGAGACGTCCACCCGTTTCCAAGCC 178 
Fr2_H2  TAACCAGTTCTCTTTGTAAGGACTTGTGCCTCTTGGGAGACGTCCACCCGTTTCCAAGCC 179 
        ************************************************************ 
 
Fr2_H1B TGGGCCACTGGCATCTCTGGAGTGTGTGGGGGTCTGGGAGGCAGGTCCCGAGCCCCCTGT 237 
Fr2_H1C TGGGCCACTGGCATCTCTGGAGTGTGTGGGGGTCTGGGAGGCAGGTCCCGAGCCCCCTGT 238 
Fr2_H2  TGGGCCACTGGCATCTCTGGAGTGTGTGGGGGTCTGGGAGGCGGGTCCCGAGCCCCCTGT 239 
        ******************************************.***************** 
 
Fr2_H1B CCTTCCCACGGCCACTGCAGTCACCCC-GTCTGCGCCGCTGTGCTGTTGTCTGCCGTGAG 296 
Fr2_H1C CCTTCCCACGGCCACTGCAGTCACCCCTGTCTGCGCCGCTGTGCTGTTGTCTGCCGTGAG 298 
Fr2_H2  CCTTCCCACGGCCACTGCAGTCACCCCTGTCTGCCCCGCTGTGCTGTTGTCTGCCGTGAG 299 
        *************************** ****** ************************* 
 
Fr2_H1B AGCCCAATCACTGCCTATACCCCTCATCACACGTCACAATGTCCCGAATTCCCAGCCTCA 356 
Fr2_H1C AGCCCAATCACTGCCTATACCCCTCATCACACGTCACAATGTCCCGAATTCCCAGCCTCA 358 
Fr2_H2  AGCCCAATCACTGCCTATACCCCTCAT--CACGTCACAATGTCCCGAATTCCCAGCCTCA 357 
        ***************************  ******************************* 
 
Fr2_H1B CCACCCCTTCTCAGTAATGACCCTGGTTGGTTGCAGGAGGTACCTACTCCATACTGAGGG 416 
Fr2_H1C CCACCCCTTCTCAGTAATGACCCTGGTTGGTTGCAGGAGGTACCTACTCCATACTGAGGG 418 
Fr2_H2  CCACCCCTTCTCAGTAATGACCCTGGTTGGTTGCAGGAGGTACCTACTCCATACTGAGGG 417 
        ************************************************************ 
 
Fr2_H1B TGAAATTAAGGGAAGGCAAAGTCCAGGCACAAGAGTGGGACCCCAGCCTCTCACTCTCAG 476 
Fr2_H1C TGAAATTAAGGGAAGGCAAAGTCCAGGCACAAGAGTGGGACCCCAGCCTCTCACTCTCAG 478 
Fr2_H2  TGAAATTAAGGGAAGGCAAAGTCCAGGCACCAGAGTGGGACCCCAGCCTCTCACTCTCAG 477 
        ******************************.***************************** 
 
Fr2_H1B TTCCACTCATCCAACTGGGACCCTCACCACGAATCTCATGATCTGATTCGGTTCCCTGTC 536 
Fr2_H1C TTCCACTCATCCAACTGGGACCCTCACCACGAATCTCATGATCTGATTCGGTTCCCTGTC 538 
Fr2_H2  TTCCACTCATCCAACTGGGACCCTCACCACGAATCTCACGATCTGATTCGGTTCCCTGTC 537 
        ************************************** ********************* 
 
Fr2_H1B TCCTCCTTCCGTCACAGATGTGAGCCAGGGCACTGCTCAGCTGTGACCCTAGGTGTTTCT 596 
Fr2_H1C TCCTCCTCCCGTCACAGATGTGAGCCAGGGCACTGCTCAGCTGTGACCCTAGGTGTTTCT 598 
Fr2_H2  TCCTCCTCCCGTCACAGATGTGAGCCAGGGCACTGCTCAGCTGTGACCCTAGGTGTTTCT 597 
        ******* **************************************************** 
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Fr2_H1B GCCTTGTTGACATGGAGAGAGCCCTTTCCCCTGAGAAGGCCTGGCCCCTTCCTGTGCTGA 656 
Fr2_H1C GCCTTGTTGACATGGAGAGAGCCCTTTCCCCTGAGAAGGCCTGGCCCCTTCCTGTGCTGA 658 
Fr2_H2  GCCTTGTTGACATGGAGAGAGCCCTTTCCCCTGAGAAGGCCTGGCCCCTTCCTGTGCTGA 657 
        ************************************************************ 
 
Fr2_H1B GCCCACAGCAGCAGGCTGGGTGTCTTGGTTGTCAGTGGTGGCACCAGGATGGAAGGGCAA 716 
Fr2_H1C GCCCACAGCAGCAGGCTGGGTGTCTTGGTTGTCAGTGGTGGCACCAGGATGGAAGGGCAA 718 
Fr2_H2  GCCCACAGCAGCAGGCTGGGTGTCTTGGTTGTCAGTGGTGGCACCAGGATGGAAGGGCAA 717 
        ************************************************************ 
 
Fr2_H1B GGCACCCAGGGCAGGCCCACAGTCCCGCTGTCCCCCACTTGCACCCTAGCTTGTAGCTGC 776 
Fr2_H1C GGCACCCAGGGCAGGCCCACAGTCCCGCTGTCCCCCACTTGCACCCTAGCTTGTAGCTGC 778 
Fr2_H2  GGCACCCAGGGCAGGCCCACAGTCCCGCTGTCCCCCACTTGCACCCTAGCTTGTAGCTGC 777 
        ************************************************************ 
 
Fr2_H1B CAACCTCCCAGACAGCCCAGCCCGCTGCTCAGCTCCACATGCATAGTATCAGCCCTCCAC 836 
Fr2_H1C CAACCTCCCAGACAGCCCAGCCCGCTGCTCAGCTCCACATGCATAGTATCAGCCCTCCAC 838 
Fr2_H2  CAACCTCCCAGACAGCCCAGCCCGCTGCTCAGCTCCACATGCATAGTATCAGCCCTCCAC 837 
        ************************************************************ 
 
Fr2_H1B ACCCGACAAAGGGGAACACACCCCCTTGGAAATGGTTCTTTTCCCCCAGTCCCAGCTGGA 896 
Fr2_H1C ACCCGACAAAGGGGAACACACCCCCTTGGAAATGGTTCTTTTCCCCCAGTCCCAGCTGGA 898 
Fr2_H2  ACCCGACAAAGGGGAACACACCCCCTTGGAAATGGTTCTTTCCCCCCAGTCCCAGCTGGA 897 
        ***************************************** ****************** 
 
Fr2_H1B AGCCATGCTGTCTGTTCTGCTGGAGCAGCTGAACATATACATAGATGTTGCCCTGCCCTC 956 
Fr2_H1C AGCCATGCTGTCTGTTCTGCTGGAGCAGCTGAACATATACATAGATGTTGCCCTGCCCTC 958 
Fr2_H2  AGCCATGCTGTCTGTTCTGCTGGAGCAGCTGAACATATACATAGATGTTGCCCTGCCCTC 957 
        ************************************************************ 
 
Fr2_H1B CCCATCTGCACCCTGTTGAGTTGTAGTTGGATTTGTCTGTTTATGCTTGGATTCACCAGA 1016 
Fr2_H1C CCCATCTGCACCCTGTTGAGTTGTAGTTGGATTTGTCTGTTTATGCTTGGATTCACCAGA 1018 
Fr2_H2  CCCATCTGCACCCTGTTGAGTTGTAGTTGGATTTGTCTGTTTATGCTTGGATTCACCAGA 1017 
        ************************************************************ 
 
Fr2_H1B GTGACTATGATAGTGAAAAGAAAAAAAAAAAAAAAAAA-GGACGCATGTATCTTGAAATG 1075 
Fr2_H1C GTGACTATGATAGTGAAAAGAAAAAAAAAAAAAAAAAAAGGACGCATGTATCTTGAAATG 1078 
Fr2_H2  GTGACTATGATAGTGAAAA---AAAAAAAAAAAAAAAAAGGACGCATGTATCTTGAAATG 1074 
        *******************   ****************.********************* 
 
Fr2_H1B CTTGTAAAGAGGTTTCTAACCCACCCTCACGAGGTGTCTCTCACCCCCACACTGGGACTC 1135 
Fr2_H1C CTTGTAAAGAGGTTTCTAACCCACCCTCACGAGGTGTCTCTCACCCCCACACTGGGACTC 1138 
Fr2_H2  CTTGTAAAGAGGTTTCTAACCCACCCTCACGAGGTGTCTCTCACCCCCACACTGGGACTC 1134 
        ************************************************************ 
 
Fr2_H1B GTGTGGCCTGTGTGGTGCCACCCTGCTGGGGCCTCCCAAGTTTTGAAAGGCTTTCCTCAG 1195 
Fr2_H1C GTGTGGCCTGTGTGGTGCCACCCTGCTGGGGCCTCCCAAGTTTTGAAAGGCTTTCCTCAG 1198 
Fr2_H2  GTGTGGCCTGTGTGGTGCCACCCTGCTGGGGCCTCCCAAGTTTTGAAAGGCTTTCCTCAG 1194 
        ************************************************************ 
 
Fr2_H1B CACCTGGGACCCAACAGAGACCAGCTTCTAGCAGCTAAGGAGGCCGTTCAGCTGTGACGA 1255 
Fr2_H1C CACCTGGGACCCAACAGAGACCAGCTTCTAGCAGCTAAGGAGGCCGTTCAGCTGTGACGA 1258 
Fr2_H2  CATCTGGGACCCAACAGAGACCAGCTTCTAGCAGCTAAGGAGGCCGTTCAGCTGTGACGA 1254 
        ** ********************************************************* 
 
Fr2_H1B AGGCCTGAAGCACAGGATTAGGACTGAAGCGATGATGTCCCCTTCCCTACTTCCCCTTGG 1315 
Fr2_H1C AGGCCTGAAGCACAGGATTAGGACTGAAGCGATGATGTCCCCTTCCCTACTTCCCCTTGG 1318 
Fr2_H2  AGGCCTGAAGCACAGGATTAGGACTGAAGCGATGATGTCCCCTTCCCTACTTCCCCTTGG 1314 
        ************************************************************ 
 
Fr2_H1B GGCTCCCTGTGTCAGGGCACAGACTAGGTCTTGTGGCTGGTCTGGCTTGCGGCGCGAGGA 1375 
Fr2_H1C GGCTCCCTGTGTCAGGGCACAGACTAGGTCTTGTGGCTGGTCTGGCTTGCGGCGCGAGGA 1378 
Fr2_H2  GGCTCCCTGTGTCAGGGCACAGACTAGGTCTTGTGGCTGGTCTGGCTTGCGGCGCGAGGA 1374 
        ************************************************************ 
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Fr2_H1B TGGTTCTCTCTGGTCATAGCCCGAAGTCTCATGGCAGTCCCAAAGGAGGCTTACAACTCC 1435 
Fr2_H1C TGGTTCTCTCTGGTCATAGCCCGAAGTCTCATGGCAGTCCCAAAGGAGGCTTACAACTCC 1438 
Fr2_H2  TGGTTCTCTCTGGTCATAGCCCGAAGTCTCACAGCAGTCCCAAAGGAGGCTTACAACTCC 1434 
        ******************************* .*************************** 
 
Fr2_H1B TGCATCACAAGAAAAAGGAAGCCACTGCCAGCTGGGGGGATCTGCAGCTCCCAGAAGCTC 1495 
Fr2_H1C TGCATCACAAGAAAAAGGAAGCCACTGCCAGCTGGGGGGATCTGCAGCTCCCAGAAGCTC 1498 
Fr2_H2  TGCATCACAAGAAAAAGGAAGCCACTGCCAGCTGGGGGGATCTGCAGCTCCCAGAAGCTC 1494 
        ************************************************************ 
 
Fr2_H1B CGTGAGCCTCAGCCACCCCTCAGACTGGGTTCCTCTCCAAGCTCGCCCTCTGGAGGGGCA 1555 
Fr2_H1C CGTGAGCCTCAGCCACCCCTCAGACTGGGTTCCTCTCCAAGCTCGCCCTCTGGAGGGGCA 1558 
Fr2_H2  CGTGAGCCTCAGCCACCCCTCAGACTGGGTTCCTCTCCAAGCTCGCCCTCTGGAGGGGCA 1554 
        ************************************************************ 
 
Fr2_H1B GCGCAGCCTCCCACCAAGGGCCCTGCGACCACAGCAGGGATTGGGATGAATTGCCTGTCC 1615 
Fr2_H1C GCGCAGCCTCCCACCAAGGGCCCTGCGACCACAGCAGGGATTGGGATGAATTGCCTGTCC 1618 
Fr2_H2  GCGCAGCCTCCCACCAAGGGCCCTGCGACCACAGCAGGGATTGGGATGAATTGCCTGTCC 1614 
        ************************************************************ 
 
Fr2_H1B TGGATCTGCTCTAGAGGCCCAAGCTGCCTGCCTGAGGAAGGATGACTTGACAAGTCAGGA 1675 
Fr2_H1C TGGATCTGCTCTAGAGGCCCAAGCTGCCTGCCTGAGGAAGGATGACTTGACAAGTCAGGA 1678 
Fr2_H2  TGGATCTGCTCTAGAGGCCCAAGCTGCCTGCCTGAGGAAGGATGACTTGACAAGTCAGGA 1674 
        ************************************************************ 
 
Fr2_H1B GACACTGTTCCCAAAGCCTTGACCAGAGCACCTCAGCCCGCTGACCTTGCACAAACTCCA 1735 
Fr2_H1C GACACTGTTCCCAAAGCCTTGACCAGAGCACCTCAGCCCGCTGACCTTGCACAAACTCCA 1738 
Fr2_H2  GACACTGTTCCCAAAGCCTTGACCAGAGCACCTCAGCCCGCTGACCTTGCACAAACTCCA 1734 
        ************************************************************ 
 
Fr2_H1B TCTGCTGCCATGAGAAAAGGGAAGCCGCCTTTGCAAAACATTGCTGCCTAAAGAAACTCA 1795 
Fr2_H1C TCTGCTGCCATGAGAAAAGGGAAGCCGCCTTTGCAAAACATTGCTGCCTAAAGAAACTCA 1798 
Fr2_H2  TCTGCTGCCATGAGAAAAGGGAAGCCGCCTTTGCAAAACATTGCTGCCTAAAGAAACTCA 1794 
        ************************************************************ 
 
Fr2_H1B GCAGCCTCAGGCCCAATTCTGCCACTTCTGGT 1827 
Fr2_H1C GCAGCCTCAGGCCCAATTCTGCCACTTCTGGT 1830 
Fr2_H2  GCAGCCTCAGGCCCAATTCTGCCACTTCTGGT 1826 
        ******************************** 
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Appendix F 
Fragment 3 (Fr3): chr17:44103934-44105914 
In the below multiple sequence alignment of the three Fr3 variants, sequence 
matches are denoted *, with sequence differences highlighted in red. The region 
of Fr3 that overlaps with Fr2 is highlighted in blue, with the XbaI internal 
restriction site underlined and italicised.  
H1B CAGACTGGGTTCCTCTCCAAGCTCGCCCTCTGGAGGGGCAGCGCAGCCTCCCACCAAGGG 60 
H1C CAGACTGGGTTCCTCTCCAAGCTCGCCCTCTGGAGGGGCAGCGCAGCCTCCCACCAAGGG 58 
H2  CAGACTGGGTTCCTCTCCAAGCTCGCCCTCTGGAGGGGCAGCGCAGCCTCCCACCAAGGG 60 
    ************************************************************ 
 
H1B CCCTGCGACCACAGCAGGGATTGGGATGAATTGCCTGTCCTGGATCTGCTCTAGAGGCCC 120 
H1C CCCTGCGACCACAGCAGGGATTGGGATGAATTGCCTGTCCTGGATCTGCTCTAGAGGCCC 118 
H2  CCCTGCGACCACAGCAGGGATTGGGATGAATTGCCTGTCCTGGATCTGCTCTAGAGGCCC 120 
    ************************************************************ 
 
H1B AAGCTGCCTGCCTGAGGAAGGATGACTTGACAAGTCAGGAGACACTGTTCCCAAAGCCTT 180 
H1C AAGCTGCCTGCCTGAGGAAGGATGACTTGACAAGTCAGGAGACACTGTTCCCAAAGCCTT 178 
H2  AAGCTGCCTGCCTGAGGAAGGATGACTTGACAAGTCAGGAGACACTGTTCCCAAAGCCTT 180 
    ************************************************************ 
 
H1B GACCAGAGCACCTCAGCCCGCTGACCTTGCACAAACTCCATCTGCTGCCATGAGAAAAGG 240 
H1C GACCAGAGCACCTCAGCCCGCTGACCTTGCACAAACTCCATCTGCTGCCATGAGAAAAGG 238 
H2  GACCAGAGCACCTCAGCCCGCTGACCTTGCACAAACTCCATCTGCTGCCATGAGAAAAGG 240 
    ************************************************************ 
 
H1B GAAGCCGCCTTTGCAAAACATTGCTGCCTAAAGAAACTCAGCAGCCTCAGGCCCAATTCT 300 
H1C GAAGCCGCCTTTGCAAAACATTGCTGCCTAAAGAAACTCAGCAGCCTCAGGCCCAATTCT 298 
H2  GAAGCCGCCTTTGCAAAACATTGCTGCCTAAAGAAACTCAGCAGCCTCAGGCCCAATTCT 300 
    ************************************************************ 
 
H1B GCCACTTCTGGTTTGGGTACAGTTAAAGGCAACCCTGAGGGACTTGGCAGTAGAAATCCA 360 
H1C GCCACTTCTGGTTTGGGTACAGTTAAAGGCAACCCTGAGGGACTTGGCAGTAGAAATCCA 358 
H2  GCCACTTCTGGTTTGGGTACAGTTAAAGGCAACCCTGAGGGACTTG-CAGTAGAAATCCA 359 
    ********************************************** ************* 
 
H1B GGGCCTCCCCTGGGGCTGGCAGCTTCGTGTGCAGCTAGAGCTTTACCTAAAAGGAAGTCT 420 
H1C GGGCCTCCCCTGGGGCTGGCAGCTTCGTGTGCAGCTAGAGCTTTACCTGAAAGGAAGTCT 418 
H2  GGGCCTCCCCTGGGGCTGGCAGCTTCGTGTGCAGCTAGAGCTTTACCTGCAAGGAAGTCT 419 
    ************************************************..********** 
 
H1B CTGGGCCCAGAACTCTCCACCAAGAGCCTCCCTGCCGTTCGCTGAGTCCCAGCAATTCTC 480 
H1C CTGGGCCCAGAACTCTCCACCAAGAGCCTCCCTGCCGTTCGCTGAGTCCCAGCAATTCTC 478 
H2  CTGGGCCCAGAACTCTCCACCAAGAGCCTCCCTGCCGTTCGCTGAGTCCCAGCAATTCT- 478 
    ***********************************************************  
 
H1B CTAAGTTGAAGGGATCTGAGAAGGAGAAGGAAATGTGGGGTAGATTTGGTGGTGGTTAGA 540 
H1C CTAAGTTGAAGGGATCTGAGAAGGAGAAGGAAATGTGGGGTAGATTTGGTGGTGGTTAGA 538 
H2  --AAGTTGAAGGGATCTGAGAAGGAGAAGGAAATGTGGGGTAGATTTGGTGGTGGTTAGA 536 
      ********************************************************** 
 
H1B GATATGCCCCCCTCATTACTGCCAACAGTTTCGGCTGCATTTCTTCACGCACCTCGGTTC 600 
H1C GATATGCCCCCCTCATTACTGCCAACAGTTTCGGCTGCATTTCTTCACGCACCTCGGTTC 598 
H2  GATATGCCCCCCTCATTACTGCCAACAGTTTCGGCCGCATTTCTTCACGCACCTCGGTTC 596 
    *********************************** ************************ 
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H1B CTCTTCCTGAAGTTCTTGTGCCCTGCTCTTCAGCACCATGGGCCTTCTTATACGGAAGGC 660 
H1C CTCTTCCTGAAGTTCTTGTGCCCTGCTCTTCAGCACCATGGGCCTTCTTATACGGAAGGC 658 
H2  CTCTTCCTGAAGTTCTTGTGCCCTGCTCTTCAGCACCATGGGCCT---TATACGGAAGGC 653 
    *********************************************   ************ 
 
H1B TCTGGGATCTCCCCCTTGTGGGG-CAGGCTCTTGGGGCCAGCCTAAGATCATGGTTTAGG 719 
H1C TCTGGGATCTCCCCCTTGTGGGGGCAGGCTCTTGGGGCCAGCCTAAGATCATGGTTTAGG 718 
H2  TCTGGGATCTCCCCCTTGTGGGG-CAGGCTCTTGGGGCCAGCCTAAGATCATGGTTTAGG 712 
    *********************** ************************************ 
 
H1B GTGATCAGTGCTGGCAGATAAATTGAAAAGGCACGCTGGCTTGTGATCTTAAATGAGGAC 779 
H1C GTGATCAGTGCTGGCAGATAAATTGAAAAGGCACGCTGGCTTGTGATCTTAAATGAGGAC 778 
H2  GTGATCAGTGCTGGCAGATAAATTGAAAAGGCACGCTGGCTTGTGATCTTAAATGAGGAC 772 
    ************************************************************ 
 
H1B AATCCCCCCAGGGCTGGGCACTCCTCCCCTCCCCTCACTTCTCCCACCTGCAGAGCCAGT 839 
H1C AATCCCCCCAGGGCTGGGCACTCCTCCCCTCCCCTCACTTCTCCCACCTGCAGAGCCAGT 838 
H2  AATCCCCCCAGGGCTGGGCACTCCTCCCCTCCCCTCACTTCTCCCACCTGCAGAGCCAGT 832 
    ************************************************************ 
 
H1B GTCCTTGGGTGGGCTAGATAGGATATACTGTATGCCGGCTCCTTCAAGCTGCTGACTCAC 899 
H1C GTCCTTGGGTGGGCTAGATAGGATATACTGTATGCCGGCTCCTTCAAGCTGCTGACTCAC 898 
H2  GTCCTTGGGTGGGCTAGATAGGATATACTGTATGCCGGCTCCTTCAAGCTGCTGACTCAC 892 
    ************************************************************ 
 
H1B TTTATCAATAGTTCCATTTAAATTGACTTCAGTGGTGAGACTGTATCCTGTTTGCTATTG 959 
H1C TTTATCAATAGTTCCATTTAAATTGACTTCAGTGGTGAGACTGTATCCTGTTTGCTATTG 958 
H2  TTTATCAATAGTTCCATTTAAATTGACTTCAGTGGTGAGACTGTATCCTGTTTGCTATTG 952 
    ************************************************************ 
 
H1B CTTGTTGTGCTATGGGGGGAGGGGGGAGGAATGTGTAAGATAGTTAACATGGGCAAAGGG 1019 
H1C CTTGTTGTGCTATGGGGGGAGGGGGGAGGAATGTGTAAGATAGTTAACATGGGCAAAGGG 1018 
H2  CTTGTTGTGCTATGGGGGGAGGGGGGAGGAATGTGTAAGATAGTTAACATGGGCAAAGGG 1012 
    ************************************************************ 
 
H1B AGATCTTGGGGTGCAGCACTTAAACTGCCTCGTAACCCTTTTCATGATTTCAACCACATT 1079 
H1C AGATCTTGGGGTGCAGCACTTAAACTGCCTCGTAACCCTTTTCATGATTTCAACCACATT 1078 
H2  AGATCTTGGGGTGCAGCACTTAAACTGCCTCGTAACCCTTTTCATGATTTCAACCACATT 1072 
    ************************************************************ 
 
H1B TGCTAGAGGGAGGGAGCAGCCACGGAGTTAGAGGCCCTTGGGGTTTCTCTTTTCCACTGA 1139 
H1C TGCTAGAGGGAGGGAGCAGCCACGGAGTTAGAGGCCCTTGGGGTTTCTCTTTTCCACTGA 1138 
H2  TGCTAGAGGGAGGGAGCAGCCACGGAGTTAGAGGCCCTTGGGGTTTCTCTTTTCCACTGA 1132 
    ************************************************************ 
 
H1B CAGGCTTTCCCAGGCAGCTGGCTAGTTCATTCCCTCCCCAGCCAGGTGCAGGCGTAGGAA 1199 
H1C CAGGCTTTCCCAGGCAGCTGGCTAGTTCATTCCCTCCCCAGCCAGGTGCAGGCGTAGGAA 1198 
H2  CAGGCTTTCCCAGGCAGCTGGCTAGTTCATTCCCTCCCCAGCCAGGTGCAGGCGTAGGAA 1192 
    ************************************************************ 
 
H1B TATGGACATCTGGTTGCTTTGGCCCGCTGCCCTCTTTCAGGGGTCCTAAGCCCACAATCA 1259 
H1C TATGGACATCTGGTTGCTTTGGCCTGCTGCCCTCTTTCAGGGGTCCTAAGCCCACAATCA 1258 
H2  TATGGACATCTGGTTGCTTTGGCCTGCTGCCCTCTTTCAGGGGTCCTAAGCCCACAATCA 1252 
    ************************ *********************************** 
 
H1B TGCCTCCCTAAGACCTTGGCATCCTTCCCTCTAAGCCGTTGGCACCTCTGTGCCACCTCT 1319 
H1C TGCCTCCCTAAGACCTTGGCATCCTTCCCTCTAAGCCGTTGGCACCTCTGTGCCACCTCT 1318 
H2  TGCCTCCCTAAGACCTTGGCATCCTTCCCTCTAAGCCGTTGGCACCTCTGTGCCACCTCT 1312 
    ************************************************************ 
 
H1B CACACTGGCTCCAGACACACAGCCTGTGCTTTTGGAGCTGAGATCACTCGCTTCACCCTC 1379 
H1C CACACTGGCTCCAGACACACAGCCTGTGCTTTTGGAGCTGAGATCACTCGCTTCACCCTC 1378 
H2  CACACTGGCTCCAGACACACAGCCTGTGCTTTTGGAGCTGAGATCACTCGCTTCACCCTC 1372 
    ************************************************************ 
 
Appendices 
283 
 
H1B CTCATCTTTGTTCTCCAAGTAAAGCCACGAGGTCGGGGCGAGGGCAGAGGTGATCACCTG 1439 
H1C CTCATCTTTGTTCTCCAAGTAAAGCCACGAGGTCGGGGCGAGGGCAGAGGTGATCACCTG 1438 
H2  CTCATCTTTGTTCTCCAAGTAAAGCCACGAGGTCGGGGCGAGGGCAGAGGTGATCACCTG 1432 
    ************************************************************ 
 
H1B CGTGTCCCATCTACAGACCTGCAGCTTCATAAAACTTCTGATTTCTCTTCAGCTTTGAAA 1499 
H1C CGTGTCCCATCTACAGACCAGCGGCTTCATAAAACTTCTGATTTCTCTTCAGCTTTGAAA 1498 
H2  CGTGTCCCATCTACAGACCTGCGGCTTCATAAAACTTCTGATTTCTCTTCAGCTTTGAAA 1492 
    *******************:**.************************************* 
 
H1B AGGGTTACCCTGGGCACTGGCCTAGAGCCTCACCTCCTAATAGACTTAGCCCCATGAGTT 1559 
H1C AGGGTTACCCTGGGCACTGGCCTAGAGCCTCACCTCCTAATAGACTTAGCCCCATGAGTT 1558 
H2  AGGGTTACCCTGGGCACTGGCCTAGAGCCTCACCTCCTAATAGACTTAGCCCCATGAGTT 1552 
    ************************************************************ 
 
H1B TGCCATGTTGAGCAGGACTATTTCTGGCACTTGCAAGTCCCATGATTTCTTCGGTAATTC 1619 
H1C TGCCATGTTGAGCAGGACTATTTCTGGCACTTGCAAGTCCCATGATTTCTTCGGTAATTC 1618 
H2  TGCCATGTTGAGCAGGACTATTTCTGGCACTTGCAAGTCCCATGATTTCTTCGGTAATTC 1612 
    ************************************************************ 
 
H1B TGAGGGTGGGGGGAGGGACATGAAATCATCTTAGCTTAGCTTTCTGTCTGTGAATGTCTA 1679 
H1C TGAGGGTGGGGGGAGGGACATGAAATCATCTTAGCTTAGCTTTCTGTCTGTGAATGTCTA 1678 
H2  TGAGGGTGGGGGGAGGGACATGAAATCATCTTAGCTTAGCTTTCTGTCTGTGAATGTCTA 1672 
    ************************************************************ 
 
H1B TATAGTGTATTGTGTGTTTTAACAAATGATTTACACTGACTGTTGCTGTAAAAGTGAATT 1739 
H1C TATAGTGTATTGTGTGTTTTAACAAATGATTTACACTGACTGTTGCTGTAAAAGTGAATT 1738 
H2  TATAGTGTATTGTGTGTTTTAACAAATGATTTACACTGACTGTTGCTGTAAAAGTGAATT 1732 
    ************************************************************ 
 
H1B TGGAAATAAAGTTATTACTCTGATTAAATAAGGTCTCCATTCATGGATTCCAAGGACAAG 1799 
H1C TGGAAATAAAGTTATTACTCTGATTAAATAAGGTCTCCATTCATGGATTCCAAGGACAAG 1798 
H2  TGGAAATAAAGTTATTACTCTGATTAAATAAGGTCTCCATTCATGGATTCCAAGGACAAG 1792 
    ************************************************************ 
 
H1B AAAGTCATATAGAATGTCTATTTTTTAAGTTCTTTCCCACGCACCCTTAGATAATTTAGC 1859 
H1C AAAGTCATATAGAATGTCTATTTTTTAAGTTCTTTCCCACGCACCCTTAGATAATTTAGC 1858 
H2  AAAGTCATATAGAATGTCTATTTTTTAAGTTCTTTCCCACGCACCCTTAGATAATTTAGC 1852 
    ************************************************************ 
 
H1B TCAGAACAGGAAATGATAGTATTAATAAAAGCTGGACATCAGGATTAACAGCTCTCTCTG 1919 
H1C TCAGAACAGGAAATGATAGTATTAATAAAAGCTGGACATCAGGATTAACAGCTCTCTCTG 1918 
H2  TCAGAACAGGAAATGATAGTATTAATAAAAGCTGGACATCAGGATTAACAGCTCTCTCTG 1912 
    ************************************************************ 
 
H1B GGGCCCTGAAGGTGAGAGTTCTCAGACTTGCTCATTTGCAGTTGCTTCTTTGTGATGCTG 1979 
H1C GGGCCCTGAAGGTGAGAGTTCTCAGACTTGCTCATTTGCAGTTGCTTCTTTGTGATGCTG 1978 
H2  GGGCCCTGAAGGTGAGAGTTCTCAGACTTGCTCATTTGCAGTTGCTTCTTTGTGATGCTG 1972 
    ************************************************************ 
 
H1B GC 1981 
H1C GC 1980 
H2  GC 1974 
    ** 
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Appendix G 
CP H1X mutations  
In the below multiple sequence alignment of the wildtype and mutated H1 CP 
variants, sequence matches are denoted * and the A120G and G596T mutations 
are highlighted in red. Exon 0 is highlighted in green. 
CP_H1  CAAATGCTCTGCGATGTGTTAAGCACTGTTTGAAATTCGTCTAATTTAAGATTTTTTTTT 60 
CP_H1X CAAATGCTCTGCGATGTGTTAAGCACTGTTTGAAATTCGTCTAATTTAAGATTTTTTTTT 60 
       ************************************************************ 
 
CP_H1  CTGACGTAACGGTTAGATTCACGTTTCTTTTTTTTTAAGTACAGTTCTACTGTATTGTAA 120 
CP_H1X CTGACGTAACGGTTAGATTCACGTTTCTTTTTTTTTAAGTACAGTTCTACTGTATTGTAG 120 
       ***********************************************************. 
 
CP_H1  CTGAGTTAGCTTGCTTTAAGCCGATTTGTTAAGGAAAGGATTCACCTTGGTCAGTAACAA 180 
CP_H1X CTGAGTTAGCTTGCTTTAAGCCGATTTGTTAAGGAAAGGATTCACCTTGGTCAGTAACAA 180 
       ************************************************************ 
 
CP_H1  AAAAGGTGGGAAAAAAGCAAGGAGAAAGGAAGCAGCCTGGGGGAAAGAGACCTTAGCCAG 240 
CP_H1X AAAAGGTGGGAAAAAAGCAAGGAGAAAGGAAGCAGCCTGGGGGAAAGAGACCTTAGCCAG 240 
       ************************************************************ 
 
CP_H1  GGGGGCGGTTTCGGGACTACGAAGGGTCGGGGCGGACGGACTCGAGGGCCGGCCACGTGG 300 
CP_H1X GGGGGCGGTTTCGGGACTACGAAGGGTCGGGGCGGACGGACTCGAGGGCCGGCCACGTGG 300 
       ************************************************************ 
 
CP_H1  AAGGCCGCTCAGGACTTCTGTAGGAGAGGACACCGCCCCAGGCTGACTGAAAGTAAAGGG 360 
CP_H1X AAGGCCGCTCAGGACTTCTGTAGGAGAGGACACCGCCCCAGGCTGACTGAAAGTAAAGGG 360 
       ************************************************************ 
 
CP_H1  CAGCGGACCCAGCGGCGGAGCCACTGGCCTTGCCCCGACCCCGCATGGCCCGAAGGAGGA 420 
CP_H1X CAGCGGACCCAGCGGCGGAGCCACTGGCCTTGCCCCGACCCCGCATGGCCCGAAGGAGGA 420 
       ************************************************************ 
 
CP_H1  CACCCACCCCCGCAACGACACAAAGACTCCAACTACAGGAGGTGGAGAAAGCGCGTGCGC 480 
CP_H1X CACCCACCCCCGCAACGACACAAAGACTCCAACTACAGGAGGTGGAGAAAGCGCGTGCGC 480 
       ************************************************************ 
 
CP_H1  CACGGAACGCGCGTGCGCGCTGCGGTCAGCGCCGCGGCCTGAGGCGTAGCGGGAGGGGGA 540 
CP_H1X CACGGAACGCGCGTGCGCGCTGCGGTCAGCGCCGCGGCCTGAGGCGTAGCGGGAGGGGGA 540 
       ************************************************************ 
 
CP_H1  CCGCGAAAGGGCAGCGCCGAGAGGAACGAGCCGGGAGACGCCGGACGGCCGAGCGGCAGG 600 
CP_H1X CCGCGAAAGGGCAGCGCCGAGAGGAACGAGCCGGGAGACGCCGGACGGCCGAGCGTCAGG 600 
       ******************************************************* **** 
 
CP_H1  GCGCTCGCGCGCGCCCACTAGTGGCCGGAGGAGAAGGCTCCCGCGGAGGCCGCGCTGCCC 660 
CP_H1X GCGCTCGCGCGCGCCCACTAGTGGCCGGAGGAGAAGGCTCCCGCGGAGGCCGCGCTGCCC 660 
       ************************************************************ 
 
CP_H1  GCCCCCTCCCCTGGGGAGGCTCGCGTTCCCGCTGCTCGCGCCTGCGCCGCCCGCCGGCCT 720 
CP_H1X GCCCCCTCCCCTGGGGAGGCTCGCGTTCCCGCTGCTCGCGCCTGCGCCGCCCGCCGGCCT 720 
       ************************************************************ 
 
CP_H1  CAGGAACGCGCCCTCTTCGCCGGCGCGCGCCCTCGCAGTCACCGCCACCCACCAGCTCCG 780 
CP_H1X CAGGAACGCGCCCTCTTCGCCGGCGCGCGCCCTCGCAGTCACCGCCACCCACCAGCTCCG 780 
       ************************************************************ 
 
CP_H1  GCACCAACAGCAGCGCCGCTGCCACCGCCCACCTTCTGCCGCCGCCACCACAGCCACCTT 840 
CP_H1X GCACCAACAGCAGCGCCGCTGCCACCGCCCACCTTCTGCCGCCGCCACCACAGCCACCTT 840 
       ************************************************************ 
Appendices 
285 
 
 
CP_H1  CTCCTCCTCCGCTGTCCTCTCCCGTCCTCGCCTCTGTCGACTATCAGGTAAGCGCCGCGG 900 
CP_H1X CTCCTCCTCCGCTGTCCTCTCCCGTCCTCGCCTCTGTCGACTATCAGGTAAGCGCCGCGG 900 
       ************************************************************ 
 
CP_H1  CTCCGAAATCTGCCTCGCCGTCCGCCTCTGTGCACCCCTGCGCCGCCGCCCCTCGCCCTC 960 
CP_H1X CTCCGAAATCTGCCTCGCCGTCCGCCTCTGTGCACCCCTGCGCCGCCGCCCCTCGCCCTC 960 
       ************************************************************ 
 
CP_H1  CCTCTCCGCAGACTGGGGCTTCGTGCGCCGGGCATCGGTCGGGGCCACCGCAGGGCCCCT 1020 
CP_H1X CCTCTCCGCAGACTGGGGCTTCGTGCGCCGGGCATCGGTCGGGGCCACCGCAGGGCCCCT 1020 
       ************************************************************ 
 
CP_H1  CCCTGCCTCCCCTGCTCGGGGGCTGGGGCCAGGGCGGCCTGGAAAGGGACCTGAGCAAGG 1080 
CP_H1X CCCTGCCTCCCCTGCTCGGGGGCTGGGGCCAGGGCGGCCTGGAAAGGGACCTGAGCAAGG 1080 
       ************************************************************ 
 
CP_H1  GATGCACGCACGCGTGAGTGCGCGCGTGTGTGTGTGCTGGAGGGTCTTCACCACCAGATT 1140 
CP_H1X GATGCACGCACGCGTGAGTGCGCGCGTGTGTGTGTGCTGGAGGGTCTTCACCACCAGATT 1140 
       ************************************************************ 
 
CP_H1  CGCGCAGACCCCAGGTGGAGGCTGTGCCGGCAGGGTGGGGCGCGGCGGCGGTGACTTGGG 1200 
CP_H1X CGCGCAGACCCCAGGTGGAGGCTGTGCCGGCAGGGTGGGGCGCGGCGGCGGTGACTTGGG 1200 
       ************************************************************ 
 
CP_H1  GGAGGGGGCTGCCCTTCACTCTCGACTGCAGCCTTTTGCCGCAATGGGCGTGTGTGTGTG 1260 
CP_H1X GGAGGGGGCTGCCCTTCACTCTCGACTGCAGCCTTTTGCCGCAATGGGCGTGTGTGTGTG 1260 
       ************************************************************ 
 
CP_H1  TGTGTGTGTGTGTGTGTGTGTGTGGAGGGGTCCGATAACGACCCCCGAAACCGAATCTGA 1320 
CP_H1X TGTGTGTGTGTGTGTGTGTGTGTGGAGGGGTCCGATAACGACCCCCGAAACCGAATCTGA 1320 
       ************************************************************ 
 
CP_H1  AATCCGCTGTCC 1332 
CP_H1X AATCCGCTGTCC 1332 
       ************ 
 
 
 
Appendix H 
The CMV immediate early promoter 
 
  1 CTCTGCTTAT ATAGACCTCC CACCGTACAC GCCTACCGCC CATTTGCGTC AATGGGGCGG  
 61 AGTTGTTACG ACATTTTGGA AAGTCCCGTT GATTTTGGTG CCAAAACAAA CTCCCATTGA  
 21 CGTCAATGGG GTGGAGACTT GGAAATCCCC GTGAGTCAAA CCGCTATCCA CGCCCATTGA  
181 TGTACTGCCA AAACCGCATC ACCATGGTAA TAGCGATGAC TAATACGTAG ATGTACTGCC  
241 AAGTAGGAAA GTCCCATAAG GTCATGTACT GGGCATAATG CCAGGCGGGC CATTTACCGT  
301 CATTGACGTC AATAGGGGGC GTACTTGGCA TATGATACAC TTGATGTACT GCCAAGTGGG  
361 CAGTTTACCG TAAATACTCC ACCCATTGAC GTCAATGGAA AGTCCCTATT GGCGTTACTA  
421 TGGGAACATA CGTCATTATT GACGTCAATG GGCGGGGGTC GTTGGGCGGT CAGCCAGGCG  
481 GGCCATTTAC CGTAAGTTAT GTAACGCGGA ACTCCATATA TGGGCTATGA ACTAATGACC  
541 CCGTAATTGA TTACTATTAA TAACT 
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Appendix I 
CP H1B vs H1C Minigenes 
In the below multiple sequence alignment of the two CP minigenes, sequence 
matches are denoted *, with sequence differences highlighted in red. Exon 0 is 
highlighted in green. 
 
CP_H1B          GGGGACAAGTTTGTACAAAAAAGCAGGCTTCCAAATGCTCTGCGATGTGTTAAGCACTGT 60 
CP_H1C          GGGGACAAGTTTGTACAAAAAAGCAGGCTTCCAAATGCTCTGCGATGTGTTAAGCACTGT 60 
                ************************************************************ 
 
CP_H1B          TTGAAATTCGTCTAATTTAAGATTTTTTTTTCTGACGTAACGGTTAGATTCACGTTTCTT 120 
CP_H1C          TTGAAATTCGTCTAATTTAAGATTTTTTTTTCTGACGTAACGGTTAGATTCACGTTTCTT 120 
                ************************************************************ 
 
CP_H1B          TTTTTTTAAGTACAGTTCTACTGTATTGTAACTGAGTTAGCTTGCTTTAAGCCGATTTGT 180 
CP_H1C          TTTTTTTAAGTACAGTTCTACTGTATTGTAACTGAGTTAGCTTGCTTTAAGCCGATTTGT 180 
                ************************************************************ 
 
CP_H1B          TAAGGAAAGGATTCACCTTGGTCAGTAACAAAAAAGGTGGGAAAAAAGCAAGGAGAAAGG 240 
CP_H1C          TAAGGAAAGGATTCACCTTGGTCAGTAACAAAAAAGGTGGGAAAAAAGCAAGGAGAAAGG 240 
                ************************************************************ 
 
CP_H1B          AAGCAGCCTGGGGGAAAGAGACCTTAGCCAGGGGGGCGGTTTCGGGACTACGAAGGGTCG 300 
CP_H1C          AAGCAGCCTGGGGGAAAGAGACCTTAGCCAGGGGGGCGGTTTCGGGACTACGAAGGGTCG 300 
                ************************************************************ 
 
CP_H1B          GGGCGGACGGACTCGAGGGCCGGCCACGTGGAAGGCCGCTCAGGACTTCTGTAGGAGAGG 360 
CP_H1C          GGGCGGACGGACTCGAGGGCCGGCCACGTGGAAGGCCGCTCAGGACTTCTGTAGGAGAGG 360 
                ************************************************************ 
 
CP_H1B          ACACCGCCCCAGGCTGACTGAAAGTAAAGGGCAGCGGACCCAGCGGCGGAGCCACTGGCC 420 
CP_H1C          ACACCGCCCCAGGCTGACTGAAAGTAAAGGGCAGCGGACCCAGCGGCGGAGCCACTGGCC 420 
                ************************************************************ 
 
CP_H1B          TTGCCCCGACCCCGCATGGCCCGAAGGAGGACACCCACCCCCGCAACGACACAAAGACTC 480 
CP_H1C          TTGCCCCGACCCCGCATGGCCCGAAGGAGGACACCCACCCCCGCAACGACACAAAGACTC 480 
                ************************************************************ 
 
CP_H1B          CAACTACAGGAGGTGGAGAAAGCGCGTGCGCCACGGAACGCGCGTGCGCGCTGCGGTCAG 540 
CP_H1C          CAACTACAGGAGGTGGAGAAAGCGCGTGCGCCACGGAACGCGCGTGCGCGCTGCGGTCAG 540 
                ************************************************************ 
 
CP_H1B          CGCCGCGGCCTGAGGCGTAGCGGGAGGGGGACCGCGAAAGGGCAGCGCCGAGAGGAACGA 600 
CP_H1C          CGCCGCGGCCTGAGGCGTAGCGGGAGGGGGACCGCGAAAGGGCAGCGCCGAGAGGAACGA 600 
                ************************************************************ 
 
CP_H1B          GCCGGGAGACGCCGGACGGCCGAGCGGCAGGGCGCTCGCGCGCGCCCACTAGTGGCCGGA 660 
CP_H1C          GCCGGGAGACGCCGGACGGCCGAGCGGCAGGGCGCTCGCGCGCGCCCACTAGTGGCCGGA 660 
                ************************************************************ 
 
CP_H1B          GGAGAAGGCTCCCGCGGAGGCCGCGCTGCCCGCCCCCTCCCCTGGGGAGGCTCGCGTTCC 720 
CP_H1C          GGAGAAGGCTCCCGCGGAGGCCGCGCTGCCCGCCCCCTCCCCTGGGGAGGCTCGCGTTCC 720 
                ************************************************************ 
 
CP_H1B          CGCTGCTCGCGCCTGCGCCGCCCGCCGGCCTCAGGAACGCGCCCTCTTCGCCGGCGCGCG 780 
CP_H1C          CGCTGCTCGCGCCTGCGCCGCCCGCCGGCCTCAGGAACGCGCCCTCTTCGCCGGCGCGCG 780 
                ************************************************************ 
 
CP_H1B          CCCTCGCAGTCACCGCCACCCACCAGCTCCGGCACCAACAGCAGCGCCGCTGCCACCGCC 840 
CP_H1C          CCCTCGCAGTCACCGCCACCCACCAGCTCCGGCACCAACAGCAGCGCCGCTGCCACCGCC 840 
                ************************************************************ 
 
CP_H1B          CACCTTCTGCCGCCGCCACCACAGCCACCTTCTCCTCCTCCGCTGTCCTCTCCCGTCCTC 900 
CP_H1C          CACCTTCTGCCGCCGCCACCACAGCCACCTTCTCCTCCTCCGCTGTCCTCTCCCGTCCTC 900 
                ************************************************************ 
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CP_H1B          GCCTCTGTCGACTATCAGGTAAGCGCCGCGGCTCCGAAATCTGCCTCGCCGTCCGCCTCT 960 
CP_H1C          GCCTCTGTCGACTATCAGGTAAGCGCCGCGGCTCCGAAATCTGCCTCGCCGTCCGCCTCT 960 
                ************************************************************ 
 
CP_H1B          GTGCACCCCTGCGCCGCCGCCCCTCGCCCTCCCTCTCCGCAGACTGGGGCTTCGTGCGCC 1020 
CP_H1C          GTGCACCCCTGCGCCGCCGCCCCTCGCCCTCCCTCTCCGCAGACTGGGGCTTCGTGCGCC 1020 
                ************************************************************ 
 
CP_H1B          GGGCATCGGTCGGGGCCACCGCAGGGCCCCTCCCTGCCTCCCCTGCTCGGGGGCTGGGGC 1080 
CP_H1C          GGGCATCGGTCGGGGCCACCGCAGGGCCCCTCCCTGCCTCCCCTGCTCGGGGGCTGGGGC 1080 
                ************************************************************ 
 
CP_H1B          CAGGGCGGCCTGGAAAGGGACCTGAGCAAGGGATGCACGCACGCGTGAGTGCGCGCGTGT 1140 
CP_H1C          CAGGGCGGCCTGGAAAGGGACCTGAGCAAGGGATGCACGCACGCGTGAGTGCGCGCGTGT 1140 
                ************************************************************ 
 
CP_H1B          GTGTGTGCTGGAGGGTCTTCACCACCAGATTCGCGCAGACCCCAGGTGGAGGCTGTGCCG 1200 
CP_H1C          GTGTGTGCTGGAGGGTCTTCACCACCAGATTCGCGCAGACCCCAGGTGGAGGCTGTGCCG 1200 
                ************************************************************ 
 
CP_H1B          GCAGGGTGGGGCGCGGCGGCGGTGACTTGGGGGAGGGGGCTGCCCTTCACTCTCGACTGC 1260 
CP_H1C          GCAGGGTGGGGCGCGGCGGCGGTGACTTGGGGGAGGGGGCTGCCCTTCACTCTCGACTGC 1260 
                ************************************************************ 
 
CP_H1B          AGCCTTTTGCCGCAATGGGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGGAGGGGT 1320 
CP_H1C          AGCCTTTTGCCGCAATGGGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGGAGGGGT 1320 
                ************************************************************ 
 
CP_H1B          CCGATAACGACCCCCGAAACCGAATCTGAAATCCGCTGTCCACAACTTTGTATACAAAAG 1380 
CP_H1C          CCGATAACGACCCCCGAAACCGAATCTGAAATCCGCTGTCCACAACTTTGTATACAAAAG 1380 
                ************************************************************ 
 
CP_H1B          TTGTCACAACTTTGTATACAAAAGTTGTCCCTGGTGGTGTTGAATATGAACTGCTGCGGT 1440 
CP_H1C          TTGTCACAACTTTGTATACAAAAGTTGTCCCTGGTGGTGTTGAATATGAACTGCTGCGGT 1440 
                ************************************************************ 
 
CP_H1B          GTTGGTAAATTAAGCAAGCAGATAGATGTAAATAACGCTTGGGCAGGAATATGGAGCACG 1500 
CP_H1C          GTTGGTAAATTAAGCAAGCAGATAGATGTAAATAACGCTTGGGCAGGAATATGGAGCACG 1500 
                ************************************************************ 
 
CP_H1B          GGATGAGGATGGGCGGCCAACTGTTAGAGAGGGTAGCAGGGAGGCTGAGATCTGCCTGCC 1560 
CP_H1C          GGATGAGGATGGGCGGCCAACTGTTAGAGAGGGTAGCAGGGAGGCTGAGATCTGCCTGCC 1560 
                ************************************************************ 
 
CP_H1B          ATGAACTGGGAGGAGAGGCTCCTCTCTCTCTTCACCCCCACTCTGCCCCCCAACACTCCT 1620 
CP_H1C          ATGAACTGGGAGGAGAGGCTCCTCTCTCTCTTCACCCCCACTCTGCCCCCCAACACTCCT 1620 
                ************************************************************ 
 
CP_H1B          CAGAACTTATCCTCTCCTCTTCTTTCCCCAGGTGAACTTTGAACCAGGATGGCTGAGCCC 1680 
CP_H1C          CAGAACTTATCCTCTCCTCTTCTTTCCCCAGGTGAACTTTGAACCAGGATGGCTGAGCCC 1680 
                ************************************************************ 
 
CP_H1B          CGCCAGGAGTTCGAAGTGATGGAAGATCACGCTGGGACGTACGGGTTGGGGGACAGGAAA 1740 
CP_H1C          CGCCAGGAGTTCGAAGTGATGGAAGATCACGCTGGGACGTACGGGTTGGGGGACAGGAAA 1740 
                ************************************************************ 
 
CP_H1B          GATCAGGGGGGCTACACCATGCACCAAGACCAAGAGGGTGACACGGACGCTGGCCTGAAA 1800 
CP_H1C          GATCAGGGGGGCTACACCATGCACCAAGACCAAGAGGGTGACACGGACGCTGGCCTGAAA 1800 
                ************************************************************ 
 
CP_H1B          GGTTAGTGGACAGCCATGCACAGCAGGCCCAGATCACTGCAAGCCAAGGGGTGGCGGGAA 1860 
CP_H1C          GGTTAGTGGACAGCCATGCACAGCAGGCCCAGATCACTGCAAGCCAAGGGGTGGCGGGAA 1860 
                ************************************************************ 
 
CP_H1B          CAGTTTGCATCCAGAATTGCAAAGAAATTTTAAATACATTATTGTCTTAGACTGTCAGTA 1920 
CP_H1C          CAGTTTGCATCCAGAATTGCAAAGAAATTTTAAATACATTATTGTCTTAGACTGTCAGTA 1920 
                ************************************************************ 
 
CP_H1B          AAGTAAAGCCTCATTAATTTGAGTGGGCCAAGATAACTCAAGCAGTGAGATAATGGCCAG 1980 
CP_H1C          AAGTAAAGCCTCATTAATTTGAGTGGGCCAAGATAACTCAAGCAGTGAGATAATGGCCAG 1980 
                ************************************************************ 
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CP_H1B          ACTCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGAAGGCCCAGGCAGGAGGATCCCTT 2040 
CP_H1C          ACACGGTGGCTCACGCCTGTAATCCCAGCACTTTGGAAGGCCCAGGCAGGAGGATCCCTT 2040 
                ** ********************************************************* 
 
CP_H1B          GAGGCCAGGAATTTGAGACCGGCCTGGGCAACATAGCAAGACCCCGTCTCTAAAATAATT 2100 
CP_H1C          GAGGCCAGGAATTTGAGACCGGCCTGGGCAACATAGCAAGACCCCGTCTCTAAAATAATT 2100 
                ************************************************************ 
 
CP_H1B          TAAAAATTAGCCAGGTGTTGTGGTGCATGTCTATAGTCCTAGCTACTCAGGATGCTGAGG 2160 
CP_H1C          TAAAAATTAGCCAGGTGTTGTGGTGCATGTCTATAGTCCTAGCTACTCAGGATGCTGAGG 2160 
                ************************************************************ 
 
CP_H1B          CAGAAGGATCACTTGAGCCCAGGAGTTCAAGGTTGCAGTAAGCTGTGATTATAAAACTGC 2220 
CP_H1C          CAGAAGGATCACTTGAGCCCAGGAGTTCAAGGTTGCAGTAAGCTGTGATTATAAAACTGC 2220 
                ************************************************************ 
 
CP_H1B          ACTCCAGCCTGAGCAACAGAGCAAGACCCTGTCAAAAAAAAAAGAAAAGAAAAAAGAAAG 2280 
CP_H1C          ACTCCAGCCTGAGCAACAGAGCAAGACCCTGTCAAAAAAAAAAGAAAAGAAAAAAGAAAG 2280 
                ************************************************************ 
 
CP_H1B          AAAGAAATTTACCTTGAGTTACCCACATGAGTGAATGTAGGGACAGAGATTTTAGGGCCT 2340 
CP_H1C          AAAGAAATTTACCTTGAGTTACCCACATGAGTGAATGTAGGGACAGAGATTTTAGGGCCT 2340 
                ************************************************************ 
 
CP_H1B          TAACAATCTCTCAAATACAGGGTACTTTTTGAGGCATTAGCCACACCTGTTAGCTTATAA 2400 
CP_H1C          TAACAATCTCTCAAATACAGGGTACTTTTTGAGGCATTAGCCACACCTGTTAGCTTATAA 2400 
                ************************************************************ 
 
CP_H1B          ATCAGTGGTATTGATTAGCATGTAAAATATGTGACTTTAAACATTGCTTTTTATCTCTTA 2460 
CP_H1C          ATCAGTGGTATTGATTAGCATGTAAAATATGTGACTTTAAACATTGCTTTTTATCTCTTA 2460 
                ************************************************************ 
 
CP_H1B          CTTAGATCAGGCCTGAGTGGCCTCTCTTTAGCAAGAGTTGGTTAGCCCTGGGATTCTTAC 2520 
CP_H1C          CTTAGATCAGGCCTGAGTGGCCTCTCTTTAGCAAGAGTTGGTTAGCCCTGGGATTCTTAC 2520 
                ************************************************************ 
 
CP_H1B          TGTAGCCACATTAATAAACAACATCGACTTCTAAACATTCTATAATACCATCTTTTGGCC 2580 
CP_H1C          TGTAGCCACATTAATAAACAACATCGACTTCTAAACATTCTATAATACTATCTTTTGGCC 2580 
                ************************************************ *********** 
 
CP_H1B          AAATTGACTTCGCCTCTTCTCGAGCACAGGGAAGGGACAATTCAGCCCTTCTAGGAGGAG 2640 
CP_H1C          AAATTTACTTCGCCTCTTCTCGAGCACAGGGAAGGGACAATTCAGCCCTTCTAGGAGGAG 2640 
                ***** ****************************************************** 
 
CP_H1B          GAGGAGGTAGTTTTCTCATTTCTATTAAGGCAACAAAAGCTGCCTTACTAAGGACATTCT 2700 
CP_H1C          GAGGAGGTAGTTTTCTCATTTCTATTAAGGCAACAAAAGCTGCCTTACTAAGGACATTCT 2700 
                ************************************************************ 
 
CP_H1B          TGGTGGAGGGCGTGACTGTCAACCACTGTGATCATTTGGGCCTCTCTTGCCCAGGCTTCC 2760 
CP_H1C          TGGTGGAGGGCGTGACTGTCAACCACTGTGATCATTTGGGCCTCTCTTGCCCAGGCTTCC 2760 
                ************************************************************ 
 
CP_H1B          CATTCTGAAAGGACAGTTTTATTGTAGGTACACATGGCTGCCATTTCAAATGTAACTCAC 2820 
CP_H1C          CATTCTGAAAGGACAGTTTTATTGTAGGTACACATGGCTGCCATTTCAAATGTAACTCAC 2820 
                ************************************************************ 
 
CP_H1B          AGCTTGTCCATCAGTCCTTGGAGGTCTTTCTATGAAAGGAGCTTGGTGGCGTCCAAACAC 2880 
CP_H1C          AGCTTGTCCATCAGTCCTTGGAGGTCTTTCTATGAAAGGAGCTTGGTGGCGTCCAAACAC 2880 
                ************************************************************ 
 
CP_H1B          CACCCAATGTCCACTTAGAAGTAAGCACCGTGTCTGCCCTGAGCTGACTCCTTTTCCAAG 2940 
CP_H1C          CACCCAATGTCCACTTAGAAGTAAGCACCGTGTCTGCCCTGAGCTGACTCCTTTTCCAAG 2940 
                ************************************************************ 
 
CP_H1B          GAAGGGGTTGGATCGCTGAGTGTTTTTCCAGGTGTCTACTTGTTGTTAATTAATAGCAAT 3000 
CP_H1C          GAAGGGGTTGGATCGCTGAGTGTTTTTCCAGGTGTCTACTTGTTGTTAATTAATAGCAAT 3000 
                ************************************************************ 
 
CP_H1B          GACAAAGCAGAAGGTTCATGCGTAGCTCGGCTTTCTGGTATTTGCTGCCCGTTGACCAAT 3060 
CP_H1C          GACAAAGCAGAAGGTTCATGCGTAGCTCGGCTTTCTGGTATTTGCTGCCCGTTGACCAAT 3060 
                ************************************************************ 
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CP_H1B          GGAAGATAAACCTTTGCCTCAGGTGGCACCACTAGCTGGTTAAGAGGCACTTTGTCCTTT 3120 
CP_H1C          GGAAGATAAACCTTTGCCTCAGGTGGCACCACTAGCTGGTTAAGAGGCACTTTGTCCTCT 3120 
                ********************************************************** * 
 
CP_H1B          CACCCAGGAGCAAACGCACATCACCTGTGTCCTCATCTGATGGCCCTGGTGTGGGGCACA 3180 
CP_H1C          CACCCAGGAGCAAACGCACATCACCTGTGTCCTCATCTGATGGCCCTGGTGTGGG-CACA 3179 
                ******************************************************* **** 
 
CP_H1B          GTCGTGTTGGCAGGGAGGGAGGTGGGGTTGGTCCCCTTTGTGGGTTTGTTGCGAGGCCGT 3240 
CP_H1C          GTCGTGTTGGCAGGGAGGGAGGTGGGGTTGGTCCCCTTTGTGGGTTTGTTGCGAGGCCGT 3239 
                ************************************************************ 
 
CP_H1B          GTTCCAGCTGTTTCCACAGGGAGCGATTTTCAGCTCCACAGGACACTGCTCCCCAGTTCC 3300 
CP_H1C          GTTCCAGCTGTTTCCACAGGGAGCGATTTTAAGCTCCACAGGACACTGCTCCCCAGTTCC 3299 
                ****************************** ***************************** 
 
CP_H1B          TCCTGAGAACAAAAGGGGGCGCTGGGGAGAGGCCACCGTTCTGAGGGCTCACTGTATGTG 3360 
CP_H1C          TCCTGAGAACAAAAGGGGGCGCTGGGGAGAGGCCACCGTTCTGAGGGCTCACTGTATGTG 3359 
                ************************************************************ 
 
CP_H1B          TTCCAGAATCTCCCCTGCAGACCCCCACTGAGGACGGATCTGAGGAACCGGGCTCTGAAA 3420 
CP_H1C          TTCCAGAATCTCCCCTGCAGACCCCCACTGAGGACGGATCTGAGGAACCGGGCTCTGAAA 3419 
                ************************************************************ 
 
CP_H1B          CCTCTGATGCTAAGAGCACTCCAACAGCGGAAGGTGGGCCCCCCTTCAGACGCCCCCTCC 3480 
CP_H1C          CCTCTGATGCTAAGAGCACTCCAACAGCGGAAGGTGGGCCCCCCTTCAGACGCCCCCTCC 3479 
                ************************************************************ 
 
CP_H1B          ATGCCTCCAGCCTGTGCTTAGCCGTGCTTTGAGCCTCCCTCCTGGCTGCATCTGCTGCTC 3540 
CP_H1C          ATGCCTCCAGCCTGTGCTTAGCCGTGCTTTGAGCCTCCCTCCTGGCTGCATCTGCTGCTC 3539 
                ************************************************************ 
 
CP_H1B          CCCCTGGCTGAGAGATGTGCTCACTCCTTCGGTGCTTTGCAGGACAGCGTGGTGGGAGCT 3600 
CP_H1C          CCCCTGGCTGAGAGATGTGCTCACTCCTTCGGTGCTTTGCAGGACAGCGTGGTGGGAGCT 3599 
                ************************************************************ 
 
CP_H1B          GAGCCTTGCGTCGATGCCTTGCTTGCTGGTGCTGAGTGTGGGCACCTTCATCCCGTGTGT 3660 
CP_H1C          GAGCCTTGCGTCGATGCCTTGCTTGCTGGTGCTGAGTGTGGGCACCTTCATCCCGTGTGT 3659 
                ************************************************************ 
 
CP_H1B          GCTCTGGAGGCAGCCACCCTTGGACAGTCCCGCGCACAGCTCCACAAAGCCCCGCTCCAT 3720 
CP_H1C          GCTCTGGAGGCAGCCACCCTTGGACAGTCCCGCGCACAGCTCCACAAAGCCCCGCTCCAT 3719 
                ************************************************************ 
 
CP_H1B          ACGATTGTCCTCCCACACCCCCTTCAAAGGCCCCCTCCTCTCTCTTTCTTCAGGGGCCAG 3780 
CP_H1C          ACGATTGTCCTCCCACACCCCCTTCAAAAGCCCCCTCCTCTCTCTTTCTTCAGGGGCCAG 3779 
                **************************** ******************************* 
 
CP_H1B          TAGGTCCCAGAGCAGCCATTTGGCTGAGGGAAGGGGCAGGTCAGTGGACATCTGATCTTG 3840 
CP_H1C          TAGGTCCCAGAGCAGCCATTTGGCTGAGGGAAGGGGCAGGTCAGTGGACATCTGATCTTG 3839 
                ************************************************************ 
 
CP_H1B          GTTTAGTATCATTCATTTTGGGGGCTCTGGGTGTGGCCTGGGCCTCTGGACTTTGGCCAC 3900 
CP_H1C          GTTTAGTATCCTTCATTTTGGGGGCTCTGGGTGTGGCCTGGGCCTCTGGACTTTGGCCAC 3899 
                ********** ************************************************* 
 
CP_H1B          GGTGTTTGTTCCAGCCCTTCTCCTAACCTGTCCTTTCCAGACACTCGGCATCTAGGTTAT 3960 
CP_H1C          GGTGTTTGTTCCAGCCCTTCTCCTAACCTGTCCTTTCCAGACACTCGGCATCTAGGTTAT 3959 
                ************************************************************ 
 
CP_H1B          TAGCACCTCGCATACTTTCTGACATGCTCCTCAGTCCTGATTTTGACCATCTTCTCTTGC 4020 
CP_H1C          TAGCACCTCGCATACTTTCCGACATGCTCCTCAGTCCTGATTTTGACCATCTTCTCTTGC 4019 
                ******************* **************************************** 
 
CP_H1B          TTCCCATCTGTGTCAGTCAAGCCGCGGAAAGCCTTCAAAGCTGACAACTCCTTATGTGTA 4080 
CP_H1C          TTCCCATCTGTGTCAGTCAAGCCGCGGAAAGCCTTCAAAGCTGACAACTCCTTATGTGTA 4079 
                ************************************************************ 
 
CP_H1B          CCCGGAAAGGCCTGGGAGTGTGCCAGGGCATTGCTCGGGAGGGACGCTGATTTGGAAGCA 4140 
CP_H1C          CCCGGAAAGGCCTGGGAGTGTGCCAGGGCATTGCTCGGGAGGGACGCTGATTTGGAAGCA 4139 
                ************************************************************ 
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CP_H1B          TTTACCTGATGAGAGACTGACAGCAGCTCCTGGTAGCCGAGCTTTCCCTCCTGCCTCTGC 4200 
CP_H1C          TTTACCTGATGAGAGACTGACAGCAGCTCCTGGTAGCCGAGCTTTCCCTCCTGCCTCTGC 4199 
                ************************************************************ 
 
CP_H1B          TGTGAAGGTGGACCCATCCAACAGTCAAATGCCTGACTCTGGACAGGAGCGGACCTATTT 4260 
CP_H1C          TGTGAAGGTGGACCCATCCAACAGTCAAACGCCTGACTCTGGACAGGAGCGGACCTATTT 4259 
                ***************************** ****************************** 
 
CP_H1B          ATTGCCATGCAAGGGACTCTGCACTTTTGAATTGTGGGTCATGGGCTTGGATTTAGGGGT 4320 
CP_H1C          ATTGCCATGCAAGGGACTCTGCACTTTTGAATTGTGGGTCATGGGCTTGGATTTAGGGGT 4319 
                ************************************************************ 
 
CP_H1B          TAGAGCTGGGAGAAGTCTTGGAAGTCACCTAGAGATGACACTGCCATTTTGCAGATGAGG 4380 
CP_H1C          TAGAGCTGGGAGAAGTCTTGGAAGTCACCTAGAGATGACACTGCCATTTTGCAGATGAGG 4379 
                ************************************************************ 
 
CP_H1B          AAACCGTCCAATAAAAATGGACCAAGGACTTGCCCAAAGCCTCACAGCAAAACCATAGGC 4440 
CP_H1C          AAACCGTCCAATCAAAATGGACCAAGGACTTGCCCAAAGCCTCACAGCAAAACCATAGGC 4439 
                ************ *********************************************** 
 
CP_H1B          CCCCGCACTAACCCCAGAGTCCCTGTGCTGTCTTAAGGATCATATAGTTGTAAGCAATCA 4500 
CP_H1C          CCCCGCACTAACCCCAGAGTCCCTGTGCTGTCTTAAGGATCATATAGTTGTAAGCAATCA 4499 
                ************************************************************ 
 
CP_H1B          TCTGGTTTTCAGTATTTCTTCTTTTAAAATGCCTGGGGCCATGCCCAGCAGTCTGTTTCA 4560 
CP_H1C          TCTGGTTTTCAGTATTTCTTCTTTTAAAATGCCTGGGGCCATGCCCAGCAGTCTGTTTCA 4559 
                ************************************************************ 
 
CP_H1B          CTGCAGCGTTTACACAGGGCTGCCGGGCTTTCCTGGTGGATGAGCTGGGCGGTTCATGAG 4620 
CP_H1C          CTGCAGCGTTTACACAGGGCTGCCGGGCTTTCCTGGTGGATGAGCTGGGCGGTTCATGAG 4619 
                ************************************************************ 
 
CP_H1B          CCAGAACCACTCAGCAGCATGTCAGTGTGCTTCCTGGGGAGCTGGTAGCAGGGGCTCCGG 4680 
CP_H1C          CCAGAACCACTCAGCAGCATGTCAGTGTGCTTCCTGGGGAGCTGGTAGCAGGGGCTCCGG 4679 
                ************************************************************ 
 
CP_H1B          GCCCTACTTCAGGGCTGCTTTCTGGCATATGGCTGATCCCCTCCTCACTCCTCCTCCCTG 4740 
CP_H1C          GCCCTACTTCAGGGCTGCTTTCTGGCATATGGCTGATCCCCTCCTCACTCCTCCTCCCTG 4739 
                ************************************************************ 
 
CP_H1B          CATTGCTCCTGCGCAAGAAGCAAAGGTGAGGGGCTGGGTATGGCTCGTCCTGGCCCCTCT 4800 
CP_H1C          CATTGCTCCTGCGCAAGAAGCAAAGGTGAGGGGCTGGGTATGGCTCGTCCTGGCCCCTCT 4799 
                ************************************************************ 
 
CP_H1B          AAGGTGGATCTCGGTGGTTTCTAGATGTGACAGCACCCTTAGTGGATGAGGGAGCTCCCG 4860 
CP_H1C          AAGGTGGATCTCGGTGGTTTCTAGATGTGACAGCACCCTTAGTGGATGAGGGAGCTCCCG 4859 
                ************************************************************ 
 
CP_H1B          GCAAGCAGGCTGCCGCGCAGCCCCACACGGAGATCCCAGAAGGAACCACAGGTGAGGGTA 4920 
CP_H1C          GCAAGCAGGCTGCCGCGCAGCCCCACACGGAGATCCCAGAAGGAACCACAGGTGAGGGTA 4919 
                ************************************************************ 
 
CP_H1B          AGCCCCAGAGACCCCCAGGCAGTCAAGGCCCTGCTGGGTGCCCCAGCTGACCTGTGACAG 4980 
CP_H1C          AGCCCCAGAGACCCCCAGGCAGTCAAGGCCCTGCTGGGTGCCCCAGCTGACCTGTGACAG 4979 
                ************************************************************ 
 
CP_H1B          AAGTGAGGGAGCTTTGCGTGTTTATCCTCCTGTGGGGCAGGAACATGGGTGGATTCTGGC 5040 
CP_H1C          AAGTGAGGGAGCTTTGCGTGTTTATCCTCCTGTGGGGCAGGAACATGGGTGGATTCTGGC 5039 
                ************************************************************ 
 
CP_H1B          TCCTGGGAATCTTGGGTTGTGAGTAGCTCGATGCCTTGGTGCTCAGTTACCTCCCTGGCT 5100 
CP_H1C          TCCTGGGAATCTTGGGTTGTGAGTAGCTCGATGCCTTGGTGCTCAGTTACCTCCCTGGCT 5099 
                ************************************************************ 
 
CP_H1B          GCCTGCCAGCCTCTCAGAGCATTTAGGGCCTTCTGGACTTCTAGATGCTCCTCATCTTGC 5160 
CP_H1C          GCCTGCCAGCCTCTCAGAGCATTTAGGGCCTTCTGGACTTCTAGATGCTCCTCATCTTGC 5159 
                ************************************************************ 
 
CP_H1B          CTCAGTCAGCGCGTCAGTTCCAGAGACTTCTCTGCAGGGTTTTCTGGGGCAGGTGGTGGC 5220 
CP_H1C          CTCAGTCAGCGCGTCAGTTCCAGAGACTTCTCTGCAGGGTTTTCTGGGGCAGGTGGTGGC 5219 
                ************************************************************ 
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CP_H1B          AGACCCGTGCCTTCTTGACACCTGAGGTCAGTCCACCCTCCTGCTCAGACTGCCCAGCAC 5280 
CP_H1C          AGACCCGTGCCTTCTTGACACCTGAGGTCAGTCCACCCTCCTGCTCAGACTGCCCAGCAC 5279 
                ************************************************************ 
 
CP_H1B          AGGGTCACCTCCCAAGGGGTGGACCCCAAGATCACCTGAGCGCACAGAGGGTGCAGATGA 5340 
CP_H1C          AGGGTCACCTCCCAAGGGGTGGACCCCAAGATCACCTGAGCGCACAGAGGGTGCAGATGA 5339 
                ************************************************************ 
 
CP_H1B          CTGGACCACACCTTTTGGTGATCTTAATGAGGTGGTCCCAGAGGAGCTCAGACATGCAAT 5400 
CP_H1C          CTGGACCACACCTTTTGGTGATCTTAATGAGGTGGTCCCAGAGGAGCTCAGACATGCAAT 5399 
                ************************************************************ 
 
CP_H1B          CTAGCATCCAGTTCTGGGACTCTGTCTCCTTTTCAAACGTATTCATGTAGAACAGGCATG 5460 
CP_H1C          CTAGCATCCAGTTCTGGGACTCTGTCTCCTTTTCAAACGTATTCATGTAGAACAGGCATG 5459 
                ************************************************************ 
 
CP_H1B          ACGAGAATGCCTTGTCAACATGGGTGATGGGGAATCAATCAGACAGGGCGCATGCCCCGT 5520 
CP_H1C          ACGAGAATGCCTTGTCAACATGGGTGATGGGGAATCAATCAGACAGGGCGCATGCCCCGT 5519 
                ************************************************************ 
 
CP_H1B          GAGCCCATTGCCCGCCCTCCCATGCCCTCAGCAGCTGCCTGGGGACAGCCAATGGCCTGG 5580 
CP_H1C          GAGCCCATTGCCCGCCCTCCCATGCCCTCAGCAGCTGCCTGGGGACAGCCAATGGCCTGG 5579 
                ************************************************************ 
 
CP_H1B          GTGTTTCTGAGGCTACCACATGGCTTCCAGGAAACTCGAGAACCTTTCTCTCCCTTGCCT 5640 
CP_H1C          GTGTTTCTGAGGCTACCACATGGCTTCCAGGAAACTCGAGAACCTTTCTCTCCCTTGCCT 5639 
                ************************************************************ 
 
CP_H1B          ACACTCTTCACACAGGCCTGTGCTGGCCAGCGGTGGGGATCCGGCATTCCTATCTTAGGT 5700 
CP_H1C          ACACTCTTCACACAGGCCTGTGCTGGCCAGCGGTGGGGATCCGGCATTCCTATCTTAGGT 5699 
                ************************************************************ 
 
CP_H1B          GCAGAAAGTGACTGACTCATTGCAGGCCTGGGAGATAAGACTGATGGCCCAGCCAGCAAG 5760 
CP_H1C          GCAGAGAGTGACTGACTCATTGCAGGCCTGGGAGATAAGACTGATGGCCCAGCCAGCAAG 5759 
                ***** ****************************************************** 
 
CP_H1B          ATGTATGGATTTCTCAGAGGCAGTGGCCTCTGTCATTGTCCTCAGGAAATGCTGGTGATT 5820 
CP_H1C          ATGTATGGATTTCTCAGAGGCAGTGGCCTCTGTCATTGTCCTCAGGAAATGCTGGTGATT 5819 
                ************************************************************ 
 
CP_H1B          CTGGTGGCCTGAGGTCAATGCATGTCAACGTGGCCAACTTGCCTTATAAACTTTTTTTCT 5880 
CP_H1C          CTGGTGGCCTGAGGTCAATGCATGTCAACGTGGCCAACTTGCCTTATAAACTTTTTTTCT 5879 
                ************************************************************ 
 
CP_H1B          GGACAATTGCGTGCACTGTCCTGTAACAGTGTCCTGTTGTTTATGATGCAGAAATAGGTG 5940 
CP_H1C          GGACAATTGCGTGCACTGTCCTGTAACAGTGTCCTGTTGTTTATGATGCAGAAATAGGTG 5939 
                ************************************************************ 
 
CP_H1B          TTTTTAAAGCCTATTGATTTTGGTACTATTAATGTGGTCAGGAACTTTCTCAGTCTTTCT 6000 
CP_H1C          TTTTTAAAGCCTATTGATTTTGGTACTATTAATGTGGTCAGGAACTTTCTCAGTCTTTCT 5999 
                ************************************************************ 
 
CP_H1B          TGTTTGGGGTGAGCTGTGGCTTCCTAAACAGGAACCCAAGACACCCCCAAAAGCTGCTCA 6060 
CP_H1C          TGTTTGGGGTGAGCTGTGGCTTCCTAAACAGGAACCCAAGACACCCCCAAAAGCTGCTCA 6059 
                ************************************************************ 
 
CP_H1B          CCAGCACTGCCAGCCTCCCTCTTACCAAGTAGCACCCGTTCAGGACATTCTGCGAAAGGC 6120 
CP_H1C          CCAGCACTGCCAGCCTCCCTCTTACCAAGTAGCACCCGTTCAGGACATTCTGCGAAAGGC 6119 
                ************************************************************ 
 
CP_H1B          ATTTGCCCAGAAGTTGGGAGGAAGGAAATGTAACATTTTGGGGCACCTACCATATGCCAG 6180 
CP_H1C          ATTTGCCCAGAAGTTGGGAGGAAGGAAATGTAACATTTTGGGGCACCTACCATATGCCAG 6179 
                ************************************************************ 
 
CP_H1B          GCACCAGGCTAAACGTGTTCACACAAATTCTCTTACTAACCCTCACCATCCTTCTACAAG 6240 
CP_H1C          GCACCAGGCTAAACGTGTTCACACAAATTCTCTTACTAACCCTCACCATCCTTCTACAAG 6239 
                ************************************************************ 
 
CP_H1B          ACAAACTAGTATCTTCATCTTGGGGTTCAAGATGAGGAAATGGAGGCTCAGAGAGGTTGA 6300 
CP_H1C          ACAAACTAGTATCTTCATCTTGGGGTTCAAGATGAGGAAATGGAGGCTCAGAGAGGTTGA 6299 
                ************************************************************ 
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CP_H1B          ATGAATGCCGGTGCCTGGATATGAACCCCATCTGCCTGACTCCGCAACCCAGGCAAAGTC 6360 
CP_H1C          ATGAATGCCGGTGCCTGGATATGAACCCCATCTGCCTGACTCCGCAACCCAGGCAAAGTC 6359 
                ************************************************************ 
 
CP_H1B          TTTCCTTGAACTTCCCAGCAGCCACTGCTTAGACACAGCCTCCACAACCATGGCTCAGCA 6420 
CP_H1C          TTTCCTTGAACTTCCCAGCAGCCACTGCTTAGACACAGCCTCCACAACCATGGCTCAGCA 6419 
                ************************************************************ 
 
CP_H1B          GCAAATTGCTTCTCTGACCTCACTCAGCCTGTGTGTCCTTGTTGAGTGAGGCATTCAGGA 6480 
CP_H1C          GCAAATTGCTTCTCTGACCTCACTCAGCCTGTGTGTCCTTGTTGAGTGAGGCATTCAGGA 6479 
                ************************************************************ 
 
CP_H1B          CCCTGGTCCCAAAGTGGAGAAAGTCTTTCCTACTAGGTCATAGCTACACCTGCATGTGGG 6540 
CP_H1C          CCCTGGTCCCAAAGTGGAGAAAGTCTTTCCTACTAGGTCATAGCTACACCTGCATGTGGG 6539 
                ************************************************************ 
 
CP_H1B          TGCTGTGCCTTTTGTTTAGTGAACTTTTATCACCAGCATCCTCAGCAATGACATTTGCAG 6600 
CP_H1C          TGCTGTGCCTTTTGTTTAGTGAACTTTTATCACCAGCATCCTCAGCAATGACATTTGCAG 6599 
                ************************************************************ 
 
CP_H1B          AGAAGCCAGAGCTGAGGCACCTTGGTATTCTTGGGATGTGACTTTCCTGAATGTTTAAGG 6660 
CP_H1C          AGAAGCCAGAGCTGAGGCACCTTGGTATTCTTGGGATGTGACTTTCCTGAATGTTTAAGG 6659 
                ************************************************************ 
 
CP_H1B          GAAAATGCCCGAAGGTACAGAGAGCTTGGTTTCTAGTAAACAATAACTGTCTTGCTTTTA 6720 
CP_H1C          GAAAATGCCCGAAGGTACAGAGAGCTTGGTTTCTAGTAAACAATAACTGTCTTGCTTTTA 6719 
                ************************************************************ 
 
CP_H1B          CCCCCCTTCATTTGCTGACACATACACCAGCACCCAACTTTTCTATACAAAGTTGTCCAG 6780 
CP_H1C          CCCCCCTTCATTTGCTGACACATACACCAGCACC-AACTTTTCTATACAAAGTTGTCCAG 6778 
                ********************************** ************************* 
 
CP_H1B          CTGAAGAAGCAGGCATTGGAGACACCCCCAGCCTGGAAGACGAAGCTGCTGGTCACGTGA 6840 
CP_H1C          CTGAAGAAGCAGGCATTGGAGACACCCCCAGCCTGGAAGACGAAGCTGCTGGTCACGTGA 6838 
                ************************************************************ 
 
CP_H1B          CCCAAGCTCGCATGGTCAGTAAAAGCAAAGACGGGACTGGAAGCGATGACAAAAAAGCCA 6900 
CP_H1C          CCCAAGCTCGCATGGTCAGTAAAAGCAAAGACGGGACTGGAAGCGATGACAAAAAAGCCA 6898 
                ************************************************************ 
 
CP_H1B          AGGGGGCTGATGGTAAAACGAAGATCGCCACACCGCGGGGAGCAGCCCCTCCAGGCCAGA 6960 
CP_H1C          AGGGGGCTGATGGTAAAACGAAGATCGCCACACCGCGGGGAGCAGCCCCTCCAGGCCAGA 6958 
                ************************************************************ 
 
CP_H1B          AGGGCCAGGCCAACGCCACCAGGATTCCAGCAAAAACCCCGCCCGCTCCAAAGACACCAC 7020 
CP_H1C          AGGGCCAGGCCAACGCCACCAGGATTCCAGCAAAAACCCCGCCCGCTCCAAAGACACCAC 7018 
                ************************************************************ 
 
CP_H1B          CCAGCTCTGGTGAACCTCCAAAATCAGGGGATCGCAGCGGCTACAGCAGCCCCGGCTCCC 7080 
CP_H1C          CCAGCTCTGGTGAACCTCCAAAATCAGGGGATCGCAGCGGCTACAGCAGCCCCGGCTCCC 7078 
                ************************************************************ 
 
CP_H1B          CAGGCACTCCCGGCAGCCGCTCCCGCACCCCGTCCCTTCCAACCCCACCCACCCGGGAGC 7140 
CP_H1C          CAGGCACTCCCGGCAGCCGCTCCCGCACCCCGTCCCTTCCAACCCCACCCACCCGGGAGC 7138 
                ************************************************************ 
 
CP_H1B          CCAAGAAGGTGGCAGTGGTCCGTACTCCACCCAAGTCGCCGTCTTCCGCCAAGAGCCGCC 7200 
CP_H1C          CCAAGAAGGTGGCAGTGGTCCGTACTCCACCCAAGTCGCCGTCTTCCGCCAAGAGCCGCC 7198 
                ************************************************************ 
 
CP_H1B          TGCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAATGTCAAGTCCAAGATCGGCTCCA 7260 
CP_H1C          TGCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAATGTCAAGTCCAAGATCGGCTCCA 7258 
                ************************************************************ 
 
CP_H1B          CTGAGAACCTGAAGCACCAGCCGGGAGGCGGGAAGTCTAGAGTGAGAGTGGCTGGCTGCG 7320 
CP_H1C          CTGAGAACCTGAAGCACCAGCCGGGAGGCGGGAAGTCTAGAGTGAGAGTGGCTGGCTGCG 7318 
                ************************************************************ 
 
CP_H1B          CGTGGAGGTGTGGGGGGCTGCGCCTGGAGGGGTAGGGCTGTGCCTGGAAGGGTAGGGCTG 7380 
CP_H1C          CGTGGAGGTGTGGGGGGCTGCGCCTGGAGGGGTAGGGCTGTGCCTGGAAGGGTAGGGCTG 7378 
                ************************************************************ 
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CP_H1B          CGCCTGGAGGTGCGCGGTTGAGCGTGGAGTCGTGGGACTGTGCATGGAGGTGTGGGGCTC 7440 
CP_H1C          CGCCTGGAGGTGCGCGGTTGAGCGTGGAGTCGTGGGACTGTGCATGGAGGTGTGGGGCTC 7438 
                ************************************************************ 
 
CP_H1B          CCCGCACCTGAGCACCCCCGCATAACACCCCAGTCCCCTCTGGACCCTCTTCAAGGAAGT 7500 
CP_H1C          CCCGCACCTGAGCACCCCCGCATAACACCCCAGTCCCCTCTGGACCCTCTTCAAGGAAGT 7498 
                ************************************************************ 
 
CP_H1B          TCAGTTCTTTATTGGGCTCTCCACTACACTGTGAGTGCCCTCCTCAGGCGAGAGAACGTT 7560 
CP_H1C          TCAGTTCTTTATTGGGCTCTCCACTACACTGTGAGTGCCCTCCTCAGGCGAGAGAACGTT 7558 
                ************************************************************ 
 
CP_H1B          CTGGCTCTTCTCTTGCCCCTTCAGCCCCTGTTAATCGGACAGAGATGGCAGGGCTGTGTC 7620 
CP_H1C          CTGGCTCTTCTCTTGCCCCTTCAGCCCCTGTTAATCGGACAGAGATGGCAGGGCTGTGTC 7618 
                ************************************************************ 
 
CP_H1B          TCCACGGCCGGAGGCTCTCATAGTCAGGGCACCCACAGCGGTTCCCCACCTGCCTTCTGG 7680 
CP_H1C          TCCACGGCCGGAGGCTCTCATAGTCAGGGCACCCACAGCGGTTCCCCACCTGCCTTCTGG 7678 
                ************************************************************ 
 
CP_H1B          GCAGAATACACTGCCACCCATAGGTCAGCATCTCCACTCGTGGGCCATCTGCTTAGGTTG 7740 
CP_H1C          GCAGAATACACTGCCACCCATAGGTCAGCATCTCCACTCGTGGGCCATCTGCTTAGGTTG 7738 
                ************************************************************ 
 
CP_H1B          GGTTCCTCTGGATTCTGGGGAGATTGGGGGTTCTGTTTTGATCAGCTGATTCTTCTGGGA 7800 
CP_H1C          GGTTCCTCTGGATTCTGGGGAGATTGGGGGTTCTGTTTTGATCAGCTGATTCTTCTGGGA 7798 
                ************************************************************ 
 
CP_H1B          GCAAGTGGGTGCTCGCGAGCTCTCCAGCTTCCTAAAGGTGGAGAAGCACAGACTTCGGGG 7860 
CP_H1C          GCAAGTGGGTGCTCGCGAGCTCTCCAGCTTCCTAAAGGTGGAGAAGCACAGACTTCGGGG 7858 
                ************************************************************ 
 
CP_H1B          GCCTGGCCTGGATCCCTTTCCCCATTCCTGTCCCTGTGCCCCTCGTCTGGGTGCGTTACC 7920 
CP_H1C          GCCTGGCCTGGATCCCTTTCCCCATTCCTGTCCCTGTGCCCCTCGTCTGGGTGCGTTACC 7918 
                ************************************************************ 
 
CP_H1B          ATGGTTTTCTATTTCATAGTTCTTAGGCAAATTGGTAAAAATCATTTCTCATCAAAACGC 7980 
CP_H1C          ATGGTTTTCTATTTCATAGTTCTTAGGCAAATTGGTAAAAATCATTTCTCATCAAAACGC 7978 
                ************************************************************ 
 
CP_H1B          TGATATTTTCACACCTCCCTGGTGTCTGCAGAAAGAACCTTCCAGAAATGCAGTCGTGGG 8040 
CP_H1C          TGATATTTTCACACCTCCCTGGTGTCTGCAGAAAGAACCTTCCAGAAATGCAGTCGTGGG 8038 
                ************************************************************ 
 
CP_H1B          AGACCCATCCAGGCCACCCCTGCTTATGGAAGAGCTGAGAAAAAGCCCCACGGGGGCATT 8100 
CP_H1C          AGACCCATCCAGGCCACCCCTGCTTATGGAAGAGCTGAGAAAAAGCCCCACGGGAGCATT 8098 
                ****************************************************** ***** 
 
CP_H1B          TGCTCAGCTTCCGTTACGCACCTAGTGGCATTGTGGGTGGGAGAGGGCTGGTGGGTGGAT 8160 
CP_H1C          TGCTCAGCTTCCGTTACGCACCTAGTGGCATTGTGGGTGGGAGAGGGCTGGTGGGTGGAT 8158 
                ************************************************************ 
 
CP_H1B          GGAAGGAGAAGGCACAGCCCCCCCTTGCAGGGACAGAGCCCTCGTACAGAAGGGACACCC 8220 
CP_H1C          GGAAGGAGAAGGCACAGCCCCCCCTTGCAGGGACAGAGCCCTCGTACAGAAGGGACACCC 8218 
                ************************************************************ 
 
CP_H1B          CACATTTGTCTTCCCCACAAAGCGGCCTGTGTCCTGCCTACGGGGTCAGGGCTTCTCAAA 8280 
CP_H1C          CACATTTGTCTTCCCCACAAAGCGGCCTGTGTCCTGCCTACGGGGTCAGGGCTTCTCAAA 8278 
                ************************************************************ 
 
CP_H1B          CCTGGCTGTGTGTCAGAATCACCAGGGGAACTTTTCAAAACTAGAGAGACTGAAGCCAGA 8340 
CP_H1C          CCTGGCTGTGTGTCAGAATCACCAGGGGAACTTTTCAAAACTAGAGAGACTGAAGCCAGA 8338 
                ************************************************************ 
 
CP_H1B          CTCCTAGATTCTAATTCTAGGTCAGGGCTAGGGGCTGAGATTGTAAAAATCCACAGGTGA 8400 
CP_H1C          CTCCTAGATTCTAATTCTAGGTCAGGGCTAGGGGCTGAGATTGTAAAAATCCACAGGTGA 8398 
                ************************************************************ 
 
CP_H1B          TTCTGATGCCCGGCAGGCTTGAGAACAGCCGCAGGGAGTTCTCTGGGAATGTGCCGGTGG 8460 
CP_H1C          TTCTGATGCCCGGCAGGCTTGAGAACAGCCGCAGGGAGTTCTCTGGGAATGTGCCGGTGG 8458 
                ************************************************************ 
 
 
 
Appendices 
294 
 
CP_H1B          GTCTAGCCAGGTGTGAGTGGAGATGCCGGGGAACTTCCTATTACTCACTCGTCAGTGTGG 8520 
CP_H1C          GTCTAGCCAGGTGTGAGTGGAGATGCCGGGGAACTTCCTATTACTCACTCGTCAGTGTGG 8518 
                ************************************************************ 
 
CP_H1B          CCGAACTCATTTTTCACTTGACCTCAGGCTGGTGAACGCTCCCCTCTGGGGTTCAGGCCT 8580 
CP_H1C          CCGAACACATTTTTCACTTGACCTCAGGCTGGTGAACGCTCCCCTCTGGGGTTCAGGCCT 8578 
                ****** ***************************************************** 
 
CP_H1B          CACGATGCCATCCTTTTGTGAAGTGAGGACCTGCAATCCCAGCTTCGTAAAGCCCGCTGG 8640 
CP_H1C          CACGATGCCATCCTTTTGTGAAGTGAGGACCTGCAATCCCAGCTTCGTAAAGCCCGCTGG 8638 
                ************************************************************ 
 
CP_H1B          AAATCACTCACACTTCTGGGATGCCTTCAGAGCAGCCCTCTATCCCTTCAGCTCCCCTGG 8700 
CP_H1C          AAATCACTCACACTTCTGGGATGCCTTCAGAGCAGCCCTCTATCCCTTCAGCTCCCCTGG 8698 
                ************************************************************ 
 
CP_H1B          GATGTGACTCAACCTCCCGTCACTCCCCAGACTGCCTCTGCCAAGTCCGAAAGTGGAGGC 8760 
CP_H1C          GATGTGACTCAACCTCCCGTCACTCCCCAGACTGCCTCTGCCAAGTCCGAAAGTGGAGGC 8758 
                ************************************************************ 
 
CP_H1B          ATCCTTGCGAGCAAGTAGGCGGGTCCAGGGTGGCGCATGTCACTCATCGAAAGTGGAGGC 8820 
CP_H1C          ATCCTTGCGAGCAAGTAGGCGGGTCCAGGGTGGCGCATGTCACTCATCGAAAGTGGAGGC 8818 
                ************************************************************ 
 
CP_H1B          GTCCTTGCGAGCAAGCAGGCGGGTCCAGGGTGGCGTGTCACTCATCCTTTTTTCTGGCTA 8880 
CP_H1C          GTCCTTGCGAGCAAGCAGGCGGGTCCAGGGTGGCGTGTCACTCATCCTTTTTTCTGGCTA 8878 
                ************************************************************ 
 
CP_H1B          CCAAAGGTGCAGATAATTAATAAGAAGCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGC 8940 
CP_H1C          CCAAAGGTGCAGATAATTAATAAGAAGCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGC 8938 
                ************************************************************ 
 
CP_H1B          TCAAAGGATAATATCAAACACGTCCCGGGAGGCGGCAGTGTGAGTACCTTCACACGTCCC 9000 
CP_H1C          TCAAAGGATAATATCAAACACGTCCCGGGAGGCGGCAGTGTGAGTACCTTCACACGTCCC 8998 
                ************************************************************ 
 
CP_H1B          ATGCGCCGTGCTGTGGCTTGAATTATTAGGAAGTGGTGTGAGTGCGTACACTTGCGAGAC 9060 
CP_H1C          ATGCGCCGTGCTGTGGCTTGAATTATTAGGAAGTGGTGTGAGTGCGTACACTTGCGAGAC 9058 
                ************************************************************ 
 
CP_H1B          ACTGCATAGAATAAATCCTTCTTGGGCTCTCAGGATCTGGCTGCGACCTCTGGGTGAATG 9120 
CP_H1C          ACTGCATAGAATAAATCCTTCTTGGGCTCTCAGGATCTGGCTGCGACCTCTGGGTGAATG 9118 
                ************************************************************ 
 
CP_H1B          TAGCCCGGCTCCCCACATTCCCCCACACGGTCCACTGTTCCCAGAAGCCCCTTCCTCATA 9180 
CP_H1C          TAGCCCGGCTCCCCACATTCCCCCACACGGTCCACTGTTCCCAGAAGCCCCTTCCTCATA 9178 
                ************************************************************ 
 
CP_H1B          TTCTAGGAGGGGGTGTCCCAGCATTTCTGGGTCCCCCAGCCTGCGCAGGCTGTGTGGACA 9240 
CP_H1C          TTCTAGGAGGGGGTGTCCCAGCATTTCTGGGTCCCCCAGCCTGCGCAGGCTGTGTGGACA 9238 
                ************************************************************ 
 
CP_H1B          GAATAGGGCAGATGACGGACCCTCTCTCCGGACCCTGCCTGGGAAGCTGAGAATACCCAT 9300 
CP_H1C          GAATAGGGCAGATGACGGACCCTCTCTCCGGACCCTGCCTGGGAAGCTGAGAATACCCAT 9298 
                ************************************************************ 
 
CP_H1B          CAAAGTCTCCTTCCACTCATGCCCAGCCCTGTCCCCAGGAGCCCCATAGCCCATTGGAAG 9360 
CP_H1C          CAAAGTCTCCTTCCACTCATGCCCAGCCCTGTCCCCAGGAGCCCCATAGCCCATTGGAAG 9358 
                ************************************************************ 
 
CP_H1B          TTGGGCTGAAGGTGGTGGCACCTGAGACTGGGCTGCCGCCTCCTCCCCCGACACCTGGGC 9420 
CP_H1C          TTGGGCTGAAGGTGGTGGCACCTGAGACTGGGCTGCCGCCTCCTCCCCCGACACCTGGGC 9418 
                ************************************************************ 
 
CP_H1B          AGGTTGACGTTGAGTGGCTCCACTGTGGACAGGTGACCCGTTTGTTCTGATGAGCGGACA 9480 
CP_H1C          AGGTTGACGTTGAGTGGCTCCACTGTGGACAGGTGACCCGTTTGTTCTGATGAGCGGACA 9478 
                ************************************************************ 
 
CP_H1B          CCAAGGTCTTACTGTCCTGCTCAGCTGCTGCTCCTACACGTTCAAGGCAGGAGCCGATTC 9540 
CP_H1C          CCAAGGTCTTACTGTCCTGCTCAGCTGCTGCTCCTACACGTTCAAGGCAGGAGCCGATTC 9538 
                ************************************************************ 
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CP_H1B          CTAAGCCTCCAGCTTATGCTTAGCCTGCGCCACCCTCTGGCAGAGACTCCAGATGCAAAG 9600 
CP_H1C          CTAAGCCTCCAGCTTATGCTTAGCCTGCGCCACCCTCTGGCAGAGACTCCAGATGCAAAG 9598 
                ************************************************************ 
 
CP_H1B          AGCCAAACCAAAGTGGCATGCCTCGAGCTTACTGAGACACTAAATCTGTTGGTTTCTGCT 9660 
CP_H1C          AGCCAAACCAAAATGGCATGCCTCGAGCTTACTGAGACACTAAATCTGTTGGTTTCTGCT 9658 
                ************ *********************************************** 
 
CP_H1B          GTGCCACCTACCCACCCTGTTGGTGTTGCTTTGTTCCTATTGCTAAAGACAGGAATGTCC 9720 
CP_H1C          GTGCCACCTACCCACCCTGTTGGTGTTGCTTTGTTCCTATTGCTAAAGACAGGAATGTCC 9718 
                ************************************************************ 
 
CP_H1B          AGGACACTGAGTGTGCAGGTGCCTGCTGGTTCTCACGTCCGAGCTGCTGAACTCCGCTGG 9780 
CP_H1C          AGGACACTGAGTGTGCAGGTGCCTGCTGGTTCTCACGTCCGAGCTGCTGAACTCCGCTGG 9778 
                ************************************************************ 
 
CP_H1B          GTCCTGCTTACTGATGGTCTTTGCTCTAGTGCTTTCCAGGGTCCGTGGAAGCTTTTCCTG 9840 
CP_H1C          GTCCTGCTTACTGATGGTCTTTGCTCTAGTGCTTTCCAGGGTCCGTGGAAGCTTTTCCTG 9838 
                ************************************************************ 
 
CP_H1B          GAATAAAGCCCACGCATCGACCCTCACAGCGCCTCCCCTCTTTGAGGCCCAGCAGATACC 9900 
CP_H1C          GAATAAAGCCCACGCATCGACCCTCACAGCGCCTCCCCTCTTTGAGGCCCAGCAGATACC 9898 
                ************************************************************ 
 
CP_H1B          CCACTCCTGCCTTTCCAGCAAGATTTTTCAGATGCTGTGCATACTCATCATATTGATCAC 9960 
CP_H1C          CCACTCCTGCCTTTCCAGCAAGATTTTTCAGATGCTGTGCATACTCATCATATTGATCAC 9958 
                ************************************************************ 
 
CP_H1B          TTTTTTCTTCATGCCTGATTGTGATCTGTCAATTTCATGTCAGGAAAGGGAGTGACATTT 10020 
CP_H1C          TTTTTTCTTCATGCCTGATTGTGATCTGTCAATTTCATGTCAGGAAAGGGAGTGACATTT 10018 
                ************************************************************ 
 
CP_H1B          TTACACTTAAGCGTTTGCTGAGCAAATGTCTGGGTCTTGCACAATGACAATGGGTCTCTG 10080 
CP_H1C          TTACACTTAAGCGTTTGCTGAGCAAATGTCTGGGTCTTGCACAATGACAATGGGTCCCTG 10078 
                ******************************************************** *** 
 
CP_H1B          TTTTTCCCAGAGGCTCTTTTGTTCTGCAGGGATTGAAGACACTCCAGTCCCACAGTCCCC 10140 
CP_H1C          TTTTTCCCAGAGGCTCTTTTGTTCTGCAGGGATTGAAGACACTCCAGTCCCACAGTCCCC 10138 
                ************************************************************ 
 
CP_H1B          AGCTCCCCTGGGGCAGGGTTGGCAGAATTTCGACAACACATTTTTCCACCCTGACTAGGA 10200 
CP_H1C          AGCTCCCCTGGGGCAGGGTTGGCAGAATTTCGACAACACATTTTTCCACCCTGACTAGGA 10198 
                ************************************************************ 
 
CP_H1B          TGTGCTCCTCATGGCAGCTGGGAACCACTGTCCAATAAGGGCCTGGGCTTACACAGCTGC 10260 
CP_H1C          TGTGCTCCTCATGGCAGCTGGGAACCACTGTCCAATAAGGGCCTGGGCTTACACAGCTGC 10258 
                ************************************************************ 
 
CP_H1B          TTCTCATTGAGTTACACCCTTAATAAAATAATCCCATTTTATCCTTTTTGTCTCTCTGTC 10320 
CP_H1C          TTCTCATTGAGTTACACCCTTAATAAAATAATCCCATTTTATCCTTTTTGTCTCTCTGTC 10318 
                ************************************************************ 
 
CP_H1B          TTCCTCTCTCTCTGCCTTTCCTCTTCTCTCTCCTCCTCTCTCATCTCCAGGTGCAAATAG 10380 
CP_H1C          TTCCTCTCTCTCTGCCTTTCCTCTTCTCTCTCCTCCTCTCTCATCTCCAGGTGCAAATAG 10378 
                ************************************************************ 
 
CP_H1B          TCTACAAACCAGTTGACCTGAGCAAGGTGACCTCCAAGTGTGGCTCATTAGGCAACATCC 10440 
CP_H1C          TCTACAAACCAGTTGACCTGAGCAAGGTGACCTCCAAGTGTGGCTCATTAGGCAACATCC 10438 
                ************************************************************ 
 
CP_H1B          ATCATAAACCAGGACGTCGAGGTGGCCAGGTGGAAGTAAAATCTGAGAAGCTTGACTTCA 10500 
CP_H1C          ATCATAAACCAGGACGTCGAGGTGGCCAGGTGGAAGTAAAATCTGAGAAGCTTGACTTCA 10498 
                ************************************************************ 
 
CP_H1B          AGGACAGAGTCCAGTCGAAGATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAG 10560 
CP_H1C          AGGACAGAGTCCAGTCGAAGATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAG 10558 
                ************************************************************ 
 
CP_H1B          GAAATAAAAAGATTGAAACCCACAAGCTGACCTTCCGCGAGAACGCCAAAGCCAAGACAG 10620 
CP_H1C          GAAATAAAAAGATTGAAACCCACAAGCTGACCTTCCGCGAGAACGCCAAAGCCAAGACAG 10618 
                ************************************************************ 
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CP_H1B          ACCACGGGGCGGAGATCGTGTACAAGTCGCCAGTGGTGTCTGGGGACACGTCTCCACGGC 10680 
CP_H1C          ACCACGGGGCGGAGATCGTGTACAAGTCGCCAGTGGTGTCTGGGGACACGTCTCCACGGC 10678 
                ************************************************************ 
 
CP_H1B          ATCTCAGCAATGTCTCCTCCACCGGCAGCATCGACATGGTAGACTCGCCCCAGCTCGCCA 10740 
CP_H1C          ATCTCAGCAATGTCTCCTCCACCGGCAGCATCGACATGGTAGACTCGCCCCAGCTCGCCA 10738 
                ************************************************************ 
 
CP_H1B          CGCTAGCTGACGAGGTGTCTGCCTCCCTGGCCAAGCAGGGTTTGGATTACAAGGATGACG 10800 
CP_H1C          CGCTAGCTGACGAGGTGTCTGCCTCCCTGGCCAAGCAGGGTTTGGATTACAAGGATGACG 10798 
                ************************************************************ 
 
CP_H1B          ACGATAAGTAAACAACTTTGTATAATAAAGTTGTCCCTGGGGCGGTCAATAATTGTGGAG 10860 
CP_H1C          ACGATAAGTAA----CTTTGTATAATAAAGTTGTCCCTGGGGCGGTCAATAATTGTGGAG 10854 
                ***********    ********************************************* 
 
CP_H1B          AGGAGAGAATGAGAGAGTGTGGAAAAAAAAAGAATAATGACCCGGCCCCCGCCCTCTGCC 10920 
CP_H1C          AGGAGAGAATGAGAGAGTGTGGAAAAAAAAAGAATAATGACCCGGCCCCCGCCCTCTGCC 10914 
                ************************************************************ 
 
CP_H1B          CCCAGCTGCTCCTCGCAGTTCGGTTAATTGGTTAATCACTTAACCTGCTTTTGTCACTCG 10980 
CP_H1C          CCCAGCTGCTCCTCGCAGTTCGGTTAATTGGTTAATCACTTAACCTGCTTTTGTCACTCG 10974 
                ************************************************************ 
 
CP_H1B          GCTTTGGCTCGGGACTTCAAAATCAGTGATGGGAGTAAGAGCAAATTTCATCTTTCCAAA 11040 
CP_H1C          GCTTTGGCTCGGGACTTCAAAATCAGTGATGGGAGTAAGAGCAAATTTCATCTTTCCAAA 11034 
                ************************************************************ 
 
CP_H1B          TTGATGGGTGGGCTAGTAATAAAATATTTAAAAAAAAACATTCAAAAACATGGCCACATC 11100 
CP_H1C          TTGATGGGTGGGCTAGTAATAAAATATTTAAAAAAAAACATTCAAAAACATGGCCACATC 11094 
                ************************************************************ 
 
CP_H1B          CAACATTTCCTCAGGCAATTCCTTTTGATTCTTTTTTCTTCCCCCTCCATGTAGAAGAGG 11160 
CP_H1C          CAACATTTCCTCAGGCAATTCCTTTTGATTCTTTTTTCTTCCCCCTCCATGTAGAAGAGG 11154 
                ************************************************************ 
 
CP_H1B          GAGAAGGAGAGGCTCTGAAAGCTGCTTCTGGGGGATTTCAAGGGACTGGGGGTGCCAACC 11220 
CP_H1C          GAGAAGGAGAGGCTCTGAAAGCTGCTTCTGGGGGATTTCAAGGGACTGGGGGTGCCAACC 11214 
                ************************************************************ 
 
CP_H1B          ACCTCTGGCCCTGTTGTGGGGGTGTCACAGAGGCAGTGGCAGCAACAAAGGATTTGAAAC 11280 
CP_H1C          ACCTCTGGCCCTGTTGTGGGGGTGTCACAGAGGCAGTGGCAGCAACAAAGGATTTGAAAC 11274 
                ************************************************************ 
 
CP_H1B          TTGGTGTGTTCGTGGAGCCACAGGCAGACGATGTCAACCTTGTGTGAGTGTGACGGGGGT 11340 
CP_H1C          TTGGTGTGTTCGTGGAGCCACAGGCAGACGATGTCAACCTTGTGTGAGTGTGACGGGGGT 11334 
                ************************************************************ 
 
CP_H1B          TGGGGTGGGGCGGGAGGCCACGGGGGAGGCCGAGGCAGGGGCTGGGCAGAGGGGAGAGGA 11400 
CP_H1C          TGGGGTGGGGCGGGAGGCCACGGGGGAGGCCGAGGCAGGGGCTGGGCAGAGGGGAGAGGA 11394 
                ************************************************************ 
 
CP_H1B          AGCACAAGAAGTGGGAGTGGGAGAGGAAGCCACGTGCTGGAGAGTAGACATCCCCCTCCT 11460 
CP_H1C          AGCACAAGAAGTGGGAGTGGGAGAGGAAGCCACGTGCTGGAGAGTAGACATCCCCCTCCT 11454 
                ************************************************************ 
 
CP_H1B          TGCCGCTGGGAGAGCCAAGGCCTATGCCACCTGCAGCGTCTGAGCGGCCGCCTGTCCTTG 11520 
CP_H1C          TGCCGCTGGGAGAGCCAAGGCCTATGCCACCTGCAGCGTCTGAGCGGCCGCCTGTCCTTG 11514 
                ************************************************************ 
 
CP_H1B          GTGGCCGGGGGTGGGGGCCTGCTGTGGGTCAGTGTGCCACCCTCTGCAGGGCAGCCTGTG 11580 
CP_H1C          GTGGCCGGGGGTGGGGGCCTGCTGTGGGTCAGTGTGCCACCCTCTGCAGGGCAGCCTGTG 11574 
                ************************************************************ 
 
CP_H1B          GGAGAAGGGACAGCGGGTAAAAAGAGAAGGCAAGCTGGCAGGAGGGTGGCACTTCGTGGA 11640 
CP_H1C          GGAGAAGGGACAGCGGGTAAAAAGAGAAGGCAAGCTGGCAGGAGGGTGGCACTTCGTGGA 11634 
                ************************************************************ 
 
CP_H1B          TGACCTCCTTAGAAAAGACTGACCTTGATGTCTTGAGAGCGCTGGCCTCTTCCTCCCTCC 11700 
CP_H1C          TGACCTCCTTAGAAAAGACTGACCTTGATGTCTTGAGAGCGCTGGCCTCTTCCTCCCTCC 11694 
                ************************************************************ 
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CP_H1B          CTGCAGGGTAGGGGGCCTGAGTTGAGGGGCTTCCCTCTGCTCCACAGAAACCCTGTTTTA 11760 
CP_H1C          CTGCAGGGTAGGGGGCCTGAGTTGAGGGGCTTCCCTCTGCTCCACAGAAACCCTGTTTTA 11754 
                ************************************************************ 
 
CP_H1B          TTGAGTTCTGAAGGTTGGAACTGCTGCCATGATTTTGGCCACTTTGCAGACCTGGGACTT 11820 
CP_H1C          TTGAGTTCTGAAGGTTGGAACTGCTGCCATGATTTTGGCCACTTTGCAGACCTGGGACTT 11814 
                ************************************************************ 
 
CP_H1B          TAGGGCTAACCAGTTCTCTTTGTAAGGACTTGTGCCTCTTGGGAGACGTCCACCCGTTTC 11880 
CP_H1C          TAGGGCTAACCAGTTCTCTTTGTAAGGACTTGTGCCTCTTGGGAGACGTCCACCCGTTTC 11874 
                ************************************************************ 
 
CP_H1B          CAAGCCTGGGCCACTGGCATCTCTGGAGTGTGTGGGGGTCTGGGAGGCAGGTCCCGAGCC 11940 
CP_H1C          CAAGCCTGGGCCACTGGCATCTCTGGAGTGTGTGGGGGTCTGGGAGGCAGGTCCCGAGCC 11934 
                ************************************************************ 
 
CP_H1B          CCCTGTCCTTCCCACGGCCACTGCAGTCACCCCGTCTGCGCCGCTGTGCTGTTGTCTGCC 12000 
CP_H1C          CCCTGTCCTTCCCACGGCCACTGCAGTCACCCCGTCTGCGCCGCTGTGCTGTTGTCTGCC 11994 
                ************************************************************ 
 
CP_H1B          GTGAGAGCCCAATCACTGCCTATACCCCTCATCACACGTCACAATGTCCCGAATTCCCAG 12060 
CP_H1C          GTGAGAGCCCAATCACTGCCTATACCCCTCATCACACGTCACAATGTCCCGAATTCCCAG 12054 
                ************************************************************ 
 
CP_H1B          CCTCACCACCCCTTCTCAGTAATGACCCTGGTTGGTTGCAGGAGGTACCTACTCCATACT 12120 
CP_H1C          CCTCACCACCCCTTCTCAGTAATGACCCTGGTTGGTTGCAGGAGGTACCTACTCCATACT 12114 
                ************************************************************ 
 
CP_H1B          GAGGGTGAAATTAAGGGAAGGCAAAGTCCAGGCACAAGAGTGGGACCCCAGCCTCTCACT 12180 
CP_H1C          GAGGGTGAAATTAAGGGAAGGCAAAGTCCAGGCACAAGAGTGGGACCCCAGCCTCTCACT 12174 
                ************************************************************ 
 
CP_H1B          CTCAGTTCCACTCATCCAACTGGGACCCTCACCACGAATCTCATGATCTGATTCGGTTCC 12240 
CP_H1C          CTCAGTTCCACTCATCCAACTGGGACCCTCACCACGAATCTCATGATCTGATTCGGTTCC 12234 
                ************************************************************ 
 
CP_H1B          CTGTCTCCTTCTCCCGTCACAGATGTGAGCCAGGGCACTGCTCAGCTGTGACCCTAGGTG 12300 
CP_H1C          CTGTCTCCTCCTCCCGTCACAGATGTGAGCCAGGGCACTGCTCAGCTGTGACCCTAGGTG 12294 
                ********* ************************************************** 
 
CP_H1B          TTTCTGCCTTGTTGACATGGAGAGAGCCCTTTCCCCTGAGAAGGCCTGGCCCCTTCCTGT 12360 
CP_H1C          TTTCTGCCTTGTTGACATGGAGAGAGCCCTTTCCCCTGAGAAGGCCTGGCCCCTTCCTGT 12354 
                ************************************************************ 
 
CP_H1B          GCTGAGCCCACAGCAGCAGGCTGGGTGTCTTGGTTGTCAGTGGTGGCACCAGGATGGAAG 12420 
CP_H1C          GCTGAGCCCACAGCAGCAGGCTGGGTGTCTTGGTTGTCAGTGGTGGCACCAGGATGGAAG 12414 
                ************************************************************ 
 
CP_H1B          GGCAAGGCACCCAGGGCAGGCCCACAGTCCCGCTGTCCCCCACTTGCACCCTAGCTTGTA 12480 
CP_H1C          GGCAAGGCACCCAGGGCAGGCCCACAGTCCCGCTGTCCCCCACTTGCACCCTAGCTTGTA 12474 
                ************************************************************ 
 
CP_H1B          GCTGCCAACCTCCCAGACAGCCCAGCCCGCTGCTCAGCTCCACATGCATAGTATCAGCCC 12540 
CP_H1C          GCTGCCAACCTCCCAGACAGCCCAGCCCGCTGCTCAGCTCCACATGCATAGTATCAGCCC 12534 
                ************************************************************ 
 
CP_H1B          TCCACACCCGACAAAGGGGAACACACCCCCTTGGAAATGGTTCTTTTCCCCCAGTCCCAG 12600 
CP_H1C          TCCACACCCGACAAAGGGGAACACACCCCCTTGGAAATGGTTCTTTTCCCCCAGTCCCAG 12594 
                ************************************************************ 
 
CP_H1B          CTGGAAGCCATGCTGTCTGTTCTGCTGGAGCAGCTGAACATATACATAGATGTTGCCCTG 12660 
CP_H1C          CTGGAAGCCATGCTGTCTGTTCTGCTGGAGCAGCTGAACATATACATAGATGTTGCCCTG 12654 
                ************************************************************ 
 
CP_H1B          CCCTCCCCATCTGCACCCTGTTGAGTTGTAGTTGGATTTGTCTGTTTATGCTTGGATTCA 12720 
CP_H1C          CCCTCCCCATCTGCACCCTGTTGAGTTGTAGTTGGATTTGTCTGTTTATGCTTGGATTCA 12714 
                ************************************************************ 
 
CP_H1B          CCAGAGTGACTATGATAGTGAAAAGAAAAAAAAAAAAAAA---GGACGCATGTATCTTGA 12777 
CP_H1C          CCAGAGTGACTATGATAGTGAAAAGAAAAAAAAAAAAAAAAAAGGACGCATGTATCTTGA 12774 
                ****************************************   ***************** 
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CP_H1B          AATGCTTGTAAAGAGGTTTCTAACCCACCCTCACGAGGTGTCTCTCACCCCCACACTGGG 12837 
CP_H1C          AATGCTTGTAAAGAGGTTTCTAACCCACCCTCACGAGGTGTCTCTCACCCCCACACTGGG 12834 
                ************************************************************ 
 
CP_H1B          ACTCGTGTGGCCTGTGTGGTGCCACCCTGCTGGGGCCTCCCAAGTTTTGAAAGGCTTTCC 12897 
CP_H1C          ACTCGTGTGGCCTGTGTGGTGCCACCCTGCTGGGGCCTCCCAAGTTTTGAAAGGCTTTCC 12894 
                ************************************************************ 
 
CP_H1B          TCAGCACCTGGGACCCAACAGAGACCAGCTTCTAGCAGCTAAGGAGGCCGTTCAGCTGTG 12957 
CP_H1C          TCAGCACCTGGGACCCAACAGAGACCAGCTTCTAGCAGCTAAGGAGGCCGTTCAGCTGTG 12954 
                ************************************************************ 
 
CP_H1B          ACGAAGGCCTGAAGCACAGGATTAGGACTGAAGCGATGATGTCCCCTTCCCTACTTCCCC 13017 
CP_H1C          ACGAAGGCCTGAAGCACAGGATTAGGACTGAAGCGATGATGTCCCCTTCCCTACTTCCCC 13014 
                ************************************************************ 
 
CP_H1B          TTGGGGCTCCCTGTGTCAGGGCACAGACTAGGTCTTGTGGCTGGTCTGGCTTGCGGCGCG 13077 
CP_H1C          TTGGGGCTCCCTGTGTCAGGGCACAGACTAGGTCTTGTGGCTGGTCTGGCTTGCGGCGCG 13074 
                ************************************************************ 
 
CP_H1B          AGGATGGTTCTCTCTGGTCATAGCCCGAAGTCTCATGGCAGTCCCAAAGGAGGCTTACAA 13137 
CP_H1C          AGGATGGTTCTCTCTGGTCATAGCCCGAAGTCTCATGGCAGTCCCAAAGGAGGCTTACAA 13134 
                ************************************************************ 
 
CP_H1B          CTCCTGCATCACAAGAAAAAGGAAGCCACTGCCAGCTGGGGGGATCTGCAGCTCCCAGAA 13197 
CP_H1C          CTCCTGCATCACAAGAAAAAGGAAGCCACTGCCAGCTGGGGGGATCTGCAGCTCCCAGAA 13194 
                ************************************************************ 
 
CP_H1B          GCTCCGTGAGCCTCAGCCACCCCTCAGACTGGGTTCCTCTCCAAGCTCGCCCTCTGGAGG 13257 
CP_H1C          GCTCCGTGAGCCTCAGCCACCCCTCAGACTGGGTTCCTCTCCAAGCTCGCCCTCTGGAGG 13254 
                ************************************************************ 
 
CP_H1B          GGCAGCGCAGCCTCCCACCAAGGGCCCTGCGACCACAGCAGGGATTGGGATGAATTGCCT 13317 
CP_H1C          GGCAGCGCAGCCTCCCACCAAGGGCCCTGCGACCACAGCAGGGATTGGGATGAATTGCCT 13314 
                ************************************************************ 
 
CP_H1B          GTCCTGGATCTGCTCTAGAGGCCCAAGCTGCCTGCCTGAGGAAGGATGACTTGACAAGTC 13377 
CP_H1C          GTCCTGGATCTGCTCTAGAGGCCCAAGCTGCCTGCCTGAGGAAGGATGACTTGACAAGTC 13374 
                ************************************************************ 
 
CP_H1B          AGGAGACACTGTTCCCAAAGCCTTGACCAGAGCACCTCAGCCCGCTGACCTTGCACAAAC 13437 
CP_H1C          AGGAGACACTGTTCCCAAAGCCTTGACCAGAGCACCTCAGCCCGCTGACCTTGCACAAAC 13434 
                ************************************************************ 
 
CP_H1B          TCCATCTGCTGCCATGAGAAAAGGGAAGCCGCCTTTGCAAAACATTGCTGCCTAAAGAAA 13497 
CP_H1C          TCCATCTGCTGCCATGAGAAAAGGGAAGCCGCCTTTGCAAAACATTGCTGCCTAAAGAAA 13494 
                ************************************************************ 
 
CP_H1B          CTCAGCAGCCTCAGGCCCAATTCTGCCACTTCTGGTTTGGGTACAGTTAAAGGCAACCCT 13557 
CP_H1C          CTCAGCAGCCTCAGGCCCAATTCTGCCACTTCTGGTTTGGGTACAGTTAAAGGCAACCCT 13554 
                ************************************************************ 
 
CP_H1B          GAGGGACTTGGCAGTAGAAATCCAGGGCCTCCCCTGGGGCTGGCAGCTTCGTGTGCAGCT 13617 
CP_H1C          GAGGGACTTGGCAGTAGAAATCCAGGGCCTCCCCTGGGGCTGGCAGCTTCGTGTGCAGCT 13614 
                ************************************************************ 
 
CP_H1B          AGAGCTTTACCTGAAAGGAAGTCTCTGGGCCCAGAACTCTCCACCAAGAGCCTCCCTGCC 13677 
CP_H1C          AGAGCTTTACCTGAAAGGAAGTCTCTGGGCCCAGAACTCTCCACCAAGAGCCTCCCTGCC 13674 
                ************************************************************ 
 
CP_H1B          GTTCGCTGAGTCCCAGCAATTCTCCTAAGTTGAAGGGATCTGAGAAGGAGAAGGAAATGT 13737 
CP_H1C          GTTCGCTGAGTCCCAGCAATTCTCCTAAGTTGAAGGGACCTGAGAAGGAGAAGGAAGTGT 13734 
                ************************************** ***************** *** 
 
CP_H1B          GGGGTAGATTTGGTGGTGGTTAGAGATATGCCCCCCTCATTACTGCCAACAGTTTCGGCT 13797 
CP_H1C          GGGGTAGATTTGGTGGTGGTTAGAGATATGCCCCCCTCATTACTGCCAACAGTTTCGGCT 13794 
                ************************************************************ 
 
CP_H1B          GCATTTCTTCACGCACCTCGGTTCCTCTTCCTGAAGTTCTTGTGCCCTGCTCTTCAGCAC 13857 
CP_H1C          GCATTTCTTCACGCACCTCGGTTCCTCTTCCTGAAGTTCTTGTGCCCTGCTCTTCAGCAC 13854 
                ************************************************************ 
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CP_H1B          CATGGGCCTTCTTATACGGAAGGCTCTGGGATCTCCCCCTTGTGGGGCAGGCTCTTGGGG 13917 
CP_H1C          CATGGGCCTTCTTATACGGAAGGCTCTGGGATCTCCCCCTTGTGGGGCAGGCTCTTGGGG 13914 
                ************************************************************ 
 
CP_H1B          CCAGCCTAAGATCATGGTTTAGGGTGATCAGTGCTGGCAGATAAATTGAAAAGGCACGCT 13977 
CP_H1C          CCAGCCTAAGATCATGGTTTAGGGTGATCAGTGCTGGCAGATAAATTGAAAAGGCACGCT 13974 
                ************************************************************ 
 
CP_H1B          GGCTTGTGATCTTAAATGAGGACAATCCCCCCAGGGCTGGGCACTCCTCCCCTCCCCTCA 14037 
CP_H1C          GGCTTGTGATCTTAAATGAGGACAATCCCCCCAGGGCTGGGCACTCCTCCCCTCCCCTCA 14034 
                ************************************************************ 
 
CP_H1B          CTTCTCCCACCTGCAGAGCCAGTGTCCTTGGGTGGGCTAGATAGGATATACTGTATGCCG 14097 
CP_H1C          CTTCTCCCACCTGCAGAGCCAGTGTCCTTGGGTGGGCTAGATAGGATATACTGTATGCCG 14094 
                ************************************************************ 
 
CP_H1B          GCTCCTTCAAGCTGCTGACTCACTTTATCAATAGTTCCATTTAAATTGACTTCAGTGGTG 14157 
CP_H1C          GCTCCTTCAAGCTGCTGACTCACTTTATCAATAGTTCCATTTAAATTGACTTCAGTGGTG 14154 
                ************************************************************ 
 
CP_H1B          AGACTGTATCCTGTTTGCTATTGCTTGTTGTGCTATGGGGGGAGGGGGGAGGAATGTGTA 14217 
CP_H1C          AGACTGTATCCTGTTTGCTATTGCTTGTTGTGCTATGGGGGGAGGGGGGAGGAATGTGTA 14214 
                ************************************************************ 
 
CP_H1B          AGATAGTTAACATGGGCAAAGGGAGATCTTGGGGTGCAGCACTTAAACTGCCTCGTAACC 14277 
CP_H1C          AGATAGTTAACATGGGCAAAGGGAGATCTTGGGGTGCAGCACTTAAACTGCCTCGTAACC 14274 
                ************************************************************ 
 
CP_H1B          CTTTTCATGATTTCAACCACATTTGCTAGAGGGAGGGAGCAGCCACGGAGTTAGAGGCCC 14337 
CP_H1C          CTTTTCATGATTTCAACCACATTTGCTAGAGGGAGGGAGCAGCCACGGAGTTAGAGGCCC 14334 
                ************************************************************ 
 
CP_H1B          TTGGGGTTTCTCTTTTCCACTGACAGGCTTTCCCAGGCAGCTGGCTAGTTCATTCCCTCC 14397 
CP_H1C          TTGGGGTTTCTCTTTTCCACTGACAGGCTTTCCCAGGCAGCTGGCTAGTTCATTCCCTCC 14394 
                ************************************************************ 
 
CP_H1B          CCAGCCAGGTGCAGGCGTAGGAATATGGACATCTGGTTGCTTTGGCCTGCTGCCCTCTTT 14457 
CP_H1C          CCAGCCAGGTGCAGGCGTAGGAATATGGACATCTGGTTGCTTTGGCCTGCTGCCCTCTTT 14454 
                ************************************************************ 
 
CP_H1B          CAGGGGTCCTAAGCCCACAATCATGCCTCCCTAAGACCTTGGCATCCTTCCCTCTAAGCC 14517 
CP_H1C          CAGGGGTCCTAAGCCCACAATCATGCCTCCCTAAGACCTTGGCATCCTTCCCTCTAAGCC 14514 
                ************************************************************ 
 
CP_H1B          GTTGGCACCTCTGTGCCACCTCTCACACTGGCTCCAGACACACAGCCTGTGCTTTTGGAG 14577 
CP_H1C          GTTGGCACCTCTGTGCCACCTCTCACACTGGCTCCAGACACACAGCCTGTGCTTTTGGAG 14574 
                ************************************************************ 
 
CP_H1B          CTGAGATCACTCGCTTCACCCTCCTCATCTTTGTTCTCCAAGTAAAGCCACGAGGTCGGG 14637 
CP_H1C          CTGAGATCACTCGCTTCACCCTCCTCATCTTTGTTCTCCAAGTAAAGCCACGAGGTCGGG 14634 
                ************************************************************ 
 
CP_H1B          GCGAGGGCAGAGGTGATCACCTGCGTGTCCCATCTACAGACCTGCAGCTTCATAAAACTT 14697 
CP_H1C          GCGAGGGCAGAGGTGATCACCTGCGTGTCCCATCTACAGACCTGCAGCTTCATAAAACTT 14694 
                ************************************************************ 
 
CP_H1B          CTGATTTCTCTTCAGCTTTGAAAAGGGTTACCCTGGGCACTGGCCTAGAGCCTCACCTCC 14757 
CP_H1C          CTGATTTCTCTTCAGCTTTGAAAAGGGTTACCCTGGGCACTGGCCTAGAGCCTCACCTCC 14754 
                ************************************************************ 
 
CP_H1B          TAATAGACTTAGCCCCATGAGTTTGCCATGTTGAGCAGGACTATTTCTGGCACTTGCAAG 14817 
CP_H1C          TAATAGACTTAGCCCCATGAGTTTGCCATGTTGAGCAGGACTATTTCTGGCACTTGCAAG 14814 
                ************************************************************ 
 
CP_H1B          TCCCATGATTTCTTCGGTAATTCTGAGGGTGGGGGGAGGGACATGAAATCATCTTAGCTT 14877 
CP_H1C          TCCCATGATTTCTTCGGTAATTCTGAGGGTGGGGGGAGGGACATGAAATCATCTTAGCTT 14874 
                ************************************************************ 
 
CP_H1B          AGCTTTCTGTCTGTGAATGTCTATATAGTGTATTGTGTGTTTTAACAAATGATTTACACT 14937 
CP_H1C          AGCTTTCTGTCTGTGAATGTCTATATAGTGTATTGTGTGTTTTAACAAATGATTTACACT 14934 
                ************************************************************ 
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CP_H1B          GACTGTTGCTGTAAAAGTGAATTTGGAAATAAAGTTATTACTCTGATTAAATAAGGTCTC 14997 
CP_H1C          GACTGTTGCTGTAAAAGTGAATTTGGAAATAAAGTTATTACTCTGATTAAATAAGGTCTC 14994 
                ************************************************************ 
 
CP_H1B          CATTCATGGATTCCAAGGACAAGAAAGTCATATAGAATGTCTATTTTTTAAGTTCTTTCC 15057 
CP_H1C          CATTCATGGATTCCAAGGACAAGAAAGTCATATAGAATGTCTATTTTTTAAGTTCTTTCC 15054 
                ************************************************************ 
 
CP_H1B          CACGCACCCTTAGATAATTTAGCTCAGAACAGGAAATGATAGTATTAATAAAAGCTGGAC 15117 
CP_H1C          CACGCACCCTTAGATAATTTAGCTCAGAACAGGAAATGATAGTATTAATAAAAGCTGGAC 15114 
                ************************************************************ 
 
CP_H1B          ATCAGGATTAACAGCTCTCTCTGGGGCCCTGAAGGTGAGAGTTCTCAGACTTGCTCATTT 15177 
CP_H1C          ATCAGGATTAACAGCTCTCTCTGGGGCCCTGAAGGTGAGAGTTCTCAGACTTGCTCATTT 15174 
                ************************************************************ 
 
CP_H1B          GCAGTTGCTTCTTTGTGATGCTGGCTACCCAGCTTTCTTGTACAAAGTGGT 15228 
CP_H1C          GCAGTTGCTTCTTTGTGATGCTGGCTACCCAGCTTTCTTGTACAAAGTGGT 15225 
                *************************************************** 
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Appendix J 
CP+rs242557 H1B vs H1C Minigenes 
In the below multiple sequence alignment of the two CP+rs242557 minigenes, 
sequence matches are denoted *, with sequence differences highlighted in red. 
Exon 0 is highlighted in green. 
 
 
CP+H1B-G        GGGGACAAGTTTGTACAAAAAAGCAGGCTTCCAAATGCTCTGCGATGTGTTAAGCACTGT 60 
CP+H1C-A        GGGGACAAGTTTGTACAAAAAAGCAGGCTTCCAAATGCTCTGCGATGTGTTAAGCACTGT 60 
                ************************************************************ 
 
CP+H1B-G        TTGAAATTCGTCTAATTTAAGATTTTTTTTTCTGACGTAACGGTTAGATTCACGTTTCTT 120 
CP+H1C-A        TTGAAATTCGTCTAATTTAAGATTTTTTTTTCTGACGTAACGGTTAGATTCACGTTTCTT 120 
                ************************************************************ 
 
CP+H1B-G        TTTTTTTAAGTACAGTTCTACTGTATTGTAACTGAGTTAGCTTGCTTTAAGCCGATTTGT 180 
CP+H1C-A        TTTTTTTAAGTACAGTTCTACTGTATTGTAACTGAGTTAGCTTGCTTTAAGCCGATTTGT 180 
                ************************************************************ 
 
CP+H1B-G        TAAGGAAAGGATTCACCTTGGTCAGTAACAAAAAAGGTGGGAAAAAAGCAAGGAGAAAGG 240 
CP+H1C-A        TAAGGAAAGGATTCACCTTGGTCAGTAACAAAAAAGGTGGGAAAAAAGCAAGGAGAAAGG 240 
                ************************************************************ 
 
CP+H1B-G        AAGCAGCCTGGGGGAAAGAGACCTTAGCCAGGGGGGCGGTTTCGGGACTACGAAGGGTCG 300 
CP+H1C-A        AAGCAGCCTGGGGGAAAGAGACCTTAGCCAGGGGGGCGGTTTCGGGACTACGAAGGGTCG 300 
                ************************************************************ 
 
CP+H1B-G        GGGCGGACGGACTCGAGGGCCGGCCACGTGGAAGGCCGCTCAGGACTTCTGTAGGAGAGG 360 
CP+H1C-A        GGGCGGACGGACTCGAGGGCCGGCCACGTGGAAGGCCGCTCAGGACTTCTGTAGGAGAGG 360 
                ************************************************************ 
 
CP+H1B-G        ACACCGCCCCAGGCTGACTGAAAGTAAAGGGCAGCGGACCCAGCGGCGGAGCCACTGGCC 420 
CP+H1C-A        ACACCGCCCCAGGCTGACTGAAAGTAAAGGGCAGCGGACCCAGCGGCGGAGCCACTGGCC 420 
                ************************************************************ 
 
CP+H1B-G        TTGCCCCGACCCCGCGTGGCCCGAAGGAGGACACCCACCCCCGCAACGACACAAAGACTC 480 
CP+H1C-A        TTGCCCCGACCCCGCATGGCCCGAAGGAGGACACCCACCCCCGCAACGACACAAAGACTC 480 
                *************** ******************************************** 
 
CP+H1B-G        CAACTACAGGAGGTGGAGAAAGCGCGTGCGCCACGGAACGCGCGTGCGCGCTGCGGTCAG 540 
CP+H1C-A        CAACTACAGGAGGTGGAGAAAGCGCGTGCGCCACGGAACGCGCGTGCGCGCTGCGGTCAG 540 
                ************************************************************ 
 
CP+H1B-G        CGCCGCGGCCTGAGGCGTAGCGGGAGGGGGACCGCGAAAGGGCAGCGCCGAGAGGAACGA 600 
CP+H1C-A        CGCCGCGGCCTGAGGCGTAGCGGGAGGGGGACCGCGAAAGGGCAGCGCCGAGAGGAACGA 600 
                ************************************************************ 
 
CP+H1B-G        GCCGGGAGACGCCGGACGGCCGAGCGGCAGGGCGCTCGCGCGCGCCCACTAGTGGCCGGA 660 
CP+H1C-A        GCCGGGAGACGCCGGACGGCCGAGCGGCAGGGCGCTCGCGCGCGCCCACTAGTGGCCGGA 660 
                ************************************************************ 
 
CP+H1B-G        GGAGAAGGCTCCCGCGGAGGCCGCGCTGCCCGCCCCCTCCCCTGGGGAGGCTCGCGTTCC 720 
CP+H1C-A        GGAGAAGGCTCCCGCGGAGGCCGCGCTGCCCGCCCCCTCCCCTGGGGAGGCTCGCGTTCC 720 
                ************************************************************ 
 
CP+H1B-G        CGCTGCTCGCGCCTGCGCCGCCCGCCGGCCTCAGGAACGCGCCCTCTTCGCCGGCGCGCG 780 
CP+H1C-A        CGCTGCTCGCGCCTGCGCCGCCCGCCGGCCTCAGGAACGCGCCCTCTTCGCCGGCGCGCG 780 
                ************************************************************ 
 
CP+H1B-G        CCCTCGCAGTCACCGCCACCCACCAGCTCCGGCACCAACAGCAGCGCCGCTGCCACCGCC 840 
CP+H1C-A        CCCTCGCAGTCACCGCCACCCACCAGCTCCGGCACCAACAGCAGCGCCGCTGCCACCGCC 840 
                ************************************************************ 
 
CP+H1B-G        CACCTTCTGCCGCCGCCACCACAGCCACCTTCTCCTCCTCCGCTGTCCTCTCCCGTCCTC 900 
CP+H1C-A        CACCTTCTGCCGCCGCCACCACAGCCACCTTCTCCTCCTCCGCTGTCCTCTCCCGTCCTC 900 
                ************************************************************ 
 
Appendices 
302 
 
CP+H1B-G        GCCTCTGTCGACTATCAGGTAAGCGCCGCGGCTCCGAAATCTGCCTCGCCGTCCGCCTCT 960 
CP+H1C-A        GCCTCTGTCGACTATCAGGTAAGCGCCGCGGCTCCGAAATCTGCCTCGCCGTCCGCCTCT 960 
                ************************************************************ 
 
CP+H1B-G        GTGCACCCCTGCGCCGCCGCCCCTCGCCCTCCCTCTCCGCAGACTGGGGCTTCGTGCGCC 1020 
CP+H1C-A        GTGCACCCCTGCGCCGCCGCCCCTCGCCCTCCCTCTCCGCAGACTGGGGCTTCGTGCGCC 1020 
                ************************************************************ 
 
CP+H1B-G        GGGCATCGGTCGGGGCCACCGCAGGGCCCCTCCCTGCCTCCCCTGCTCGGGGGCTGGGGC 1080 
CP+H1C-A        GGGCATCGGTCGGGGCCACCGCAGGGCCCCTCCCTGCCTCCCCTGCTCGGGGGCTGGGGC 1080 
                ************************************************************ 
 
CP+H1B-G        CAGGGCGGCCTGGAAAGGGACCTGAGCAAGGGATGCACGCACGCGTGAGTGCGCGCGTGT 1140 
CP+H1C-A        CAGGGCGGCCTGGAAAGGGACCTGAGCAAGGGATGCACGCACGCGTGAGTGCGCGCGTGT 1140 
                ************************************************************ 
 
CP+H1B-G        GTGTGTGCTGGAGGGTCTTCACCACCAGATTCGCGCAGACCCCAGGTGGAGGCTGTGCCG 1200 
CP+H1C-A        GTGTGTGCTGGAGGGTCTTCACCACCAGATTCGCGCAGACCCCAGGTGGAGGCTGTGCCG 1200 
                ************************************************************ 
 
CP+H1B-G        GCAGGGTGGGGCGCGACGGCGGTGACTTGGGGGAGGGGGCTGCCCTTCACTCTCGACTGC 1260 
CP+H1C-A        GCAGGGTGGGGCGCGGCGGCGGTGACTTGGGGGAGGGGGCTGCCCTTCACTCTCGACTGC 1260 
                *************** ******************************************** 
 
CP+H1B-G        AGCCTTTTGCCGCAATGGGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTG----GAGGGGT 1316 
CP+H1C-A        AGCCTTTTGCCGCAATGGGCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGGAGGGGT 1320 
                *************************************************    ******* 
 
CP+H1B-G        CCGATAACGACCCCCGAAACCGAATCTGAAATCCGCTGTCCGCTAGCTGGGACAGATCCT 1376 
CP+H1C-A        CCGATAACGACCCCCGAAACCGAATCTGAAATCCGCTGTCCGCTAGCTGGGACAGATCCT 1380 
                ************************************************************ 
 
CP+H1B-G        CAGTGGAACATGACTCTGTAACGAGAGCATTTTGTTTTGTCAAAATGAGAACATATTATT 1436 
CP+H1C-A        CAGTGGAACATGACTCTGTAACGAGAGCATTTTGTTTTGTCAAAATGAGAACATATTATT 1440 
                ************************************************************ 
 
CP+H1B-G        GCCTTTCATCTGATTGTAAACATAATACATGTTTATAAAACAGTATAATGAGACAAAAAT 1496 
CP+H1C-A        GCCTTTCATCTGATTGTAAACATAATACATGTTTATAAAACAGTATAATGAGACAAAAAT 1500 
                ************************************************************ 
 
CP+H1B-G        GTAGACACTAATAAGGGAAAATCTCCCTAATTGTATTTCTCTTCACAGAGAAAGCCCCTG 1556 
CP+H1C-A        GTAGACACTAATAAGGGAAAATCTCCCTAATTGTATTTCTCTTCACAGAGAAAGCCCCTG 1560 
                ************************************************************ 
 
CP+H1B-G        TTGGGCATATATACTCTAGTTTGCTTATTTGTTTGACTACACATATATGTATTCTTTTCT 1616 
CP+H1C-A        TTGGGCATATATACTCTAGTTTGTTTATTTGTTTGACTACACATATATGTATTCTTTTCT 1620 
                *********************** ************************************ 
 
CP+H1B-G        TATGTATAAAAATTCTGAACATGCACATTTCTGCAACTACTGTTTTCACTTGATGATGCA 1676 
CP+H1C-A        TATGTATAAAAATTCTGAACATGCACATTTCTGCAACTACTGTTTTCACTTGATGATGCA 1680 
                ************************************************************ 
 
CP+H1B-G        TGGACCTCTCTAGAGTGTACGTTTCTTCTTCCTTACAAAGCAGTTGGCTTCGCCCAGGGT 1736 
CP+H1C-A        TGGACCTCTCTAGAGTGTACGTTTCTTCTTCCTTACAAAGCAGTTGGCTTCGCCCAGGGT 1740 
                ************************************************************ 
 
CP+H1B-G        GCACCAGGACACGGTTTTGGCTCTGTCCCCAGGGTGTCACGGGACCAGGGGATGATCTCA 1796 
CP+H1C-A        ACACCAGGACACGGTTTTGGCTCTGTCCCCAGGGTGTCACGGGACCAGGGGATGATCTCA 1800 
                 *********************************************************** 
 
CP+H1B-G        CAGGGTCTGCCATCTGCCCTGCCTGGCCGGAGGCTGCATCGAGAGGGCCAAGGGGCACCA 1856 
CP+H1C-A        CAGGGTCTGCCATCTGCCCTGCCTGGCCGGAGGCTGCATCGAGAGGGCCAAGGGGCACCA 1860 
                ************************************************************ 
 
CP+H1B-G        CGTGTCGTGGGTACTGTCAAACAAGAGCCTTCAGAGCCTTCCACAGTCTTTCTTTTGCTT 1916 
CP+H1C-A        CGTGTCGTGGGTACTGTCAAACAAGAGCCTTCAGAGCCTTCCACAGTCTTTCTTTTGCTT 1920 
                ************************************************************ 
 
CP+H1B-G        CCCAGCATTGCTTCCCCGCTGGTGGACTCTGAATCTAGAACTAGCTCCAGGCGCCTCTCC 1976 
CP+H1C-A        CCCAGCATTGCTTCCCCGCTGGTGGACTCTGAATCTAGAACTAGCTCCAGGCGCCTCTCC 1980 
                ************************************************************ 
 
 
 
Appendices 
303 
 
CP+H1B-G        AAATTCAGACGGGAGCTGGGGCACTATTATAATGCAAATCTAGGCAAAGCCCTCCCAATA 2036 
CP+H1C-A        AAATTCAGACGGGAGCTGGGGCACTATTATAATGCAAATCTAGGCAAAGCCCTCCCAATA 2040 
                ************************************************************ 
 
CP+H1B-G        CCAGGATCCAGAATGGGGTGGGGCCCTTTGCCCTGAAAAGCTGTTTAGTTTGAAAATACA 2096 
CP+H1C-A        CCAGGATCCAGAATGGGGTGGGGCCCTTTGCCCTGAAAAGCTGTTTAGTTTGAAAATACA 2100 
                ************************************************************ 
 
CP+H1B-G        AACAGGAGACAGAAAAGTTTGGCTAAATTAATGGATAAAGTTTTAACGATGGTAACCATA 2156 
CP+H1C-A        AACAGGAGACAGAAAAGTTTGGCTAAATTAATGGATAAAGTTTTAACGATGGTAACCATA 2160 
                ************************************************************ 
 
CP+H1B-G        GTAGGGTTCATCGACAGCCACAACTTTGTATACAAAAGTTGTCCCTGGTGGTGTTGAATA 2216 
CP+H1C-A        GTAGGGTTCATCGACAGCCACAACTTTGTATACAAAAGTTGTCCCTGGTGGTGTTGAATA 2220 
                ************************************************************ 
 
CP+H1B-G        TGAACTGCTGCGGTGTTGGTAAATTAAGCAAGCAGATAGATGTAAATAACGCTTGGGCAG 2276 
CP+H1C-A        TGAACTGCTGCGGTGTTGGTAAATTAAGCAAGCAGATAGATGTAAATAACGCTTGGGCAG 2280 
                ************************************************************ 
 
CP+H1B-G        GAATATGGAGCACGGGATGAGGATGGGCGGCCAACTGTTAGAGAGGGTAGCAGGGAGGCT 2336 
CP+H1C-A        GAATATGGAGCACGGGATGAGGATGGGCGGCCAACTGTTAGAGAGGGTAGCAGGGAGGCT 2340 
                ************************************************************ 
 
CP+H1B-G        GAGATCTGCCTGCCATGAACTGGGAGGAGAGGCTCCTCTCTCTCTTCACCCCCACTCTGC 2396 
CP+H1C-A        GAGATCTGCCTGCCATGAACTGGGAGGAGAGGCTCCTCTCTCTCTTCACCCCCACTCTGC 2400 
                ************************************************************ 
 
CP+H1B-G        CCCCCAACACTCCTCAGAACTTATCCTCTCCTCTTCTTTCCCCAGGTGAACTTTGAACCA 2456 
CP+H1C-A        CCCCCAACACTCCTCAGAACTTATCCTCTCCTCTTCTTTCCCCAGGTGAACTTTGAACCA 2460 
                ************************************************************ 
 
CP+H1B-G        GGATGGCTGAGCCCCGCCAGGAGTTCGAAGTGATGGAAGATCACGCTGGGACGTACGGGT 2516 
CP+H1C-A        GGATGGCTGAGCCCCGCCAGGAGTTCGAAGTGATGGAAGATCACGCTGGGACGTACGGGT 2520 
                ************************************************************ 
 
CP+H1B-G        TGGGGGACAGGAAAGATCAGGGGGGCTACACCATGCACCAAGACCAAGAGGGTGACACGG 2576 
CP+H1C-A        TGGGGGACAGGAAAGATCAGGGGGGCTACACCATGCACCAAGACCAAGAGGGTGACACGG 2580 
                ************************************************************ 
 
CP+H1B-G        ACGCTGGCCTGAAAGGTTAGTGGACAGCCATGCACAGCAGGCCCAGATCACTGCAAGCCA 2636 
CP+H1C-A        ACGCTGGCCTGAAAGGTTAGTGGACAGCCATGCACAGCAGGCCCAGATCACTGCAAGCCA 2640 
                ************************************************************ 
 
CP+H1B-G        AGGGGTGGCGGGAACAGTTTGCATCCAGAATTGCAAAGAAATTTTAAATACATTATTGTC 2696 
CP+H1C-A        AGGGGTGGCGGGAACAGTTTGCATCCAGAATTGCAAAGAAATTTTAAATACATTATTGTC 2700 
                ************************************************************ 
 
CP+H1B-G        TTAGACTGTCAGTAAAGTAAAGCCTCATTAATTTGAGTGGGCCAAGATAACTCAAGCAGT 2756 
CP+H1C-A        TTAGACTGTCAGTAAAGTAAAGCCTCATTAATTTGAGTGGGCCAAGATAACTCAAGCAGT 2760 
                ************************************************************ 
 
CP+H1B-G        GAGATAATGGCCAGACTCGGTGGCTCACGCCTGTAATCCCAGCACTTTGGAAGGCCCAGG 2816 
CP+H1C-A        GAGATAATGGCCAGACACGGTGGCTCACGCCTGTAATCCCAGCACTTTGGAAGGCCCAGG 2820 
                **************** ******************************************* 
 
CP+H1B-G        CAGGAGGATCCCTTGAGGCCAGGAATTTGAGACCGGCCTGGGCAACATAGCAAGACCCCG 2876 
CP+H1C-A        CAGGAGGATCCCTTGAGGCCAGGAATTTGAGACCGGCCTGGGCAACATAGCAAGACCCCG 2880 
                ************************************************************ 
 
CP+H1B-G        TCTCTAAAATAATTTAAAAATTAGCCAGGTGTTGTGGTGCATGTCTATAGTCCTAGCTAC 2936 
CP+H1C-A        TCTCTAAAATAATTTAAAAATTAGCCAGGTGTTGTGGTGCATGTCTATAGTCCTAGCTAC 2940 
                ************************************************************ 
 
CP+H1B-G        TCAGGATGCTGAGGCAGAAGGATCACTTGAGCCCAGGAGTTCAAGGTTGCAGTAAGCTGT 2996 
CP+H1C-A        TCAGGATGCTGAGGCAGAAGGATCACTTGAGCCCAGGAGTTCAAGGTTGCAGTAAGCTGT 3000 
                ************************************************************ 
 
CP+H1B-G        GATTATAAAACTGCACTCCAGCCTGAGCAACAGAGCAAGACCCTGTCAAAAAAAAAAGAA 3056 
CP+H1C-A        GATTATAAAACTGCACTCCAGCCTGAGCAACAGAGCAAGACCCTGTCAAAAAAAAAAGAA 3060 
                ************************************************************ 
 
 
 
Appendices 
304 
 
CP+H1B-G        AAGAAAAAAGAAAGAAAGAAATTTACCTTGAGTTACCCACATGAGTGAATGTAGGGACAG 3116 
CP+H1C-A        AAGAAAAAAGAAAGAAAGAAATTTACCTTGAGTTACCCACATGAGTGAATGTAGGGACAG 3120 
                ************************************************************ 
 
CP+H1B-G        AGATTTTAGGGCCTTAACAATCTCTCAAATACAGGGTACTTTTTGAGGCATTAGCCACAC 3176 
CP+H1C-A        AGATTTTAGGGCCTTAACAATCTCTCAAATACAGGGTACTTTTTGAGGCATTAGCCACAC 3180 
                ************************************************************ 
 
CP+H1B-G        CTGTTAGCTTATAAATCAGTGGTATTGATTAGCATGTAAAATATGTGACTTTAAACATTG 3236 
CP+H1C-A        CTGTTAGCTTATAAATCAGTGGTATTGATTAGCATGTAAAATATGTGACTTTAAACATTG 3240 
                ************************************************************ 
 
CP+H1B-G        CTTTTTATCTCTTACTTAGATCAGGCCTGAGTGGCCTCTCTTTAGCAAGAGTTGGTTAGC 3296 
CP+H1C-A        CTTTTTATCTCTTACTTAGATCAGGCCTGAGTGGCCTCTCTTTAGCAAGAGTTGGTTAGC 3300 
                ************************************************************ 
 
CP+H1B-G        CCTGGGATTCTTACTGTAGCCACATTAATAAACAACATCGACTTCTAAACATTCTATAAT 3356 
CP+H1C-A        CCTGGGATTCTTACTGTAGCCACATTAATAAACAACATCGACTTCTAAACATTCTATAAT 3360 
                ************************************************************ 
 
CP+H1B-G        ACCATCTTTTGGCCAAATTGACTTCGCCTCTTCTCGAGCACAGGGAAGGGACAATTCAGC 3416 
CP+H1C-A        ACTATCTTTTGGCCAAATTTACTTCGCCTCTTCTCGAGCACAGGGAAGGGACAATTCAGC 3420 
                ** **************** **************************************** 
 
CP+H1B-G        CCTTCTAGGAGGAGGAGGAGGTAGTTTTCTCATTTCTATTAAGGCAACAAAAGCTGCCTT 3476 
CP+H1C-A        CCTTCTAGGAGGAGGAGGAGGTAGTTTTCTCATTTCTATTAAGGCAACAAAAGCTGCCTT 3480 
                ************************************************************ 
 
CP+H1B-G        ACTAAGGACATTCTTGGTGGAGGGCGTGACTGTCAACCACTGTGATCATTTGGGCCTCTC 3536 
CP+H1C-A        ACTAAGGACATTCTTGGTGGAGGGCGTGACTGTCAACCACTGTGATCATTTGGGCCTCTC 3540 
                ************************************************************ 
 
CP+H1B-G        TTGCCCAGGCTTCCCATTCTGAAAGGACAGTTTTATTGTAGGTACACATGGCTGCCATTT 3596 
CP+H1C-A        TTGCCCAGGCTTCCCATTCTGAAAGGACAGTTTTATTGTAGGTACACATGGCTGCCATTT 3600 
                ************************************************************ 
 
CP+H1B-G        CAAATGTAACTCACAGCTTGTCCATCAGTCCTTGGAGGTCTTTCTATGAAAGGAGCTTGG 3656 
CP+H1C-A        CAAATGTAACTCACAGCTTGTCCATCAGTCCTTGGAGGTCTTTCTATGAAAGGAGCTTGG 3660 
                ************************************************************ 
 
CP+H1B-G        TGGCGTCCAAACACCACCCAATGTCCACTTAGAAGTAAGCACCGTGTCTGCCCTGAGCTG 3716 
CP+H1C-A        TGGCGTCCAAACACCACCCAATGTCCACTTAGAAGTAAGCACCGTGTCTGCCCTGAGCTG 3720 
                ************************************************************ 
 
CP+H1B-G        ACTCCTTTTCCAAGGAAGGGGTTGGATCGCTGAGTGTTTTTCCAGGTGTCTACTTGTTGT 3776 
CP+H1C-A        ACTCCTTTTCCAAGGAAGGGGTTGGATCGCTGAGTGTTTTTCCAGGTGTCTACTTGTTGT 3780 
                ************************************************************ 
 
CP+H1B-G        TAATTAATAGCAATGACAAAGCAGAAGGTTCATGCGTAGCTCGGCTTTCTGGTATTTGCT 3836 
CP+H1C-A        TAATTAATAGCAATGACAAAGCAGAAGGTTCATGCGTAGCTCGGCTTTCTGGTATTTGCT 3840 
                ************************************************************ 
 
CP+H1B-G        GCCCGTTGACCAATGGAAGATAAACCTTTGCCTCAGGTGGCACCACTAGCTGGTTAAGAG 3896 
CP+H1C-A        GCCCGTTGACCAATGGAAGATAAACCTTTGCCTCAGGTGGCACCACTAGCTGGTTAAGAG 3900 
                ************************************************************ 
 
CP+H1B-G        GCACTTTGTCCTTTCACCCAGGAGCAAACGCACATCACCTGTGTCCTCATCTGATGGCCC 3956 
CP+H1C-A        GCACTTTGTCCTCTCACCCAGGAGCAAACGCACATCACCTGTGTCCTCATCTGATGGCCC 3960 
                ************ *********************************************** 
 
CP+H1B-G        TGGTGTGGGGCACAGTCGTGTTGGCAGGGAGGGAGGTGGGGTTGGTCCCCTTTGTGGGTT 4016 
CP+H1C-A        TGGTGTGGG-CACAGTCGTGTTGGCAGGGAGGGAGGTGGGGTTGGTCCCCTTTGTGGGTT 4019 
                ********* ************************************************** 
 
CP+H1B-G        TGTTGCGAGGCCGTGTTCCAGCTGTTTCCACAGGGAGCGATTTTCAGCTCCACAGGACAC 4076 
CP+H1C-A        TGTTGCGAGGCCGTGTTCCAGCTGTTTCCACAGGGAGCGATTTTAAGCTCCACAGGACAC 4079 
                ******************************************** *************** 
 
CP+H1B-G        TGCTCCCCAGTTCCTCCTGAGAACAAAAGGGGGCGCTGGGGAGAGGCCACCGTTCTGAGG 4136 
CP+H1C-A        TGCTCCCCAGTTCCTCCTGAGAACAAAAGGGGGCGCTGGGGAGAGGCCACCGTTCTGAGG 4139 
                ************************************************************ 
 
 
 
Appendices 
305 
 
CP+H1B-G        GCTCACTGTATGTGTTCCAGAATCTCCCCTGCAGACCCCCACTGAGGACGGATCTGAGGA 4196 
CP+H1C-A        GCTCACTGTATGTGTTCCAGAATCTCCCCTGCAGACCCCCACTGAGGACGGATCTGAGGA 4199 
                ************************************************************ 
 
CP+H1B-G        ACCGGGCTCTGAAACCTCTGATGCTAAGAGCACTCCAACAGCGGAAGGTGGGCCCCCCTT 4256 
CP+H1C-A        ACCGGGCTCTGAAACCTCTGATGCTAAGAGCACTCCAACAGCGGAAGGTGGGCCCCCCTT 4259 
                ************************************************************ 
 
CP+H1B-G        CAGACGCCCCCTCCATGCCTCCAGCCTGTGCTTAGCCGTGCTTTGAGCCTCCCTCCTGGC 4316 
CP+H1C-A        CAGACGCCCCCTCCATGCCTCCAGCCTGTGCTTAGCCGTGCTTTGAGCCTCCCTCCTGGC 4319 
                ************************************************************ 
 
CP+H1B-G        TGCATCTGCTGCTCCCCCTGGCTGAGAGATGTGCTCACTCCTTCGGTGCTTTGCAGGACA 4376 
CP+H1C-A        TGCATCTGCTGCTCCCCCTGGCTGAGAGATGTGCTCACTCCTTCGGTGCTTTGCAGGACA 4379 
                ************************************************************ 
 
CP+H1B-G        GCGTGGTGGGAGCTGAGCCTTGCGTCGATGCCTTGCTTGCTGGTGCTGAGTGTGGGCACC 4436 
CP+H1C-A        GCGTGGTGGGAGCTGAGCCTTGCGTCGATGCCTTGCTTGCTGGTGCTGAGTGTGGGCACC 4439 
                ************************************************************ 
 
CP+H1B-G        TTCATCCCGTGTGTGCTCTGGAGGCAGCCACCCTTGGACAGTCCCGCGCACAGCTCCACA 4496 
CP+H1C-A        TTCATCCCGTGTGTGCTCTGGAGGCAGCCACCCTTGGACAGTCCCGCGCACAGCTCCACA 4499 
                ************************************************************ 
 
CP+H1B-G        AAGCCCCGCTCCATACGATTGTCCTCCCACACCCCCTTCAAAAGCCCCCTCCTCTCTCTT 4556 
CP+H1C-A        AAGCCCCGCTCCATACGATTGTCCTCCCACACCCCCTTCAAAAGCCCCCTCCTCTCTCTT 4559 
                ************************************************************ 
 
CP+H1B-G        TCTTCAGGGGCCAGTAGGTCCCAGAGCAGCCATTTGGCTGAGGGAAGGGGCAGGTCAGTG 4616 
CP+H1C-A        TCTTCAGGGGCCAGTAGGTCCCAGAGCAGCCATTTGGCTGAGGGAAGGGGCAGGTCAGTG 4619 
                ************************************************************ 
 
CP+H1B-G        GACATCTGATCTTGGTTTAGTATCCTTCATTTTGGGGGCTCTGGGTGTGGCCTGGGCCTC 4676 
CP+H1C-A        GACATCTGATCTTGGTTTAGTATCCTTCATTTTGGGGGCTCTGGGTGTGGCCTGGGCCTC 4679 
                ************************************************************ 
 
CP+H1B-G        TGGACTTTGGCCACGGTGTTTGTTCCAGCCCTTCTCCTAACCTGTCCTTTCCAGACACTC 4736 
CP+H1C-A        TGGACTTTGGCCACGGTGTTTGTTCCAGCCCTTCTCCTAACCTGTCCTTTCCAGACACTC 4739 
                ************************************************************ 
 
CP+H1B-G        GGCATCTAGGTTATTAGCACCTCGCATACTTTCTGACATGCTCCTCAGTCCTGATTTTGA 4796 
CP+H1C-A        GGCATCTAGGTTATTAGCACCTCGCATACTTTCCGACATGCTCCTCAGTCCTGATTTTGA 4799 
                ********************************* ************************** 
 
CP+H1B-G        CCATCTTCTCTTGCTTCCCATCTGTGTCAGTCAAGCCGCGGAAAGCCTTCAAAGCTGACA 4856 
CP+H1C-A        CCATCTTCTCTTGCTTCCCATCTGTGTCAGTCAAGCCGCGGAAAGCCTTCAAAGCTGACA 4859 
                ************************************************************ 
 
CP+H1B-G        ACTCCTTATGTGTACCCGGAAAGGCCTGGGAGTGTGCCAGGGCATTGCTCGGGAGGGACG 4916 
CP+H1C-A        ACTCCTTATGTGTACCCGGAAAGGCCTGGGAGTGTGCCAGGGCATTGCTCGGGAGGGACG 4919 
                ************************************************************ 
 
CP+H1B-G        CTGATTTGGAAGCATTTACCTGATGAGAGACTGACAGCAGCTCCTGGTAGCCGAGCTTTC 4976 
CP+H1C-A        CTGATTTGGAAGCATTTACCTGATGAGAGACTGACAGCAGCTCCTGGTAGCCGAGCTTTC 4979 
                ************************************************************ 
 
CP+H1B-G        CCTCCTGCCTCTGCTGTGAAGGTGGACCCATCCAACAGTCAAATGCCTGACTCTGGACAG 5036 
CP+H1C-A        CCTCCTGCCTCTGCTGTGAAGGTGGACCCATCCAACAGTCAAACGCCTGACTCTGGACAG 5039 
                ******************************************* **************** 
 
CP+H1B-G        GAGCGGACCTATTTATTGCCATGCAAGGGACTCTGCACTTTTGAATTGTGGGTCATGGGC 5096 
CP+H1C-A        GAGCGGACCTATTTATTGCCATGCAAGGGACTCTGCACTTTTGAATTGTGGGTCATGGGC 5099 
                ************************************************************ 
 
CP+H1B-G        TTGGATTTAGGGGTTAGAGCTGGGAGAAGTCTTGGAAGTCACCTAGAGATGACACTGCCA 5156 
CP+H1C-A        TTGGATTTAGGGGTTAGAGCTGGGAGAAGTCTTGGAAGTCACCTAGAGATGACACTGCCA 5159 
                ************************************************************ 
 
CP+H1B-G        TTTTGCAGATGAGGAAACCGTCCAATAAAAATGGACCAAGGACTTGCCCAAAGCCTCACA 5216 
CP+H1C-A        TTTTGCAGATGAGGAAACCGTCCAATCAAAATGGACCAAGGACTTGCCCAAAGCCTCACA 5219 
                ************************** ********************************* 
 
 
 
Appendices 
306 
 
CP+H1B-G        GCAAAACCATAGGCCCCCGCACTAACCCCAGAGTCCCTGTGCTGTCTTAAGAATCAAATA 5276 
CP+H1C-A        GCAAAACCATAGGCCCCCGCACTAACCCCAGAGTCCCTGTGCTGTCTTAAGGATCATATA 5279 
                *************************************************** **** *** 
 
CP+H1B-G        GTTGTAAGCAATCATCTGGTTTTCAGTATTTCTTCTTTTAAAATGCCTGGGGCCATGCCC 5336 
CP+H1C-A        GTTGTAAGCAATCATCTGGTTTTCAGTATTTCTTCTTTTAAAATGCCTGGGGCCATGCCC 5339 
                ************************************************************ 
 
CP+H1B-G        AGCAGTCTGTTTCACTGCAGCGTTTACACAGGGCTGCCGGGCTTTCCTGGTGGATGAGCT 5396 
CP+H1C-A        AGCAGTCTGTTTCACTGCAGCGTTTACACAGGGCTGCCGGGCTTTCCTGGTGGATGAGCT 5399 
                ************************************************************ 
 
CP+H1B-G        GGGCGGTTCATGAGCCAGAACCACTCAGCAGCATGTCAGTGTGCTTCCTGGGGAGCTGGT 5456 
CP+H1C-A        GGGCGGTTCATGAGCCAGAACCACTCAGCAGCATGTCAGTGTGCTTCCTGGGGAGCTGGT 5459 
                ************************************************************ 
 
CP+H1B-G        AGCAGGGGCTCCGGGCCCTACTTCAGGGCTGCTTTCTGGCATATGGCTGATCCCCTCCTC 5516 
CP+H1C-A        AGCAGGGGCTCCGGGCCCTACTTCAGGGCTGCTTTCTGGCATATGGCTGATCCCCTCCTC 5519 
                ************************************************************ 
 
CP+H1B-G        ACTCCTCCTCCCTGCATTGCTCCTGCGCAAGAAGCAAAGGTGAGGGGCTGGGTATGGCTC 5576 
CP+H1C-A        ACTCCTCCTCCCTGCATTGCTCCTGCGCAAGAAGCAAAGGTGAGGGGCTGGGTATGGCTC 5579 
                ************************************************************ 
 
CP+H1B-G        GTCCTGGCCCCTCTAAGGTGGATCTCGGTGGTTTCTAGATGTGACAGCACCCTTAGTGGA 5636 
CP+H1C-A        GTCCTGGCCCCTCTAAGGTGGATCTCGGTGGTTTCTAGATGTGACAGCACCCTTAGTGGA 5639 
                ************************************************************ 
 
CP+H1B-G        TGAGGGAGCTCCCGGCAAGCAGGCTGCCGCGCAGCCCCACACGGAGATCCCAGAAGGAAC 5696 
CP+H1C-A        TGAGGGAGCTCCCGGCAAGCAGGCTGCCGCGCAGCCCCACACGGAGATCCCAGAAGGAAC 5699 
                ************************************************************ 
 
CP+H1B-G        CACAGGTGAGGGTAAGCCCCAGAGACCCCCAGGCAGTCAAGGCCCTGCTGGGTGCCCCAG 5756 
CP+H1C-A        CACAGGTGAGGGTAAGCCCCAGAGACCCCCAGGCAGTCAAGGCCCTGCTGGGTGCCCCAG 5759 
                ************************************************************ 
 
CP+H1B-G        CTGACCTGTGACAGAAGTGAGGGAGCTTTGCGTGTTTATCCTCCTGTGGGGCAGGAACAT 5816 
CP+H1C-A        CTGACCTGTGACAGAAGTGAGGGAGCTTTGCGTGTTTATCCTCCTGTGGGGCAGGAACAT 5819 
                ************************************************************ 
 
CP+H1B-G        GGGTGGATTCTGGCTCCTGGGAATCTTGGGTTGTGAGTAGCTCGATGCCTTGGTGCTCAG 5876 
CP+H1C-A        GGGTGGATTCTGGCTCCTGGGAATCTTGGGTTGTGAGTAGCTCGATGCCTTGGTGCTCAG 5879 
                ************************************************************ 
 
CP+H1B-G        TTACCTCCCTGGCTGCCTGCCAGCCTCTCAGAGCATTTAGGGCCTTCTGGACTTCTAGAT 5936 
CP+H1C-A        TTACCTCCCTGGCTGCCTGCCAGCCTCTCAGAGCATTTAGGGCCTTCTGGACTTCTAGAT 5939 
                ************************************************************ 
 
CP+H1B-G        GCTCCTCATCTTGCCTCAGTCAGCGCGTCAGTTCCAGAGACTTCTCTGCAGGGTTTTCTG 5996 
CP+H1C-A        GCTCCTCATCTTGCCTCAGTCAGCGCGTCAGTTCCAGAGACTTCTCTGCAGGGTTTTCTG 5999 
                ************************************************************ 
 
CP+H1B-G        GGGCAGGTGGTGGCAGACCCGTGCCTTCTTGACACCTGAGGTCAGTCCACCCTCCTGCTC 6056 
CP+H1C-A        GGGCAGGTGGTGGCAGACCCGTGCCTTCTTGACACCTGAGGTCAGTCCACCCTCCTGCTC 6059 
                ************************************************************ 
 
CP+H1B-G        AGACTGCCCAGCACAGGGTCACCTCCCAAGGGGTGGACCCCAAGATCACCTGAGCGCACA 6116 
CP+H1C-A        AGACTGCCCAGCACAGGGTCACCTCCCAAGGGGTGGACCCCAAGATCACCTGAGCGCACA 6119 
                ************************************************************ 
 
CP+H1B-G        GAGGGTGCAGATGACTGGACCACACCTTTTGGTGATCTTAATGAGGTGGTCCCAGAGGAG 6176 
CP+H1C-A        GAGGGTGCAGATGACTGGACCACACCTTTTGGTGATCTTAATGAGGTGGTCCCAGAGGAG 6179 
                ************************************************************ 
 
CP+H1B-G        CTCAGACATGCAATCTAGCATCCAGTTCTGGGACTCTGTCTCCTTTTCAAACGTATTCAT 6236 
CP+H1C-A        CTCAGACATGCAATCTAGCATCCAGTTCTGGGACTCTGTCTCCTTTTCAAACGTATTCAT 6239 
                ************************************************************ 
 
CP+H1B-G        GTAGAACAGGCATGACGAGAATGCCTTGTCAACATGGGTGATGGGGAATCAATCAGACAG 6296 
CP+H1C-A        GTAGAACAGGCATGACGAGAATGCCTTGTCAACATGGGTGATGGGGAATCAATCAGACAG 6299 
                ************************************************************ 
 
 
 
Appendices 
307 
 
CP+H1B-G        GGCGCATGCCCCGTGAGCCCATTGCCCGCCCTCCCATGCCCTCAGCAGCTGCCTGGGGAC 6356 
CP+H1C-A        GGCGCATGCCCCGTGAGCCCATTGCCCGCCCTCCCATGCCCTCAGCAGCTGCCTGGGGAC 6359 
                ************************************************************ 
 
CP+H1B-G        AGCCAATGGCCTGGGTGTTTCTGAGGCTACCACATGGCTTCCAGGAAACTCGAGAACCTT 6416 
CP+H1C-A        AGCCAATGGCCTGGGTGTTTCTGAGGCTACCACATGGCTTCCAGGAAACTCGAGAACCTT 6419 
                ************************************************************ 
 
CP+H1B-G        TCTCTCCCTTGCCTACACTCTTCACACAGGCCTGTGCTGGCCAGCGGTGGGGATCCGGCA 6476 
CP+H1C-A        TCTCTCCCTTGCCTACACTCTTCACACAGGCCTGTGCTGGCCAGCGGTGGGGATCCGGCA 6479 
                ************************************************************ 
 
CP+H1B-G        TTCCTATCTTAGGTGCAGAAAGTGACTGACTCATTGCAGGCCTGGGAGATAAGACTGATG 6536 
CP+H1C-A        TTCCTATCTTAGGTGCAGAGAGTGACTGACTCATTGCAGGCCTGGGAGATAAGACTGATG 6539 
                ******************* **************************************** 
 
CP+H1B-G        GCCCAGCCAGCAAGATGTATGGATTTCTCAGAGGCAGTGGCCTCTGTCATTGTCCTCAGG 6596 
CP+H1C-A        GCCCAGCCAGCAAGATGTATGGATTTCTCAGAGGCAGTGGCCTCTGTCATTGTCCTCAGG 6599 
                ************************************************************ 
 
CP+H1B-G        AAATGCTGGTGATTCTGGTGGCCTGAGGTCAATGCATGTCAACGTGGCCAACTTGCCTTA 6656 
CP+H1C-A        AAATGCTGGTGATTCTGGTGGCCTGAGGTCAATGCATGTCAACGTGGCCAACTTGCCTTA 6659 
                ************************************************************ 
 
CP+H1B-G        TAAACTTTTTTTCTGGACAATTGCGTGCACTGTCCTGTAACAGTGTCCTGTTGTTTATGA 6716 
CP+H1C-A        TAAACTTTTTTTCTGGACAATTGCGTGCACTGTCCTGTAACAGTGTCCTGTTGTTTATGA 6719 
                ************************************************************ 
 
CP+H1B-G        TGCAGAAATAGGTGTTTTTAAAGCCTATTGATTTTGGTACTATTAATGTGGTCAGGAACT 6776 
CP+H1C-A        TGCAGAAATAGGTGTTTTTAAAGCCTATTGATTTTGGTACTATTAATGTGGTCAGGAACT 6779 
                ************************************************************ 
 
CP+H1B-G        TTCTCAGTCTTTCTTGTTTGGGGTGAGCTGTGGCTTCCTAAACAGGAACCCAAGACACCC 6836 
CP+H1C-A        TTCTCAGTCTTTCTTGTTTGGGGTGAGCTGTGGCTTCCTAAACAGGAACCCAAGACACCC 6839 
                ************************************************************ 
 
CP+H1B-G        CCAAAAGCTGCTCACCAGCACTGCCAGCCTCCCTCTTACCAAGTAGCACCCGTTCAGGAC 6896 
CP+H1C-A        CCAAAAGCTGCTCACCAGCACTGCCAGCCTCCCTCTTACCAAGTAGCACCCGTTCAGGAC 6899 
                ************************************************************ 
 
CP+H1B-G        ATTCTGCGAAAGGCATTTGCCCAGAAGTTGGGAGGAAGGAAATGTAACATTTTGGGGCAC 6956 
CP+H1C-A        ATTCTGCGAAAGGCATTTGCCCAGAAGTTGGGAGGAAGGAAATGTAACATTTTGGGGCAC 6959 
                ************************************************************ 
 
CP+H1B-G        CTACCATATGCCAGGCACCAGGCTAAACGTGTTCACACAAATTCTCTTACTAACCCTCAC 7016 
CP+H1C-A        CTACCATATGCCAGGCACCAGGCTAAACGTGTTCACACAAATTCTCTTACTAACCCTCAC 7019 
                ************************************************************ 
 
CP+H1B-G        CATCCTTCTACAAGACAAACTAGTATCTTCATCTTGGGGTTCAAGATGAGGAAATGGAGG 7076 
CP+H1C-A        CATCCTTCTACAAGACAAACTAGTATCTTCATCTTGGGGTTCAAGATGAGGAAATGGAGG 7079 
                ************************************************************ 
 
CP+H1B-G        CTCAGAGAGGTTGAATGAATGCCGGTGCCTGGATATGAACCCCATCTGCCTGACTCCGCA 7136 
CP+H1C-A        CTCAGAGAGGTTGAATGAATGCCGGTGCCTGGATATGAACCCCATCTGCCTGACTCCGCA 7139 
                ************************************************************ 
 
CP+H1B-G        ACCCAGGCAAAGTCTTTCCTTGAACTTCCCAGCAGCCACTGCTTAGACACAGCCTCCACA 7196 
CP+H1C-A        ACCCAGGCAAAGTCTTTCCTTGAACTTCCCAGCAGCCACTGCTTAGACACAGCCTCCACA 7199 
                ************************************************************ 
 
CP+H1B-G        ACCATGGCTCAGCAGCAAATTGCTTCTCTGACCTCACTCAGCCTGTGTGTCCTTGTTGAG 7256 
CP+H1C-A        ACCATGGCTCAGCAGCAAATTGCTTCTCTGACCTCACTCAGCCTGTGTGTCCTTGTTGAG 7259 
                ************************************************************ 
 
CP+H1B-G        TGAGGCATTCAGGACCCTGGTCCCAAAGTGGAGAAAGTCTTTCCTACTAGGTCATAGCTA 7316 
CP+H1C-A        TGAGGCATTCAGGACCCTGGTCCCAAAGTGGAGAAAGTCTTTCCTACTAGGTCATAGCTA 7319 
                ************************************************************ 
 
CP+H1B-G        CACCTGCATGTGGGTGCTGTGCCTTTTGTTTAGTGAACTTTTATCACCAGCATCCTCAGC 7376 
CP+H1C-A        CACCTGCATGTGGGTGCTGTGCCTTTTGTTTAGTGAACTTTTATCACCAGCATCCTCAGC 7379 
                ************************************************************ 
 
 
 
Appendices 
308 
 
CP+H1B-G        AATGACATTTGCAGAGAAGCCAGAGCTGAGGCACCTTGGTATTCTTGGGATGTGACTTTC 7436 
CP+H1C-A        AATGACATTTGCAGAGAAGCCAGAGCTGAGGCACCTTGGTATTCTTGGGATGTGACTTTC 7439 
                ************************************************************ 
 
CP+H1B-G        CTGAATGTTTAAGGGAAAATGCCCGAAGGTACAGAGAGCTTGGTTTCTAGTAAACAATAA 7496 
CP+H1C-A        CTGAATGTTTAAGGGAAAATGCCCGAAGGTACAGAGAGCTTGGTTTCTAGTAAACAATAA 7499 
                ************************************************************ 
 
CP+H1B-G        CTGTCTTGCTTTTACCCCCCTTCATTTGCTGACACATACACCAGCACCCAACTTTTCTAT 7556 
CP+H1C-A        CTGTCTTGCTTTTACCCCCCTTCATTTGCTGACACATACACCAGCACCCAACTTTTCTAT 7559 
                ************************************************************ 
 
CP+H1B-G        ACAAAGTTGTCCAGCTGAAGAAGCAGGCATTGGAGACACCCCCAGCCTGGAAGACGAAGC 7616 
CP+H1C-A        ACAAAGAAGTCCAGCTGAAGAAGCAGGCATTGGAGACACCCCCAGCCTGGAAGACGAAGC 7619 
                ******  **************************************************** 
 
CP+H1B-G        TGCTGGTCACGTGACCCAAGCTCGCATGGTCAGTAAAAGCAAAGACGGGACTGGAAGCGA 7676 
CP+H1C-A        TGCTGGTCACGTGACCCAAGCTCGCATGGTCAGTAAAAGCAAAGACGGGACTGGAAGCGA 7679 
                ************************************************************ 
 
CP+H1B-G        TGACAAAAAAGCCAAGGGGGCTGATGGTAAAACGAAGATCGCCACACCGCGGGGAGCAGC 7736 
CP+H1C-A        TGACAAAAAAGCCAAGGGGGCTGATGGTAAAACGAAGATCGCCACACCGCGGGGAGCAGC 7739 
                ************************************************************ 
 
CP+H1B-G        CCCTCCAGGCCAGAAGGGCCAGGCCAACGCCACCAGGATTCCAGCAAAAACCCCGCCCGC 7796 
CP+H1C-A        CCCTCCAGGCCAGAAGGGCCAGGCCAACGCCACCAGGATTCCAGCAAAAACCCCGCCCGC 7799 
                ************************************************************ 
 
CP+H1B-G        TCCAAAGACACCACCCAGCTCTGGTGAACCTCCAAAATCAGGGGATCGCAGCGGCTACAG 7856 
CP+H1C-A        TCCAAAGACACCACCCAGCTCTGGTGAACCTCCAAAATCAGGGGATCGCAGCGGCTACAG 7859 
                ************************************************************ 
 
CP+H1B-G        CAGCCCCGGCTCCCCAGGCACTCCCGGCAGCCGCTCCCGCACCCCGTCCCTTCCAACCCC 7916 
CP+H1C-A        CAGCCCCGGCTCCCCAGGCACTCCCGGCAGCCGCTCCCGCACCCCGTCCCTTCCAACCCC 7919 
                ************************************************************ 
 
CP+H1B-G        ACCCACCCGGGAGCCCAAGAAGGTGGCAGTGGTCCGTACTCCACCCAAGTCGCCGTCTTC 7976 
CP+H1C-A        ACCCACCCGGGAGCCCAAGAAGGTGGCAGTGGTCCGTACTCCACCCAAGTCGCCGTCTTC 7979 
                ************************************************************ 
 
CP+H1B-G        CGCCAAGAGCCGCCTGCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAATGTCAAGTC 8036 
CP+H1C-A        CGCCAAGAGCCGCCTGCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAATGTCAAGTC 8039 
                ************************************************************ 
 
CP+H1B-G        CAAGATCGGCTCCACTGAGAACCTGAAGCACCAGCCGGGAGGCGGGAAGTCTAGAGTGAG 8096 
CP+H1C-A        CAAGATCGGCTCCACTGAGAACCTGAAGCACCAGCCGGGAGGCGGGAAGTCTAGAGTGAG 8099 
                ************************************************************ 
 
CP+H1B-G        AGTGGCTGGCTGCGCGTGGAGGTGTGGGGGGCTGCGCCTGGAGGGGTAGGGCTGTGCCTG 8156 
CP+H1C-A        AGTGGCTGGCTGCGCGTGGAGGTGTGGGGGGCTGCGCCTGGAGGGGTAGGGCTGTGCCTG 8159 
                ************************************************************ 
 
CP+H1B-G        GAAGGGTAGGGCTGCGCCTGGAGGTGCGCGGTTGAGCGTGGAGTCGTGGGACTGTGCATG 8216 
CP+H1C-A        GAAGGGTAGGGCTGCGCCTGGAGGTGCGCGGTTGAGCGTGGAGTCGTGGGACTGTGCATG 8219 
                ************************************************************ 
 
CP+H1B-G        GAGGTGTGGGGCTCCCCGCACCTGAGCACCCCCGCATAACACCCCAGTCCCCTCTGGACC 8276 
CP+H1C-A        GAGGTGTGGGGCTCCCCGCACCTGAGCACCCCCGCATAACACCCCAGTCCCCTCTGGACC 8279 
                ************************************************************ 
 
CP+H1B-G        CTCTTCAAGGAAGTTCAGTTCTTTATTGGGCTCTCCACTACACTGTGAGTGCCCTCCTCA 8336 
CP+H1C-A        CTCTTCAAGGAAGTTCAGTTCTTTATTGGGCTCTCCACTACACTGTGAGTGCCCTCCTCA 8339 
                ************************************************************ 
 
CP+H1B-G        GGCGAGAGAACGTTCTGGCTCTTCTCTTGCCCCTTCAGCCCCTGTTAATCGGACAGAGAT 8396 
CP+H1C-A        GGCGAGAGAACGTTCTGGCTCTTCTCTTGCCCCTTCAGCCCCTGTTAATCGGACAGAGAT 8399 
                ************************************************************ 
 
CP+H1B-G        GGCAGGGCTGTGTCTCCACGGCCGGAGGCTCTCATAGTCAGGGCACCCACAGCGGTTCCC 8456 
CP+H1C-A        GGCAGGGCTGTGTCTCCACGGCCGGAGGCTCTCATAGTCAGGGCACCCACAGCGGTTCCC 8459 
                ************************************************************ 
 
 
 
Appendices 
309 
 
CP+H1B-G        CACCTGCCTTCTGGGCAGAATACACTGCCACCCATAGGTCAGCATCTCCACTCGTGGGCC 8516 
CP+H1C-A        CACCTGCCTTCTGGGCAGAATACACTGCCACCCATAGGTCAGCATCTCCACTCGTGGGCC 8519 
                ************************************************************ 
 
CP+H1B-G        ATCTGCTTAGGTTGGGTTCCTCTGGATTCTGGGGAGATTGGGGGTTCTGTTTTGATCAGC 8576 
CP+H1C-A        ATCTGCTTAGGTTGGGTTCCTCTGGATTCTGGGGAGATTGGGGGTTCTGTTTTGATCAGC 8579 
                ************************************************************ 
 
CP+H1B-G        TGATTCTTCTGGGAGCAAGTGGGTGCTCGCGAGCTCTCCAGCTTCCTAAAGGTGGAGAAG 8636 
CP+H1C-A        TGATTCTTCTGGGAGCAAGTGGGTGCTCGCGAGCTCTCCAGCTTCCTAAAGGTGGAGAAG 8639 
                ************************************************************ 
 
CP+H1B-G        CACAGACTTCAGGGGCCTGGCCTGGATCCCTTTCCCCATTCCTGTCCCTGTGCCCCTCGT 8696 
CP+H1C-A        CACAGACTTCGGGGGCCTGGCCTGGATCCCTTTCCCCATTCCTGTCCCTGTGCCCCTCGT 8699 
                ********** ************************************************* 
 
CP+H1B-G        CTGGGTGCGTTACCATGGTTTTCTATTTCATAGTTCTTAGGCAAATTGGTAAAAATCATT 8756 
CP+H1C-A        CTGGGTGCGTTACCATGGTTTTCTATTTCATAGTTCTTAGGCAAATTGGTAAAAATCATT 8759 
                ************************************************************ 
 
CP+H1B-G        TCTCATCAAAACGCTGATATTTTCACACCTCCCTGGTGTCTGCAGAAAGAACCTTCCAGA 8816 
CP+H1C-A        TCTCATCAAAACGCTGATATTTTCACACCTCCCTGGTGTCTGCAGAAAGAACCTTCCAGA 8819 
                ************************************************************ 
 
CP+H1B-G        AATGCAGTCGTGGGAGACCCATCCAGGCCACCCCTGCTTATGGAAGAGCTGAGAAAAAGC 8876 
CP+H1C-A        AATGCAGTCGTGGGAGACCCATCCAGGCCACCCCTGCTTATGGAAGAGCTGAGAAAAAGC 8879 
                ************************************************************ 
 
CP+H1B-G        CCCACGGGGGCATTTGCTCAGCTTCCGTTACGCACCTAGTGGCATTGTGGGTGGGAGAGG 8936 
CP+H1C-A        CCCACGGGAGCATTTGCTCAGCTTCCGTTACGCACCTAGTGGCATTGTGGGTGGGAGAGG 8939 
                ******** *************************************************** 
 
CP+H1B-G        GCTGGTGGGTGGATGGAAGGAGAAGGCACAGCCCCCCCTTGCAGGGACAGAGCCCTCGTA 8996 
CP+H1C-A        GCTGGTGGGTGGATGGAAGGAGAAGGCACAGCCCCCCCTTGCAGGGACAGAGCCCTCGTA 8999 
                ************************************************************ 
 
CP+H1B-G        CAGAAGGGACACCCCACATTTGTCTTCCCCACAAAGCGGCCTGTGTCCTGCCTACGGGGT 9056 
CP+H1C-A        CAGAAGGGACACCCCACATTTGTCTTCCCCACAAAGCGGCCTGTGTCCTGCCTACGGGGT 9059 
                ************************************************************ 
 
CP+H1B-G        CAGGGCTTCTCAAACCTGGCTGTGTGTCAGAATCACCAGGGGAACTTTTCAAAACTAGAG 9116 
CP+H1C-A        CAGGGCTTCTCAAACCTGGCTGTGTGTCAGAATCACCAGGGGAACTTTTCAAAACTAGAG 9119 
                ************************************************************ 
 
CP+H1B-G        AGACTGAAGCCAGACTCCTAGATTCTAATTCTAGGTCAGGGCTAGGGGCTGAGATTGTAA 9176 
CP+H1C-A        AGACTGAAGCCAGACTCCTAGATTCTAATTCTAGGTCAGGGCTAGGGGCTGAGATTGTAA 9179 
                ************************************************************ 
 
CP+H1B-G        AAATCCACAGGTGATTCTGATGCCCGGCAGGCTTGAGAACAGCCGCAGGGAGTTCTCTGG 9236 
CP+H1C-A        AAATCCACAGGTGATTCTGATGCCCGGCAGGCTTGAGAACAGCCGCAGGGAGTTCTCTGG 9239 
                ************************************************************ 
 
CP+H1B-G        GAATGTGCCGGTGGGTCTAGCCAGGTGTGAGTGGAGATGCCGGGGAACTTCCTATTACTC 9296 
CP+H1C-A        GAATGTGCCGGTGGGTCTAGCCAGGTGTGAGTGGAGATGCCGGGGAACTTCCTATTACTC 9299 
                ************************************************************ 
 
CP+H1B-G        ACTCGTCAGTGTGGCCGAACATATTTTTCACTTGACCTCAGGCTGGTGAACGCTCCCCTC 9356 
CP+H1C-A        ACTCGTCAGTGTGGCCGAACACATTTTTCACTTGACCTCAGGCTGGTGAACGCTCCCCTC 9359 
                ********************* ************************************** 
 
CP+H1B-G        TGGGGTTCAGGCCTCACGATGCCATCCTTTTGTGAAGTGAGGACCTGCAATCCCAGCTTC 9416 
CP+H1C-A        TGGGGTTCAGGCCTCACGATGCCATCCTTTTGTGAAGTGAGGACCTGCAATCCCAGCTTC 9419 
                ************************************************************ 
 
CP+H1B-G        GTAAAGCCCGCTGGAAATCACTCACACTTCTGGGATGCCTTCAGAGCAGCCCTCTATCCC 9476 
CP+H1C-A        GTAAAGCCCGCTGGAAATCACTCACACTTCTGGGATGCCTTCAGAGCAGCCCTCTATCCC 9479 
                ************************************************************ 
 
CP+H1B-G        TTCAGCTCCCCTGGGATGTGACTCAACCTCCCGTCACTCCCCAGACTGCCTCTGCCAAGT 9536 
CP+H1C-A        TTCAGCTCCCCTGGGATGTGACTCAACCTCCCGTCACTCCCCAGACTGCCTCTGCCAAGT 9539 
                ************************************************************ 
 
 
 
Appendices 
310 
 
CP+H1B-G        CCGAAAGTGGAGGCATCCTTGCGAGCAAGTAGGCGGGTCCAGGGTGGCGCATGTCACTCA 9596 
CP+H1C-A        CCGAAAGTGGAGGCATCCTTGCGAGCAAGTAGGCGGGTCCAGGGTGGCGCATGTCACTCA 9599 
                ************************************************************ 
 
CP+H1B-G        TCGAAAGTGGAGGCGTCCTTGCGAGCAAGCAGGCGGGTCCAGGGTGGCGTGTCACTCATC 9656 
CP+H1C-A        TCGAAAGTGGAGGCGTCCTTGCGAGCAAGCAGGCGGGTCCAGGGTGGCGTGTCACTCATC 9659 
                ************************************************************ 
 
CP+H1B-G        CTTTTTTCTGGCTACCAAAGGTGCAGATAATTAATAAGAAGCTGGATCTTAGCAACGTCC 9716 
CP+H1C-A        CTTTTTTCTGGCTACCAAAGGTGCAGATAATTAATAAGAAGCTGGATCTTAGCAACGTCC 9719 
                ************************************************************ 
 
CP+H1B-G        AGTCCAAGTGTGGCTCAAAGGATAATATCAAACACGTCCCGGGAGGCGGCAGTGTGAGTA 9776 
CP+H1C-A        AGTCCAAGTGTGGCTCAAAGGATAATATCAAACACGTCCCGGGAGGCGGCAGTGTGAGTA 9779 
                ************************************************************ 
 
CP+H1B-G        CCTTCACACGTCCCATGCGCCGTGCTGTGGCTTGAATTATTAGGAAGTGGTGTGAGTGCG 9836 
CP+H1C-A        CCTTCACACGTCCCATGCGCCGTGCTGTGGCTTGAATTATTAGGAAGTGGTGTGAGTGCG 9839 
                ************************************************************ 
 
CP+H1B-G        TACACTTGCGAGACACTGCATAGAATAAATCCTTCTTGGGCTCTCAGGATCTGGCTGCGA 9896 
CP+H1C-A        TACACTTGCGAGACACTGCATAGAATAAATCCTTCTTGGGCTCTCAGGATCTGGCTGCGA 9899 
                ************************************************************ 
 
CP+H1B-G        CCTCTGGGTGAATGTAGCCCGGCTCCCCACATTCCCCCACACGGTCCACTGTTCCCAGAA 9956 
CP+H1C-A        CCTCTGGGTGAATGTAGCCCGGCTCCCCACATTCCCCCACACGGTCCACTGTTCCCAGAA 9959 
                ************************************************************ 
 
CP+H1B-G        GCCCCTTCCTCATATTCTAGGAGGGGGTGTCCCAGCATTTCTGGGTCCCCCAGCCTGCGC 10016 
CP+H1C-A        GCCCCTTCCTCATATTCTAGGAGGGGGTGTCCCAGCATTTCTGGGTCCCCCAGCCTGCGC 10019 
                ************************************************************ 
 
CP+H1B-G        AGGCTGTGTGGACAGAATAGGGCAGATGACGGACCCTCTCTCCGGACCCTGCCTGGGAAG 10076 
CP+H1C-A        AGGCTGTGTGGACAGAATAGGGCAGATGACGGACCCTCTCTCCGGACCCTGCCTGGGAAG 10079 
                ************************************************************ 
 
CP+H1B-G        CTGAGAATACCCATCAAAGTCTCCTTCCACTCATGCCCAGCCCTGTCCCCAGGAGCCCCA 10136 
CP+H1C-A        CTGAGAATACCCATCAAAGTCTCCTTCCACTCATGCCCAGCCCTGTCCCCAGGAGCCCCA 10139 
                ************************************************************ 
 
CP+H1B-G        TAGCCCATTGGAAGTTGGGCTGAAGGTGGTGGCACCTGAGACTGGGCTGCCGCCTCCTCC 10196 
CP+H1C-A        TAGCCCATTGGAAGTTGGGCTGAAGGTGGTGGCACCTGAGACTGGGCTGCCGCCTCCTCC 10199 
                ************************************************************ 
 
CP+H1B-G        CCCGACACCTGGGCAGGTTGACGTTGAGTGGCTCCACTGTGGACAGGTGACCCGTTTGTT 10256 
CP+H1C-A        CCCGACACCTGGGCAGGTTGACGTTGAGTGGCTCCACTGTGGACAGGTGACCCGTTTGTT 10259 
                ************************************************************ 
 
CP+H1B-G        CTGATGAGCGGACACCAAGGTCTTACTGTCCTGCTCAGCTGCTGCTCCTACACGTTCAAG 10316 
CP+H1C-A        CTGATGAGCGGACACCAAGGTCTTACTGTCCTGCTCAGCTGCTGCTCCTACACGTTCAAG 10319 
                ************************************************************ 
 
CP+H1B-G        GCAGGAGCCGATTCCTAAGCCTCCAGCTTATGCTTAGCCTGCGCCACCCTCTGGCAGAGA 10376 
CP+H1C-A        GCAGGAGCCGATTCCTAAGCCTCCAGCTTATGCTTAGCCTGCGCCACCCTCTGGCAGAGA 10379 
                ************************************************************ 
 
CP+H1B-G        CTCCAGATGCAAAGAGCCAAACCAAAGTGGCATGCCTCGAGCTTACTGAGACACTAAATC 10436 
CP+H1C-A        CTCCAGATGCAAAGAGCCAAACCAAAATGGCATGCCTCGAGCTTACTGAGACACTAAATC 10439 
                ************************** ********************************* 
 
CP+H1B-G        TGTTGGTTTCTGCTGTGCCACCTACCCACCCTGTTGGTGTTGCTTTGTTCCTATTGCTAA 10496 
CP+H1C-A        TGTTGGTTTCTGCTGTGCCACCTACCCACCCTGTTGGTGTTGCTTTGTTCCTATTGCTAA 10499 
                ************************************************************ 
 
CP+H1B-G        AGACAGGAATGTCCAGGACACTGAGTGTGCAGGTGCCTGCTGGTTCTCACGTCCGAGCTG 10556 
CP+H1C-A        AGACAGGAATGTCCAGGACACTGAGTGTGCAGGTGCCTGCTGGTTCTCACGTCCGAGCTG 10559 
                ************************************************************ 
 
CP+H1B-G        CTGAACTCCGCTGGGTCCTGCTTACTGATGGTCTTTGCTCTAGTGCTTTCCAGGGTCCGT 10616 
CP+H1C-A        CTGAACTCCGCTGGGTCCTGCTTACTGATGGTCTTTGCTCTAGTGCTTTCCAGGGTCCGT 10619 
                ************************************************************ 
 
 
 
Appendices 
311 
 
CP+H1B-G        GGAAGCTTTTCCTGGAATAAAGCCCACGCATCGACCCTCACAGCGCCTCCCCTCTTTGAG 10676 
CP+H1C-A        GGAAGCTTTTCCTGGAATAAAGCCCACGCATCGACCCTCACAGCGCCTCCCCTCTTTGAG 10679 
                ************************************************************ 
 
CP+H1B-G        GCCCAGCAGATACCCCACTCCTGCCTTTCCAGCAAGATTTTTCAGATGCTGTGCATACTC 10736 
CP+H1C-A        GCCCAGCAGATACCCCACTCCTGCCTTTCCAGCAAGATTTTTCAGATGCTGTGCATACTC 10739 
                ************************************************************ 
 
CP+H1B-G        ATCATATTGATCACTTTTTTCTTCATGCCTGATTGTGATCTGTCAATTTCATGTCAGGAA 10796 
CP+H1C-A        ATCATATTGATCACTTTTTTCTTCATGCCTGATTGTGATCTGTCAATTTCATGTCAGGAA 10799 
                ************************************************************ 
 
CP+H1B-G        AGGGAGTGACATTTTTACACTTAAGCGTTTGCTGAGCAAATGTCTGGGTCTTGCACAATG 10856 
CP+H1C-A        AGGGAGTGACATTTTTACACTTAAGCGTTTGCTGAGCAAATGTCTGGGTCTTGCACAATG 10859 
                ************************************************************ 
 
CP+H1B-G        ACAATGGGTCCCTGTTTTTCCCAGAGGCTCTTTTGTTCTGCAGGGATTGAAGACACTCCA 10916 
CP+H1C-A        ACAATGGGTCCCTGTTTTTCCCAGAGGCTCTTTTGTTCTGCAGGGATTGAAGACACTCCA 10919 
                ************************************************************ 
 
CP+H1B-G        GTCCCACAGTCCCCAGCTCCCCTGGGGCAGGGTTGGCAGAATTTCGACAACACATTTTTC 10976 
CP+H1C-A        GTCCCACAGTCCCCAGCTCCCCTGGGGCAGGGTTGGCAGAATTTCGACAACACATTTTTC 10979 
                ************************************************************ 
 
CP+H1B-G        CACCCTGACTAGGATGTGCTCCTCATGGCAGCTGGGAACCACTGTCCAATAAGGGCCTGG 11036 
CP+H1C-A        CACCCTGACTAGGATGTGCTCCTCATGGCAGCTGGGAACCACTGTCCAATAAGGGCCTGG 11039 
                ************************************************************ 
 
CP+H1B-G        GCTTACACAGCTGCTTCTCATTGAGTTACACCCTTAATAAAATAATCCCATTTTATCCTT 11096 
CP+H1C-A        GCTTACACAGCTGCTTCTCATTGAGTTACACCCTTAATAAAATAATCCCATTTTATCCTT 11099 
                ************************************************************ 
 
CP+H1B-G        TTTGTCTCTCTGTCTTCCTCTCTCTCTGCCTTTCCTCTTCTCTCTCCTCCTCTCTCATCT 11156 
CP+H1C-A        TTTGTCTCTCTGTCTTCCTCTCTCTCTGCCTTTCCTCTTCTCTCTCCTCCTCTCTCATCT 11159 
                ************************************************************ 
 
CP+H1B-G        CCAGGTGCAAATAGTCTACAAACCAGTTGACCTGAGCAAGGTGACCTCCAAGTGTGGCTC 11216 
CP+H1C-A        CCAGGTGCAAATAGTCTACAAACCAGTTGACCTGAGCAAGGTGACCTCCAAGTGTGGCTC 11219 
                ************************************************************ 
 
CP+H1B-G        ATTAGGCAACATCCATCATAAACCAGGACGTCGAGGTGGCCAGGTGGAAGTAAAATCTGA 11276 
CP+H1C-A        ATTAGGCAACATCCATCATAAACCAGGACGTCGAGGTGGCCAGGTGGAAGTAAAATCTGA 11279 
                ************************************************************ 
 
CP+H1B-G        GAAGCTTGACTTCAAGGACAGAGTCCAGTCGAAGATTGGGTCCCTGGACAATATCACCCA 11336 
CP+H1C-A        GAAGCTTGACTTCAAGGACAGAGTCCAGTCGAAGATTGGGTCCCTGGACAATATCACCCA 11339 
                ************************************************************ 
 
CP+H1B-G        CGTCCCTGGCGGAGGAAATAAAAAGATTGAAACCCACAAGCTGACCTTCCGCGAGAACGC 11396 
CP+H1C-A        CGTCCCTGGCGGAGGAAATAAAAAGATTGAAACCCACAAGCTGACCTTCCGCGAGAACGC 11399 
                ************************************************************ 
 
CP+H1B-G        CAAAGCCAAGACAGACCACGGGGCGGAGATCGTGTACAAGTCGCCAGTGGTGTCTGGGGA 11456 
CP+H1C-A        CAAAGCCAAGACAGACCACGGGGCGGAGATCGTGTACAAGTCGCCAGTGGTGTCTGGGGA 11459 
                ************************************************************ 
 
CP+H1B-G        CACGTCTCCACGGCATCTCAGCAATGTCTCCTCCACCGGCAGCATCGACATGGTAGACTC 11516 
CP+H1C-A        CACGTCTCCACGGCATCTCAGCAATGTCTCCTCCACCGGCAGCATCGACATGGTAGACTC 11519 
                ************************************************************ 
 
CP+H1B-G        GCCCCAGCTCGCCACGCTAGCTGACGAGGTGTCTGCCTCCCTGGCCAAGCAGGGTTTGGA 11576 
CP+H1C-A        GCCCCAGCTCGCCACGCTAGCTGACGAGGTGTCTGCCTCCCTGGCCAAGCAGGGTTTGGA 11579 
                ************************************************************ 
 
CP+H1B-G        TTACAAGGATGACGACGATAAGTGAACAACTTTGTATAATAAAGTTGTCCCTGGGGCGGT 11636 
CP+H1C-A        TTACAAGGATGACGACGATAAGTGAACAACTTTGTATAATAAAGTTGTCCCTGGGGCGGT 11639 
                ************************************************************ 
 
CP+H1B-G        CAATAATTGTGGGGAGGAGAGAATGAGAGAGTGTGGAAAAAAAAAGAATAATGACCCGGC 11696 
CP+H1C-A        CAATAATTGTGGAGAGGAGAGAATGAGAGAGTGTGGAAAAAAAAAGAATAATGACCCGGC 11699 
                ************ *********************************************** 
 
 
 
Appendices 
312 
 
CP+H1B-G        CCCCGCCCTCTGCCCCCAGCTGCTCCTCGCAGTTCGGTTAATTGGTTAATCACTTAACCT 11756 
CP+H1C-A        CCCCGCCCTCTGCCCCCAGCTGCTCCTCGCAGTTCGGTTAATTGGTTAATCACTTAACCT 11759 
                ************************************************************ 
 
CP+H1B-G        GCTTTTGTCACTCGGCTTTGGCTCGGGACTTCAAAATCAGTGATGGGAGTAAGAGCAAAT 11816 
CP+H1C-A        GCTTTTGTCACTCGGCTTTGGCTCGGGACTTCAAAATCAGTGATGGGAGTAAGAGCAAAT 11819 
                ************************************************************ 
 
CP+H1B-G        TTCATCTTTCCAAATTGATGGGTGGGCTAGTAATAAAATATTTAAAAAAAAACATTCAAA 11876 
CP+H1C-A        TTCATCTTTCCAAATTGATGGGTGGGCTAGTAATAAAATATTTAAAAAAAAACATTCAAA 11879 
                ************************************************************ 
 
CP+H1B-G        AACATGGCCACATCCAACATTTCCTCAGGCAATTCCTTTTGATTCTTTTTTCTTCCCCCT 11936 
CP+H1C-A        AACATGGCCACATCCAACATTTCCTCAGGCAATTCCTTTTGATTCTTTTTTCTTCCCCCT 11939 
                ************************************************************ 
 
CP+H1B-G        CCATGTAGAAGAGGGAGAAGGAGAGGCTCTGAAAGCTGCTTCTGGGGGATTTCAAGGGAC 11996 
CP+H1C-A        CCATGTAGAAGAGGGAGAAGGAGAGGCTCTGAAAGCTGCTTCTGGGGGATTTCAAGGGAC 11999 
                ************************************************************ 
 
CP+H1B-G        TGGGGGTGCCAACCACCTCTGGCCCTGTTGTGGGGGTGTCACAGAGGCAGTGGCAGCAAC 12056 
CP+H1C-A        TGGGGGTGCCAACCACCTCTGGCCCTGTTGTGGGGGTGTCACAGAGGCAGTGGCAGCAAC 12059 
                ************************************************************ 
 
CP+H1B-G        AAAGGATTTGAAACTTGGTGTGTTCGTGGAGCCACAGGCAGACGATGTCAACCTTGTGTG 12116 
CP+H1C-A        AAAGGATTTGAAACTTGGTGTGTTCGTGGAGCCACAGGCAGACGATGTCAACCTTGTGTG 12119 
                ************************************************************ 
 
CP+H1B-G        AGTGTGACGGGGGTTGGGGTGGGGCGGGAGGCCACGGGGGAGGCCGAGGCAGGGGCTGGG 12176 
CP+H1C-A        AGTGTGACGGGGGTTGGGGTGGGGCGGGAGGCCACGGGGGAGGCCGAGGCAGGGGCTGGG 12179 
                ************************************************************ 
 
CP+H1B-G        CAGAGGGGAGAGGAAGCACAAGAAGTGGGAGTGGGAGAGGAAGCCACGTGCTGGAGAGTA 12236 
CP+H1C-A        CAGAGGGGAGAGGAAGCACAAGAAGTGGGAGTGGGAGAGGAAGCCACGTGCTGGAGAGTA 12239 
                ************************************************************ 
 
CP+H1B-G        GACATCCCCCTCCTTGCCGCTGGGAGAGCCAAGGCCTATGCCACCTGCAGCGTCTGAGCG 12296 
CP+H1C-A        GACATCCCCCTCCTTGCCGCTGGGAGAGCCAAGGCCTATGCCACCTGCAGCGTCTGAGCG 12299 
                ************************************************************ 
 
CP+H1B-G        GCCGCCTGTCCTTGGTGGCCGGGGGTGGGGGCCTGCTGTGGGTCAGTGTGCCACCCTCTG 12356 
CP+H1C-A        GCCGCCTGTCCTTGGTGGCCGGGGGTGGGGGCCTGCTGTGGGTCAGTGTGCCACCCTCTG 12359 
                ************************************************************ 
 
CP+H1B-G        CAGGGCAGCCTGTGGGAGAAGGGACAGCGGGTAAAAAGAGAAGGCAAGCTGGCAGGAGGG 12416 
CP+H1C-A        CAGGGCAGCCTGTGGGAGAAGGGACAGCGGGTAAAAAGAGAAGGCAAGCTGGCAGGAGGG 12419 
                ************************************************************ 
 
CP+H1B-G        TGGCACTTCGTGGATGACCTCCTTAGAAAAGACTGACCTTGATGTCTTGAGAGCGCTGGC 12476 
CP+H1C-A        TGGCACTTCGTGGATGACCTCCTTAGAAAAGACTGACCTTGATGTCTTGAGAGCGCTGGC 12479 
                ************************************************************ 
 
CP+H1B-G        CTCTTCCTCCCTCCCTGCAGGGTAGGGGGCCTGAGTTGAGGGGCTTCCCTCTGCTCCACA 12536 
CP+H1C-A        CTCTTCCTCCCTCCCTGCAGGGTAGGGGGCCTGAGTTGAGGGGCTTCCCTCTGCTCCACA 12539 
                ************************************************************ 
 
CP+H1B-G        GAAACCCTGTTTTATTGAGTTCTGAAGGTTGGAACTGCTGCCATGATTTTGGCCACTTTG 12596 
CP+H1C-A        GAAACCCTGTTTTATTGAGTTCTGAAGGTTGGAACTGCTGCCATGATTTTGGCCACTTTG 12599 
                ************************************************************ 
 
CP+H1B-G        CAGACCTGGGACTTTAGGGCTAACCAGTTCTCTTTGTAAGGACTTGTGCCTCTTGGGAGA 12656 
CP+H1C-A        CAGACCTGGGACTTTAGGGCTAACCAGTTCTCTTTGTAAGGACTTGTGCCTCTTGGGAGA 12659 
                ************************************************************ 
 
CP+H1B-G        CGTCCACCCGTTTCCAAGCCTGGGCCACTGGCATCTCTGGAGTGTGTGGGGGTCTGGGAG 12716 
CP+H1C-A        CGTCCACCCGTTTCCAAGCCTGGGCCACTGGCATCTCTGGAGTGTGTGGGGGTCTGGGAG 12719 
                ************************************************************ 
 
CP+H1B-G        GCAGGTCCCGAGCCCCCTGTCCTTCCCACGGCCACTGCAGTCACCCCGTCTGCGCCGCTG 12776 
CP+H1C-A        GCAGGTCCCGAGCCCCCTGTCCTTCCCACGGCCACTGCAGTCACCCCGTCTGCGCCGCTG 12779 
                ************************************************************ 
 
 
 
Appendices 
313 
 
CP+H1B-G        TGCTGTTGTCTGCCGTGAGAGCCCAATCACTGCCTATACCCCTCATCACACGTCACAATG 12836 
CP+H1C-A        TGCTGTTGTCTGCCGTGAGAGCCCAATCACTGCCTATACCCCTCATCACACGTCACAATG 12839 
                ************************************************************ 
 
CP+H1B-G        TCCCGAATTCCCAGCCTCACCACCCCTTCTCAGTAATGACCCTGGTTGGTTGCAGGAGGT 12896 
CP+H1C-A        TCCCGAATTCCCAGCCTCACCACCCCTTCTCAGTAATGACCCTGGTTGGTTGCAGGAGGT 12899 
                ************************************************************ 
 
CP+H1B-G        ACCTACTCCATACTGAGGGTGAAATTAAGGGAAGGCAAAGTCCAGGCACAAGAGTGGGAC 12956 
CP+H1C-A        ACCTACTCCATACTGAGGGTGAAATTAAGGGAAGGCAAAGTCCAGGCACAAGAGTGGGAC 12959 
                ************************************************************ 
 
CP+H1B-G        CCCAGCCTCTCACTCTCAGTTCCACTCATCCAACTGGGACCCTCACCACGAATCTCATGA 13016 
CP+H1C-A        CCCAGCCTCTCACTCTCAGTTCCACTCATCCAACTGGGACCCTCACCACGAATCTCATGA 13019 
                ************************************************************ 
 
CP+H1B-G        TCTGATTCGGTTCCCTGTCTCCTTCTCCCGTCACAGATGTGAGCCAGGGCACTGCTCAGC 13076 
CP+H1C-A        TCTGATTCGGTTCCCTGTCTCCTCCTCCCGTCACAGATGTGAGCCAGGGCACTGCTCAGC 13079 
                *********************** ************************************ 
 
CP+H1B-G        TGTGACCCTAGGTGTTTCTGCCTTGTTGACATGGAGAGAGCCCTTTCCCCTGAGAAGGCC 13136 
CP+H1C-A        TGTGACCCTAGGTGTTTCTGCCTTGTTGACATGGAGAGAGCCCTTTCCCCTGAGAAGGCC 13139 
                ************************************************************ 
 
CP+H1B-G        TGGCCCCTTCCTGTGCTGAGCCCACAGCAGCAGGCTGGGTGTCTTGGTTGTCAGTGGTGG 13196 
CP+H1C-A        TGGCCCCTTCCTGTGCTGAGCCCACAGCAGCAGGCTGGGTGTCTTGGTTGTCAGTGGTGG 13199 
                ************************************************************ 
 
CP+H1B-G        CACCAGGATGGAAGGGCAAGGCACCCAGGGCAGGCCCACAGTCCCGCTGTCCCCCACTTG 13256 
CP+H1C-A        CACCAGGATGGAAGGGCAAGGCACCCAGGGCAGGCCCACAGTCCCGCTGTCCCCCACTTG 13259 
                ************************************************************ 
 
CP+H1B-G        CACCCTAGCTTGTAGCTGCCAACCTCCCAGACAGCCCAGCCCGCTGCTCAGCTCCACATG 13316 
CP+H1C-A        CACCCTAGCTTGTAGCTGCCAACCTCCCAGACAGCCCAGCCCGCTGCTCAGCTCCACATG 13319 
                ************************************************************ 
 
CP+H1B-G        CATAGTATCAGCCCTCCACACCCGACAAAGGGGAACACACCCCCTTGGAAATGGTTCTTT 13376 
CP+H1C-A        CATAGTATCAGCCCTCCACACCCGACAAAGGGGAACACACCCCCTTGGAAATGGTTCTTT 13379 
                ************************************************************ 
 
CP+H1B-G        TCCCCCAGTCCCAGCTGGAAGCCATGCTGTCTGTTCTGCTGGAGCAGCTGAACATATACA 13436 
CP+H1C-A        TCCCCCAGTCCCAGCTGGAAGCCATGCTGTCTGTTCTGCTGGAGCAGCTGAACATATACA 13439 
                ************************************************************ 
 
CP+H1B-G        TAGATGTTGCCCTGCCCTCCCCATCTGCACCCTGTTGAGTTGTAGTTGGATTTGTCTGTT 13496 
CP+H1C-A        TAGATGTTGCCCTGCCCTCCCCATCTGCACCCTGTTGAGTTGTAGTTGGATTTGTCTGTT 13499 
                ************************************************************ 
 
CP+H1B-G        TATGCTTGGATTCACCAGAGTGACTATGATAGTGAAAAGAAAAAAAAAAAAAAA---GGA 13553 
CP+H1C-A        TATGCTTGGATTCACCAGAGTGACTATGATAGTGAAAAGAAAAAAAAAAAAAAAAAAGGA 13559 
                ******************************************************   *** 
 
CP+H1B-G        CGCATGTATCTTGAAATGCTTGTAAAGAGGTTTCTAACCCACCCTCACGAGGTGTCTCTC 13613 
CP+H1C-A        CGCATGTATCTTGAAATGCTTGTAAAGAGGTTTCTAACCCACCCTCACGAGGTGTCTCTC 13619 
                ************************************************************ 
 
CP+H1B-G        ACCCCCACACTGGGACTCGTGTGGCCTGTGTGGTGCCACCCTGCTGGGGCCTCCCAAGTT 13673 
CP+H1C-A        ACCCCCACACTGGGACTCGTGTGGCCTGTGTGGTGCCACCCTGCTGGGGCCTCCCAAGTT 13679 
                ************************************************************ 
 
CP+H1B-G        TTGAAAGGCTTTCCTCAGCACCTGGGACCCAACAGAGACCAGCTTCTAGCAGCTAAGGAG 13733 
CP+H1C-A        TTGAAAGGCTTTCCTCAGCACCTGGGACCCAACAGAGACCAGCTTCTAGCAGCTAAGGAG 13739 
                ************************************************************ 
 
CP+H1B-G        GCCGTTCAGCTGTGACGAAGGCCTGAAGCACAGGATTAGGACTGAAGCGATGATGTCCCC 13793 
CP+H1C-A        GCCGTTCAGCTGTGACGAAGGCCTGAAGCACAGGATTAGGACTGAAGCGATGATGTCCCC 13799 
                ************************************************************ 
 
CP+H1B-G        TTCCCTACTTCCCCTTGGGGCTCCCTGTGTCAGGGCACAGACTAGGTCTTGTGGCTGGTC 13853 
CP+H1C-A        TTCCCTACTTCCCCTTGGGGCTCCCTGTGTCAGGGCACAGACTAGGTCTTGTGGCTGGTC 13859 
                ************************************************************ 
 
 
 
Appendices 
314 
 
CP+H1B-G        TGGCTTGCGGCGCGAGGATGGTTCTCTCTGGTCATAGCCCGAAGTCTCATGGCAGTCCCA 13913 
CP+H1C-A        TGGCTTGCGGCGCGAGGATGGTTCTCTCTGGTCATAGCCCGAAGTCTCATGGCAGTCCCA 13919 
                ************************************************************ 
 
CP+H1B-G        AAGGAGGCTTACAACTCCTGCATCACAAGAAAAAGGAAGCCACTGCCAGCTGGGGGGATC 13973 
CP+H1C-A        AAGGAGGCTTACAACTCCTGCATCACAAGAAAAAGGAAGCCACTGCCAGCTGGGGGGATC 13979 
                ************************************************************ 
 
CP+H1B-G        TGCAGCTCCCAGAAGCTCCGTGAGCCTCAGCCACCCCTCAGACTGGGTTCCTCTCCAAGC 14033 
CP+H1C-A        TGCAGCTCCCAGAAGCTCCGTGAGCCTCAGCCACCCCTCAGACTGGGTTCCTCTCCAAGC 14039 
                ************************************************************ 
 
CP+H1B-G        TCGCCCTCTGGAGGGGCAGCGCAGCCTCCCACCAAGGGCCCTGCGACCACAGCAGGGATT 14093 
CP+H1C-A        TCGCCCTCTGGAGGGGCAGCGCAGCCTCCCACCAAGGGCCCTGCGACCACAGCAGGGATT 14099 
                ************************************************************ 
 
CP+H1B-G        GGGATGAATTGCCTGTCCTGGATCTGCTCTAGAGGCCCAAGCTGCCTGCCTGAGGAAGGA 14153 
CP+H1C-A        GGGATGAATTGCCTGTCCTGGATCTGCTCTAGAGGCCCAAGCTGCCTGCCTGAGGAAGGA 14159 
                ************************************************************ 
 
CP+H1B-G        TGACTTGACAAGTCAGGAGACACTGTTCCCAAAGCCTTGACCAGAGCACCTCAGCCCGCT 14213 
CP+H1C-A        TGACTTGACAAGTCAGGAGACACTGTTCCCAAAGCCTTGACCAGAGCACCTCAGCCCGCT 14219 
                ************************************************************ 
 
CP+H1B-G        GACCTTGCACAAACTCCATCTGCTGCCATGAGAAAAGGGAAGCCGCCTTTGCAAAACATT 14273 
CP+H1C-A        GACCTTGCACAAACTCCATCTGCTGCCATGAGAAAAGGGAAGCCGCCTTTGCAAAACATT 14279 
                ************************************************************ 
 
CP+H1B-G        GCTGCCTAAAGAAACTCAGCAGCCTCAGGCCCAATTCTGCCACTTCTGGTTTGGGTACAG 14333 
CP+H1C-A        GCTGCCTAAAGAAACTCAGCAGCCTCAGGCCCAATTCTGCCACTTCTGGTTTGGGTACAG 14339 
                ************************************************************ 
 
CP+H1B-G        TTAAAGGCAACCCTGAGGGACTTGGCAGTAGAAATCCAGGGCCTCCCCTGGGGCTGGCAG 14393 
CP+H1C-A        TTAAAGGCAACCCTGAGGGACTTGGCAGTAGAAATCCAGGGCCTCCCCTGGGGCTGGCAG 14399 
                ************************************************************ 
 
CP+H1B-G        CTTCGTGTGCAGCTAGAGCTTTACCTAAAAGGAAGTCTCTGGGCCCAGAACTCTCCACCA 14453 
CP+H1C-A        CTTCGTGTGCAGCTAGAGCTTTACCTGAAAGGAAGTCTCTGGGCCCAGAACTCTCCACCA 14459 
                ************************** ********************************* 
 
CP+H1B-G        AGAGCCTCCCTGCCGTTCGCTGAGTCCCAGCAATTCTCCTAAGTTGAAGGGATCTGAGAA 14513 
CP+H1C-A        AGAGCCTCCCTGCCGTTCGCTGAGTCCCAGCAATTCTCCTAAGTTGAAGGGACCTGAGAA 14519 
                **************************************************** ******* 
 
CP+H1B-G        GGAGAAGGAAATGTGGGGTAGATTTGGTGGTGGTTAGAGATATGCCCCCCTCATTACTGC 14573 
CP+H1C-A        GGAGAAGGAAGTGTGGGGTAGATTTGGTGGTGGTTAGAGATATGCCCCCCTCATTACTGC 14579 
                ********** ************************************************* 
 
CP+H1B-G        CAACAGTTTCGGCTGCATTTCTTCACGCACCTCGGTTCCTCTTCCTGAAGTTCTTGTGCC 14633 
CP+H1C-A        CAACAGTTTCGGCTGCATTTCTTCACGCACCTCGGTTCCTCTTCCTGAAGTTCTTGTGCC 14639 
                ************************************************************ 
 
CP+H1B-G        CTGCTCTTCAGCACCATGGGCCTTCTTATACGGAAGGCTCTGGGATCTCCCCCTTGTGGG 14693 
CP+H1C-A        CTGCTCTTCAGCACCATGGGCCTTCTTATACGGAAGGCTCTGGGATCTCCCCCTTGTGGG 14699 
                ************************************************************ 
 
CP+H1B-G        GCAGGCTCTTGGGGCCAGCCTAAGATCATGGTTTAGGGTGATCAGTGCTGGCAGATAAAT 14753 
CP+H1C-A        GCAGGCTCTTGGGGCCAGCCTAAGATCATGGTTTAGGGTGATCAGTGCTGGCAGATAAAT 14759 
                ************************************************************ 
 
CP+H1B-G        TGAAAAGGCACGCTGGCTTGTGATCTTAAATGAGGACAATCCCCCCAGGGCTGGGCACTC 14813 
CP+H1C-A        TGAAAAGGCACGCTGGCTTGTGATCTTAAATGAGGACAATCCCCCCAGGGCTGGGCACTC 14819 
                ************************************************************ 
 
CP+H1B-G        CTCCCCTCCCCTCACTTCTCCCACCTGCAGAGCCAGTGTCCTTGGGTGGGCTAGATAGGA 14873 
CP+H1C-A        CTCCCCTCCCCTCACTTCTCCCACCTGCAGAGCCAGTGTCCTTGGGTGGGCTAGATAGGA 14879 
                ************************************************************ 
 
CP+H1B-G        TATACTGTATGCCGGCTCCTTCAAGCTGCTGACTCACTTTATCAATAGTTCCATTTAAAT 14933 
CP+H1C-A        TATACTGTATGCCGGCTCCTTCAAGCTGCTGACTCACTTTATCAATAGTTCCATTTAAAT 14939 
                ************************************************************ 
 
 
 
Appendices 
315 
 
CP+H1B-G        TGACTTCAGTGGTGAGACTGTATCCTGTTTGCTATTGCTTGTTGTGCTATGGGGGGAGGG 14993 
CP+H1C-A        TGACTTCAGTGGTGAGACTGTATCCTGTTTGCTATTGCTTGTTGTGCTATGGGGGGAGGG 14999 
                ************************************************************ 
 
CP+H1B-G        GGGAGGAATGTGTAAGATAGTTAACATGGGCAAAGGGAGATCTTGGGGTGCAGCACTTAA 15053 
CP+H1C-A        GGGAGGAATGTGTAAGATAGTTAACATGGGCAAAGGGAGATCTTGGGGTGCAGCACTTAA 15059 
                ************************************************************ 
 
CP+H1B-G        ACTGCCTCGTAACCCTTTTCATGATTTCAACCACATTTGCTAGAGGGAGGGAGCAGCCAC 15113 
CP+H1C-A        ACTGCCTCGTAACCCTTTTCATGATTTCAACCACATTTGCTAGAGGGAGGGAGCAGCCAC 15119 
                ************************************************************ 
 
CP+H1B-G        GGAGTTAGAGGCCCTTGGGGTTTCTCTTTTCCACTGACAGGCTTTCCCAGGCAGCTGGCT 15173 
CP+H1C-A        GGAGTTAGAGGCCCTTGGGGTTTCTCTTTTCCACTGACAGGCTTTCCCAGGCAGCTGGCT 15179 
                ************************************************************ 
 
CP+H1B-G        AGTTCATTCCCTCCCCAGCCAGGTGCAGGCGTAGGAATATGGACATCTGGTTGCTTTGGC 15233 
CP+H1C-A        AGTTCATTCCCTCCCCAGCCAGGTGCAGGCGTAGGAATATGGACATCTGGTTGCTTTGGC 15239 
                ************************************************************ 
 
CP+H1B-G        CTGCTGCCCTCTTTCAGGGGTCCTAAGCCCACAATCATGCCTCCCTAAGACCTTGGCATC 15293 
CP+H1C-A        CTGCTGCCCTCTTTCAGGGGTCCTAAGCCCACAATCATGCCTCCCTAAGACCTTGGCATC 15299 
                ************************************************************ 
 
CP+H1B-G        CTTCCCTCTAAGCCGTTGGCACCTCTGTGCCACCTCTCACACTGGCTCCAGACACACAGC 15353 
CP+H1C-A        CTTCCCTCTAAGCCGTTGGCACCTCTGTGCCACCTCTCACACTGGCTCCAGACACACAGC 15359 
                ************************************************************ 
 
CP+H1B-G        CTGTGCTTTTGGAGCTGAGATCACTCGCTTCACCCTCCTCATCTTTGTTCTCCAAGTAAA 15413 
CP+H1C-A        CTGTGCTTTTGGAGCTGAGATCACTCGCTTCACCCTCCTCATCTTTGTTCTCCAAGTAAA 15419 
                ************************************************************ 
 
CP+H1B-G        GCCACGAGGTCGGGGCGAGGGCAGAGGTGATCACCTGCGTGTCCCATCTACAGACCTGCA 15473 
CP+H1C-A        GCCACGAGGTCGGGGCGAGGGCAGAGGTGATCACCTGCGTGTCCCATCTACAGACCTGCA 15479 
                ************************************************************ 
 
CP+H1B-G        GCTTCATAAAACTTCTGATTTCTCTTCAGCTTTGAAAAGGGTTACCCTGGGCACTGGCCT 15533 
CP+H1C-A        GCTTCATAAAACTTCTGATTTCTCTTCAGCTTTGAAAAGGGTTACCCTGGGCACTGGCCT 15539 
                ************************************************************ 
 
CP+H1B-G        AGAGCCTCACCTCCTAATAGACTTAGCCCCATGAGTTTGCCATGTTGAGCAGGACTATTT 15593 
CP+H1C-A        AGAGCCTCACCTCCTAATAGACTTAGCCCCATGAGTTTGCCATGTTGAGCAGGACTATTT 15599 
                ************************************************************ 
 
CP+H1B-G        CTGGCACTTGCAAGTCCCATGATTTCTTCGGTAATTCTGAGGGTGGGGGGAGGGACATGA 15653 
CP+H1C-A        CTGGCACTTGCAAGTCCCATGATTTCTTCGGTAATTCTGAGGGTGGGGGGAGGGACATGA 15659 
                ************************************************************ 
 
CP+H1B-G        AATCATCTTAGCTTAGCTTTCTGTCTGTGAATGTCTATATAGTGTATTGTGTGTTTTAAC 15713 
CP+H1C-A        AATCATCTTAGCTTAGCTTTCTGTCTGTGAATGTCTATATAGTGTATTGTGTGTTTTAAC 15719 
                ************************************************************ 
 
CP+H1B-G        AAATGATTTACACTGACTGTTGCTGTAAAAGTGAATTTGGAAATAAAGTTATTACTCTGA 15773 
CP+H1C-A        AAATGATTTACACTGACTGTTGCTGTAAAAGTGAATTTGGAAATAAAGTTATTACTCTGA 15779 
                ************************************************************ 
 
CP+H1B-G        TTAAATAAGGTCTCCATTCATGGATTCCAAGGACAAGAAAGTCATATAGAATGTCTATTT 15833 
CP+H1C-A        TTAAATAAGGTCTCCATTCATGGATTCCAAGGACAAGAAAGTCATATAGAATGTCTATTT 15839 
                ************************************************************ 
 
CP+H1B-G        TTTAAGTTCTTTCCCACGCACCCTTAGATAATTTAGCTCAGAACAGGAAATGATAGTATT 15893 
CP+H1C-A        TTTAAGTTCTTTCCCACGCACCCTTAGATAATTTAGCTCAGAACAGGAAATGATAGTATT 15899 
                ************************************************************ 
 
CP+H1B-G        AATAAAAGCTGGACATCAGGATTAACAGCTCTCTCTGGGGCCCTGAAGGTGAGAGTTCTC 15953 
CP+H1C-A        AATAAAAGCTGGACATCAGGATTAACAGCTCTCTCTGGGGCCCTGAAGGTGAGAGTTCTC 15959 
                ************************************************************ 
 
CP+H1B-G        AGACTTGCTCATTTGCAGTTGCTTCTTTGTGATGCTGGCTACCCAGCTTTCTTGTACAAA 16013 
CP+H1C-A        AGACTTGCTCATTTGCAGTTGCTTCTTTGTGATGCTGGCTACCCAGCTTTCTTGTACAAA 16019 
                ************************************************************ 
 
 
 
Appendices 
316 
 
CP+H1B-G        GTGGT 16018 
CP+H1C-A        GTGGT 16024 
                ***** 
 
 
 
Appendix K 
UCSC annotations of the CP and SD regions 
Both regions are enriched for transcription factor binding and exhibit open 
chromatin structures and DNase I hypersensitivity. 
 
 
